19th Euretina Congress Paris
5-8 September 2019
Palais des Congrès, Paris, France
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boards &amp; Officers</td>
<td>2</td>
</tr>
<tr>
<td>President’s letter</td>
<td>3</td>
</tr>
<tr>
<td>Programme Overview</td>
<td>4</td>
</tr>
<tr>
<td>Surgical Skills Training Course</td>
<td>8</td>
</tr>
<tr>
<td>Scientific Programme – Thursday</td>
<td>11</td>
</tr>
<tr>
<td>Scientific Programme – Friday</td>
<td>33</td>
</tr>
<tr>
<td>Scientific Programme – Saturday</td>
<td>63</td>
</tr>
<tr>
<td>Scientific Programme – Sunday</td>
<td>89</td>
</tr>
<tr>
<td>ePoster Presentations</td>
<td>109</td>
</tr>
<tr>
<td>Video Competition</td>
<td>137</td>
</tr>
<tr>
<td>General Information</td>
<td>139</td>
</tr>
<tr>
<td>Sponsors</td>
<td>142</td>
</tr>
<tr>
<td>Congress Centre Plan</td>
<td>144</td>
</tr>
<tr>
<td>Exhibition Plans</td>
<td>146</td>
</tr>
<tr>
<td>List of Exhibitors &amp; Booth Numbers</td>
<td>148</td>
</tr>
<tr>
<td>EuroTimes Satellite Education Programme</td>
<td>155</td>
</tr>
<tr>
<td>Index</td>
<td>160</td>
</tr>
</tbody>
</table>
BOARDS & OFFICERS

President
Sebastian Wolf SWITZERLAND

Incoming President
Frank Holz GERMANY

General Secretary
Anat Loewenstein ISRAEL

Immediate Past President
Jan van Meurs THE NETHERLANDS

Past President
Ursula Schmidt-Erfurth AUSTRIA

Board Members
José García-Arumí SPAIN
Morten la Cour DENMARK
Alistair Laidlaw UK
Edoardo Midena ITALY
Stefan Seregard SWEDEN
Ramin Tadayoni FRANCE

Co-Opted Board Members
Pravin Dugel USA
Andrzej Grzybowski POLAND
Caroline C.W. Klaver THE NETHERLANDS
Xiaoxin Li CHINA
Yuichiro Ogura JAPAN
Giuseppe Querques ITALY

Programme Committee
Sebastian Wolf SWITZERLAND (CHAIRPERSON)
Frank Holz GERMANY
Morten la Cour DENMARK
Alistair Laidlaw UK
Anat Loewenstein ISRAEL
Ursula Schmidt-Erfurth AUSTRIA
Ramin Tadayoni FRANCE
Jan van Meurs THE NETHERLANDS

Past Presidents
Jan van Meurs THE NETHERLANDS
Ursula Schmidt-Erfurth AUSTRIA
Francesco Bandello ITALY
Gisbert Richard GERMANY
Bill Aylward UK
José Cunha-Vaz PORTUGAL
Borja Corcóstegui SPAIN
Rosario Brancato ITALY
Dear Colleagues,

It is my pleasure to welcome you, on behalf of the Board of the European Society of Retina Specialists, to the 18th EURETINA Congress in Vienna.

The success of the annual congress has been well documented in its 18-year history. From a meeting of only 200 delegates in 2001, EURETINA today hosts over 5000 delegates, making it the largest retina congress in the world.

The society’s contribution to education has increased in recent years with the introduction of a successful observership scheme and an online education program. The newly designed website has become an educational hub for doctors, with a CME accredited e-learning platform (EURETINA inSight), an electronic newsletter (EURETINA Brief), and the newly launched EURETINA Player, which showcases recorded expert interviews and panel discussions. EURETINA will this year also invest in research with the development of a retinal clinical research funding initiative to offer grant opportunities to successful candidates from across Europe.

Furthermore, in light of the tremendous growth of the annual congress, the Board has taken time to assess the environmental impact associated with an event of this scope. We have made a commitment this year to reduce waste, lower carbon emissions, and use sustainably and ethically-sourced congress materials. These include biodegradable delegate bags and recycled paper and lanyards.

The success of the EURETINA Congress is a culmination of the efforts of each chairperson, speaker and delegate, who has travelled to be here today. On behalf of the Board I extend my sincere gratitude to each of you and wish you a rewarding congress and a pleasant stay in the City of Music!

Yours sincerely,

Sebastian Wolf
President of EURETINA
Surgical Skills Training Courses

Instructors: I. Krebs AUSTRIA
K. Krepler AUSTRIA
U. Stolba AUSTRIA

Thursday 20 September
Schubert 1

<table>
<thead>
<tr>
<th>Course No.</th>
<th>Course Name</th>
<th>Course Time</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>First Approach to Vitreoretinal Surgery</td>
<td>09.00 – 12.00</td>
<td>€175 (plus VAT)</td>
</tr>
<tr>
<td>02</td>
<td>Combined Surgery with Intraocular Tamponade</td>
<td>13.00 – 16.00</td>
<td>€175 (plus VAT)</td>
</tr>
</tbody>
</table>

Friday 21 September
Schubert 1

<table>
<thead>
<tr>
<th>Course No.</th>
<th>Course Name</th>
<th>Course Time</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>03</td>
<td>Vitrectomy for Complicated Cataract Surgery</td>
<td>09.00 – 12.00</td>
<td>€175 (plus VAT)</td>
</tr>
<tr>
<td>04</td>
<td>Buckle Surgery</td>
<td>12.30 – 15.30</td>
<td>€175 (plus VAT)</td>
</tr>
</tbody>
</table>

First Approach to Vitreoretinal Surgery (Course 01)
First steps with 23g techniques explained step by step and practiced on pigs’ eyes. Participants should have experience in anterior segment microsurgery.

Combined Surgery with Intraocular Tamponade (Course 02)
The combined procedure including cataract surgery, IOL implantation, 23g vitrectomy and fluid/gas exchange are demonstrated and practiced on pigs’ eyes. Participants should have skills in anterior segment surgery or should have participated in Course 1.

Vitrectomy for Complicated Cataract Surgery (Course 03)
Surgical repair for dropped lenses or removal of luxated IOLs are explained and practiced on pigs’ eyes. Participants should be skilled in anterior segment surgery or should have participated in Courses 1 or 2.

Buckle Surgery (Course 04)
Finding the retinal break and sealing it with radial or oraparallel sponges are explained and practiced on model eyes. No microsurgical experience is required.
SPEAKERS’ CORNER
PRESENTED POSTERS
ORAL PRESENTATION OF HIGHEST SCORING POSTERS
THURSDAY, FRIDAY, SATURDAY, SUNDAY
E·POSTER TERMINALS
LOCATION: ENTRANCE, HALL D
SEE PROGRAMME OVERVIEW FOR SESSION DETAILS
DOWNLOAD THE CONGRESS APP

EURETINA APP

‘euretina 2018’
Any web enabled device
m.euretina.org

Free wi-fi throughout the congress centre
THURSDAY
20 September
THURSDAY 20 SEPTEMBER

08.30 – 16.00

INSTRUCTIONAL COURSE

130th Retinal Detachment Course
Room: Lehar 4

08.30 Welcome
I. Kreissig GERMANY

1. Fellow Eye of Retinal Detachment
Moderators: I. Kreissig GERMANY
S. Mennel AUSTRIA

1.1 Lattice degeneration and breaks in fellow eye:
What to do or what not to do?
S. Mennel AUSTRIA

2. Diagnostics: Rhegmatogenous Primary Retinal Detachment

2.1 The 4 rules to find the primary break
I. Kreissig GERMANY

2.2 A detachment without a break: What to try first?
V. Ferrara ITALY

3. Cerclage Without Drainage

3.1 A look at cerclage after 50 years: Indications, complications, long-term results
I. Kreissig GERMANY

4. Minimal Segmental Buckling with Sponge(S) Without Drainage

Moderators: V. Ferrara ITALY
A. Kothari GERMANY

4.1 Indications, optimal tamponaded of break(s), video of surgery; complications, long-term anatomic and functional results
S. Mennel AUSTRIA

4.2 Differential diagnosis of residual fluid
N. Sivkova BULGARIA

10.30 Coffee break

10.50

5. Gas Operation

Moderators: T. Bocker GERMANY
J. Schmidt GERMANY
A. Sudhalkar INDIA

5.1 Pneumatic retinopexy for uncomplicated detachments
J. Schmidt GERMANY

6. Primary Vitrectomy

6.1 Rationalie, indications, complications, long-term results
V. Ferrara ITALY

6.2 Comparison of 20-, 23-, 25-gauge ppv:
Indications, complications, results
A. Kothari INDIA

7. Minimal Segmental Buckling for Complicated Detachments

7.1 Reoperation: The 4 rules to find the undetected break
I. Kreissig GERMANY

7.2 How to minimise the risk of PVR
A. Sudhalkar INDIA

7.3 PVR-C1/C2 detachments. Try buckling first:
Long-term anatomic and functional results
J. Schmidt GERMANY

12.20 Group Photo

12.40 Lunch break
13.40

8. The Diabetic Eye
Moderators:  N. Sivkova BULGARIA  
D. Tognetto ITALY
8.1 Classification of diabetic retinopathy
A. Kothari INDIA
8.2 Laser coagulation: Indications and results
D. Tognetto ITALY
8.3 Intravitreal pharmacotherapy: Indications and results
T. Boeker GERMANY
8.4 Discussion of diabetic cases:
Presenter: V. Ferrara ITALY
Panel:  T. Boeker GERMANY  
A. Kothari INDIA  
I. Kreissig GERMANY  
S. Mennel AUSTRIA  
J. Schmidt GERMANY  
N. Sivkova BULGARIA  
A. Sudhalkar INDIA  
D. Tognetto ITALY

9. Comparison of Present Techniques for Repair of Primary Retinal Detachment
9.1 Temporary balloon buckle vs. pneumatic retinopexy vs. segmental buckling vs. primary vitrectomy
T. Boeker GERMANY

10. Various
10.1 Misdiagnosis of retinoschisis
N. Sivkova BULGARIA
10.2 Ambulatory double patching
S. Mennel AUSTRIA

11. Case Presentations
Moderator: I. Kreissig GERMANY
Presenter: T. Boeker GERMANY
Panel:  V. Ferrara ITALY  
A. Kothari INDIA  
S. Mennel AUSTRIA  
J. Schmidt GERMANY  
N. Sivkova BULGARIA  
A. Sudhalkar INDIA  
D Tognetto ITALY

12. Distribution of Diplomas
16.00 End of course
THURSDAY 20 SEPTEMBER

08.30 – 18.30

INSTRUCTIONAL COURSE

Posterior Uveitis on the Move: Basics & New Developments

Room: Lehar 3

Course Organisers:  C. Pavésio  UK
                    C.P. Herbort  SWITZERLAND

I. Diagnosis, Work-Up & Investigational Procedures

08.30  C. Pavésio  UK, C.P. Herbort  SWITZERLAND
       Introduction

08.35  M. Khairallah  TUNISIA
       Introduction: Clinical assessment of posterior uveitis

09.00  A. Denniston  UK
       Investigational work-up of posterior uveitis

09.25  C.P. Herbort  SWITZERLAND
       Precise and quantitative management of posterior uveitis is at hand: Laser flare photometry and angiographic work-up

10.00  F. Pichi  ABU DHABI
       OCT in posterior uveitis

10.15  Discussion

10.30  Coffee break

II. Main Entities

IIa. Infectious

10.50  C. Pavésio  UK
       Toxoplasmosis and other parasites

11.10  A. Abu El Asrar  SAUDI ARABIA
       Tuberculosis

11.25  M. Stanford  UK
       Viral retinitis

11.40  P. Kestelyn  BELGIUM
       Syphilis

11.55  M. Stanford  UK
       Endogenous Endophthalmitis

IIb1. Non-Infectious

12.10  A. Abu El Asrar  SAUDI ARABIA
       Behçet

12.25  C.P. Herbort  SWITZERLAND
       Choriocapillaritis – MEWDS
       APMPPE, Multifocal Choroiditis & Sepiginous choroiditis

13.00  Cases & Discussion

13.15  Lunch Break

IIb2. Non-Infectious

14.15  A. Abu El Asrar  SAUDI ARABIA
       Stromal choroiditis I: VKH

14.30  P. Kestelyn  BELGIUM
       Stromal choroiditis II: Sympathetic ophthalmitis

14.45  C. Pavésio  UK
       Stromal choroiditis III: Birdshot Retinochoroiditis

15.00  N. Jones  UK
       Sarcoidosis

15.15  Cases, Controversies & Discussion

16.00  Coffee Break

III. Treatment, Complications & Surgery

16.15  C. Pavésio  UK
       Local therapies in posterior uveitis

16.35  M. Khairallah  TUNISIA
       Steroids and immunosuppressives

16.55  A. Denniston  UK
       Biologics

17.10  Discussion

IV. Complications & Surgery

17.25  F. Pichi  ABU DHABI
       Inflammatory cystoid macular oedema (CMO)

17.40  N. Jones  UK
       Cataract

17.55  M. Westcott  UK
       Glaucoma

18.10  Discussion

18.30  End of course
08.30 – 10.00

SYMPOSIUM
FRIENDS GROUP

Controversies in the Management of Endophthalmitis

Room D5

Chairperson: C. Chiquet FRANCE

08.30 J. van Meurs THE NETHERLANDS
Intravitreal injections alone
08.45 C. Chiquet FRANCE
Vitrectomy
09.00 M. de Smet SWITZERLAND
Endoscopy
09.15 C. Creuzot-Garcher FRANCE
Steroids and other anti-inflammatory drugs
09.30 Discussion
10.00 End of symposium

08.30 – 10.00

SYMPOSIUM
ARTIFICIAL INTELLIGENCE GROUP

Innovations in Ophthalmology: Spotlight on Artificial Intelligence Applications

Room D2

Chairperson: T. Aslam UK

08.30 P. Keane UK
Development and validation of a deep learning algorithm for diagnosis of macular disease
08.40 U. Schmidt-Erfurth AUSTRIA
Preferred practices of anti-VEGF treatments for myopic CNV in Asia
08.50 K. Balaskas UK
The role of the reading centre in artificial intelligence
09.00 T. Aslam UK
Linking machine learning with physiological modelling to determine optimum w-AMD treatment pathways
09.10 A. Tufail UK
Artificial intelligence: Where do we go from here?
09.20 Discussion
10.00 End of symposium
08.30 – 10.00

INSTRUCTIONAL COURSE 1
Neovascular Age-Related Macular Degeneration: Questions Beyond Anti-VEGF Treatment
Room: Strauss 3

Course Organisers:  
I. Mantel SWITZERLAND  
T.J. Wolfensberger SWITZERLAND

08.30  
I. Mantel SWITZERLAND  
Anti-VEGF refractory AMD and its differential diagnosis

08.42  
R. Schlingemann THE NETHERLANDS  
Pigment epithelium detachment in anti-VEGF treatment for AMD

08.54  
A. Ambresin FRANCE  
How to manage choroidal polypoidal vasculopathy in AMD

09.06  
J.A. Pournaras SWITZERLAND  
Management of large submacular haemorrhages in AMD: Inject or operate?

09.18  
T.J. Wolfensberger SWITZERLAND  
AMD and vitreomacular traction: Vitrectomy or ocriplasmin

09.30  
S. Zweifel SWITZERLAND  
How to handle cataract surgery in patients with AMD?

09.42  
Discussion

10.00  
End of course

08.30 – 10.00

INSTRUCTIONAL COURSE 2
New Frontiers & Perspectives in Diffuse DME
Room D4

Course Organisers:  
M. la Cour DENMARK  
D. Pelayes ARGENTINA

08.30  
F. Bandello ITALY  
Angio-OCT in insulin dependent diabetics without diabetic retinopathy

08.40  
R. Cano MEXICO  
Ultra widefield angiography in diabetic macular edema

08.50  
M. Larsen DENMARK  
New trends in pharmacotherapy in DME

09.00  
G. Gabela ECUADOR  
Treatment of diffuse DME with subthreshold laser

09.10  
M. la Cour DENMARK  
DME and cataract surgery, what do we know?

09.20  
C. Mayer GERMANY  
Outcome in phacovitrectomy in eyes with DME

09.30  
F. Graue MEXICO  
Surgical management, time for surgery?

09.40  
N. Bornfeld GERMANY  
DME and proliferative diabetic retinopathy, what is the best strategy?

09.50  
Discussion

10.00  
End of course
08.30 – 10.00

INSTRUCTIONAL COURSE 3

Local Anaesthesia for Vitreoretinal Surgery: Focus on Subtenon’s Anaesthesia

Room: Lehar 2

Course Organisers: F. Lersch SWITZERLAND
                  M. Zinkernagel SWITZERLAND

08.30  F. Lersch SWITZERLAND
       Orbital anatomy and local anaesthesia techniques to minimise risk and maximise satisfaction in VR cases

08.42  M. Zinkernagel SWITZERLAND
       Patient selection for local anaesthesia

08.54  B. Chanana INDIA
       Local anaesthesia for scleral buckling: Advantages and pitfalls

09.06  M. Buckle UK
       Local anaesthesia for ROP treatment and neonatal imaging

09.18  R. Ling UK
       Regional anaesthesia in vitreoretinal surgery: Complications and their management. The surgeon's perspective

09.30  K. Allman UK
       Regional anaesthesia in vitreoretinal surgery: Complications and their management. The anaesthetist's perspective

09.42  Discussion

10.00  End of course

09.00 – 10.30

EURETINA MAIN SESSION 1

Ocular Oncology for Surgical & Medical Retina Specialists

Hall D3

Chairpersons: H. Heimann UK
              S. Seregard SWEDEN

09.00  S. Seregard SWEDEN
       Introduction

09.10  H. Heimann UK
       How modern imaging can aid in the differential diagnosis of small intraocular tumours

09.20  L. Zografos SWITZERLAND
       Intravitreal treatment of radiation- and tumour-associated macular oedema

09.30  N. Bornfeld GERMANY
       How to diagnose intraocular lymphoma - clinical presentation and biopsy techniques

09.40  N. Bechrakis AUSTRIA
       Surgical resection as an alternative to enucleation in large uveal melanoma - risks and benefits

09.50  B. Damato USA
       Prediction of metastatic disease in patients with uveal melanoma and screening recommendations

10.00  M. Sagoo UK
       Critical evaluation of systemic, intracameral and ophthalmic artery chemotherapy for retinoblastoma

10.10  Discussion

10.30  End of session
09.00 – 10.30
FREE PAPER SESSION 1
Imaging I
Room C1
Chairperson: C.J. Boon THE NETHERLANDS

09.00  L. Frizziero, R. Parrozzani, F. Leonardi, E. Pilotto, G. Miglionico, E. Midena ITALY
Retinal vascular and neural remodeling secondary to optic nerve axonal degeneration: A study using optical coherence tomography angiography

09.06  J. M. Ruiz-Moreno, J. Ruiz-Medrano, F. Lugo, B. Sirvent, I. Flores-Moreno, A. Royuela SPAIN
Automatic quantification of geographic atrophy associated to age-related macular degeneration

09.12  V. Juncal, A. Abadeh, A. Berger, D. Chow CANADA
Projection artifact removal changes the visualization of optical coherence tomography angiography images

09.18  M. Barrasso Rodrigo, A. Ale Chilet, T. Hernandez, C. Oliva, J. Gascon, A. Adan, J. Zarranz-Ventura SPAIN
Evaluation of perifoveal vascular network in type I diabetes mellitus using optical coherence tomography angiography and relationship with diabetic retinopathy grade

09.24  S. Müller, P. Charbel Issa, T. Heeren, F. Holz, P. Herrmann GERMANY
Macular pigment distribution as predictor of disease progression in macular telangiectasia type 2

09.30  S. Palkovits, S. Georgiev, M. Ullrich, N. Hirnschall, O. Findl AUSTRIA
Retinal sensitivity assessed by microperimetry in patients with different types of cataract

09.36  M. Diab, M. El Shehari, M. Omar SAUDI ARABIA
Retinal imaging in premature infants using the Pictor non-contact digital camera

09.42  S. Schmitz-Valckenberg, S. Liakopoulos, E. Ziemssen, B. Muller, J. Voegeler, C. Brinkmann, G. Spital GERMANY
Interpretation of SD-OCT imaging data in real-life conditions versus standardized reading center analysis in eyes with diabetic macular edema (DME) – 24 months results of the ORCA study

09.48  S. Vujosevic, C. Toma, V. Gatti, A. Muraca, L. Masoero, M. Brambilla, S. De Cilla ITALY
Evaluation of quantitative macular perfusion parameters in patients with diabetes mellitus with and without diabetic retinopathy by two different swept-source OCT-Angiography instruments

09.54  A. Tan, K. Teo, K. Devarajan, L. Xian Hui, L. Schmetterer, T. Wong, G. Cheung SINGAPORE
Development and validation of a novel measure of the choroidal vasculature as an imaging biomarker for the diagnosis of polypoidal choroidal vasculopathy

10.00  M. Tian, S. Wolf, M. Zinkernagel, M. Munk, K. Schaal SWITZERLAND
Evaluation of three different swept source OCT angiography slabs for the detection of features of diabetic retinopathy

Peripapillary and macular neurovascular coupling in autosomal dominant optic atrophy: An OCTA study

10.12  P. Corazza, A. Vagge, R. Vagge, P. Camicione, P. Capris, C. Traverso, M. Nicolo ITALY
Correlation between infrared images, OCT angiography and en face OCT in patients with choroidal freckling affected by neurofibromatosis type 1

10.18  E. Ivanova, P. Volodin, V. Solomin RUSSIA
Optical coherence tomography angiography and fluorescein angiography imaging in identifying the defects of the retinal pigment epithelium in central serous chorioretinopathy: comparison of results

10.30  End of session
FREE PAPER SESSION 2

Vascular Diseases & Diabetic Retinopathy I

Room D1

Chairperson: M. Battaglia-Parodi ITALY

09.00 – 10.30

09.00 A. Rauf, A. Aftab UK
Incidence of serous macular detachment patients with macular edema secondary to diabetes mellitus

09.06 A. Abdelhamid KUWAIT
Quantitative assessment of outer retinal layer and photoreceptor outer segment layer and their relation to visual acuity in diabetic macular edema

09.12 J. Garcia-Arumí, F. Gomez-Ulla, E. Cervera, A. Navea, L. Arias, J. Araiz SPAIN
A phase IV study to assess efficacy and safety of a treat-and-extend regimen of aflibercept for treatment of macular edema secondary to central retinal vein occlusion in naïve patients. Neuton study

09.18 I. Kozak, D. Brown, S. Lampen, J. Chhablani UAE
Management of Coats’ disease microaneurysms with FFA-guided navigated laser

09.24 I. Carneiro, J. Coelho, M. Macedo, M. Furtado, M. Lume PORTUGAL
Multimodal imaging and functional correlation with microperimetry in patients with macular telangiectasia type 2

09.30 L. Schmetterer, J. Chua, T. Wong, E. Lamoureux SINGAPORE
Relationship of dietary fish intake to diabetic retinopathy in patients with type 2 diabetes

09.36 P. Dugel, V. Karageozian, H. Karageozian, J. Park, M. Sarayba, L. Karageozian USA
Randomized, prospective, double-masked, controlled phase 2b trial to evaluate the safety and efficacy of ALG-1001 (Luminate®) in diabetic macular edema (DME)

09.42 S. Gómez Sánchez, X. Valdeperas, M. Esteve, B. Oller-Sales SPAIN
Influence of the vitreomacular interface on the course of diabetic macular edema (DME) after treatment with intravitreal injections of anti-vascular endothelial growth factor agents (antiVEGF)

Choroidal structure changes in diabetic patients without diabetic retinopathy

09.54 A. Augustin GERMANY
The first report comparing the 3 year outcomes of iluvien® (fluocinolone acetonide) in vitrectomised and non-vitrectomised eyes in patients with DME – results from RETRO-IDEAL

10.00 H. Zhang CHINA
Effect of intravitreal conbercept on aqueous humor cytokines in macular edema secondary to central retinal vein occlusion

10.06 A. Alé-Chilet, M. Barraso, T. Hernadez, C. Oliva, J. Gascon, A. Adan, J. Zarranz-Ventura SPAIN
Cardiovascular risk factors impact in perifoveal flow in type 1 diabetes mellitus assessed by OCT angiography

10.12 M. Inatani, T. Higashide, K. Matsushita, T. Kubota, M. Kobayashi, Y. Iwamoto, S. Leal JAPAN
Efficacy and safety of intravitreal aflibercept injection in Japanese patients with neovascular glaucoma: Outcomes from the phase 3 VEGA study

10.18 A. Korol, T. Kustryn, O. Zadorozhnyy, I. Nasinnyk, A. Nevksa UKRAINE
Ranibizumab versus aflibercept for myopic choroidal neovascularization: 24 month results in real-life data

10.30 End of session
THURSDAY 20 SEPTEMBER

10.45 – 12.15 INTERACTIVE

SPEAKERS’ CORNER 1

AMD

Taking place within the EURETINA Speaker’s Corner (Entrance Hall D), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

10.45  C. Yasar, O. Tok, L. Tok TURKEY
       Vitamin D and optical coherence tomography in neovascular age-related macular degeneration

10.50  S.H. Kim, T. Rim, T. Yoo, J. Kwak, S.E. Kim, S.S. Kim SOUTH KOREA
       A nationwide incidence of clinical exudative neovascular age-related macular degeneration under real-world medical system of South Korea and related injection use during 2010-2015

10.55  G. Tsokolas, H. Almuhtase, A. Lottery UK
       Use of intravitreal (IVI) bevacizumab for the treatment of choroidal neovascular membrane secondary to Sorsby fundus dystrophy

11.00  Y. Toklu, U. Ozen, M. Yorgun, A. Ipek TURKEY
       Evaluation of ocular blood flow with color doppler ultrasonography after intravitreal aflibercept injection

11.05  F. Bandello, G. Staurenghi, F. Ricci, E. Midena, F. Viola, L. Colombo, S. Bassanini ITALY
       Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: Twelve-month results of the TWEYEa study

11.10  L. Chang, M. Yuan CHINA
       One-year results of intravitreal conbercept therapy between two different angiographic subtypes of polypoidal choroidal vasculopathy

11.15  C. Lee, E. Choi, S. Lee SOUTH KOREA
       Long-term incidence and growth of chorioretinal atrophy in patients with polypoidal choroidal vasculopathy

11.20  S. Joseph, S. Umeed, R. Sivaraj UK
       A clinical evaluation of efficacy of stereotactic radiotherapy in reducing the frequency of anti –VEGF injections in wet AMD

11.25  A. Daly, V. McGrath, C. Fasser, K. Gordon, U. Chackrava, R. Henderson, C. Medifindt IRELAND
       A global coalition of patient organisations collaborated to develop a multi stakeholder educational toolkit to improve education and outcomes of age-related macular degeneration – AMD

11.30  J. Robinson, R. Crosby-Nwaobi, S. Sivaprasad UK
       Complete audit cycle on loading phase of aflibercept for treatment naive neovascular age-related macular degeneration (nAMD)

11.35  L. Raja, K. Fasler, S. Wagner, K. Kortuem, K. Balaskas, N. Pontikos, P. Keane UK
       One and two-year visual acuity outcomes after treatment for neovascular age-related macular degeneration at a large tertiary ophthalmic hospital

11.40  A. Hobby, B. Huntjens, O. Mahroo, D. Crabb, A. Binns UK
       Association between number of injections during long-term anti VEGF therapy and retinal electrophysiological parameters

11.45  R. Angermann, T. Rauchegeger, M. Kralinger, C. Zehetner AUSTRIA
       Effectiveness of aflibercept in exudative age-related macular degeneration: Real-life data study Innsbruck

11.50  C. Yun, J. Ahn, B. Lee, S. Kim, J. Oh SOUTH KOREA
       Variations in chorioretinal vasculatures in patients with age-related macular degeneration

11.55  I. Jamiołkowska, M. Figurska, M. Rekas POLAND
       Analysis of choroidal thickness changes in patients with exudative age-related macular degeneration treated with aflibercept

12.00  T. Koutresi, H. Al Muhtaseb, A. Lottery, G. De Salvo UK
       Novel phenotypic association of Sorsby fundus dystrophy with with polypoidal choroidal vasculopathy

12.05  Discussion

12.15  End of session
11.00 – 12.30

**EURETINA MAIN SESSION 2**

The EURETINA Guidelines for Management of Retinal Disease

Hall D3

Chairpersons: U. Schmidt-Erfurth *AUSTRIA*
              A. Grzybowski *POLAND*

11.00 U. Schmidt-Erfurth *AUSTRIA*
Where is anti-VEGF therapy now: Achievements & Challenges

11.10 E. Midena *ITALY*
Neovascular AMD: The ten key messages

11.20 F. Bandello *ITALY*
Diabetic macular edema: The ten key messages

11.30 A. Loewenstein *ISRAEL*
Vein occlusion: The ten key messages

11.40 A. Grzybowski *POLAND*
A state-of-the-art in endophthalmitis in anti-VEGF therapy

11.50 D. Martin *USA*
The future needs and progress in anti-VEGF therapy

12.00 Discussion

12.30 End of session

11.00 – 12.30

**EURETINA UPDATE SESSION 1**

Paediatric Retina Surgery

Room C1

Chairpersons: K. Drenser *USA*
              G. Caputo *FRANCE*

11.00 G. Caputo *FRANCE*
Persistent foetal vasculature

11.10 A. Kychenthal *CHILE*
Advanced stages of ROP

11.20 S.C. Wong *UK*
Rhegmatogenous retinal detachment

11.30 W. Chi Wu *TAIWAN*
Retinal haemorrhages

11.40 F. Metge *FRANCE*
Coat’s disease

11.50 M. Trese *USA*
FEVR

12.00 Discussion

12.30 End of session
11.00 – 12.30

**SYMPOSIUM CLUB JULES GONIN**

Myths in Vitreoretinal Surgery

Room D1

**Chairpersons:** J. van Meurs *THE NETHERLANDS*
T.J. Wolfensberger *SWITZERLAND*

11.00  R. Tadayoni *FRANCE*
Vitreous haemorrhage should be regularly followed by ultrasound

11.15  J. van Meurs *THE NETHERLANDS*
Vitrectomy for endophthalmitis is dangerous

11.30  A. Laidlaw *UK*
High myopia is a contraindication for vaginal delivery

11.45  D. Wong *UK*
Physical activity is contraindicated after retinal detachment surgery

12.00  T.J. Wolfensberger *SWITZERLAND*
LASIK increases the risk for retinal detachment

12.15  Discussion

12.30  End of session

11.00 – 12.30

**FREE PAPER SESSION 3**

Uveitis

Room D5

**Chairperson:** S. Seregard *SWEDEN*

11.00  C. Rangel, M. Parra, M. Corrales, R. Sanchez-Avila, C. Varon, E. Villarreal, D. Villarreal *COLOMBIA*
Endophthalmitis in Colombia: Etiology, antimicrobial susceptibilities and treatment outcomes

11.06  A. Upadhyay, D. Das, K. Gupta, H. Bhattacharjee *INDIA*
Uveitis in pediatric population at a tertiary eye care centre in North-East India

11.12  E. Sorozhkina, N. Balatskaya, G. Davidova, T. Lisitsina *RUSSIA*
Serum inflammatory chemokine profile in Behçet’s disease patients with ocular involvement.

11.18  C. Jumroendararasame, I. Toraktrakul *THAILAND*
Resolution patterns of cytomegalovirus retinitis

11.24  D. Alex, M. Gopalakrishnan, G. Anantharaman *INDIA*
A rare entity: Case series of idiopathic unilateral retinochoroidal inflammatory diseases

11.30  C. Pavésio, W. Tucker, C. Heinz *UK*
The first European presentation of the safety and efficacy outcomes with the 0.18 mg fluocinolone acetonide implant (FAc) for the treatment of non-infectious posterior segment uveitis (NIU-PS)-12 month interim analyses from an ongoing 36 month trial

11.36  R. Khoramnia, L. Weber, S. Marx, A. Scheuerle, C. Mayer, G. Auffarth *GERMANY*
Injectable 0.19 mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema

11.42  M. Ferrara, L. Eggenschwiler, A. Stephenson, A. Montieth, N. Nahkoul, R. Araajo-Miranda, C. Foster *ITALY*
Pediatric uveitis: experience in a tertiary referral center in the United States

11.48  A. Marchese, E. Miserocchi, G. Modorati, G. Querques, F. Bandello *ITALY*
Spectrum of vitreous abnormalities in primary vitreocentral lymphoma: new insights by multimodal imaging

12.00  H. Adusumilli, L. Krupa, N. Shetty, S. Ballal, V. S *INDIA*
Clinical presentation, outcomes, management algorithms, role of newer antibiotics and anti fungals in management of endogenous endophthalmitis (EE) in Indian population in a tertiary care hospital
11.00 – 12.30
SYMPOSIUM
ASIA PACIFIC VITREORETINA SOCIETY (APVRS)
Management of Pathologic Myopia
Room D2

Chairpersons:
A. Chang AUSTRALIA
P. Ruamviboonsuk THAILAND
H. Terasaki JAPAN

11.00  T.Y. Wong SINGAPORE
Can we prevent myopia or stop progression of pathologic myopia

11.15  T. Lai HONG KONG
Preferred practices of anti-VEGF treatments for myopic CNV in Asia

11.30  H. Terasaki JAPAN
Classification and management of myopic traction maculopathy

11.45  A. Chang AUSTRALIA
Complications of myopic maculopathy surgery

Panel Discussion on Interesting Cases
12.00  P. Ruamviboonsuk THAILAND
Case presentation

12.05  W. Ki Lee SOUTH KOREA
Case presentation

12.10  B. Chananan INDIA
Case presentation

12.15  S.J. Chen TAIWAN
Case presentation

12.20  K. Fong MALAYSIA
Case presentation

12.25  Discussion

12.30  End of symposium
THURSDAY 20 SEPTEMBER

11.00 – 12.30

INSTRUCTIONAL COURSE 5
Optimising Injection Clinics: Models to Organise a Successful Intravitreal Clinic

Room D4

Course Organiser: M. Zinkernagel SWITZERLAND

11.00 S. Wolf SWITZERLAND
'Just in time' anti-VEGF treatment

11.12 N. Feltgen GERMANY
Involving referring ophthalmologists in decision making and patient care: Strategic management of intravitreal clinics

11.24 P. Lanzetta ITALY
Optimal allocation of human resources in intravitreal clinics

11.36 G. Turner UK
Lean management in a nationalised healthcare system: How to reduce work burden for physicians without increasing the number of steps for intravitreal therapy

11.48 T.A. Ciulla USA
Lean six sigma process improvement in intravitreal injection clinics

12.00 M. Zinkernagel SWITZERLAND
Models for creating effective core processes in anti-VEGF therapy

12.12 Discussion

12.30 End of course
11.00 – 12.30

INSTRUCTIONAL COURSE 6

Central Serous Chorioretinopathy: Diagnosis & Treatment

Room: Lehar 2

Course Organiser: C.J. Boon THE NETHERLANDS

11.00  J. Chhablani  INDIA
Diagnosis of CSC

11.10  T. Theelen  THE NETHERLANDS
OCT and OCT angiography aspects of CSC

11.20  C.J. Boon  THE NETHERLANDS
Differential diagnosis of CSC

11.30  E. de Jong  THE NETHERLANDS
Genetics and pathophysiology of CSC

11.40  S. Yzer  THE NETHERLANDS
Neovascularisation and polypoidal choroidal vasculopathy in CSC

11.50  S. Fauser  GERMANY
Micropulse laser treatment in CSC

12.00  C. Hoyng  THE NETHERLANDS
Photodynamic therapy in CSC

12.10  G. Querques  ITALY
Other treatments for CSC

12.20  Discussion

12.30  End of course

14.15 – 15.45

SPEAKERS’ CORNER 2

Mixed Session I

Taking place within the EURETINA Speakers’ Corner (Entrance Hall D), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

Moderator:  G. Querques  ITALY

14.15  K. Mousavi  SPAIN
Effectiveness of adalimumab for refractory tubercular serpiginous like choroiditis in a patient with previous history of Eales’s disease

14.20  S. Parreira, D. Lopes, I. Machado, F. Freitas, N. Campos  PORTUGAL
Changes in retinal non-perfusion following aflibercept versus panretinal photocoagulation in treatment naïve proliferative diabetic retinopathy – CLARITY sub study

14.25  H. Adusumilli, H. Sharma, N. Shetty, V. S, M. Vankalaku  INDIA
Clinico-pathological correlation of subretinal drusenoid like deposits on fundus with renal biopsy findings in patients with chronic kidney disease of various etiologies

14.30  J. Simicak, M. Rybarikova, O. Vlalcil, S. Kalabova, V. Bodnar, J. Halek  CZECH REPUBLIC
Identifying severe forms of ROP using WINROP algorithm in the Czech Republic (3-year follow up)

14.35  I. Wong, N. Fung  HONG KONG
Visual outcome correlates with retinal changes on baseline spectral-domain optical coherence tomography in diabetic macular edema

Combined treatment of intravitreal ranibizumab and oral supplementation with docosahexaenoic acid and antioxidants for diabetic macular edema: results at 36 months of a randomized controlled single-blind clinical trial

14.45  T. Shiraya, F. Araki, K. Kure, T. Kaiya, S. Kato  JAPAN
Correlation between anterior chamber flare changes and therapeutic effects of anti-vascular endothelial growth factor injections on diabetic macular edema

14.50  N. Jayawickrema, J. Kuganabal, S. Senanayal  SRI LANKA
Cilioretinal artery occlusion in a previously healthy adolescent diagnosed with infective endocarditis

14.55  E. Zamystsikiy, A. Zolotarev  RUSSIA
Personalized threshold laser photocoagulation for DME treatment

15.00  S. Vasudevan, S. Joshi, G. Ayachit  INDIA
Unheeded FCEs (Focal choroidal Excavations) in recurrent CSC
14.00 – 16.00

EURETINA MAIN SESSION 3

Decision Making in Challenging Cases

Hall D3

Chairpersons:
A. Gaudric FRANCE
A. Tufail UK
J.R. Vingerling THE NETHERLANDS

14.30 S. Schmitz-Valckenberg SWITZERLAND
Should we treat subclinical CNV discovered by OCT-A?

14.37 A. Tufail UK
Is it valuable to tolerate subretinal fluid in the treatment of type 1 CNV?

14.44 J. Zarranz-Ventura SPAIN
Do you rely on OCT-A to retreat CNV?

14.51 R. da Silva PORTUGAL
If a PDR associated with DME is treated by anti-VEGF, is it safe to space out injections?

14.58 J.R. Vingerling THE NETHERLANDS
Do you stop anti-VEGFs in persistent RVO related CME without binocular problems?

15.05 Y. Ikuno JAPAN
Should we operate early myopic foveoschisis to avoid complications?

15.12 R. Schumann GERMANY
Can we expect visual improvement in some lamellar macular hole after surgery?

15.19 C.J. Boon THE NETHERLANDS
What to do in chronic CSCR when serous retinal detachment recurs after PDT?

15.26 A. Daruich-Matet FRANCE
How to manage Coat’s disease with central macular lipid exudation?

15.33 Discussion

16.00 End of session
14.30 – 16.00

EURETINA UPDATE SESSION 2

Retinal Vascular Diseases

Room C1

Chairpersons:  R. Schlingemann THE NETHERLANDS
                A. Loewenstein ISRAEL

14.30  P. Udaondo SPAIN
       New developments in the understanding and treatment of choroidal vascular disease

14.40  R. Schlingemann THE NETHERLANDS
       Pathophysiology of macular edema, diabetic and other

14.50  N. Waheed USA
       OCT Angiography in macular edema, diabetic and other

15.00  A. Loewenstein ISRAEL
       Management of diabetic macular edema in 2018

15.10  A. Augustin GERMANY
       Steroids in diabetic macular edema

15.20  J. García-Arumí SPAIN
       Surgery in macular edema, diabetic and other

15.30  G. Staurenghi ITALY
       Imaging aspects of vascular disease

15.40  Discussion

16.00  End of session

14.30 – 16.00

FREE PAPER SESSION 4

Vitreoretinal Surgery I

Room D1

Chairpersons:  J. van Meurs THE NETHERLANDS
                T.J. Wolfensberger SWITZERLAND

14.30  D. Steel, J. Suleman, S. Dodds, J. Rees UK
       Optic disc pit maculopathy: A two-year nationwide prospective study

       Retinal detachment in albinism

14.42  J. Klein, S. Bohnacker, A. Nasseri, N. Feucht, C. Lohmann, M. Maier GERMANY
       Correlation of operative morphology and postoperative visual outcome in patients with full thickness macular hole (FTMH)

14.48  S. Abou-Ltaif, A. Logeswaran, L. Wickham UK
       Vitreomacular traction surgery: Outcome predictive factors

14.54  B. Yahaghi, M. Abrishami, E. Babaei IRAN
       Simultaneous bilateral vitrectomy for bilateral acute endophthalmitis after intravitral bevacizumab injection

15.00  S. Loukovaara, J. Haukka FINLAND
       The repair of primary rhegmatogenous retinal detachment - Comparison of standard pars plana vitrectomy and combined vitrectomy with phacoemulsification and standard foldable intraocular lens implantation

15.06  A. Barak, A. Ben-Shabat, R. Schneider, A. Zeitouny, S. Zimmer, E. Segev, A. Loewenstein ISRAEL
       Placing the surgeon in the center - A novel 3D visualization platform for retina surgery providing transparent display, data overlay and guidance

15.12  V. Cacioppo, A. Govetto, P. Radice, G. Virgili, A. Scialdone ITALY
       Premacular membrane formation after scleral buckling for primary rhegmatogenous retinal detachment: a prospective study and pathophysiological insights

15.18  A. Jalil, N. Patton, M. Ahmed, T. Ivanova, C. Baumann, S. Charles, S. Chang UK
       The Manchester large macular hole study: Is it time to reclassify large macular holes?

15.24  R. Laiginhas, A. Rocha, J. Chibante PORTUGAL
       Inverted internal limiting membrane flap technique for large macular hole surgery – functional and anatomical outcomes

15.30  M. Raimundo, M. Queiroz, J. Simao, P. Gil, C. Mateus, J. Figueira PORTUGAL
       Long-term functional and anatomical outcomes following macular hole surgery: 5-year follow-up study
14.30 – 16.00

**SYMPOSIUM**
**EUROPEAN VISION CLINICAL RESEARCH (EVICR.NET)**

**Focus on Multinational Clinical Research**

**Room D5**

**Chairpersons:**  
F. Bandello **ITALY**  
J. Cunha-Vaz **PORTUGAL**  
H. Scholl **SWITZERLAND**

14.30  
**F. Bandello** **ITALY**, **J. Cunha-Vaz** **PORTUGAL**,  
H. Scholl **SWITZERLAND**  
Introduction

14.40  
**F. Holz** **GERMANY**  
MACUSTAR - A European study funded by IM12 in patients with intermediate AMD

14.50  
**R. Finger** **GERMANY**  
MACUSTAR - Novel clinical endpoints for clinical trials in iAMD

15.00  
**H. Scholl** **SWITZERLAND**  
New developments in retinal dystrophies

15.10  
**B. Lorenz** **GERMANY**  
European reference network on rare eye diseases

15.20  
**C. Martinho** **PORTUGAL**  
EVICR.net update

15.30  
Round-table discussion on new perspectives for retinal disease treatments  
F. Bandello **ITALY**  
J. Cunha-Vaz **PORTUGAL**  
S. Fauser **GERMANY**  
G. Lambrou **SWITZERLAND**  
H. Scholl **GERMANY**  
S. Schneider **UK**

Conclusion & Questions  
J. Cunha-Vaz **PORTUGAL**

16.00  
End of symposium
14.30 – 16.00

**SYMPOSIUM**
**RETINATECH:**
**BIO-ENGINEERING SESSION**

Where Surgery Meets Technology
Room D2

Chairpersons:  C. Eckardt *Germany*
                T. Rossi *Italy*
                K. Packo *USA*
                D. Wong *UK*

14.30  **D. Wong  UK**
Welcome and introduction

14.32  **C. Awh  USA**
New devices for vitreoretinal surgery

14.40  **D. Wong  UK**
Silicone oil removal: Are we doing the right thing?

14.48  **T. Hassan  USA**
New considerations for operating room sterility

14.56  **C. Eckardt  Germany**
29er spotlight

15.04  **M. Romano  Italy**
Comparison between different 3D heads up systems: Psychometric skill testing

15.12  **P. Stanga  UK**
Hypersonic vitrectomy: European clinical experience. What’s new?

15.20  **T. Rossi  Italy**
Mathematical models of vitreous fluidics

15.28  **M. de Smet  Switzerland**
Mitigating risk in robotic surgery

15.36  **D. Chow  Canada**
TECH news: An update

15.44  **T. Rossi  Italy**
Computer modelling of vitreous motion

15.52  Discussion

16.00  End of symposium

14.30 – 16.00

**INSTRUCTIONAL COURSE 7**

Managing Diabetic Macular Edema: Pearls & Pitfalls

Room: Strauss 3

Course Organisers:  E. Midena *Italy*
                    A. Joussen *Germany*

14.30  **A. Joussen  Germany**
The pathogenesis of DME: the paradigm for a new treatment approach

14.45  **T. Peto  UK**
The screening of DME around: Present and future perspectives

15.00  **E. Pilotto  Italy**
Multimodal retinal imaging in DME: Is it essential?

15.15  **E. Midena  Italy**
DME treatment: From RCT studies to daily practice

15.30  **S. Sivaprasad  UK**
Intriguing DME cases

15.45  Discussion

16.00  End of course
THURSDAY 20 SEPTEMBER

14.30 – 16.00

INSTRUCTIONAL COURSE 8
Uveitis Pearls for the Retina Specialist
Room D4

Course Organisers:  D. Grewal USA
                    M. Munk SWITZERLAND

14.30  W. Tucker UK
       Algorithmic approach for uveitis diagnosis

14.50  M. Munk SWITZERLAND
       Using imaging to monitor disease activity and treatment response

15.10  P. Lin USA
       Local and systemic treatment options in uveitis

15.30  D. Grewal USA
       Vitreoretinal surgical approaches in uveitis

15.50  Discussion

16.30  End of course

14.30 – 16.00

INSTRUCTIONAL COURSE 9
Understanding the Management of Proliferative Diabetic Retinopathy
Room: Lehar 2

Course Organisers:  A. Laidlaw UK
                    M. Mohamed UK

14.30  A. Laidlaw UK
       Welcome and introduction

14.35  L. Downey UK
       Pathophysiology of proliferative diabetic retinopathy

15.00  S. Mann UK
       Medical risk factors for progression of diabetic retinopathy

15.10  S. Mann UK
       Classification of diabetic retinopathy, follow up/screening intervals at each stage

15.20  M. Mohamed UK
       PRP: when to start, where to do it, how much to do and when to stop

15.35  N. Davies UK
       Evidence for anti-VEGF drugs: is PRP redundant?

15.40  A. Laidlaw UK
       Vitrectomy in proliferative diabetic retinopathy: vitreous haemorrhage and traction

15.50  Discussion

16.00  End of course
16.00 – 17.00

Opening Ceremony & EURETINA Lecture

Hall D3

Chairperson: S. Wolf SWITZERLAND (PRESIDENT, EURETINA)

16.00 President's Welcome
S. Wolf SWITZERLAND

16.10 EURETINA Lecture 2018

Tackling the Global Burden of Diabetic Retinopathy: From Epidemiology to Artificial Intelligence
T.Y. Wong SINGAPORE

Presentation of Certificate
A. Loewenstein ISRAEL (GENERAL SECRETARY, EURETINA)

16.40 EURETINA Video Competition Awards
F. Holz GERMANY (INCOMING PRESIDENT, EURETINA)

16.50 Closing Remarks
S. Wolf SWITZERLAND

17.00 End of Ceremony
Welcome Reception

Thursday 20 September
17.00
Foyer Lecture Hall D3

All Delegates Welcome
FRIDAY
21 September
**FRIDAY 21 SEPTEMBER**

**08.00 – 09.30**

**EURETINA MAIN SESSION 4**

**Novelties & Late Breaking Developments in Retina & Technology**

**Hall D3**

**Chairpersons:**
- P. Dugel USA
- J. García-Arumí SPAIN
- R. Tadayoni FRANCE

08.00  **J. García-Arumí SPAIN**
Recent advances in surgical techniques: New trends and expectations

08.12  **U. Schmidt-Erfurth AUSTRIA**
Assisted analysis, revolution of imaging: What’s next?

08.24  **P. Dugel USA**
Important drugs in the pipeline

08.36  **T.A. Ciulla USA**
Genetic therapy: Reinventing genes

08.48  **R. Tadayoni FRANCE**
Novel understanding of normal and abnormal retinal vascularization under the light of new imagery

**Late Breaking Presentations**

09.00  **S. Pasu UK**
Positioning in macular hole surgery (PIMS) trial

09.09  **S.F. Wolf SWITZERLAND**
Focal view apple research kit: Redefining clinical trials

09.18  **A. Barak ISRAEL**
Human trials of cell therapy for retinal disease

09.27  Discussion

09.30  End of session

**08.00 – 09.30**

**EURETINA UPDATE SESSION 3**

**Uveitis**

**Room C1**

**Chairperson:**  C. Pavésio UK

08.00  **P. Keane UK**
OCT: How can it help us?

08.10  **P. Neri ITALY**
OCT-A: What have we learnt?

08.20  **A. Denniston UK**
EQUATOR and vitreous haze

08.30  **C. Pavésio UK**
Local therapies: How good are they?

08.40  **M. de Smet SWITZERLAND**
Biologics: Where are we now?

08.50  **T. Barisani-Asenbauer AUSTRIA**
Paediatric uveitis: What is new?

09.00  Discussion

09.30  End of session
## FREE PAPER SESSION 5

### Vitreoretinal Surgery II

**Room C4**

**Chairpersons:**  
B. Stanzel **GERMANY**  
P. Tranos **GREECE**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Country</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>R. Hillier, T. Felfeli, V. Juncal, C. Lampert, Monte, Francisconi, M. Mak, R. Muni <strong>UK</strong></td>
<td>Metamorphopsia and OCT changes following retinal detachment repair: Pneumatic retinopexy versus vitrectomy ('PIVOT' 1 year data)</td>
<td></td>
</tr>
<tr>
<td>08.12</td>
<td>A. Oner, Z. Gonen, D. Sevim, N. Sinim, M. Cetin, Y. Ozkul <strong>TURKEY</strong></td>
<td>First year results of subretinal adipose tissue derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa</td>
<td></td>
</tr>
<tr>
<td>08.18</td>
<td>R. Frisina, E. Midena <strong>ITALY</strong></td>
<td>Double inverted flap surgical technique for treatment of idiopathic lamellar macular hole associated with atypical epiretinal membrane</td>
<td></td>
</tr>
<tr>
<td>08.24</td>
<td>M. Dogramaci, D. Steel <strong>UK</strong></td>
<td>Pneumatic intraocular forceps analysis of movement inaccuracies and sources of movement errors</td>
<td></td>
</tr>
<tr>
<td>08.30</td>
<td>S. Rizzo, T. Caporossi <strong>ITALY</strong></td>
<td>Minimal endo-illumination levels during three-dimensional heads-up vitreoretinal surgery for rhegmatogenous retinal detachment (RRD)</td>
<td></td>
</tr>
<tr>
<td>08.36</td>
<td>D. Vogt, R. Liegl, S. Stefanov, F. Hagenau, A. Wolf, S. Priglinger, R. Schumann <strong>GERMANY</strong></td>
<td>Macular surgery in myopic foveoschisis: Optical coherence tomography findings and histopathological correlation</td>
<td></td>
</tr>
<tr>
<td>08.42</td>
<td>F. Vilaplana, J. Nadal, J. Temprano, G. Julio, M. Olivera, R. Barraquer <strong>SPAIN</strong></td>
<td>Endophthalmitis in eyes with osteo-keratoprosthesis</td>
<td></td>
</tr>
<tr>
<td>08.48</td>
<td>Y. Khazardzhan, L. Boriskina, O. Sharifova, A. Balalin <strong>RUSSIA</strong></td>
<td>Analysis of the results of laser vitreolysis of peripapillary Weiss ring</td>
<td></td>
</tr>
<tr>
<td>08.54</td>
<td>K. Kumar, S. Balasubramaniam, A. Agarwal <strong>INDIA</strong></td>
<td>Risk factors for poor visual outcome following inverted ILM flap technique in large macular holes</td>
<td></td>
</tr>
<tr>
<td>09.00</td>
<td>A. Pollreisz, E. Pablik, T. Huebl, U. Schmidt-Erfurth, C. Scholda <strong>AUSTRIA</strong></td>
<td>Effect of changes in surgical strategies for the treatment of primary rhegmatogenous retinal detachment on functional and anatomical outcomes: a retrospective analysis of 816 cases from the years 2004 to 2012</td>
<td></td>
</tr>
<tr>
<td>09.06</td>
<td>N. Ucgun, C. Zeki Fikret <strong>TURKEY</strong></td>
<td>Effect of epiretinal and internal limiting membrane peeling on long-term visual outcomes for diabetic macular edema</td>
<td></td>
</tr>
<tr>
<td>09.12</td>
<td>A. Boixadera Espax, A. Calvo Alvarez, O. Subira Gonzalez, V. Martinez-Castillo <strong>SPAIN</strong></td>
<td>Primary giant retinal tear: functional and anatomical results</td>
<td></td>
</tr>
<tr>
<td>09.18</td>
<td>M. Menke, M. Dysli, A. Ebneter, M. Zinkernagel, S. Wolf, H. Grabe, M. Abeeg <strong>SWITZERLAND</strong></td>
<td>Patients with epiretinal membranes display retrograde maculopathy after surgical peeling the internal limiting membrane</td>
<td></td>
</tr>
<tr>
<td>09.30</td>
<td><strong>End of session</strong></td>
<td><strong>End of session</strong></td>
<td></td>
</tr>
</tbody>
</table>
FRIDAY 21 SEPTEMBER

08.00 – 09.30

FREE PAPER SESSION 6

AMD I

Room D1

Chairpersons:  T. Aslam UK
M. la Cour DENMARK

08.00  J. Leandro, J. Beato, A. Pedrosa, J. Pinheiro-Costa, M. Falcao, F. Falcao-Reis, Â. Carneiro PORTUGAL
Clinical characteristics of the Charles Bonnet syndrome in patients with neovascular age-related macular degeneration: The importance of early detection

08.06  S. Baillif, L. Kodjikian, E. Fourmaux, F. Coscas, C. Faure, S. Cohen, M. Weber FRANCE
A real-world study to monitor wet age-related macular degeneration patients treated with intravitreal aflibercept: 12-month outcomes of RAINBOW stratified by treatment regimen

08.12  J. Monés SPAIN
Complement C5 inhibition as a potential treatment for geographic atrophy secondary to dry age-related macular degeneration

08.18  S. Doguizi TURKEY
Imaging characteristics of pigment epithelial detachments associated with neovascular age related macular degeneration and their response to intravitreal aflibercept therapy

08.24  E. van Dijk, J. Brinks, E. de Jong, S. van der Maarel, P. Quax, O. Meijer, C. Boon THE NETHERLANDS
The effect of corticosteroids on human choroidal endothelial cells: a model to study central serous chorioretinopathy

08.30  A. Fujita, K. Kataoka, J. Takeuchi, Y. Nakano, Y. Ito, H. Terasaki JAPAN
Evaluation of polypoidal choroidal vasculopathy with B-scan flow images of swept source optical coherence tomography angiography

08.36  M. Figueroa, F. Holz, W. Macfadden, S. Parikh SPAIN
Treatment patterns of ranibizumab 0.5 mg over time in treatment-naïve patients with neovascular age-related macular degeneration: results from LUMINOUS™, a global real-world study

08.42  C. Tan, S. Parikh, T. Lim SINGAPORE
Evaluation of indocyanine green angiographic features in symptomatic macular polypoidal choroidal vasculopathy over 24 months: results from the EVEREST II study

08.48  G. Staurenghi, N. Holekamp, J. Mones, F. Tang, R. Cantrell, C. Brittain, J. Ehrlich, H. Lin, C.C. Wykoff ITALY
Natural history of geographic atrophy secondary to age-related macular degeneration: Proxima A data from the 1-year analysis of 100 patients

08.54  L. von der Emde, M. Pfau, S. Thiele, R. Hassenrik, M. Fleckenstein, F. Holz, S. Schmitz-Valckenberg GERMANY
Dark-adapted two color fundus-controlled perimetry and multimodal imaging to correlate structure and function in neovascular age-related macular degeneration

09.00  C. Awh, G. Bartaeselli, F. Tang, S. Erickson, N. Singh, S. Gune USA
LADDER trial of the port delivery system for ranibizumab: Preliminary study results

09.06  J. Hind, M. Edington, S. Ramamurthi, D. Gilmour, M. Gupta, M. Gavin UK
4 year “real world” outcomes of intravitreal Aflibercept for ARMD in Glasgow

09.12  N. Eter, C. Jochmann, G. Keramas, H. Sachs, H. Schilling, J. Wachtlin, P. Wiedemann, C. Framme GERMANY
PERSEUS 24-month analysis: A prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in patients with wet age-related macular degeneration

09.18  P. Prakash UK
3 years audit comparing the results of visual outcome, treatment frequency and number of visits using ranibizumab prn vs ranibizumab treat and extend vs aflibercept (as per license in UK) in patients with neovascular age-related macular degeneration

09.30  End of session
08.00 – 09.30

SYMPOSIUM
BRAZILIAN STUDY GROUP OF RETINAL INFECTIOUS DISEASES (BRASGRID)
Retinal Infectious Diseases in the Developing World: Clinical Spectrum, Treatment & Complications
Room D5

Chairpersons: R.N.G. Vianna BRAZIL
F.B.O. Porto BRAZIL

08.00  R.N.G. Vianna BRAZIL
Infectious white-dot syndromes

08.10  F.B.O. Porto BRAZIL
The enigma of retinal vasculitis

08.20  V. Bravo-Filho BRAZIL
Ocular findings in congenital Zika virus syndrome

08.30  L.H. Lima BRAZIL
Multimodal imaging in ocular syphilis

08.40  E. Cunha de Sousa BRAZIL
Diffuse unilateral subacute neuroretinitis: Multimodal imaging and treatment

08.50  M. Auxiliadora Monteiro Frazao BRAZIL
Ocular toxoplasmosis: Diagnosis and management of challenging cases

09.00  Discussion

09.30  End of symposium

08.00 – 09.30

SYMPOSIUM
EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH (EVER)
Recognition of Key Signs on OCT Influencing our Decisions in Daily Practice
Room C2

Chairpersons: C.J. Pournaras SWITZERLAND
C. Creuzot-Garcher FRANCE

08.00  A. Gaudric FRANCE
Morphology of the retinal vascular structure analysed by 3D RAP

08.15  F. Bandello ITALY
Diabetic retinopathy: OCT-A on the diagnosis, management and therapeutic decisions

08.30  F. Coscas FRANCE
OCT-A: RVO treatment and follow-up

08.45  C. Creuzot-Garcher FRANCE
AMD: OCT-A based diagnosis, management and treatment

09.00  C.J. Pournaras SWITZERLAND
OCT-A biomarkers for the macular churgical pathologies

09.15  L. Zografos SWITZERLAND
Anterior segment OCT-A evaluation

09.30  End of symposium
FRIDAY 21 SEPTEMBER

08.00 – 09.30

SYMPOSIUM

Novel Approaches to the Management of Macular Haemorrhage

Room: Strauss 3

Chairpersons: L.O. Hattenbach GERMANY
C.F. Arndt GERMANY

08.00  S. Bopp GERMANY
A novel approach to the classifications of macular haemorrhages - impact on clinical decision making

08.15  C.F. Arndt GERMANY
Agony of choice or clear thing?
Subretinal rt-PA vs. pneumatic displacement

08.30  A. Mirshali GERMANY
Anti-VEGF monotherapy in the management of macular haemorrhage

08.45  L.O. Hattenbach GERMANY
Minimally invasive and digitally assisted surgical treatment of macular haemorrhages

09.00  B. Paroloni ITALY
Autologous choroidal RPE patch transplantation in haemorrhagic age-related macular degeneration

09.15  Discussion

09.30  End of symposium

08.00 – 09.30

INSTRUCTIONAL COURSE 10

Scleral Buckling for Rhegmatogenous Retinal Detachment:
Mastering the Dying Art

Room C3

Course Organiser: B. Chanana INDIA

08.00  B. Chanana INDIA
Indications and basic principles of scleral buckling

08.10  L. Verma INDIA
Technique of conventional scleral buckling surgery

08.20  H. Heimann UK
Cryotherapy: Principles/procedure & advantages/disadvantages

08.30  M. Zinkernagel SWITZERLAND
Sub-retinal fluid drainage: Indications, dry tap and different techniques

08.40  D. Shroff INDIA
Complications of scleral buckling surgery

08.50  P. Ruamviboonsuk THAILAND
Long term outcome of scleral buckling without retinopexy

09.00  B. Chanana INDIA
Role of scleral buckling in the modern era and endoillumination-assisted scleral buckling

09.10  Discussion

09.30  End of course
FRIDAY 21 SEPTEMBER

08.00 – 09.30

INSTRUCTIONAL COURSE 11
Management of Diabetic Macular Edema: Current Definitions, Classification, Imaging, & Emerging Treatment Paradigms
Room D2

Course Organiser: N. Davies UK

08.00  M. Mohamed UK
Pathogenesis, biomarkers in serum and intraocular fluid

08.12  S. Mann UK
Screening, monitoring and management of early DME

08.24  N. Davies UK
Imaging DME - FFA, OCT-A, FAF and colour imaging

08.36  S. Mann UK
Management ladder: Laser, anti-VEGF therapy and steroids

08.48  M. Mohamed UK
Cataract surgery in DME

09.00  A. Laidlaw UK
Vitrectomy in DME

09.12  Discussion

09.30  End of course

08.00 – 09.30

INSTRUCTIONAL COURSE 12
Intraocular Tumours Series I: Differential Diagnosis of Ocular Melanoma
Room D4

Course Organisers: A. Schalenbourg SWITZERLAND
N. Bechrakis AUSTRIA

08.00  L. Desjardins FRANCE
Differential diagnosis of small pigmented choroidal tumors

08.12  I. Seibel GERMANY
Differential diagnosis of un-pigmented choroidal tumors

08.24  A. Schalenbourg SWITZERLAND
Differential diagnosis of intra-ocular vascular tumors

08.36  N. Bechrakis AUSTRIA
Tumours of the iridociliary complex. Diagnosis and management

08.48  N. Cassoux FRANCE
Differential diagnosis of lymphoproliferative tumors

09.00  H. Heimann UK
Biopsy techniques for ocular tumors

09.12  Discussion

09.30  End of course
FRIDAY 21 SEPTEMBER

10.15 – 11.45 INTERACTIVE

SPEAKERS’ CORNER 3

Vascular Diseases I

Taking place within the EURETINA Speakers’ Corner (Entrance Hall D), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

Moderator: D. Fischer GERMANY

10.15 H. Clarke, A. Sepetis, C. Rennie, A. Lotery, D. Sahu, D. Inzerillo, B. Gupta UK
Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. One year results in real world settings

10.20 J. Ramu, L. Nicholson, P. Hykin, S. Sivaprasad UK
Changes in retinal non-perfusion following aflibercept versus panretinal photocoagulation in treatment naive proliferative diabetic retinopathy – CLARITY sub study

Feasibility study for the introduction of automated retinal image analysis software into routine high volume diabetic retinopathy screening in the United Kingdom

10.30 M. Niestrata-Ortiz, P. Fichna, W. Stankiewicz, E. Papavasile, M. Stopa UK
Thickening of the choroid in children with type 1 diabetes mellitus and no diabetic retinopathy

Retinal nerve fibre layer thickness in diabetic patients

10.40 M. Teo, R. Muniraju, P. Ursell UK
Real world data of 20,066 cataract operations – Incidence of post-operative macular oedema in diabetic patients with or without diabetic retinopathy

10.45 V. Felcida, P. Lip UK
Fluocinolone acetonide intravitreal implant (Iluvien) as the treatment for chronic macular oedema (MO) in retinal vein occlusions (RVO): case-series of one year result

10.50 A. Maaelej, R. Ben-Sessi, A. Khallouli, Y. Oueslati, H. Gharasalla, R. Rannen TUNISIA
The effects of hyperbaric oxygen therapy on diabetic retinopathy

10.55 C. Wright UK
Nutrition matters in diabetic macular edema (DME) – or does it? A clinical analysis of the evidence supporting the use of food interventions in a combined approach to treating DME

Outcomes in different subtypes of diabetic macular edema treated with ozurdex: anatomical and functional results in cystoid macular edema

11.05 A. Dale, N. Walker, S. Aldington, S. Chave, P. Scanlon UK
Diabetic retinopathy and maculopathy levels in an English county

11.10 I. Damian, R. Manoiu, S. Nicoara ROMANIA
Intravitreal bevacizumab as an adjunct to vitrectomy for vitreous hemorrhage in patients with proliferative diabetic retinopathy

11.15 G. Spital, G. Lang, S. Liakopoulos, C. Junkes, C. Quiering, S. Schmitz-Valckenberg GERMANY
DIVERSE: Non-inferiority of ranibizumab administered at the discretion of the investigator to standard care (pro re nata administration) in diabetic macula edema: A 12-month, randomized, controlled, VA-assessor blinded, multicenter, phase IV trial

11.20 Y. Sugiura, F. Okamoto, T. Hiraoka, T. Oshika JAPAN
Relationship between metamorphopsia and inner retinal structure following intravitreal ranibizumab injection for branch retinal vein occlusion

11.25 C. Arruabarrena, C. Beckford, M. Teus SPAIN
OCT in diabetic telemedicine screening

11.30 V. Matsuikova, D. Vyslouzilova CZECH REPUBLIC
Limiting factors of improvement of visual acuity after half-fluence photodynamic therapy in patients with chronic central serous chorioretinopathy

11.35 C. Panadreu, A. Singh, M. Toma UK
What is the efficacy of oral sucrose and non-nutritive sucking on pain response in retinopathy of prematurity screening examinations

11.40 Discussion

11.45 End of session
KEYNOTE LECTURE
Kreissig Lecture
Hall D3
Chairperson: I. Kreissig GERMANY

Introduction
S. Wolf SWITZERLAND (PRESIDENT, EURETINA)

Keynote
A. Joussen GERMANY
Insights into Diabetic Retinopathy

Presentation of the Award
I. Kreissig GERMANY

THE EuroVeRsion CASE CONTEST
Room C1
The EuroVeRsion Case Contest is an international competitive Vitreo Retinal multimedia case presentation symposium. It combines the best elements of educational high quality case presentations by trainee Vitreo Retinal Surgeons with the vital competitive element.

Candidates are competing for two prestigious prizes:
• The EuroVeRsion Jury Prize, awarded on merit by independent judges.
• The EuroVeRsion Audience Prize which, like all referenda, depends entirely on how many of your side you can persuade to attend and vote.

A break from the usual formal EURETINA programme, this infotainment symposium will sort out the true leaders in European Retina. Don’t be on the losing team! European National Retinal Societies have been invited to submit a candidate, from whom the best ten entries have been selected to compete in this final.

Chairpersons: A. Laidlaw UK
F. Dhawahir-Scala UK
N. Patton UK

Judges: J. Folke Kiilgaard DENMARK
A. Grzybowski POLAND
H. Heimann GERMANY
K. Krepler AUSTRIA
Y. Le Mer FRANCE
C. Marques-Neves PORTUGAL
I. Relimpio SPAIN
M. Romano ITALY
S. Saidkasimova UK
P. Stavrakas GREECE
K. van Overdam THE NETHERLANDS
T.J. Wolfensberger SWITZERLAND
FRIDAY 21 SEPTEMBER

11.00 – 12.30

SYMPOSIUM
SPANISH VITREORETINAL SOCIETY
SYMPOSIUM (SERV)

Diagnostic & Therapeutic Utility of the New Imaging Technologies in Retino-Choroidal Pathology

Room C4

Chairpersons:  J.M. Ruiz-Moreno *Spain*
J. García-Arumí *Spain*

11.00  J. García-Arumí *Spain*
Intraoperative OCT: What is the added value today

11.15  J.M. Ruiz-Moreno *Spain*
Choroidal visualisation. Study of the choroid with OCT angiography

11.30  A. García-Layana *Spain*
OCT Angiography in diabetic macular edema

11.45  L. Arias *Spain*
Activity criteria of CNV in AMD: OCT-angiography vs. fluorescein angiography vs. OCT

12.00  Discussion
12.30  End of session

11.00 – 12.30

FREE PAPER SESSION 7
Imaging II
Room D1

Chairperson:  J-F. Korobelnik *France*

11.00  O. Balta *Turkey*
Retinal toxicity because of hydroxychloroquine

11.06  R. Nair, S. Manoj, S. Arun *India*
Prognostic Tomographic Features associated with poorer vision in eyes with Idiopathic Epi-retinal Membranes (ERMs)

11.12  J. Siedlecki, E. Vounotrypidis, D. Vogt, F. Hagenau, A. Wolf, S. Priglinger, R. Schumann *Germany*
Simultaneous MacTel type 1 and lamellar hole associated epiretinal proliferation detected by multimodal imaging

11.18  K. Gocho, D. Kubota, S. Kikuchi, H. Takahashi, S. Kameya *Japan*
High-resolution adaptive optics retinal imaging analysis of foveal hypoplasia with a novel PAX6 mutation

11.24  V. Puri, Z. Ali, T. Aslam, S. Mahmoud, Y. D'Souza *UK*
A novel OCTA algorithm to assess retinal ischaemia in diabetic eye disease

11.30  N. Ulianova, S. Burdeinik *Ukraine*
Morphometric features of choroid in patients with progressive myopia according to SS-OCTA

11.36  E. Pedanova, O. Klepinina *Russia*
Indocyanine green angiography and optical coherence tomography angiography in visualization of neovascularization associated with chronic central serous chorioretinopathy: what is better?

11.42  A. Sharma, Y. Reddy, U. Halder, S. Abdul Kader, A. Shetty *India*
Analysis of the foveal avascular zone in diabetic retinopathy evaluated with OCT-angiography

11.48  A. Bagchi, R. Schwartz, S. Sivaprasad, J. Nunez de Rio, P. Hykin *UK*
Different spectral domain optical coherence tomography phenotypes of capillary non-perfusion in patients with proliferative diabetic retinopathy

11.54  G. Kaya *Turkey*
Choroidal thickness measurements by optical coherence tomography in patients with obesity

12.00  M. Pastore, G. Cirigliano, R. Lorenzo Belfanti, R. Merli, A. Perrotta, R. D’Aloisio, D. Tognetto *Italy*
Swept-source optical coherence tomography biometry to detect foveal disease in patients scheduled for cataract surgery
Peripapillary neuro-vascular coupling in the early stages of diabetic retinopathy

12.12  M. Barraso Rodrigo, A. Ale-Chilet, O. Cristian, H. Teresa, G. Jesus, A. Adan, Z. Javier SPAIN
Comparison of perifoveal vascular network parameters obtained in 3x3 mm and 6x6 mm scans of optical coherence tomography angiography in type I diabetes mellitus patients

12.18  R. Singh, M. Dogra, R. Vijayvergia, S. Singh, P. Baigai INDIA
Optical Coherence Tomography Angiography (OCTA) and fundus fluorescein angiography (FFA) findings in asymptomatic patients of Takayasu Arteritis (TA)

12.30  End of session

11.00 – 12.30
FREE PAPER SESSION 8
AMD II
Room D5
Chairpersons: K. Balaskas UK
S. Schmitz-Valckenberg SWITZERLAND

11.00  I. Mantel, A. Schalenbourg, L. Zografos SWITZERLAND
The clinical and imaging spectrum of peripheral exudative hemorrhagic chorioretinopathy

11.06  M. Ohji, A. Okada, K. Takahashi, M. Kobayashi, Y. Terano JAPAN
Two different treat-and-extend dosing regimens of intravitreal aflibercept in Japanese patients with wet age-related macular degeneration: 96-week results of the ALTAIR study

Efficacy of intravitreal aflibercept administered using treat-and-extend regimen over 2 years in patients with neovascular age-related macular degeneration: baseline characteristics of ARIES

11.18  M. Dalalishvili, K. Takhchidi, G. Kachalina, T. Kasminina RUSSIA
Differential diagnostics of reticular pseudodruses based on modern research methods

Validation of the RetmarkerAMD software for the grading of AMD

11.30  D. Barthelmes, V. Nguyen, R. Essex, N. Morlet, M. Gillies, V. Dailen SWITZERLAND
Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration

Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with ranibizumab using a treat and extend regimen: 24 month results from the randomised, multi-centre, single masked FLUID study

11.42  A. Invernizzi, K. Teo, V. Nguyen, M. Daniell, D. Squirrell, D. Barthelmes, M. Gillies ITALY
Type 3 neovascularization (retinal angiomatous proliferation) treated with anti-vascular endothelial growth factor: real world outcomes at 24 months

11.48  R. Strauss, X. Kong, A. Ho, M. Michaelides, M. Ip, S. West, H. Scholl AUSTRIA
Progression of Stargardt disease as measured by spectral-domain optical coherence tomography (SD-OCT) in the ProgStar Study
11.54  A. Dirani, S. Javidi, F. Antaki, T. Cordahi, M. Saab, G. Cordahi  CANADA
Long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration: Up to nine-year follow up

12.00  I. Muftuoglu, W. Freeman  USA
Ganglion cell complex evaluation in dry age related macular degeneration

12.06  R. Perrott-Reynolds, T. Ly, S. Banerjee  UK
OCT Angiography: Real world experience in neovascular AMD new patient clinic using the topanon DRI OCT triton

12.12  M. Nelson  USA
Chronic central serous retinopathy (CSR) and type 1 occult neovascularization

12.18  L.H. Lima, T. Cabral, C. Regatieri, V. Mahajan, R. Belfort Jr  BRAZIL
Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers

12.30  End of session

11.00 – 12.30

AFIV SYMPOSIUM

OCT-A in Retina Disease
Room C2

Chairpersons:  A. Loewenstein  ISRAEL
              G. Querques  ITALY

11.00  V. Capuano  FRANCE
Quiescent CNV in retinal diseases

11.09  A. Ohayon  ITALY
Neovascular area and vessel density comparison between 2 swept-source optical coherence tomography angiography devices

11.18  G. Querques  ITALY
Nascent type 3 NV

11.27  S. Mrejen  FRANCE
Sensitivity of 840nm SD-OCTA in detecting type 1 NV according to the height of PED

11.36  H. Oubraham  FRANCE
Is OCT-A follow up different between PRN and T&E regimen in NV-AMD?

Guest Lecture
11.40  U. Chakravarthy  UK
5-year results of the IVAN trial

Innovations in Retinal Disease

Moderators:  A. Barak  ISRAEL
             F. Amoroso  FRANCE

11.55  A. Barak  ISRAEL
Phase I/II interim results of human embryonic stem cell derived RPE in advanced dry AMD

12.04  R. Amer  ISRAEL
Autoimmune retinopathy: presentation, association and outcomes

12.13  N. Mathalone  ISRAEL
The effect of silicone oil tamponade on subfoveal choroidal thickness

12.21  F. Amoroso  FRANCE
Peripheral navigated laser: moving into clinical practice

12.30  End of session
11.00 – 12.30

**SYMPOSIUM**

**Toxicity of Intraocular Surgery Tools: How to Recognize and Prevent Them**

Room: Strauss 3

Chairperson: **J.C. Pastor SPAIN**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00</td>
<td><strong>J.C. Pastor</strong> SPAIN</td>
<td></td>
</tr>
<tr>
<td>11.10</td>
<td><strong>K. Januschowsky</strong> GERMANY</td>
<td></td>
</tr>
<tr>
<td>11.20</td>
<td><strong>R. Coco</strong> SPAIN</td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td><strong>M. Romano</strong> ITALY</td>
<td></td>
</tr>
<tr>
<td>11.40</td>
<td><strong>M. Spitzer</strong> GERMANY</td>
<td></td>
</tr>
<tr>
<td>11.50</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td>End of session</td>
<td></td>
</tr>
</tbody>
</table>

11.00 – 12.30

**INSTRUCTIONAL COURSE 13**

**Anti-Angiogenesis in Modern Times**

Room C3

Course Organiser: **U. Schmidt-Erfurth AUSTRIA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00</td>
<td><strong>U. Schmidt-Erfurth</strong> AUSTRIA</td>
<td></td>
</tr>
<tr>
<td>11.15</td>
<td><strong>D. Martin</strong> USA</td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td><strong>N. Waheed</strong> USA</td>
<td></td>
</tr>
<tr>
<td>11.45</td>
<td><strong>A. Loewenstein</strong> ISRAEL</td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td><strong>P. Dugel</strong> USA</td>
<td></td>
</tr>
<tr>
<td>12.15</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td>End of course</td>
<td></td>
</tr>
</tbody>
</table>
FRIDAY 21 SEPTEMBER

11.00 – 12.30

INSTRUCTIONAL COURSE 14

Geographic Atrophy Secondary in AMD: Key Issues on Diagnosis, Classifications & Management

Room D2

Course Organisers:  F. Holz GERMANY  
                    S. Schmitz-Valckenberg GERMANY

11.00  S. Schmitz-Valckenberg GERMANY  
       Terminology and imaging

11.15  G. Staurenghi ITALY  
       CAM report: Towards a severity scale for dry AMD

11.30  F. Holz GERMANY  
       Natural history and biomarkers for geographic atrophy progression

11.45  A. Tufail UK  
       Current and future clinical management of geographic atrophy patients

12.00  C. Hoyng THE NETHERLANDS  
       Differential diagnosis of geographic atrophy: pearls and pitfalls

12.15  Discussion

12.30  End of course

11.00 – 12.30

INSTRUCTIONAL COURSE 15

Intraocular Tumours Series II: Ocular Tumours in Children

Room D4

Course Organisers:  F. Meunier BELGIUM  
                    P. Temming GERMANY

11.00  B. Müller GERMANY  
       Differential diagnosis of retinoblastoma

11.18  F. Meunier BELGIUM  
       Clinical advances in the local treatment of retinoblastoma

11.36  N. Bornfeld GERMANY  
       Uveal melanoma in children and young adults

11.54  P. Temming GERMANY  
       Enucleation for UM, treatment of EOW

12.12  Discussion

12.30  End of course
12.15 – 13.45  

INTERACTIVE

SPEAKERS’ CORNER 4

Mixed Session II

Taking place within the EURETINA Speakers’ Corner (Entrance Hall D), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

12.15  

V. Stavrev, N. Sivkova, D. Koleva-Georgieva  
BULGARIA

Quantitative assessment of foveal avascular zone in patients with early and intermediate nonexudative age-related macular degeneration using optical coherence tomography-angiography

12.20  

S. Wijetilleka, G. Williams, C. Yeo  
UK

Are poorer sighted people more polite?

12.25  

Y. Komuku, H. Fukuyama, H. Ivami, F. Gomi  
JAPAN

Efficacy of polyp-selective photodynamic therapy with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy

12.30  

M. Acebes Garcia, M. Crespo, M. Prieto  
SPAIN

Functional and anatomical outcomes of superior inverted internal limiting membrane (ILM) flap in macular hole (MH) surgery

12.35  

A. Sengul, I. Perente, O. Artunay, A. Kockar, R. Rasier, E. Yuzbasiog  
TURKEY

Intravitreal ranibizumab therapy for choroidal neovascularization secondary to pathological myopia: 3 year outcome

12.40  

M. Qureshi, A. Smith  
UK

Combined phacoemulsification and intravitreal dexamethasone implant (ozurdex) in retinal vein occlusion patients with cataract and macular oedema

12.45  

A.G. Kocak Altintas, C. Ilhan, M. Citirik  
TURKEY

Subhyaloid fluid resorption on optic disc pit during the treatment of choroidal neovascular membrane in contralateral eye

12.50  

J. Leandro, S. Penas, E. Brandao, S. Fernandes, F. Falcao-Rei, S. Estrela-Silva  
PORTUGAL

New ABCA 4 mutations in a Portuguese cohort of patients with Stargardt disease

12.55  

V. Sarao, D. Veritti, E. Borrelli, S. Sadda, M. Cozzi, G. Staurenghi, P. Lanzetta  
ITALY

Chromaticity analysis comparing a white light confocal imaging device versus a flash fundus camera

13.00  

L. Kuchlewein, L. Schoels, P. Llavona, A. Grimm, S. Biskup, E. Zrenner, S. Kohl  
GERMANY

Phenotypic spectrum of autosomal recessive retinitis pigmentosa without posterior column ataxia caused by mutations in the FLVCR1 gene

13.05  

M. Kitano, R. Obata, T. Inoue, T. Hara  
JAPAN

Retinal sensitivity of pigment epithelial detachment in patients with age-related macular degeneration

13.10  

A. Karapeyan, P. Ouyang, L. Tang, M. Gemilyan  
ARMENIA

Choroidal thickness in relation to ethnicity measured using enhanced depth imaging optical coherence tomography

13.15  

A. Walkden, L. Fu, N. Jones, L. Steeples  
UK

Optical coherence tomography angiography and ultra wide-field retinal imaging in severe oclusive systemic lupus erythematosus retinal vasculitis

13.20  

M. Eldeeb, A. Abadieh, D. Chow  
CANADA

Changes in foveal avascular zone area are associated with functional and structural outcomes in center-involving diabetic macular edema

13.25  

B. Dominguez Garcia, A. Gomez Escobar, M. Diaz Grana, F. Espejo Arjona, I. Relimpio Lopez  
SPAIN

Melanocytoma of optic disc in six cases

13.30  

J. Sambricio, B. de-Lucas-Viejo, M. Fernandez, A. de-Pablo-Cabrera  
SPAIN

Multimodal imaging of two different choroidal osteomas in the same eye

13.35  

C. Tomkinson  
UK

OCT-A Angiography: Imaging of choroidal and retinal tumours

13.40  

Discussion

13.45  

End of session
**FRIDAY 21 SEPTEMBER**

**14.00 – 15.00**

**SYMPOSIUM AMSTERDAM RETINA DEBATE**

Hall D3

Chairperson: S. Lesnik-Oberstein *The Netherlands*

Debate 1: Scleral Buckling is No Longer Relevant (Especially if Combined with Vitrectomy)

14.00 For: K. Drenser *USA*
Against: H. Heimann *UK*

Debate 2: Laser in Medical Retina Will Become Obsolete Due to Intravitreal Treatments

14.30 For: M. Engelbert *USA*
Against: D. Keegan *Ireland*

15.00 End of debate

**14.15 – 16.15**

**INSTRUCTIONAL COURSE 17**

Surgical Controversies in Vitrectomy for Retinal Detachment

Room C3

Course Organisers: P. Stanga *UK*
P. Stavrakas *Greece*

14.30 P. Stanga *UK*
Introduction

*Intra-Operative Visualisation Technologies*

14.35 R. Tadayoni *France*
Intra-operative OCT: Is it a ‘must-have’?

14.40 S. Gotzaridis *Greece*
Heads-up digitally assisted or through the microscope vitreoretinal surgery?

*New Developments In Surgical Techniques*

14.45 Y. Le Mer *France*
Management of macular complications after RD surgery

14.50 T. Williamson *UK*
Posturing modalities

14.55 T.J. Wolfensberger *Switzerland*
Management of residual subretinal fluid

15.00 P. Stanga *UK*
Hypersonic vitrectomy

15.05 J. Garcia-Arumi *Spain*
Retinal detachment complicated by PVR: pro 360 encirclement

15.10 G. Pertile *Italy*
Selection of intraocular gases

15.15 C. Mateo *Spain*
Selection and removal of silicone oils

15.20 P. Tranos *Greece*
Retinal detachment in uveitis and trauma

15.25 F. Patelli *Italy*
RD in high myopia

*Economics Of Retinal Detachment Surgery*

15.30 T. Boeker *Germany*
Cost analysis of vitrectomy vs buckling

*Surgical Management By The Experts: Interactive Discussion Of Cases*

Moderator: P. Stavrakas *Greece*

15.35 Discussion

16.00 End of course
14.30 – 16.00

SYMPOSIUM
MACULA SOCIETY
The Most Exciting Developments in Retina
Room C1

Chairpersons: P. Dugel USA
M. Zarbin USA

14.30 S. Wolf SWITZERLAND
Analysis of the intestinal microbiome in neovascular AMD

14.38 R. MacLaren UK
Gene therapy in chronic diseases: ready or not?

14.46 S. Sivaprasad UK
MacTel: New insights into physiology

14.54 P.J. Rosenfield USA
C3 inhibition for geographic atrophy in AMD

15.02 U. Schmidt-Erfurth AUSTRIA
Why the location of fluid matters in nvAMD

15.10 F. Bandello ITALY
Microangiopathy versus neuroretinal damage as the first pathogenic mechanism of diabetic retinopathy

15.18 A. Loewenstein ISRAEL
RVO Studies: Results of recent comparative studies

15.26 F. Holz GERMANY
Brolucizumab: The next generation anti-VEGFA

15.34 P. Dugel USA
The angiopoietin pathway: Impactful or impossible?

15.42 M. Zarbin USA
Real life outcomes versus clinical trials: A dangerous gap?

15.50 Discussion

16.00 End of session

14.30 – 16.00

SYMPOSIUM
EUROPEAN SCHOOL FOR ADVANCED STUDIES (ESASO)
Head-Up Surgery
Room C4

Chairpersons: M. Battaglia-Parodi ITALY
B. Corcóstegui SPAIN
B. Falcomata ITALY
G. Guarnaccia ITALY

14.30 M. Battaglia-Parodi ITALY
Introduction and welcome

14.42 A. Junemann GERMANY
The ILM in vitreoretinal surgery: The bad and the good

14.54 E. El-Rayes EGYPT
Managing vitreomacular surface with digital visualisation

15.06 S. Rizzo ITALY
High magnification in digital surgery

15.18 R. Rejdak POLAND
Combined cataract surgery and pars plana vitrectomy in complicated cases

15.30 Discussion

16.00 End of symposium
FRIDAY 21 SEPTEMBER

14.30 – 16.00
FREE PAPER SESSION 9
Vascular Diseases & Diabetic Retinopathy II

Room D1

Chairpersons: E. Stefánsson ICELAND
S-Y. Yu SOUTH KOREA

14.30 M. Lukic, P. Patel, R. Hamilton, R. Rajendram UK
Real-life anatomical and visual acuity outcomes in
treatment-naive patients treated with intravitreal aflibercept
for diabetic macular oedema; 18 months results

14.36 M. Saleh, B. Guyon FRANCE
EVAPOR: Evaluation of Argon versus Pascal® laser
efficacy on diabetic macular edema resorption

14.42 P. Schlottmann, L. Tuomi, L. Hill, M. Hemphill,
Z. Haskova ARGENTINA
Predictors of early diabetic retinopathy improvement in
patients with diabetic macular edema who received 3 or
more monthly ranibizumab injections

14.48 C. Bailey, U. Chakravarthy, A. Lotery, G. Menon,
J. Talks UK
A national audit of UK electronic medical records
(EMRs) to assess the safety and effectiveness of the
ILUVIEN (fluocinolone acetonide) 190 micrograms
intravitreal implant in patients with chronic diabetic
macular oedema (DMO)

14.54 D. Eichenbaum, J. Sahni, S. Sadikhoz,
M. Pauly-Evers, P. Szczesny, R. Weikert USA
Anti-VEGF/Anti–angiopoietin-2 bispecific antibody
RG7716 in diabetic macular edema: Key secondary and
exploratory outcomes in the phase 2 BOULEVARD
clinical trial

15.00 J. Cardigos, S. Crisostomo, M. Alves, J. Cunha-Vaz,
A. Papoila, L. Abegao Pinto,
J. Tavares Ferreira PORTUGAL
Choroid of diabetic patients without observed retinal
vascular changes: A longitudinal study

15.06 I. Marques, L. Mendes, A. Santos, D. Alves,
J. Cunha-Vaz, M. Durbin PORTUGAL
Characterization of the initial stages of diabetic retinal
disease using OCT and OCTA

15.12 H. Al Hasid, M. Lamba, R. Vider UAE
Prolonged oxygen support and retinopathy of prematurity
(ROP) recurrence post intravitreal anti vascular endothelial
growth factor (VEGF) injection in zone 1

15.18 U. Chakravarthy, S. Taylor, C. Bailey, F. Koch,
J. Castro Sousa UK
Does the duration of chronic diabetic oedema influence
the effectiveness and safety outcomes achieved
in patients treated with ILUVIEN (fluocinolone
acetonide)? Clinical insights from the ILUVIEN registry
safety study

15.24 T. Rodrigues, J. Marques, M. Soares, J. Teles,
A. Martins, S. Simao, R. Silva PORTUGAL
Parafoveal capillary density changes in the early
stages of diabetic retinopathy evaluated with OCT-
angiography

15.30 A. Santos, D. Alves, J. Wang, J. Miller, R. Silva,
J. Figueira, J. Cunha-Vaz PORTUGAL
Choroidal predictors for visual response to anti-VEGF
treatment in DME patients, using swept source OCT

15.36 R. Muni, M. Bamakrid, V. Juncal, M. Mak CANADA
Changes in aqueous cytokine levels following treatment
with aflibercept in treatment naïve patients with diabetic
macular edema

15.42 E. Durbant, C. Radoi, C. Arndt FRANCE
Intravitreal triamcinolone injections in non-arteritic
anterior ischemic optic neuropathy – 7 years follow-up

15.48 G. Adriono, A. Victor, T. Gondhowiardjo INDONESIA
Fenofibrate treatment in diabetic retinopathy with
dyslipidemia: Effects on central macular thickness
and macular volume, and serum endothelial nitric
synthase, vascular cell adhesion molecule 1, and vascular
endothelial growth factor levels

16.00 End of session
14.30 – 16.00

FREE PAPER SESSION 10

AMD III

Room D5

Chairperson:  D. Fischer  GERMANY

14.30  S. Razavi, P. Dugel, G. Lang, Y. Ogura, A. Weichselberger  FRANCE
Predictive analysis of the 12-week dosing status at week 48 for patients receiving brolucizumab in the HAWK and HARRIER studies

14.36  I. Westborg, M. Loevestam Adrian  SWEDEN
Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet AMD: Real-world data from the INSIGHT study in the Swedish macula register

14.42  M. Gillies, V. Daen, V. Nguyen, R. Essex, R. Guymer, D. Barthelmes  AUSTRALIA
Prevalence and characteristics of geographic atrophy in eyes with neovascular age-related macular degeneration treated with vascular endothelial growth factor inhibitors

Positive cellular effects induced by the nanosecond laser in the mouse and human posterior eye

Follow-up of type 3 neovascularization with B-scan flow optical coherence tomography angiography

15.00  R. Schwartz, A. Lamin, P. Hykin, S. Sivaprasad  UK
OCTA may be used as a clinical decision tool to determine treatment interval in treat and extend regimen in choroidal neovascularization secondary to age-related macular degeneration

15.06  D. Ahmed, M. Stattin, A. Graf, J. Forster, I. Krebs, S. Ansari-Shahrezai  AUSTRIA
Relationship between drusen characteristics and type 2 macular neovascularization in age-related macular degeneration

Lampalizumab for geographic atrophy secondary to age-related macular degeneration: Pooled results of the chroma and spectri phase 3 randomized clinical trials

15.18  B. Gerendas, M. Michl, A. Kaider, A. Sadeghipour, S. Waldstein, U. Schmidt-Erfurth  AUSTRIA
Imaging biomarkers predictive for visual acuity in neovascular age-related macular degeneration

Intravitreal aflibercept with and without rescue photodynamic therapy in polypoidal choroidal vasculopathy: 2-year results of the PLANET study

15.30  A. Burés Jelstrup, R. Navarro, E. Pomares, B. Corcóstegui  SPAIN
Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD). 104 weeks results. BIOIMAGE Study

15.36  R. Aydin, T. Tezel  USA
Increased intraaretinal radial reflectance (retinal flare) as an optical coherence tomographic coherence tomographic biomarker for the diagnosis of retinal angiomatosus proliferation

15.42  M. Schmid, L. Faes, L. Bachmann, M. Thiel  SWITZERLAND
Test-retest reliability and diagnostic accuracy of Alleye, a patient self-test for the detection of wet age-related macular degeneration

15.48  A. Rajendran, F. Astrid, N. Dorothea, S. Liam, C. Usha, V. Praveen, R. Ravindran  INDIA
Genetic risk factors influencing late age-related macular degeneration in India

16.00  End of session
14.30 – 16.00

SYMPOSIUM
INTERNATIONAL FAN CLUB (IFAN)
Room C2
Chairperson: M. van Schooneveld THE NETHERLANDS
Retinal imaging cases for discussion with a panel and audience
Panel:
P. Jaki SLOVENIA
A. Leys BELGIUM
G. Staurenghi ITALY
M. van Schooneveld THE NETHERLANDS

14.30 – 16.00

INSTRUCTIONAL COURSE 16
OCT: How to Understand What We See
Room: Strauss 3
Course Organiser: J-F. Korobelnik FRANCE

14.30 G. Staurenghi ITALY
Overview on OCT-A

14.42 J. Cunha-Vaz PORTUGAL
OCT-A in diabetic retinopathy

14.54 N. Eter GERMANY
OCT-A in AMD

15.06 M.B. Rougier FRANCE
OCT-A and optic disc

15.18 J-F. Korobelnik FRANCE
Qualification in OCT-A: What for?

15.30 Discussion

16.00 End of course
14.30 – 16.00

INSTRUCTIONAL COURSE 18
The Amsterdam Basic Medical Retina Course: Part I
Room D2

Course Organisers: C.J. Boon THE NETHERLANDS
R. Schlingemann THE NETHERLANDS

Course Topics
- Basics and practical application of OCT
- Basics and practical application of OCT-angiography
- Basics and practical application of fluorescein angiography
- Basics and practical application of indocyanin angiography and fundus autofluorescence
- Differential diagnosis and practical management of hereditary retinal dystrophies
- Differential diagnosis and practical management of acute and chronic central serous chorioretinopathy

16.00 End of course

---

14.30 – 16.00

INSTRUCTIONAL COURSE 19
Intraocular Tumours Series III: Treatment for Ocular Melanoma
Room D4

Course Organisers: S. Leyvraz GERMANY
S. Seregard SWEDEN

14.30 J. Folke Kiilgaard DENMARK
Brachytherapy

14.42 J. Heufelder GERMANY
Treatment of proton beam therapy and other percutaneous methods

14.54 A. Joussen GERMANY
How to avoid toxic tumour syndrome

15.06 S. Seregard SWEDEN
Enucleation for UM, treatment of EOW

15.18 T. Kivela FINLAND
What are the best screening measures and systemic follow-up?

15.30 S. Leyvraz GERMANY
Metastatic uveal melanoma

15.42 Discussion

16.00 End of course
FRIDAY 21 SEPTEMBER

15.00 – 16.00
KEYNOTE LECTURE
Gisbert Richard Lecture
Hall D3
Chairperson: S. Wolf SWITZERLAND

Welcome
F. Holz GERMANY (INCOMING PRESIDENT, EURETINA)

Keynote
D. Wong UK
Physics of Internal and External Tamponade

Presentation of the Award
G. Richard GERMANY

15.00 – 16.30
SPEAKERS’ CORNER 5
Vitreoretinal Surgery

Taking place within the EURETINA Speakers’ Corner (Entrance Hall D), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

15.00 A. Bennis, F. Chraibi, M. Abdellaoui, I. Benatiya MOROCCO
Visual outcome and prognostic factors after primary surgery of rhegmatogenous retinal detachment: Multivariate and univariate statistical analysis (about 347 eyes)

15.05 R. Rahman, A. Patil UK
The incidence of retinal breaks induced by posterior hyaloid face separation during 27-gauge pars plana vitrectomy

15.10 M. Miliienko, D. Zhmuryk, N. Pasechnik, V. Vit, N. Khramenko, N. Molchanik, S. Slobodyanik UKRAINE
The comparison of the influence of perfluorocarbon liquid, heavy silicone oil and silicone oil 5700 cs on the bioelectrical functional activity and the structure of a rabbit eye retina

Clinical characteristics and surgical outcome of pediatric and early adulthood retinal detachment

15.20 D. Guven, M. Demir, D. Ozcan, S. Tiryaki Demir, H. Kacar, S. Cevher, M. Arslantas TURKEY
Clinical and multimodal imaging findings and electrical stimulation perceptual thresholds of three retinitis pigmentosa patients implanted with Argus II retinal prosthesis

15.25 N. Unlu, M.A. Acar, D. Hazirolan, G. Uney, F. Ornek TURKEY
Triamcinolone acetonide particles resembling a foreign body under epiretinal membrane in a silicone oil filled eye

15.30 M. Bentivoglio, C. Valmaggia, C. Lang, H. Scholl, J. Guber SWITZERLAND
Analysis of surgical factors influencing outcome after retinal detachment surgery

15.35 A. Altun, S. Aki TURKEY
Effect of internal limiting membrane peeling during vitreoretinal surgery on visual outcomes and macula

15.40 P. Maitra, A. Venkatraman, A. Maitray INDIA
Rate of anatomical and functional recovery after double membrane peeling (DMP) for epiretinal membrane (ERM) and role of secondary intervention in non-improving patients
**FRIDAY 21 SEPTEMBER**

**16.30 – 18.00**

**EURETINA MAIN SESSION 5**

**AMD**

Hall D3

Chairpersons:  
S. Wolf Switzerland  
M. la Cour Denmark  
F. Bandello Italy

**16.30**  
F. Holz Germany  
Dry AMD – how to proceed?

**16.40**  
R. Guymer Australia  
Nanosecond laser results

**16.50**  
E. Fletcher Australia  
Nanosecond laser results pre-clinical

**17.00**  
M. la Cour Denmark / F. Bandello Italy  
Current management of exudative AMD

**17.10**  
P. Dugel USA  
New studies in exudative AMD

**17.20**  
M. Goldstein Israel  
Long-term effects of anti-VEGF

**17.30**  
B. Parodi Battaglia Italy  
Biomarkers of CNV

**17.40**  
M. Zinkernagel Switzerland  
Gut, genes and AMD

**17.50**  
Discussion

**18.00**  
End of session

---

**15.45**  
A. Karamitsos, I. Masri, D. Koutsimpogeorgos Greece  
Bilateral progression of full thickness macular hole in Alport syndrome

**15.50**  
R. Rahman, S. Kolluru UK  
To investigate the incidence of postoperative anterior chamber (AC) fibrin in eyes undergoing 27 gauge combined phakovitrectomy for rhegmatogenous retinal detachment (RRD) repair and proliferative diabetic retinopathy (PDR) with sub-tenon’s steroid

**15.55**  
23-gauge transconjunctival vitrectomy for posterior segment intraocular foreign bodies: Visual and anatomical outcomes and prognostic factors

**16.00**  
N. Berker, C. Can, P. Yilmazbas Turkey  
Vitrectoral surgery in an eye with severe corneal penetrating eye injury, suprachoroidal haemorrhage and retinal detachment

**16.05**  
G. Erdogan, I. Perente, E. Eris, O. Artunay Turkey  
Use of tissue adhesive in choroidal coloboma-associated retinal detachment

**16.10**  
U. Kanj, P. Nagarajan, S. Pagliarini UK  
Persistent post-operative macular oedema secondary to intraretinal silicone oil bubbles: An unusual cause

**16.15**  
H. Hamoudi, U. Corell Christensen, M. la Cour Denmark  
Epiretinal membrane surgery: an analysis of 2-step sequential or combined phacovitrectomy surgery on refraction and macular anatomy in a prospective trial

**16.20**  
Discussion

**16.30**  
End of session
FRIDAY 21 SEPTEMBER

16.30 – 18.00

FREE PAPER SESSION 11

New Drug Treatment & Technology I

Room C1

Chairpersons: C.C.W. Klaver THE NETHERLANDS
B. LeRoy BELGIUM

16.30  F. Patelli, L. Colombo, G. Savaresi, P. Ferri,
T. Nuzzo, L. Rossetti ITALY
Evaluation of a portable artificial vision device among
patients affected by retinitis pigmentosa implanted with
Argus II retina prosthesis

16.36  J. Zarranz-Ventura SPAIN
Assessing the effectiveness of fluocinolone acetonide
(0.2 micrograms/day FAc) and dexamethasone (DEX
700 micrograms) steroid implants in DME phase III
pivotal trials using the area-under-the-curve (AUC)
method: The constant analysis

16.42  J. Christoforidis, K. Briley, K. Binzel, L. Wei,
K. Kumar, K. La Perle, M. Knoppy USA
Systemic biodistribution and intravitreal pharmacokinetic
properties of bevacizumab, ranibizumab and aflibercept
in a non-human primate model

16.48  Y. Solberg, C. Dysli, S. Wolf,
M. Zinkernagel SWITZERLAND
Fluorescence lifetime imaging ophthalmoscopy:
Quantitative analysis in macular telangiectasia type 2

16.54  S. Mamtora, T. Sandinha, A. Ajith, A. Song,
D. Steel UK
Smart Phone Ophthalmoscopy- a potential replacement
for the direct ophthalmoscope

17.00  R. Shah INDIA
Use of biosimilar ranibuzumab (razumab) in
macular pathology

17.06  J. Olea Vallejo, M. Gomez-Resa,
M. Cervera-Peris SPAIN
Silicone oil microdroplets contamination source for
intravitreal injections

17.12  B. Schworm, T. Herold, A. Wolf, S. Priglinger,
N. Luft GERMANY
Subthreshold Laser Treatment in chronic central serous
chorioretinopathy: a prospective interventional study

17.18  M. Porcu, J. Hamouz, J. Dusova, T. Van Bergan,
P. Barbeaux, J. Feyen, M. Peeters BELGIUM
Anti-inflammatory effects of the PIGF neutralizing
antibody THR-317 in patients with diabetic macular edema

17.24  B. LeRoy, J. Bennett, S. Russell, D. Chung,
K. High, Z. Yu, A. Maguire BELGIUM
Year 3 results and age-stratified analyses for a phase 3 trial of voretigene neparvovec in RPE65 mutation–
associated inherited retinal disease

17.30  M. Fischer, G. Ochakovski, T. Peters, I. Seitz,
R. MacLaren, K. Bartz-Schmidt, B. Wilhelm GERMANY
Improved retinal sensitivity in a Phase 2 choroideremia
gene therapy trial

17.36  M. Patricio, C. Martinez-Fernandez Dela Camara,
C. Cox, C. Blue, A. Barnard, R. MacLaren UK
Biocompatibility and stability of a viral vector used in
retinal gene therapy

17.42  Y. Le Mer, M. Muqit, D. Palanker, J. Sahel FRANCE
Sub-retinal implantations of PRIMA wireless
photovoltaic chip, a new surgical technique for atrophic
dry age-related macular degeneration: Technical
feasibility and early results

17.48  A. Sharma, B. Kuppermann, F. Bandello, P. Lanzetta,
A. Loewenstein, S. Wook Park, V. Saravanath INDIA
Intraocular pressure (IOP) after intravitreal
dexamethasone implant (ozurdex) In different geographic
populations in real-world- GEODEX-IOP study

18.00 End of session
FRIDAY 21 SEPTEMBER

16.30 – 18.00

FREE PAPER SESSION 12

Imaging III

Room C4

Chairperson: A. Laidlaw UK

16.30 R. D’Aloisio, R. Giglio, M. Di Nicola, C. De Giacinto, D. Tognetto, T. Peto ITALY
Detecting diabetic maculopathy in patients with type 2 diabetes mellitus: accuracy of retinal imaging modalities

Integrity of outer retinal layers as a predictor of visual acuity in retinitis pigmentosa

Relationship between neovascular density in swept source OCT angiography and clinical activity in treated age-related macular degeneration

16.48 S. Zweifel, J. Baur, M. Al-Sheikh, A. Nowak SWITZERLAND
Swept source optical coherence tomography findings in patients with Fabry disease

16.54 N. Mehrotra, M. Nagpal, R. Juneja INDIA
Correlation of panorama optical coherence tomography angiography characteristics of active and healing serpigenous like choroiditis with indocyanine green angiography

17.00 A. Mansour, M. Stewart, S. Yassine, C. Mehanna, R. Hamam, L. Lima, A. Shinojima LEBANON
Foveal avascular zone in nanophthalmos: The collaborative nanophthalmos OCTA study

17.06 C. Dysli, M. Dysli, S. Wolf, M. Zinkernagel SWITZERLAND
Influence of age and lens status in fluorescence lifetime imaging ophthalmoscopy (FLIO)

17.12 D. Alex, I. V, M. Gopalakrishnan, G. Anantharaman INDIA
Lateral elongation of flat irregular pigment epithelial detachment: A novel OCT biomarker in pachychoroidal disease spectrum

17.18 L. Pierro, A. Arrigo, L. Iuliano, L. Capone, F. Bandello ITALY
OCT and OCT-A analysis in hyperreflective foveal spikes (HFS): a new sign of vitreomacular interface disease

Vascular remodelling of myopic choroidal neovascularization treated with ranibizumab

17.30 M. Saleh, C. Mouroux FRANCE
Evolution of choroidal neovascularization secondary to chronic central serous chorioretinopathy assessed by OCT-A

17.36 A. Pajtler Rosar, M. Cozzi, E. Borelli, V. Sarao, P. Lanzetta, S. Sadda, G. Staurenghi ITALY
Choroidal thickness influences green emission autofluorescence component intensity in eyes with geographic atrophy due to age-related macular degeneration: A color fundus autofluorescence study

17.42 J. Dabad Moreno, J. Toledo Negrete, M. Asencio Duran, J. Garcia Martinez, L. Morales SPAIN
OCT Angiography: Imaging and risk factors in melanocytic tumors

17.48 Discussion

18.00 End of session
## 16.30 – 18.00

### FREE PAPER SESSION 13

#### Mixed Session I

**Room D1**

**Chairperson:** T. Theelen THE NETHERLANDS

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Real-world results of aflibercept versus ranibizumab for the</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>treatment of exudative AMD using a fixed regimen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.36</td>
<td>R. Fayzrakhmanov, M. Bikbov</td>
<td>Russia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Local changes in cytokines with various neovascularization types</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.42</td>
<td>T. Burke, R. Rajendram</td>
<td>UK</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Longitudinal follow-up of dome-shaped macula (DSM)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.48</td>
<td>M. Diab, M. El Shehari, M. Omar</td>
<td>Saudi Arabia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Outcomes of additional posterior to ridge diode laser versus</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>conventional laser anterior to ridge in severe stage 3 retinopathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>— a randomized control trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.54</td>
<td>A. Almarzooqi, S. Vounotrypidis, T. Kreutzer, R. Schumann, S.</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Priglinger, A. Wolf</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment of chronic cystoid macular edema in aphakic or</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>severely affected traumatic eyes with scleral-fixated fluocinolone</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>acetamide implants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00</td>
<td>H. Deniz Demir, S. Alim, A. Yilmaz, S. Demir</td>
<td>Turkey</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The effect of chronic obstructive pulmonary disease on choroidal</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>thickness measured by optical coherence tomography</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.06</td>
<td>M. Mazzola, C. Metrangolo, S. Donati, E. Premi, L. Premoli, C.</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Azzolini</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>High-resolution multimodal retinal imaging of type 2 acute macular</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>neuroretinopathy lesions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.12</td>
<td>A. Dvalishvili, H. Aslankara, A. Kocakaya, C. Yildirim</td>
<td>Georgia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Results of a randomised controlled trial comparing combined</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>intravitreal dexamethasone implant (ozurdex) versus</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>intravitreal lucentis (ranibizumab) in patients with</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>diabetic macular edema at the time of cataract surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.18</td>
<td>J. Ruiz-Medrano, L. Zografos, A. Schalenbourg</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study of choroidal metastases using ultra-widefield angiography:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contributions to diagnosis and therapeutic approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.24</td>
<td>P. Dhir, M. Burman, K. Bhattacharjee, D. Das, H. Deka, R. Soibum, D.</td>
<td>India</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mishra</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Retinoblastoma: Killer with a countdown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30</td>
<td>N. Fung, A. Mak, W. Lam</td>
<td>Hong Kong</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Using optical coherence tomography and autofluorescence to monitor</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>treatment response of intravitreal methotrexate for primary</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>vitreoretinal lymphoma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
16.30 – 18.00

SYMPOSIUM
PATIENT WELL-BEING GROUP
Patient Well-Being in Age Related Macular Degeneration
Room D5

Chairperson:  T. Aslam  UK

16.30  D. Crabb  UK
How does macular degeneration affect quality of life?

16.40  Z. Ali  UK
Patient perceptions on use of technology

16.50  T. Aslam  UK
Depression and anxiety in patients with wet AMD

17.00  A. Denniston  UK
Beyond acuity: How to measure what really matters to patients?

17.10  H. Senra  UK
Patient responses to chronic disease and how to support them

17.20  E. Pilotto  Italy
Fixation and reading

17.30  Discussion

18.00  End of symposium

16.30 – 18.30

INSTRUCTIONAL COURSE 20
Concepts in Vitreoretinal Surgery
Room C2

Course Organisers:  A. Grosso  Italy
E. Sigler  USA

Part I Concepts in Vitreoretinal Surgery

16.30  A. Grosso/P. Ceruti  Italy
Rethinking our paradigm in postoperative visits: From microbiology to bedside

16.40  P. Roberta  Italy
Antimicrobial stewardship

16.50  G. Scarpa  Italy
Office-based, minimally invasive approach to extensive macula haemorrhage

17.00  M. Romano  Italy
Intraoperative dyes and retinal toxicity

17.10  M. Engelbert  USA
Current role for scleral buckles

17.20  G. Querques  Italy
Optical coherence tomography angiography in pseudophakic cystoid macular oedema compared to diabetic macular oedema: Qualitative and quantitative evaluation of retinal vasculature

Part II Vitreous Microsurgery

17.30  E. Sigler  USA
Forceps membrane peeling in vitreoretinal surgery

17.40  T. Rossi  The Netherlands
Sutureless scleral fixation lens

17.50  J. Randolph  USA
Cutter delamination of epiretinal membrane in neovascular retinal detachment

18.00  J. Calzada  USA
Scissors delamination of epiretinal membrane in neovascular retinal detachment

18.10  Discussion

18.30  End of course
FRIDAY 21 SEPTEMBER

16.30 – 18.00
INSTRUCTIONAL COURSE 21
Proliferative Vitreoretinopathy, Surgical Management & Improved Techniques
Room: Strauss 3
Course Organiser: J. García-Arumí SPAIN

16.30  B. Corcóstegui SPAIN
Risk factors in proliferative vitreoretinopathy

16.42  E. El-Rayes EGYPT
Vitreomacular interface epiretinal membranes management

16.54  T.J. Wolfensberger SWITZERLAND
Retinomy-retinectomy in PVR: When and how

17.06  J. García-Arumí SPAIN
Membrane peeling: Staining and PCFL: Viscodissection in closed funnel

17.18  S. Rizzo ITALY
Endotamponades in PVR

17.30  Discussion

18.00  End of course

16.30 – 18.30
INSTRUCTIONAL COURSE 22
Management of Retinopathy of Prematurity
Room C3
Course Organiser: G. Caputo FRANCE

16.30  M.E. Hartnett USA
Physiopathology of ROP

16.40  D. Moshfeghi USA
ROP screening: who and how?

16.50  A. Kychenthal CHILE
Laser treatment and adjunctive general therapies

17.00  K. Drenser USA
The place of anti-VEGF therapy in ROP

17.10  M. Blair USA
Long term follow-up on ROP treated patients

17.20  Discussion

18.00  End of course
16.30 – 18.00

INSTRUCTIONAL COURSE 23

The Amsterdam Basic Medical Retina Course: Part II

Room D2

Course Organisers: C.J. Boon THE NETHERLANDS
R. Schlingemann THE NETHERLANDS

Course Topics
- Practical management of diabetic retinopathy and diabetic macular edema
- Differential diagnosis and practical management of retinal vein occlusion
- Management of the patient with dry age-related macular degeneration
- Differential diagnosis and practical management of exudative age-related macular degeneration
- Practical management of choroidal neovascularization and atrophy in myopic macular degeneration
- Diagnosis and practical management of macular teleangiectasia type I and II and ocular complications of pseudoxanthoma elasticum

18.00 End of course

16.30 – 18.00

INSTRUCTIONAL COURSE 24

Intraocular Tumours Series IV: Advances in Genetics in Ocular Oncology

Room D4

Course Organisers: N. Bornfeld GERMANY
V. Cohen UK

16.30 V. Cohen UK
Differential diagnosis of retinoblastoma

16.48 F. Meunier BELGIUM
Clinical advances in the local treatment of retinoblastoma

17.06 N. Bornfeld GERMANY
Uveal melanoma in children and young adults

17.24 P. Temming GERMANY
Enucleation for UM, treatment of EOW

17.42 Discussion

18.00 End of course
YOURS provides a platform to ensure that issues and focus points of Young Retina Specialist are heard. Sign up for free Membership (under 40s) at the EURETINA Resource Centre (Booth C300, Exhibition Hall C) or online.

**Don’t miss the Young Retina Specialists Day**

**Saturday 22nd September 2018**
10.00 – 16.15
Room C2

**Programme Outline**

**YOURS Symposium**
Organiser: Y. Subhi  **DENMARK**

**YOURS Science Slam**
Organisers: C.J. Boon  **THE NETHERLANDS**, C. Dysli  **SWITZERLAND**, M. Fleckenstein  **GERMANY**

**YOURS Mystery Cases**
Organisers: M.S. Singh  **USA**, R. Mastropasqua  **ITALY**

**Ophthalmologica Lecture 2018**
Keynote Presentation

For more information go to [www.euretina.org/yours](http://www.euretina.org/yours)
SATURDAY

22 September
SATURDAY 22 SEPTEMBER

08.00 – 09.30

**EURETINA MAIN SESSION 6**

**Proliferative Diabetic Retinopathy in 2018: Pragmatic Application of Evidence Based Medicine**

Hall D3

**Chairpersons:**
- A. Laidlaw **UK**
- E. Midena **ITALY**
- M. Goldstein **ISRAEL**

08.00  **M. Larsen** **DENMARK**
Pathophysiology, classification, threshold for laser

08.10  **E. Pilotto** **ITALY**
Retinal photocoagulation: Pros and cons

08.20  Anti VEGF and proliferative diabetic retinopathy trial data:
   i. Clarity: S. Sivaprasad **UK**
   ii. Protocol S: J. Wells **USA**

08.30  **R. Schlingemann** **THE NETHERLANDS**
How might Protocol S and Clarity results be generalised in current practice?

08.40  **N. Bressler** **USA**
Cost effectiveness of anti-VEGF therapy for PDR

08.50  **D. Steel** **UK**
Vitrectomy in PDR 2018

09.00  Chaired panel discussion – pragmatic evidence based management of PDR in 2018

**Specific scenarios:**
- Severe NPDR, treat don’t treat?
- Low risk NVD/E, treat don’t treat: what with?
- HRC: no macular edema
- HRC: with macular edema
- Persistent NV after standard PRP
- Mild vitreous haemorrhage after full PRP
- Florid PDR no previous treatment

09.30  End of session

08.00 – 09.30

**EURETINA UPDATE SESSION 4**

**Epidemiology of Retinal Diseases**

Room C1

**Chairpersons:**
- R. Finger **GERMANY**
- C.C.W. Klaver **THE NETHERLANDS**

08.00  **G. Buitendijk** **THE NETHERLANDS**
Age-related macular degeneration

08.10  **T. Peto** **UK**
Diabetic retinopathy

08.20  **C. Hammond** **UK**
Myopic retinopathy

08.30  **J. Li** **GERMANY**
Retinal vascular disorders

08.40  **T. Jackson** **UK**
Retinal detachment

08.50  **C. Sanchez** **THE NETHERLANDS**
Automated grading of retinal diseases

09.00  Discussion

09.30  End of session
08.00 – 09.30
FREE PAPER SESSION 14
Vitreoretinal Surgery III
Room C4

Chairpersons:  P. Lanzetta *ITALY*
               S. Rizzo *ITALY*

08.00  O. Toygar, M. Mestanoglu, C. Riemann *TURKEY*
       Intraoperative ocular manometry in silicone oil filled eyes with a Boston type 1 keratoprosthesis

08.06  T. Ho, S. Wang *TAIWAN*
       Foveolar internal limiting membrane preserving and epiretinal proliferative tissue repositioning surgery of lamellar hole epiretinal proliferation associated with epiretinal membrane

08.12  C. Skevas, M. Spitzer, M. Casagrande *GERMANY*
       Retinal detachment after endophthalmitis

08.18  D.K. Misra, R. Soibam, P. Dhir, A. Upadhayay, H. Bhattacharjee *INDIA*
       Comparison of temporal inverted internal limiting membrane flap technique with classic inverted internal limiting membrane flap technique in large (more than 700 microns) macular holes

08.24  S. Donati, M. Todarello, G. Martire, M. Mazzola, C. Azzolini *ITALY*
       Multimodal evaluation of visual function after ab interno surgery for rhegmatogenous retinal detachment

       Retinal toxicity related to the use of a mixture of perfluorooctane and perfluorohexyloctane: Failure of another indirect cytotoxicity analysis

08.36  M. Dunaieva, S. Ustymenko, L. Bereznyuk, S. Fokina, M. Gavura *UKRAINE*
       Intravitreal triamcinolone injection in the treatment of persistent and recurrent macular hole

08.42  S. Chiu, R. Sheard, S. Habal, K. Spiteri-Cornish, Y. Ramkissoon, S. Winder, A. Chawla *UK*
       Visual outcomes in submacular haemorrhage treated with vitrectomy and subretinal tissue plasminogen activator (tPA)

08.48  E. Foo, K. Spiteri-Cornish *UK*
       Early surgical intervention in non-diabetic vitreous haemorrhage: Case series

08.54  S. Kaynak, R. Aydin *TURKEY*
       Optimal location for encircling scleral buckle placement: Is it still 12 millimeters away from the limbus?

09.00  C. Yildirim, H. Aslankara, A. Kocakaya, A. Dvalishvili *TURKEY*
       Visual and clinical outcomes of 23G trans-conjunctival pars plana vitrectomy for macular hole, a comparison of phaco-vitrectomy with only vitrectomy

09.06  K. Faridpooya, S. van Romunde, M. Cereda, Y. Douven, M. de Smet, J. van Meurs *THE NETHERLANDS*
       Clinical evaluation of a robot-assisted intraocular OCT-distance sensor for vitreoretinal surgery

09.12  J. Klaas, J. Klaas, P. Rechlä, N. Feucht, C. Lohmann, M. Maier *GERMANY*
       Prognostic value of SD-OCT in patients with macular involving rhegmatogenous retinal detachment - a modified classification of the macular status

09.18  L. Abeywickrama, E. Papavasileiou, S. Velissaris, C. Garnavou-Xirou, O. Theodorou, M. Niestrata-Ortiz, T. Jackson *UK*
       Characteristics, socioeconomic status and ethnic variations of primary idiopathid macular hole repair in vitreoretinal centers in the United Kingdom

09.30  End of session
SATURDAY 22 SEPTEMBER

08.00 – 09.30

FREE PAPER SESSION 15

Vascular Diseases & Diabetic Retinopathy III

Room C2

Chairpersons: J. Keunen THE NETHERLANDS
J. Luttrull USA

08.00  G. Mathur INDIA
Comparative rural/urban diabetic retinopathy prevalence study using low cost fundus camera

08.06  X. Li CHINA
Chinese guideline of DME: Background, evidence and limitation

08.12  G. Lang, A. Stahl, G. Spital, K. Lorenz, J. Voegeler, C. Quiering, S. Liakopoulos GERMANY
Evaluation of ranibizumab and panretinal laser photocoagulation (PRP) in proliferative diabetic retinopathy (PDR) – 24-months observational follow-up of the PRIDE study

08.18  C. Busch, M. Iglicki, D. Zur, S. Fraser-Bell, I. Lains, A. Loewenstein, M. Rehak GERMANY
Stay or switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema

08.24  L. Malheiro, C. Abreu, V. Lages, J. Coelho, M. Furtado, M. Lume PORTUGAL
The influence of the vitreomacular interface on the response to anti-VEGF treatment in branch retinal venous occlusions

08.30  J-F. Korobelnik, L. Kodjikian, V. Dainen, C. Faure, R. Tadayoni, A. Giocanti-Auregan, P. Massin FRANCE
A real-world study to monitor patients with diabetic macular edema treated with intravitreal aflibercept: Interim analysis of APOLLON

08.36  D. Buryakov RUSSIA
The combined laser treatment technology as an alternative to conventional laser treatment of diabetic macular edema

08.42  S. Crisostomo, J. Cardigos, M. Alves, J. Cunha-Vaz, A. Papoila, L. Abecao Pinto, J. Ferreira PORTUGAL
Retina of diabetic patients without observed retinal vascular changes: A longitudinal study

08.48  K. Tsuboi, M. Kamei JAPAN
Retinal vasculature and structural changes by projection-resolved optical coherence tomography angiography in branch retinal vein occlusion

08.54  N. Artha Dewi, D. Hapsari, R. Safaruddin, H. Sujuti INDONESIA
The role of angiopoietin-2 inhibitor on retinal pericycle loss reduction

09.00  S. Stewart, J. Yeong, G. Virgili, A. Azuara-Blanco, N. Lois UK
Pragmatism of randomized clinical trials on ranibizumab for the treatment of diabetic macular edema: Impact on clinical outcomes

09.06  R. Dai, A. Bian, X. Zhang CHINA
PlGF and VEGF changes after intravitreous injections of conbercept in PDR patients

09.12  A. Arrigo, F. Romano, S. Mercuri, R. Lattanzio, F. Bandello, M. Battaglia Parodi ITALY
Intravitreal ranibizumab for branch retinal vein occlusion complicated with macular edema in patients younger than 50 years

09.18  M.A. Jimenez Santos, M. Escobar, R. Torres Imaz, J. Donate Lopez SPAIN
Predictive factors of better outcomes by monotherapy with an intravitreal dexamethasone implant (ozurdex®) for branch retinal vein occlusion in clinical practice

09.30  End of session
08.00 – 09.30

SYMPOSIUM
EUROPEAN ACADEMY
OF OPHTHALMOLOGY (EAO)

New Technologies for Diabetic Retinopathy
Room C3

Chairperson:  A. Grzybowski  POLAND

08.00  A. Grzybowski  POLAND
Screening (and telescreening)

08.10  J. Cunha-Vaz  PORTUGAL
OCT

08.20  F. Bandello  ITALY
UWF Imaging

08.30  E. Midena  ITALY
New laser modalities

08.40  A. Loewenstein  ISRAEL
New molecules for intra-vitreous therapies

08.50  Discussion

09.30  End of symposium

08.00 – 09.30

SYMPOSIUM
EGYPTIAN VITREORETINAL SOCIETY (EGVRS)

Surgical Removal of Retained Intraocular Foreign Bodies: Challenges & Techniques
Room D1

Chairpersons:  M. Nabih  EGYPT
               M. Soliman  EGYPT

08.00  M. Soliman  EGYPT
An overview in the management of IOFBs

08.15  W. Soliman  EGYPT
Iris shelf and AC exit technique for IOFBs removal

08.30  M. Nabih  EGYPT
Hybrid vitrectomy for IOFBs

08.45  M. Farouk  EGYPT
IOFBs removal by shake-hands technique

09.00  M. Tarek  EGYPT
Cowboy loop for IOFB removal

09.15  M. Soliman  EGYPT
Siderosis bulbi: Any hope for visual recovery

09.30  End of symposium
SATURDAY 22 SEPTEMBER

08.00 – 09.30

INSTRUCTIONAL COURSE 25
Fluorescein ICG & OCT-A in Macular Diseases
Room D5

Course Organiser:  D. Pauleikhoff  GERMANY

08.00   D. Pauleikhoff  GERMANY
Multimodal imaging in macular diseases: An introduction

08.12   S. Wolf  SWITZERLAND
Role of angiographic imaging tools (FA, ICG and OCT-A) in macular diagnostic

08.24   G. Staurenghi  ITALY
The role of FA and ICGA in differential diagnosis in the angio-OCT era

08.36   A. Tufail  UK
OCT-A and SD-OCT during anti-VEGF therapy in exudative AMD

08.48   F. Sallo  UK
Multimodal imaging in macular diagnostics: MacTel type 2

09.00   Discussion

09.30   End of course

08.00 – 09.30

INSTRUCTIONAL COURSE 26
Macular Surgery: Decision Making in Daily Practice
Room D2

Course Organisers:  F. Bottoni  ITALY
                   R. Schumann  GERMANY

08.00   S. Priglinger  GERMANY
Vitreomacular traction: When to proceed directly to surgery

08.12   H. Hoerauf  GERMANY
Epiretinal gliosis: When is surgery indicated

08.24   R. Schumann  GERMANY
Diabetic macular edema: Vitrectomy in the era of anti-VEGF and steroids

08.36   R. Tadayoni  FRANCE
Macular holes: Various types require different strategies

08.48   F. Bottoni  ITALY
Myopic maculopathy: How to manage complicated cases

09.00   M. Figueroa  SPAIN
Optic pit: When to wait and when to act

09.12   J. van Meurs  THE NETHERLANDS
Subretinal haemorrhage: Which interventional procedure fits best

09.24   Discussion

09.30   End of course
08.00 – 09.30

INSTRUCTIONAL COURSE 27
Challenging & Complicated Vitreoretinal Surgeries

Room D4

Course Organiser:  N. Sundaram INDIA

08.00  N. Sundaram INDIA
Expulsive choroidal haemorrhage

08.18  TBC
Endophthalmitis

08.36  D. Pelayes ARGENTINA
Tractional retinal detachment

08.54  D. Ruiz SPAIN
Proliferative vitreoretinopathy

09.12  Discussion

09.30  End of course
SATURDAY 22 SEPTEMBER

09.30 – 11.00  INTERACTIVE

SPEAKERS’ CORNER 6

Vascular Diseases II

Taking place within the EURETINA Speakers’ Corner (Entrance Hall D), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

Moderator: R. Finger  GERMANY

09.30  W. Sing Lim, M. Rashad, L. Sivaselvam, S. Mann  UK
One year outcome following aflibercept intravitreal injections for diabetic macular oedema in a busy teaching hospital environment

09.35  M. Kotoula, V. Nikolaos, P. Elena, V. Vasiliki, T. Alexandra, T. Evagelia  GREECE
Introducing the term QALY on the therapy of diabetic macula edema with anti-VEGF using as a database the patients of a tertiary hospital of central Greece

09.40  E. Zolotareva, S. Karst, C. Scholda, U. Schmidt-Erfurth  AUSTRIA
Trends in treatment of diabetic retinopathy in the period from 2006 to 2014

09.45  A. Bhatnagar  UK
Real-world outcomes following 36-months of treatment with 0.2µg/day fluocinolone acetonide implant

09.50  S. Attia, A. Mahmoud, S. Zina, T. Dridi, B. Jelliti, U. Schmidt-Erfurth  TUNISIA
Multimodal imaging in paracentral acute middle maculopathy

09.55  L. Tök, L. Seyrek, O. Tok  TURKEY
Efficiency of low dose intravitreal ranibizumab treatment in aggressive posterior premature retinopathy

10.00  A. Fursova, M. Tarasov, N. Chubar, M. Vasilyeva, E. Sokolova, M. Filipenko  RUSSIA
Association between variants in VEGF and VEGFR2 genes and response to anti-VEGF treatment in diabetic macular edema

10.05  G. Saban, S. Gonul, A. Huseynov, S. Gedik, B. Turgut Ozturk, B. Bakbak  TURKEY
Lateral retinoic retinal artery occlusion caused by cosmetic facial autologous fat filler injections

10.10  L. Toto, L. Di Antonio, D’Aloisio, A. Mastropasqua, M. Palmieri, M. Di Nicola, L. Matropasqua  ITALY
Relationship between aqueous humor cytokine level changes, retinal thickness modification and vascular changes after intravitreal aflibercept for diabetic macular edema

10.15  C. Tomkinson, A. Hopkins  UK
Misdiagnosis of a direct carotid-cavernous fistula: A case series

10.20  N. Palarie, T. Pasenco, L. Vudu  MOLDOVA
Comparison of two different doses of combined bevacizumab/triamcinolone acetonid intravitreal injection in the treatment of refractory diabetic macular edema

10.25  J.T. Kim, E. Park  SOUTH KOREA
Correlation of foveal avascular zone and foveal photoreceptor integrity in diabetic retinopathy using swept source optical coherence tomography angiography

10.30  D. Lipatov, O. Vikulova, E. Bessmertnaya, A. Tolkacheva, T. Chistiykov, M. Shestakova, I. Dedov  RUSSIA
Epidemiology of diabetic retinopathy in the Russian Federation according to the Federal register of patients with diabetes (2013-2016)

10.35  M.J. Vieira  PORTUGAL
Premacular hemorrhage successfully treated with (Nd):YAG laser

10.40  J. DaCosta, J. Talks  UK
Optical coherence tomography angiography parameters to predict visual acuity in diabetic retinopathy

10.45  J. Sambricio, B. de-Lucas-Viejo, L. Palmero-Fernandez  SPAIN
Macular telangiectasias type 1 treated with intravitreal dexamethasone implant

10.50  S. Nalcaci, C. Degirmenci, F. Afrashi, C. Akkin, J. Mentes  TURKEY
Etiological factors in young patients with retinal vein occlusion

10.55  Discussion

11.00  End of session
10.00 – 17.15

YOUNG RETINA SPECIALISTS (YOURS) DAY 2018

Room C2

10.00 – 11.30

YOURS Symposium
New Developments in Retinal Research & Treatment

Organisers: D. Fischer GERMANY
Y. Subhi DENMARK

10.00 E. van Dijk THE NETHERLANDS
Central serous chorioretinopathy: sex, stress and steroids?

10.10 D. Ting SINGAPORE
Application of artificial intelligence in ophthalmology: Where are we now? what’s next?

10.20 O. Georgiadis UK
Outcome after transplantation of a human embryonic stem cell-derived RPE in patients with advanced nAMD

10.30 M. Hata JAPAN/CANADA
Bietti crystalline dystrophy: Pathologic clarification and development of novel therapies

10.40 S. DeSilva UK
Long term restoration of visual function by human melanopsin gene therapy

10.50 J. Neubauer DENMARK
Cellular immune response to AAV gene therapy in the primate area

11.00 Discussion

11.30 End of session

11.30 – 12.00

Coffee Break

12.00 – 13.30

YOURS Science Slam

Organisers: C.J. Boon THE NETHERLANDS
C. Dysli SWITZERLAND
M. Fleckenstein GERMANY

12.00 T. van Rijssen THE NETHERLANDS
Central serous chorioretinopathy: focal or diffuse, which treatment should I use?

12.08 M. Krogh Nielsen DENMARK
Geographic atrophy: The Cluedo perspective

12.16 M. Alberti DENMARK
Characterising surgical skill in macular surgery: Another measure of grey hair or valuable for patient care?

12.24 L. von der Emde GERMANY
Catch me if you can!: Deep-learning-based identification of concealed OCT biomarkers

12.32 Y. Solberg SWITZERLAND
Searching for stars: Fluorescence lifetime imaging in Stargardt disease

12.40 R. Sacconi ITALY
Choriocapillaris changes in ageing as measured by SS-OCTA

12.48 A. Pajtler Rosar SLOVENIA

12.56 S. Apostolopoulos SWITZERLAND

13.04 K. Jiramongkolchai USA
ROP: Back to the ABC’s

13.12 Discussion

13.30 End of session

13.30 – 14.15

Lunch Break

14.15 – 15.45

Mystery Cases

Organisers: M.S. Singh USA
R. Mastropasqua ITALY

14.15 E. van Dijk THE NETHERLANDS

14.23 K. Teo SINGAPORE

14.31 N. Brennan UK

14.39 M. Lupidi ITALY

14.47 D.K. Misra INDIA

14.55 G. McGowan UK

15.03 K. Spiteri Cornish UK

15.11 S. Demirel TURKEY

15.45 – 16.15

Ophthalmologica Lecture
Keynote Lecture

16.15 – 17.15

Closing Reception
SATURDAY 22 SEPTEMBER

11.00 – 12.30

**EURETINA MAIN SESSION 7**

**Imaging**

Hall D3

Chairpersons:  
- F. Holz **GERMANY**  
- W. Drexler **AUSTRIA**  
- G. Staurenghi **ITALY**

11.00  
**U. Chakravarthy** **INDIA**  
Agreement between OCT angiography and FA/ICG in neo-vascular AMD

11.10  
**E. Midena** **ITALY**  
Single Layer OCT, OCT angiography, and functional correlates in diabetic patients

11.20  
**T. Peto** **UK**  
Retinal vascular biomarkers for Alzheimer’s disease

11.30  
**W. Harmening** **GERMANY**  
Adaptive optics-SLO single photoreceptor imaging and psychophysics

11.40  
**P. Keane** **UK**  
The use of artificial intelligence/deep learning in the analysis of retinal images

11.50  
**P. Maloca** **UK**  
Full volume render virtual reality OCT

12.00  
Discussion

12.30  
End of session

11.00 – 12.30

**EURETINA UPDATE SESSION 5**

**Inherited Retinal Diseases**

Room C1

Chairperson: **B. LeRoy** **BELGIUM**

11.00  
**C.J. Boon** **THE NETHERLANDS**  
RPGR-related retinal dystrophies

11.15  
**B. LeRoy** **BELGIUM**  
RDH12-related retinal dystrophies

11.30  
**S. Downes** **UK**  
Choroideraemia

11.45  
**D. Fischer** **GERMANY**  
Update on achromatopsia & blue cone monochromacy

12.00  
**I. Audo** **FRANCE**  
Update on congenital stationary night blindness

12.15  
Discussion

12.30  
End of session
11.00 – 12.30

FREE PAPER SESSION 16
Vascular Diseases & Diabetic Retinopathy IV

Room C4

Chairpersons: F. Bandello ITALY
P. Stanga UK

11.00
R. Patel, K. Michael, S. Chakrabarti UK
The management of neovascular retinal vein occlusions in post intravitreal treatment patients

11.06
T. Qian, S. Yu CHINA
Correlation between polyv size and presence of blood flow signals in polyps by optical coherence tomography angiography for polypoidal choroidal vasculopathy

11.12
P. Brito, J. Costa, N. Gomes, S. Costa, J. Correia-Pinto, R. Silva PORTUGAL
Association of peripheral blood proinflammatory factors with intravitreal corticosteroid treatment in persistent diabetic macular edema

11.18
S. Vasudevan, D. Joshi, D. Ayachit INDIA
OCT biomarkers in refractory DME: Boon or bane?

11.30
T. Ozturk, S. Ipek, M. Kaya, N. Kocak, S. Kaynak TURKEY
Comparison of the outcomes of two different intravitreal treatment protocols in treatment-naïve phakic eyes with macular vein occlusion

11.36
C. Isanta Otal, F. Bartol-Puyal, B. Abadia Alvarez, P. Calvo Perez, G. Verdes Sanz, L. Pablo Juelve, A. Ferreras Amez SPAIN
Influence of arterial hypertension on choroidal thinning in type 2 diabetic patients

11.42
O. Ruiz Moreno, F. Bartol-Puyal, C. Isanta Otal, B. Abadia Alvarez, P. Calvo Perez, G. Verdes Sanz, L. Pablo Juve SPAIN
Relationship between mean haemoglobin A1c levels for 5 years and diabetic retinopathy and choroidopathy

11.48
R. Marques, F. Caiado, J. Prates Canelas, S. Vaz-Pereira PORTUGAL
Vascular retinopathy screening in pregnancy – results from a cross-sectional study

11.54
A. Campos, J. Sousa, A. do Carmo, E. Campos, F. Caramelo, F. Ambrosio, R. Silva PORTUGAL
Evaluation of markers of outcome in diabetic macular edema

12.00
F. Romano, A. Arrigo, S. Mercuri, R. Lattanzio, F. Bandello, M. Battaglia-Parodi ITALY
Visual outcomes after intravitreal ranibizumab for macular edema secondary to juvenile central retinal vein occlusion

12.06
S. Parikh, P. Mitchell, W. Macfadden SWITZERLAND
Evolution of baseline characteristics of treatment-naïve patients with diabetic macular edema over 4 years of enrollment into the LUMINOUS study

12.12
F. Ghassemi, A. Amini IRAN
Randomized clinical trial of intravitreal bevacizumab versus intravitreal bevacizumab combined with losartan in the treatment of diabetic macular edema

12.18
Microaneurysm turnover is a predictor of diabetic retinopathy progression

12.24
D. Bhatia, J. DaCosta, J. Talks UK

12.30
End of session
SATURDAY 22 SEPTEMBER

11.00 – 12.30

INSTRUCTIONAL COURSE 28

3D Digital Vitrectomy Evolution
Update by Experts

Room C3

Course Organisers: A. Nikolakopoulos GREECE
C. Riemann USA
V. Ferrara ITALY

Faculty: T. Aaberg USA
C. Awh USA
D. Chow CANADA
P. Dugel USA
M. Figueroa SPAIN
S. Gotzaridis GREECE
K. Kadonosono JAPAN
M. Mura SAUDI ARABIA
Y. Oshima JAPAN
E. Paroikakis GREECE
J.A. Pournaras SWITZERLAND
S. Rizzo ITALY

11.00 – 12.30

SYMPOSIUM

THE AMERICAN SOCIETY OF RETINA SPECIALISTS (ASRS)

Room D1

Chairpersons: C. Awh USA
P. Ferrone USA

11.00 P. Dugel USA
Brolucizumab for exudative age-related macular degeneration

11.10 P. Ferrone USA
Retinal detachments in patients with Sticklers syndrome

11.20 R. Tadayoni FRANCE
The science behind 3-D vitrectomy

11.30 A. Loewenstein ISRAEL
Sustained released drug delivery for AMD

11.40 P. Stalmans BELGIUM
Robotic surgery - are we there yet?

11.50 T. Hassan USA
Outcomes of anti-VEGF treatment for choroidal neovascularisation in fellow eyes of previously treated neovascular AMD patients

12.00 P. Kaiser USA
Update on conbercept for AMD

12.30 End of symposium
11.00 – 12.30

INSTRUCTIONAL COURSE 29
Endophthalmitis: From Bench to Bedside
Room D5

Course Organiser: C. Chiquet FRANCE

11.00 C. Chiquet FRANCE
Microbiological diagnosis

11.15 M. Saleh FRANCE
New antibiotics in curative treatment

11.30 T.J. Wolfensberger SWITZERLAND
Management of endophthalmitis after intravitreal injections

11.45 J. van Meurs THE NETHERLANDS
Role of vitrectomy and steroids

12.00 P. Montan SWEDEN
Prophylaxis

12.15 Discussion

12.30 End of course

11.00 – 12.30

INSTRUCTIONAL COURSE 30
Uveitis: Contemporary Diagnostic & Therapeutic Procedures
Room D2

Course Organiser: M. Funk AUSTRIA

11.00 E. Miserocchi ITALY
Update on diagnosis of uveitis

11.20 M. Funk AUSTRIA
Imaging in uveitis: When to do and what to do

11.40 U. Pleyer GERMANY
New developments in treatment and surgery in uveitis

12.00 J. de Boer THE NETHERLANDS
Paediatric uveitis: How to approach diagnosis and management in children with uveitis

12.20 Discussion

12.30 End of session
11.00 – 12.30

INSTRUCTIONAL COURSE 31
Complications of Vitreoretinal Surgery
Room D4

Course Organisers: A. Laidlaw UK
P. Sullivan UK

11.00 P. Sullivan UK
Complications of scleral buckling

11.12 A. Laidlaw UK
Retinal trauma during vitrectomy

11.24 C. Pavésio UK
Inflammation and infection after vitreoretinal surgery

11.36 P. Sullivan UK
Post vitrectomy cataract

11.48 A. Laidlaw UK
Complications of diabetic vitrectomy

12.00 P. Sullivan UK
Intraocular haemorrhage during vitrectomy

12.12 Discussion

12.30 End of course

12.45 – 14.15

INTERACTIVE

SPEAKERS’ CORNER 7
Mixed Session III

Taking place within the EURETINA Speakers’ Corner (Entrance Hall D), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

Moderator: S. Gotzaridis GREECE

12.45 I. Garcia-Basterra, J. Mora-Castilla,
A. Gonzalez-Gomez, J. Diaz-Bernal SPAIN
Signs of choroidal melanoma. Are they always present?

12.50 D. Lorenzo, J. Caminal, L. Arias, P. Garcia-Bru,
E. Cobos, B. Dias, N. Padron-Perez SPAIN
Prognostic factors and decision tree for long-term survival in metastatic uveal melanoma

Multimodal imaging of presumed solitary circumscribed retinal astrocytic proliferation

13.00 J. Montero-Moreno, C. Gonzalez-Uruena,
M. Fernandez-Munoz, C. Díez-Montero SPAIN
Retinal layers changes in eyes affected by liquid perfluoro-octane toxicity

13.05 V. Chaudhary, S. Mullen, J. Qian, R. Muni,
T. Ceyhan, M. Nguyen, M. Mak CANADA
Retina abstracts at the Canadian ophthalmological society conferences - A level of evidence analysis

13.10 L. Xu, C. Liu, R. Li, D. Liu CHINA
Efficacy of reduced-fluence photodynamic therapy with anti-vascular endothelial growth factor therapy for serous retinal pigment epithelial detachment

13.15 P. Efstratiou, D. Karagiannis, L. Kontomichos,
G. Batsos, E. Ktenia GREECE
The effect of eplerenone in chronic central serous chorioretinopathy refractory to PDT therapy

13.20 A. Saatci, E. Karatas, Z. Ayhan, A. Yaman TURKEY
The results of topical brinzolamide treatment in X linked juvenile retinoschisis

13.25 V. Chaudhary, J. Qian, J. Barbosa, W. Xie CANADA
Efficacy of a tele-retinal referral system for treatment times

13.30 J.G. Jeung, H. Hwang, S. Kim, K. Kang SOUTH KOREA
The anti-angiogenic effect of tectorigin on a mouse model of retinopathy of prematurity

13.35 M. Prieto del Cura, J. Gonzalez-Guijarro SPAIN
Impact of ocular complications on visual outcome in adult patients with uveitis

13.40 P. Kulkarni, S. Deol, P. Kumar UK
Real world experience of ozurdex (0.7mg) implant in the management of non-infectious uveitis in a tertiary hospital
14.00 – 16.00

**ESCRS/EURETINA SYMPOSIUM**

**The Diabetic Eye**

**Hall A1**

**Chairpersons:** B. Cochener **FRANCE (ESCRS)**
S. Wolf **SWITZERLAND (EURETINA)**

14.00 **C. Stehouwer** **THE NETHERLANDS**
New concepts and treatments of diabetes

14.15 **R. Finger** **GERMANY**
Epidemiology of diabetic eye diseases in Europe

14.30 Discussion

14.40 **M. la Cour** **DENMARK**
Timing and preparation for cataract surgery

14.55 **M. Nubile** **ITALY**
The impact of diabetes on the ocular surface

15.10 Discussion

15.20 **R. Nuijts** **THE NETHERLANDS**
Postsurgical CME: Strategies for prophylaxis and treatment

15.35 **A. Laidlaw** **UK**
Combined surgery in diabetic retinopathy: Indications and outcomes

15.50 Discussion

16.00 End of session
**FREE PAPER SESSION 17**

**AMD IV**

Room C1

**Chairperson:** A. Grzybowski *POLAND*

**14.30**

R. Tadayoni, E. Souied, F. Holz, P. Dugel, A. Weichselberger *FRANCE*

Comparative assessment of retinal fluid in patients treated with brolucizumab and aflibercept: 36–48 Week data from HAWK and HARRIER

**14.36**

A. Cusumano, B. Falsini, E. Giardina, R. Cascella, J. Sebastiani, J. Marshall *ITALY*

Short-term assessment of retinal function following 2RT laser treatment for intermediate AMD: a pilot study including electrophysiology

**14.42**

S. Bolme, D. Austeng, T. Follestad, T. Sund Morken *NORWAY*

Comparison of physician and nurse-administered intravitreal injections of anti-vascular endothelial growth factor, a randomized noninferiority trial

**14.48**

F. Holz, P. Mitchell, W. MacFadden, S. Parikh *GERMANY*

Treatment patterns in prior ranibizumab-treated patients with neovascular age-related macular degeneration: real-world outcomes from the LUMINOUS study

**15.00**

S. Kadayifcilar, F. Bezci Aygun, R. Ozgul, B. Eldem *TURKEY*

Evaluation of the frequency of complement factor I gene polymorphism in a Turkish age related macular degeneration population

**15.06**

A. Wolf, C. Junkes, U. Rosen, P. Enders, M. Maier, S. Liakopoulos *GERMANY*

Dynamics of systemic free VEGF-A in AMD patients during anti-VEGF treatment with ranibizumab versus aflibercept

**15.12**

M. Zinkernagel, V. Berget, S. Wolf *SWITZERLAND*

Following excitement and anxiety response under intravitreal injection: The FEAR study

**15.18**

J. Monés, A. Khanani, Y. Yang, A. Weichselberger *SPAIN*

The q12w dosing status with brolucizumab in patients with neovascular age-related macular degeneration and the impact of baseline characteristics: Results from the Phase III HAWK and HARRIER trials

**15.24**

R. Guymer, F. Chen, J. Arnold, W. Heriot, U. Chakravarthy, S. Durkin, C. Luu *AUSTRALIA*

Subthreshold nanosecond laser intervention to slow progression in intermediate laser intervention to slow progression in intermediate age-related macular degeneration

**15.30**

S. Moradian, H. Behboodi, H. Nikkhah, Y. Alizadeh, H. Ahmadi, R. Nourinia, S. Karimi *IRAN*

A population-based study on the prevalence and risk factors of age-related macular degeneration in northern Iran: The Gilan Eye Study

**15.36**

H. Gerding, L. Hefner, M. Timmermann, K. Hurtikova, G. Varadi, G. Somfai *SWITZERLAND*

Ten-year outcome of anti-VEGF treatment in patients with age-related Macular degeneration

**15.42**

V. Capuano, R. Sekfali, G. Mimoun, S. Cohen, G. Querques, F. Bandello, E. Souied *FRANCE*

Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks

**16.00**

End of session
14.30 – 16.00

FREE PAPER SESSION 18

New Drug Treatment & Technology II

Room C4

Chairpersons: C. Hoyng THE NETHERLANDS
G. Staurenghi ITALY

14.30 P. Stanga UK
Complement C5 inhibition as a potential treatment for autosomal recessive Stargardt disease (STGD1): Design of a clinical trial assessing a novel treatment and primary outcome measure

14.36 A. Stahl, D. Lepore, B. Fleck, N. Marlow, J. Li, A. Zhu, A. Fielder GERMANY
Ranibizumab for the treatment of retinopathy of prematurity: Twenty-four week, randomized, multi-center, open-label RAINBOW study

14.42 Y. Solberg, C. Dysli, S. Wolf, M. Zinkernagel SWITZERLAND
Fluorescence lifetime imaging ophthalmoscopy for the monitoring of lesion progression in Stargardt disease

14.48 P. Arendt, D. Kokona, A. Ebneter, M. Zinkernagel SWITZERLAND
Effect of microglia depletion on the disease course of experimental choroidal neovascularization in mice

14.54 B. Kuppermann, D. Boyer, B. Mills, J. Yang, H. Klassen USA
Safety and activity of a single, intravitreal injection of human retinal progenitor cells for treatment of retinitis pigmentosa (RP)

15.00 B. Stanzel, Z. Liu, T. Ilmarinen, H. Hongisto, V. Barathi, G. Tan, H. Skottman GERMANY
OCT- Histopathologic correlation of Integration of submacular hESC-RPE monolayers xenografts in monkeys with a compromised blood retinal barrier

15.06 T. Hu, I. Van Hove, M. Vanhove, M. Porcu, B. Jonckx, P. Barbeaux, J. Feyen BELGIUM
Therapeutic effect of the potent integrin antagonist THR-687 in the cynomolgus laser-induced choroidal neovascularization model confirms its potential as novel treatment for sight-threatening retinal pathologies

Year 1 time to mobility test completion in a voriotengene neprivovove trial in subjects with RPE65 mutation–associated inherited retinal disease

15.18 E. Zrenner GERMANY
Experiences with electronic retina implant alpha (RI-ALPHA) in more than 60 blind patients with inherited retinal dystrophies

15.24 R. Hua CHINA
Therapeutic mechanism of conbercept for inflammatory choroidal neovascularization

15.30 U. Kayabasi TURKEY
Inhibition of mTOR pathway to prevent photoreceptor cell damage

15.36 Y. Cheng, M. Zhao, J. Liang CHINA
A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity

15.42 V. Chaudhary, J. Qian, J. Barbosa CANADA
Time to treatment – Utilizing a tele-retinal referral system for wet age-related macular degeneration and diabetic macular edema

15.48 R. Mittal, K. Vohra, V. Mittal INDIA
Role of Endocyclo photocoagulation (ECP) in refractory silicon oil induced glaucoma

16.00 End of session
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30</td>
<td>S. Rizzo</td>
<td>Italy</td>
</tr>
<tr>
<td>14.38</td>
<td>J. García-Arumí</td>
<td>Spain</td>
</tr>
<tr>
<td>14.46</td>
<td>P. Ferrone</td>
<td>Italy</td>
</tr>
<tr>
<td>14.54</td>
<td>C. Riemann</td>
<td>USA</td>
</tr>
<tr>
<td>15.02</td>
<td>K. Rezaei</td>
<td>USA</td>
</tr>
<tr>
<td>15.10</td>
<td>V. Morales-Canton</td>
<td>Mexico</td>
</tr>
<tr>
<td>15.18</td>
<td>K. Sabti</td>
<td>Kuwait</td>
</tr>
<tr>
<td>15.26</td>
<td>C. Eckardt</td>
<td>Germany</td>
</tr>
<tr>
<td>15.34</td>
<td>R. Tadayoni</td>
<td>France</td>
</tr>
<tr>
<td>15.42</td>
<td>M. Figueroa</td>
<td>Spain</td>
</tr>
<tr>
<td>15.50</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16.00</td>
<td>End of symposium</td>
<td></td>
</tr>
</tbody>
</table>

**FREE PAPER SESSION 19**

**Vitreoretinal Surgery IV**

Room D1

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30</td>
<td>A. Charonis, D. Spourdalakis, E. Stranga, E. Mavrikakis</td>
<td>Greece</td>
</tr>
<tr>
<td></td>
<td>Macular displacement after rhegmatogenous retinal detachment repair: Risk factors and functional sequelae</td>
<td></td>
</tr>
<tr>
<td>14.36</td>
<td>S. Elgouhary</td>
<td>Egypt</td>
</tr>
<tr>
<td></td>
<td>Safety of silicone oil removal in cases of gunshot perforating eye injuries</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pars plana vitrectomy with intraocular tamponade for primary rhegmatogenous retinal detachment</td>
<td></td>
</tr>
<tr>
<td>14.48</td>
<td>P. Bhende, A. Maitray</td>
<td>India</td>
</tr>
<tr>
<td></td>
<td>Retinal break during microincision vitrectomy surgery (MiIVS) in eyes with stage 4 and 5 retinopathy of prematurity (ROP): All is not lost!</td>
<td></td>
</tr>
<tr>
<td>14.54</td>
<td>J. Garweg</td>
<td>Switzerland</td>
</tr>
<tr>
<td></td>
<td>The charme of 27G, efficacy and safety of 23g vitrectomy - Hybrid 23/27 gauge vitrectomy</td>
<td></td>
</tr>
<tr>
<td>15.00</td>
<td>M. Benzerroug, S. Coisy, B. Briend, B. Boussion, C. Mazit</td>
<td>France</td>
</tr>
<tr>
<td></td>
<td>Tissue plasminogen activator-assisted vitrectomy for submacular hemorrhage due to age-related macular degeneration</td>
<td></td>
</tr>
<tr>
<td>15.06</td>
<td>S. Saw, Y. Wong, A. Yeo, T. Wong, C. Cheng, D. Hoang, E. Lamoureaux</td>
<td>Singapore</td>
</tr>
<tr>
<td></td>
<td>Prevalence and risk factors for myopic macular degeneration among adults in Singapore</td>
<td></td>
</tr>
<tr>
<td>15.12</td>
<td>F. Sousa Neves, J. Braga, P. Sepulveda, M. Bilhoto</td>
<td>Portugal</td>
</tr>
<tr>
<td></td>
<td>Myopic retinal detachment and macular hole closure with autologous neurosensory retinal free flap</td>
<td></td>
</tr>
<tr>
<td>15.18</td>
<td>I. Muftuoglu, W. Freeman</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td>Identification of factors related to subfoveal detachment secondary to epiretinal membrane</td>
<td></td>
</tr>
<tr>
<td>15.24</td>
<td>M. Farvardin, M. Johari, M. Afarid, M. Nami, R. Farvardin</td>
<td>Iran</td>
</tr>
<tr>
<td></td>
<td>Early safety and performance results of the first experience in Argus II retinal prosthesis implantations in Iran</td>
<td></td>
</tr>
<tr>
<td>15.30</td>
<td>D. Allegrini, M. Ferrara, G. Iardi, G. Cennamo, B. Parolini, C. Mariotti, M. Romano</td>
<td>Italy</td>
</tr>
<tr>
<td></td>
<td>Müller cell and macular peeling-induced retinal damage with different dyes: Functional and histopathological results</td>
<td></td>
</tr>
</tbody>
</table>
14.30 – 16.00

INSTRUCTIONAL COURSE 32
Digital Imaging in Retina
Room D5

Course Organiser: U. Schmidt-Erfurth AUSTRIA

14.30 U. Schmidt-Erfurth AUSTRIA
Artificial intelligence in medical imaging

14.45 D. Martin USA
IRIS - A large dimension access to big clinical data

15.00 H. Bogunovic AUSTRIA
What can machine learning do for the clinicians?

15.15 S. Waldstein AUSTRIA
Understanding and managing AMD using image analysis

15.30 B. Gerendas AUSTRIA
Learning and tools for DME diagnosis and therapy

15.45 A. Sadeghipour AUSTRIA
A digital understanding of real-world retina

16.00 End of course
SATURDAY 22 SEPTEMBER

14.30 – 16.00

INSTRUCTIONAL COURSE 33
Scleral Buckling: Rejuvenating the Dying Art!
Room D2
Course Organiser: S. Rai Gupta INDIA

Basics
14.30 D. Singh INDIA
Selection of cases is the first step towards success
14.40 S. Rai Gupta INDIA
The technique of scleral buckling: Do’s and don’t’s
14.50 U. Behera INDIA
The sub-retinal fluid drainage: When, how and how much?
15.00 Discussion

Modifications
15.05 D. Singh INDIA
Sub-retinal fluid drainage: The way I do it
15.15 J. Singh INDIA
Belt without buckle can work
15.25 R. Narula INDIA
Chandelier assisted scleral buckling: Making it easier to learn and perform
15.35 Discussion

Complications Management
15.40 J. Singh INDIA
Fear factor: How to sail through complications
15.50 Discussion
16.00 End of course

14.30 – 16.00

INSTRUCTIONAL COURSE 34
Subthreshold Laser Surgery: Advantages & Disadvantages of Micropulse & Other Subthreshold Laser Techniques
Room D4
Course Organiser: J. Keunen THE NETHERLANDS

14.30 J. Keunen THE NETHERLANDS
Introduction: What’s new in subthreshold laser surgery and what have we learned so far?
14.45 V. Chong UK
Basic principles of micropulse laser and differences to other subthreshold laser techniques
15.00 E. Midena ITALY
Subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation in DME
15.15 J. Luttrull USA
Safety of transfoveal subthreshold diode micropulse laser and important new developments
15.30 J. Keunen THE NETHERLANDS
Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: Evaluation of a prospective treatment protocol
15.45 J. Keunen THE NETHERLANDS, J. Luttrull USA, E. Midena ITALY, V. Chong UK
Presentation of challenging cases, followed by active panel discussion (including a case with a serious complication)
16.00 End of course
## SATURDAY 22 SEPTEMBER

### MIXED SESSION IV

**SPEAKERS’ CORNER 8**

Taking place within the EURETINA Speakers’ Corner (Entrance Hall D), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

**Moderator:** T. Aslam *(UK)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Poster Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td>M. Diab, M. El Shehari, M. Omar <em>(SAUDI ARABIA)</em>&lt;br&gt;A predictive score for retinopathy of prematurity by using clinical risk factors and serum insulin-like growth factor-1 levels</td>
</tr>
<tr>
<td>16.05</td>
<td>S. Gedik, B. Arazay, B. Turgut Ozturk, S. Gonul, A. Bozkurt Oflaz <em>(TURKEY)</em>&lt;br&gt;Measurement of aqueous flare in patients with non-arteritic anterior ischemic optic neuropathy treated with systemic corticosteroid treatment</td>
</tr>
<tr>
<td>16.15</td>
<td>S. Szegedi, K. Fondi, N. Luft, R. Werkmeister, D. Schmidl, L. Schmetterer, G. Garhoefer <em>(AUSTRIA)</em>&lt;br&gt;Measurement of flicker induced hyperaemia in retinal vessels and the optic nerve head using laser speckle flowgraphy</td>
</tr>
<tr>
<td>16.20</td>
<td>R.M. Coco-Martin, J. Munoz-Cuellar <em>(SPAIN)</em>&lt;br&gt;Clinical characterization and frequency of observation of hereditary retinal diseases. Multicentric study in Panama</td>
</tr>
<tr>
<td>16.25</td>
<td>D.M. Butu, A. Neville, A. Fakin, C. Hammond, A. Webster, M. Michaelides, O. Mahroo <em>(UK)</em>&lt;br&gt;Parameters of cone system function measured using a portable electroretinography device in patients with ABCA4 retinopathy with and without peripheral involvement as determined by ultra-widefield autofluorescence imaging</td>
</tr>
<tr>
<td>16.45</td>
<td>M.R. Sanabria, P. Ibanez Ayuso, P.C. Monar <em>(SPAIN)</em>&lt;br&gt;Understanding the physiopathology of retinal arterial macroaneurysms through the optical coherence tomography angiography</td>
</tr>
<tr>
<td>16.50</td>
<td>H. Qi, E. Jin <em>(CHINA)</em>&lt;br&gt;MicroPulse laser therapy as an adjunct to intravitreal conbercept for diffuse diabetic macular edema</td>
</tr>
<tr>
<td>16.55</td>
<td>T. Qian <em>(CHINA)</em>&lt;br&gt;One-year outcomes of conbercept therapy for diffuse diabetic macular edema</td>
</tr>
<tr>
<td>17.00</td>
<td>M. Dogan, M. Sahaner, M. Erol <em>(TURKEY)</em>&lt;br&gt;One-year outcomes of intravitreal aflibercept injection for diabetic macular edema treatment in naive patients</td>
</tr>
<tr>
<td>17.05</td>
<td>R. Lejoyeux, M. Lehmman, F. Azan, P. Rothschild, R. Tadayoni <em>(FRANCE)</em>&lt;br&gt;Baseline predictive factors for bilateral retinal detachment</td>
</tr>
<tr>
<td>17.10</td>
<td>F. Okamoto, S. Morikawa, Y. Okamoto, T. Oshika <em>(JAPAN)</em>&lt;br&gt;Open globe injuries in Japan</td>
</tr>
<tr>
<td>17.15</td>
<td>H. Hasebe, H. Terashima, N. Matsuoka, E. Ueda, R. Sasaki, H. Yoshimo, T. Fukuchi <em>(JAPAN)</em>&lt;br&gt;Postoperative changes of foveal hyper reflective lesion in OCT images of surgically closed macular hole</td>
</tr>
<tr>
<td>17.20</td>
<td>A. Khudiakov, V. Rudenko <em>(RUSSIA)</em>&lt;br&gt;The comparative analysis of surgical treatment of large macular holes with air and silicone oil tamponade</td>
</tr>
<tr>
<td>17.25</td>
<td>Discussion</td>
</tr>
<tr>
<td>17.30</td>
<td>End of session</td>
</tr>
</tbody>
</table>
16.30 – 18.00

**EURETINA MAIN SESSION 8**

**Research**

**Hall D3**

**Chairpersons:** R. MacLaren *UK*
C.C.W. Klaver *THE NETHERLANDS*

16.30  **B. LeRoy** *BELGIUM*
Genetics in retinal disease

16.38  **C.C.W. Klaver** *THE NETHERLANDS*
Genetics in retinal disease

16.46  Discussion

16.50  **D. Fischer** *GERMANY*
Gene Therapy achromatopsia CNGA3

16.58  **J. Bainbridge** *UK*
Gene Therapy achromatopsia CNGB3

17.06  Discussion

17.10  **S. Kleinlogel** *SWITZERLAND*
Optogenetics for end-stage retinitis pigmentosa

17.18  **R. MacLaren** *UK*
Gene therapy for retinitis pigmentosa

17.26  Discussion

17.30  **S. Rizzo** *ITALY*
The Argus II retinal implant for retinitis pigmentosa

17.38  **F. Gekeler** *GERMANY*
The AMS subretinal implant for retinitis pigmentosa

17.46  Discussion

18.00  End of session

---

16.30 – 18.00

**FREE PAPER SESSION 20**

**Mixed Session II**

**Room C1**

**Chairpersons:** F. Boscia *ITALY*
E. Pilotto *ITALY*

16.30  **I. Mallias, P. Mylova, A. Tassiopoulou** *GREECE*
Fundus autofluorescence and multicolor imaging comparison in assessing disease severity in patients suffering from geographic atrophy

16.36  **C. Leisser, M. Ruiss, C. Pilwachs, O. Findl** *AUSTRIA*
One-year results of vitrectomy with ILM peeling with ILM flap translocation and gas-tamponade for surgical repair of macular holes

16.42  **D. Ahnood, A. Souriti, G. Williams** *UK*
Assessing patient acceptance of laser pre-treatment to reduce injection burden in diabetic macular oedema: A large scale postal survey

16.48  **C. Favard, E. Frau, S. Tick, C. Francois, M. Mauger-Faasse** *FRANCE*
SSOCT and SSOCT-angiography analysis of circumscribed choroidal hemangiomas

16.54  **J. Tee, Y. Yang, A. Kalitzeos, A. Webster, J. Bainbridge, R. Weleber, M. Michaelides** *UK*
Natural history study of visual function and disease progression in RPGR-associated retinopathy

17.00  **A. Jain, M. Sindal, U. Pan, B. Singh** *INDIA*
To assess trends in antibiotic sensitivity of Pseudomonas and compare multi-drug resistance (MDR) between endophthalmitis cases presenting in two consecutive 6 year time-frame in a tertiary center of South India

17.06  **B. Pershin, M. Alexey, M. Vladimir, S. Anna, S. Natalia, P. Anastasia** *RUSSIA*
Cytomegalovirus retinitis diagnostics and treatment in children after hematopoietic stem cell transplantation

17.12  **H. Arruda, S. Campos, P. Alfaiaete, J. Pereira, M. Santos, M. Vieira, J. Castro Sousa** *PORTUGAL*
Choroidal thickness in 9 to 10 year old pre-term and low birth weight children

17.18  **K. Ghasemi Falavarjani, H. Shenazandi, D. Naseri, P. Anvari, A. Sedaghat, M. Hashemi, A. Sadun** *IRAN*
Correlation of optic disc morphometry and optic disc microvasculature assessed with optical coherence tomography angiography

17.24  **C. Formento, A. Shaikh, S. Sivaprasad, R. Crosby-Nwaobi** *UK*
The use of novel non-invasive interventions to improve the patient experience of intravitreal injections (IVT): Gaze fixation
17.30  E. Runhart, R. Sangermano, S. Cornelis, L. van den Born, C. Hoyng, F. Cremers THE NETHERLANDS
The common ABCA4 variant p.As1868Ile shows non-penetrance and variable expression of Stargardt disease when present in trans with severe variants

17.36  R. Crosby-Nwaobi, R. Hamiton, S. Sivaprasad UK
Patient reported intravitreal injection (IVT) -related anxiety in the IVT service

17.42  A. Oishi, M. Oishi, M. Miyata, T. Hirashima, T. Hasegawa, S. Numa, A. Tsujikawa JAPAN
Multimodal imaging for differential diagnosis of Bietti crystalline dystrophy

17.48  J. Fortun, N. Bagheri, M. Paez-Escamilla, J. Townsend, H. Flynn, W. Harbour USA
Surgical approach and outcomes of pars plana vitrectomy in eyes harboring a treated posterior uveal melanoma

18.00  End of session

16.30 – 18.00
FREE PAPER SESSION 21
Vascular Diseases & Diabetic Retinopathy V
Room C4

Chairpersons:  U. Chakravarthy UK
              Y. Le Mer FRANCE

16.30  D.V. Singh, R. Reddy, G. Mathur, A. Sharma INDIA
Impact of steroid challenge test on incidence of ocular hypertension after dexamethasone (DEX) implant injection for diabetic macular edema

16.36  A. Vural, I. Perente, F. Yigit TURKEY
Simultaneous fluorescein angiographic and optical coherence tomography findings after intravitreal aflibercept monotherapy in the treatment of retinopathy of prematurity

16.42  S. Kimyon TURKEY
Comparison of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity affecting zone 1

16.48  R. Rajalakshmi, R. Subashini, R. Anjana, V. Mohan INDIA
Comparison of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity affecting zone 1

16.54  S. Di Simplicio, J. Hogg UK
A retrospective comparison of aflibercept and ranibizumab in the management of macular oedema secondary to retinal vein occlusion

17.00  F. Pichi, K. Freund, D. Sarraf UAE
Venous malformations of the retina and the brain: New associations of congenital retinal macrovessel

17.06  M. Kalanov, M. Bikbov, R. Fayzrakhmanov, R. Zaynullin RUSSIA
Optimal period for vitreoretinal intervention on the background of preliminary anti-VEGF therapy at proliferative diabetic retinopathy

17.12  E. Ozmert, T. Celik, S. Demirel, F. Sermet TURKEY
Role of inflammation on retinal microcirculation in diabetic eyes: Correlation between aqueous flare intensity and microvascular findings in optic coherence tomography angiography

17.18  J. Wang, C. Yang, C. Lai, H. Choi, C. Tsai, S. Chen, C. Kuo TAIWAN
Real-world outcomes of ranibizumab treatment in Taiwanese patients with visual impairment due to diabetic macular edema; results from the 12-month Phase IV, multi-center, observational RENOWNED study

17.24  A. Abdullatif, A. Saady, H. Foud, T. Macky, Y. Helmy, K. Mansour EGYPT
The value of prednisolone acetate provocative test before intravitreal triamcinolone acetonide injections
17.30  **R. Jorge, L. Toscano, K. Messias, J. Ribeiro, A. Messias**  **BRAZIL**
Proliferative diabetic retinopathy treated with intravitreal ranibizumab and laser photocoagulation targeted to ischemic retina

17.36  **C. Ucgul Atilgan, K. Atilgan**  **TURKEY**
Quantitative analysis of the effect of microalbuminuria on superficial and deep capillary plexus of macula in patients with type-2 diabetes mellitus by using optical coherence tomography angiography.

17.42  **J. Costa, P. Brito, N. Gomes, G. Calvão-Santos, S. Rufino**  **PORTUGAL**
Subfoveal choroidal volume and anatomic response to anti-vascular endothelial growth factor agents in patients with diabetic macular edema

17.48  **M. Sevik, O. Sahin, M. Eraslan**  **TURKEY**
Patients with increased intraocular pressure after single intravitreal dexamethasone implant (ozurdex)

18.00  End of session

---

16.30 – 18.00

**SYMPOSIUM OPHTHALMOLOGY INNOVATION SUMMIT (OIS)**

**Innovations in Retina**

Room C3

Chairpersons:  **E. Cunningham**  **USA**  
**S. Wolf**  **SWITZERLAND**

16.30  **E. Cunningham**  **USA**
Tips for aspiring entrepreneurs

16.50  Recent and upcoming milestones in retina

17.00  **Panel Discussion**
-  **E. Cunningham**  **USA**
-  **A. Loewenstein**  **ISRAEL**
-  **S. Wolf**  **SWITZERLAND**

18.00  End of session
16.30 – 18.00

SYMPOSIUM
EUROLAM
Clinical & Surgical Cases of Unusual Presentation & Complex Resolution

Room D1

Chairpersons:
- F. Bandello ITALY
- F. Graue MEXICO
- F. March de Ribot SPAIN
- D. Pelayes ARGENTINA

16.30 A. Loewenstein ISRAEL
Case presentation

16.40 R. Cano MEXICO
Pachychoroid and central serous chorioretinopathy

16.50 C. Abdala COLOMBIA
Case presentation

17.00 G. Richard GERMANY
Case presentation

17.10 A. Joussen GERMANY
Surgery for complex tumour situations

17.20 S. Seregard SWEDEN
Case presentation

17.30 G. Gabela ECUADOR
Case presentation

17.40 M. la Cour DENMARK
Clinical endpoints for use in the training of surgeons

17.50 F. March de Ribot SPAIN
Case presentation

18.00 End of session

16.30 – 18.00

INSTRUCTIONAL COURSE 35
Forlini Trauma School

Room D5

Course Organisers:
- M. Forlini ITALY
- A. Nikolakopoulos GREECE
- V. Reppucci ITALY

16.30 A. Nikolakopoulos GREECE
Blunt ocular injuries and lens subluxation

16.37 W. Schrader GERMANY
Decisions in severe ocular trauma: When to reconstruct, give up reconstruction or refer

16.44 P. Sullivan UK
Suture techniques for scleral injuries

16.51 F. Fayad JORDAN
Posterior segment perforating injuries

16.58 K. Sabti KUWAIT
Endoscopy for severe posterior segment trauma

17.05 M. Forlini ITALY
Complex cases in ocular trauma

17.12 M. Mura SAUDIA ARABIA
Chorioretectomy

17.19 M. Khalife LEBANON
IOFBs removal: Techniques, tips and pitfalls

17.26 S. Natarajan INDIA
Unusual intraocular foreign bodies

17.33 N. Mehrotra INDIA
Managing a variety of IOFBs

17.40 Discussion

18.00 End of course
SATURDAY 22 SEPTEMBER

16.30 – 18.00

INSTRUCTIONAL COURSE 36
Pathology & Interventions in the Suprachoroidal Space

Room D2

Course Organiser: S. Saidkasimova UK

16.30  S. Saidkasimova UK
       Anatomy, physiology and pathophysiology

16.40  E. Feron BELGIUM
       Suprachoroidal haemorrhage and its management

16.50  A. Laidlaw UK
       Choroidal effusions and ocular hypotony management

17.00  L. Au UK
       Suprachoroidal glaucoma devices

17.10  P. Szurman GERMANY
       Suprachoroidal buckling for peripheral breaks

17.20  E. Al-Rayes EGYPT
       Suprachoroidal macular buckling

17.30  E. Al-Rayes EGYPT
       Suprachoroidal drug delivery systems

17.40  P. Allen AUSTRALIA
       Suprachoroidal retinal prosthesis

17.50  Discussion

18.00  End of course

16.30 – 18.00

INSTRUCTIONAL COURSE 37
Update on Imaging & Treatment Options for Chorioretinal Disorders in High Myopia

Room D4

Course Organisers: L. Arias SPAIN
                 J.M. Ruiz-Moreno SPAIN

16.30  A. Garcia-Layana SPAIN
       Genetics in myopia

16.45  J.M. Ruiz-Moreno SPAIN
       Multimodal imaging study of myopic maculopathy

17.00  M. Figueroa SPAIN
       Myopic foveoschisis and lamellar macular holes: What’s new?

17.15  J. Garcia-Arumí SPAIN
       New surgical trends in myopic macular holes

17.30  L. Arias SPAIN
       Current controversies for the management of retinal detachment in high myopia

17.45  Discussion

18.00  End of course
SUNDAY
23 September
SUNDAY 23 SEPTEMBER

08.00 – 09.30

SYMPOSIUM

GERMAN RETINA SOCIETY

Revelations & Fugacious Fashions in VR Surgery

Hall D3

Chairpersons:  H. Helbig  GERMANY
               D. Pauleikhoff  GERMANY

08.00  A. Wolf  GERMANY
       Two for one: Combined phako-vitrectomy

08.15  S. Bopp  GERMANY
       Ancient surgery: Is 20G vitrectomy outdated?

08.30  H. Heimann  UK
       More ancient surgery: Who still needs a buckle?

08.45  A. Stahl  GERMANY
       Intraoperative OCT in vitreoretinal surgery:
       A must or nice to have?

09.00  N. Feltgen  GERMANY
       Dead ends and flops in VR surgery and what we have
       learned from it

09.15  Discussion

09.30  End of symposium

08.00 – 09.30

FREE PAPER SESSION 22

Imaging IV

Room C1

Chairperson:  D. Pelayes  ARGENTINA

08.00  M. Jarc-Vidmar, A. Fakin, D. Glavac, M. Sustar, M. Hawlina, P. Jakl-Mekjavic  SLOVENIA
       Interesting phenotype and electrophysiological findings
       in Slovene family with Best vitelliform dystrophy with
       the pAla243Val BEST1 mutation

08.06  I. Akkoyun, A. Ecevit, N. Sahinoglu-Keskek, C. Ozturk, Z. Kayhan, G. Yilmaz  TURKEY
       Quantitative Assessment of Foveal Avascular Zone
       Using Optical Coherence Tomography Angiography in
       Zone-I ROP After Laserphotocoagulation

08.12  A. Shinojima, E. Bousquet, C. Lavia, A. Gaudric, R. Tadayomi  FRANCE
       Natural course of late-phase hypofluorescent areas on
       indocyanine green angiography in patients with central
       serous chorioretinopathy

08.18  F. Romano, A. Arriго, E. Di Marco, F. Bandello, M. Battaglia-Parodi  ITALY
       Ellipsoid zone mapping in best vitelliform macular
       dystrophy: A 2-year follow-up study

08.24  M. Dotti Boada, M. Barraso-Rodrigo, A. Ale-Chilet, C. Oliva, Z. Chu, R. Wang, J. Zarranz-Ventura  SPAIN
       Impact of the scan field on flow measurements
       in the superficial and deep capillary plexuses of
       diabetic eyes using Optical Coherence Tomography
       Angiography (OCTA)

08.30  P. Topcu Yilmaz, E. Ozdemir, M. Alp  TURKEY
       Optical coherence tomography angiography findings in
       Behcet's disease

08.36  A. Arrigo, F. Romano, E. Aragona, F. Bandello, M. Battaglia-Parodi  ITALY
       New insights in choroideremia provided by combined
       OCT and OCTA analysis

08.42  I. Papasavvas, A. Dirani, J. Pournaras, M. Zola, M. Sherif, A. Ambresin  SWITZERLAND
       Influence of structural SD-OCT characteristics in the
       detection of choroidal neovascularization due to AMD
       using OCT angiography

08.48  A. Nghiem, P. Nderuti, M. Lukic, M. Khatun, K. Kortum, K. Balaskas, D. Sim  UK
       Comparing diabetic retinopathy lesions in ultrawide
       field images and colour fundus photography

08.54  E. Borrelli, M. Gupta Nittala, A. Rosar, V. Sarao, P. Lanzetta, G. Staurenghi, S. Sadda  USA
       Comparison of short-wavelength blue-light
       autofluorescence and conventional blue-light
       autofluorescence to quantify geographic atrophy lesions
09.00  A. Pajtler Rosar, G. Casalino, M. Cozzi, F. Bottoni, N. Vidovic Valentincic, C. Pavésio, G. Staurenghi ITALY
Natural course of unilateral acute idiopathic maculopathy: New insights from autofluorescence Imaging

09.06  R. Geraldes, R. Soares, F. Fonseca, S. Ventura, R. Leitao, J. Chibante PORTUGAL
Optical coherence tomography angiography of the foveal avascular zone in children diagnosed with retinopathy of prematurity

09.12  J.A. Pournaras, M. Zola, I. Papasavvas, L. Marchionno, A. Ambresin SWITZERLAND
Comparison of multicolour imaging technique with en-face OCT in the visualisation of idiopathic epiretinal membrane

09.18  D. Lopes, S. Parreira, T. Loureiro, A. Miranda, I. Machado, N. Campos PORTUGAL
Vascular density evaluation using optical coherence tomography angiography in patients treated with hydroxychloroquine

09.30  End of session

08.00  Y. Alibet, O. Zadorozhnyy, G. Levytska, N. Pasyechnikova UKRAINE
Ciliary body structures imaging after preoperative anti-inflammatory treatment in patients with rhegmatogenous retinal detachment complicated by choroidal detachment

08.06  K. Xu, E. Chin, D. Almeida USA
Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors: Management and visual outcomes

08.12  J. Neffendorf, M. Faigenbaum, R. Wong, A. Laidlaw, T. Williamson UK
Intra-operative complications in phaco-vitrectomy for epiretinal membrane and macular hole: Outcomes from one thousand consecutive eyes

08.18  C. Franciscioni, R. Hillier, T. Felfeli, M. Mak, R. Muni CANADA
Vision-related functioning in patients undergoing pneumatic retinopexy vs vitrectomy for primary rhegmatogenous retinal detachment: Sub-analysis of the PIVOT trial

08.24  N. Bleidißel, S. Bohnacker, N. Feucht, C. Lohmann, M. Maier GERMANY
Functional and morphological outcomes in patients with large idiopathic full-thickness macular holes using the inverted internal limiting membrane flap technique

08.30  M. Aly ITALY
A comparative study between the 25 and 27 gauge vitrectomy in macular surgery

08.36  K. Akiyama, K. Fujinami, K. Watanabe, K. Tsunoda, T. Noda JAPAN
Integrity of outer retinal layers after internal limiting membrane peeling during vitrectomy for macula-on retinal detachment

08.42  L. Arana, A. Grandinetti, C. Moreira Jr, A. Moreira BRAZIL
Analysis of sclerotomies by optical coherence tomography and granuloma formation in 23 gauge vitrectomy with releasable suture, non-releasable and sutureless sclerotomies

08.48  J. Potic, C. Bergin, C. Giacuzzo, L. Konstantinidis, A. Daruich, T. J. Wolfensberger SWITZERLAND
Vision-related quality of life in patients with macula-ON versus macula-OFF retinal detachment measured by a shorter version of NEI VFQ-25
08.00 – 09.30

FREE PAPER SESSION 24

Vascular Diseases & Diabetic Retinopathy VI

Room D1

Chairpersons:  S. Gotzaridis GREECE  
R. Mastropasqua UK

08.00  F. Almamoori JORDAN  
Swept source OCT (En-Face) imaging in conjunction with (retinal flow) OCT angio map “marking out” deep capillary plexus ischemia in paracentral acute middle maculopathy

08.06  M. Figueras-Roca, J. Matas, A. Sala-Puigdollers, S. Alforja, J. Zarranz-Ventura, A. Adan, B. Molins SPAIN  
Aqueous humour cytokine levels may predict diabetic macular edema response to intravitreal dexamethasone implant injection

08.12  A. Ophir ISRAEL  
Diffuse diabetic macular edema: The disclosed pathogenesis line and its clinical implications

08.18  D. Maltsev, A. Kulikov, B. Uplanchiwar, L. Lima, J. Chhablani RUSSIA  
Direct navigated laser photocoagulation as primary treatment for retinal arterial macroaneurysms

08.24  S. Kerci, M. Zengin, O. Karti, H. Sayran TURKEY  
The assessment of optical coherence tomography findings in diabetic retinopathy patients with macular edema according to retinopathy stages

08.30  O. Kolenko, E. Sorokin RUSSIA  
The relationship of endothelial dysfunction, free radical oxidation and morphometric parameters of the macular retina in women with preeclampsia

08.36  H. Al-Nashar, M. AlNaimy EGYPT  
Changes in choroidal thickness measured by swept source optical coherence tomography in diabetic macular edema

08.42  H. Mieno, K. Yoneda, K. Kojima, K. Nagata, N. Terao, C. Sotozono JAPAN  
Aflibercept treat-and-extend regimen for diabetic macular edema: A prospective clinical trial

08.48  S. Mishra INDIA  
Intravitreal dexamethasone implant versus ranibizumab for treatment of non-proliferative diabetic macular edema: A prospective, randomised and blinded Indian study
08.54 J. Zarranz-Ventura, A. Ale-Chilet, M. Barraso, J. Gascon, C. Oliva, T. Hernandez, A. Adan Spain
Glycated Haemoglobin (HbA1c) levels correlate with superficial perifoveal network vessel and perfusion density assessed by optical coherence tomography angiography (OCTA) in type 1 diabetes mellitus: A large scale prospective OCTA study

09.00 M. Michl, X. Liu, A. Kaider, A. Sadeghipour, S. Waldstein, U. Schmidt-Erfurth, B. Gerendas Austria
Imaging biomarkers for visual acuity in macular oedema due to retinal vein occlusion

The outcomes of switching from a short to a long-term intravitreal corticosteroid implant therapy for diabetic macular edema

09.12 H. Almuhtaseb, I. Stratton, P. Scanlon, A. Lotery UK
Inter-centre heterogeneity using anti-VEGF injections in patients with diabetic macular oedema: data analysis from the UK aflibercept users group

09.18 L. Nicholson, J. Ramu, J. Bainbridge, P. Hykin, S. Talks, S. Sivaprasad UK
Retinal non-perfusion characteristics on ultra-widefield angiography in eyes with severe non-proliferative diabetic retinopathy and proliferative diabetic retinopathy

09.30 End of session
SUNDAY 23 SEPTEMBER

08.00 – 09.30

INSTRUCTIONAL COURSE 38
Macular Dystrophies
Room C2

Course Organiser: G. Querques ITALY

08.00  I. Audo FRANCE
X-linked retinoschisis

08.10  Discussion

08.15  C.J. Boon THE NETHERLANDS
Pattern dystrophies

08.25  Discussion

08.30  C. Hoyng THE NETHERLANDS
Stargardt disease

08.40  Discussion

08.45  C. Hoyng THE NETHERLANDS
Macular dystrophies mimicking AMD

08.55  Discussion

09.00  B. LeRoy BELGIUM
Cone dystrophies

09.10  Discussion

09.15  G. Querques ITALY
Best disease

09.25  Discussion

09.30  End of course

08.00 – 09.30

INSTRUCTIONAL COURSE 39
OCT-Angiography in Clinical Practice from the OCTANE (OCT Angiography NEtwork) Study Group: Real-world Experience & Challenges
Room C3

Course Organiser: K. Balaskas UK

08.00  R. Gale UK
OCT-A interpretation and artifacts

08.10  I. Pearce UK
OCT-A in diagnosis of neovascular AMD

08.20  K. Balaskas UK
OCT-A for the follow-up and assessment of response to treatment in neovascular AMD

08.30  F. Ghanchi UK
OCT-A in non-AMD choroidal neovascularisation

08.40  G. Staurenghi ITALY
Angio OCT in macular atrophy

08.50  A. Lotery UK
OCT-A in central serous chorioretinopathy

09.00  J. Talks UK
OCT-A in diabetic retinopathy

09.10  S. Sivaprasad UK
OCT-A in retinal vein occlusions

09.20  Discussion

09.30  End of course
08.00 – 09.30

INSTRUCTIONAL COURSE 40

Submacular Haemorrhages in AMD: A Practical Guide to Management

Room D2

Course Organiser:  D. Steel  UK

08.00  G. McGowan  UK
Epidemiology, mechanisms of visual loss, risk factors and classification

08.10  Z. Koshy  UK
Anti-VEGFs alone?

08.20  W. Heriot  AUSTRALIA
Pneumatic displacement

08.30  J. Hillenkamp  GERMANY
Vitrectomy and subretinal TPA/anti-VEGF

08.40  D. Yorston  UK
Results, complications and limitations: How do the two techniques compare?

08.50  Panel discussion:
W. Heriot  AUSTRALIA
J. Hillenkamp  GERMANY
Z. Koshy  UK
G. McGowan  UK
D. Steel  UK
J. van Meurs  THE NETHERLANDS
D. Yorston  UK

09.30  End of course

08.00 – 09.30

INSTRUCTIONAL COURSE 41

New Insights in Imaging & Therapeutic Strategies for Macular Holes & Myopic Macular Traction Syndrome

Room D4

Course Organiser:  G. Pertile  ITALY

08.00  G. Pertile  ITALY
Introduction

08.05  A. Polito  ITALY
Physiopathology of idiopathic and myopic full thickness macular holes

08.15  F. Bottoni  ITALY
What’s new in lamellar macular hole

08.25  G. Prigione  ITALY
Inverted ILM flap and transplanted ILM for macular hole: Surgical techniques

08.35  M. Mete  ITALY
The dynamic healing process after surgery for idiopathic and myopic macular hole with inverted flap technique

08.45  C. Mateo  SPAIN
Myopic traction maculopathy: Pearls, tricks, pitfalls and adventures

08.55  G. Pertile  ITALY
Tips and tricks for VR surgery in high myopic eyes

09.05  Discussion

09.30  End of course
09.45 – 11.15  
INTERACTIVE

SPEAKERS’ CORNER 9

Imaging

Taking place within the EURETINA Speakers’ Corner (Entrance Hall D), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

- **09.45**  
  J. Leandro, R. Santos-Silva, A. Rocha Sousa, S. Fernandes, R. Oliveira, F. Falcao-Reis, S. Estrela Silva **PORTUGAL**  
  Cone dystrophy with supernormal rod responses: The Portuguese KCNV2 gene mutation

- **09.50**  
  H. Terashima, H. Hasebe, Y. Sato, N. Matsuoka, T. Fukuchi **JAPAN**  
  Relationship between optical coherence tomography angiography and visual field sensitivity for macular non-perfusion in branch retinal vein occlusion

- **09.55**  
  T. Nishi, N. Ogata, K. Shinomiya, Y. Mitamura **JAPAN**  
  Thickness of retinal layers in children with history of retinopathy of prematurity

- **10.00**  
  D. Chakraborty, S. Basak, S. Majumdar, A. Mukherjee, T. Sinha **INDIA**  
  Pre-operative macular SD OCT in 5000 consecutive cataract patients

- **10.05**  
  H. Fukuyama, F. Gomi, Y. Komuku, H. Iwami **JAPAN**  
  Evaluation of the vascular structure of polypoidal choroidal vasculopathy after photodynamic therapy combined with anti-VEGF agents by means of optical coherence tomography angiography

- **10.10**  
  T. Iwase, Y. Ogasawara, K. Yamamoto, E. Ra, H. Terasaki **JAPAN**  
  Relationship between abnormalities of photoreceptor microstructures and microvascular structures determined by optical coherence tomography angiography in eyes with branch retinal vein occlusion

- **10.15**  
  J. Hafner, M. Salas, S. Karst, C. Scholda, W. Drexler, M. Pircher, U. Schmidt-Erfurth **AUSTRIA**  
  Longitudinal changes of retinal microaneurysms in diabetes imaged with in vivo adaptive optics optical coherence tomography

- **10.20**  
  V. NEROEV, A. NOVIKOVA, P. ILYUKHIN, M. RYABINA, K. RAMAZANOVA, T. KISELEVA **RUSSIA**  
  Ocular hemodynamic changes in patients with retinal capillary hemangiomas

- **10.25**  
  M. Latasiewicz, A. Gonzalez Ventosa, E. Milla Grino, L. Quintana Porras, A. Adan Civera **SPAIN**  
  Multimodal retinal imaging of familial amyloidotic polyneuropathy

- **10.30**  
  B. Eldem, S. Kadayifcilar, A. Agin, H. Sonmez, A. Bayataroglu, S. Demir, S. Ozen **TURKEY**  
  Optical coherence tomography parameters in juvenile systemic lupus erythematosus

- **10.35**  
  N. Celik, G. Auffarth, G. Szabo, S. Korkmaz-Icoz, J. Kopitz, S. Loganathan **GERMANY**  
  Smartphone-funduscopy in rats

- **10.40**  
  J.H. Gonzalez-Cortes, A. Ruiz, E. Gutierrez, J. Davila, A. Olvera-Barrios, C. Azuara **MEXICO**  
  Comparison of macular perfusion values in healthy eyes and eyes with diabetic retinopathy (DR), a spectral-domain optical coherence tomography angiography (OCT-A) analysis with the angioplex metrix™

- **10.45**  
  R. Roohipoor, M. Zarei, H. Riazi **IRAN**  
  Retinal pigment epithelial detachment in acute harada disease: Rapid resolution of a rare finding with anti-inflammatory treatment

- **10.50**  
  I. Chatziralli, G. Theodossiadis, D. Panagiotidis, P. Pousoulidi, P. Theodossiadis **GREECE**  
  Choriocapillaris’ alterations in the presence of reticular pseudodrusen compared to Drusen: Study based on OCTA findings

- **10.55**  
  S. Wang, T. Ho **TAIWAN**  
  Biomarkers of myopic traction maculopathy identified by optical coherence tomography angiography: A pathognomonic analysis

- **11.00**  
  A. Fujita, Y. Aoyama, Y. Hashimoto, T. Inoue, R. Obata **JAPAN**  
  Visual function in resolved central serous chorioretinopathy correlates with residual ellipsoid zone quantified by binarization of optical coherence tomography images

- **11.05**  
  S. Minami, Y. Ito, K. Kataoka, J. Takeuchi, Y. Nakano, H. Ito, H. Terasaki **JAPAN**  
  Analysis of macular shape in normal eyes using swept source optical coherence tomography

- **11.10**  
  Discussion

- **11.15**  
  End of session
10.00 – 11.30

**EURETINA MAIN SESSION 9**

**Vitreoretinal Surgery**

Hall D3

Chairpersons:  
J. García-Arumí **SPAIN**  
A. Laidlaw **UK**  
J. van Meurs **THE NETHERLANDS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00</td>
<td>G. Pertile</td>
<td><strong>ITALY</strong></td>
<td><em>Intraocular foreign body removal: Tips and tricks</em></td>
</tr>
<tr>
<td>10.10</td>
<td>E. El-Rayes</td>
<td><strong>EGYPT</strong></td>
<td><em>Paediatric retinal detachment</em></td>
</tr>
<tr>
<td>10.20</td>
<td>J. García-Arumí</td>
<td><strong>SPAIN</strong></td>
<td><em>Surgical management of optic pit maculopathy: Which is the best technique?</em></td>
</tr>
<tr>
<td>10.30</td>
<td>A. Assi</td>
<td><strong>LEBANON</strong></td>
<td><em>Endoillumination buckle</em></td>
</tr>
<tr>
<td>10.40</td>
<td>K. van Overdam</td>
<td><strong>THE NETHERLANDS</strong></td>
<td><em>Removal of vitreoschisis-induced vitreous cortex remnants</em></td>
</tr>
<tr>
<td>10.50</td>
<td>W. Heriot, D. Steel</td>
<td><strong>AUSTRALIA, UK</strong></td>
<td><em>Cold-fusion</em></td>
</tr>
<tr>
<td>11.00</td>
<td>G. Caputo</td>
<td><strong>FRANCE</strong></td>
<td><em>Retinopathy of prematurity</em></td>
</tr>
<tr>
<td>11.10</td>
<td></td>
<td></td>
<td><em>Discussion</em></td>
</tr>
<tr>
<td>11.30</td>
<td></td>
<td></td>
<td><em>End of session</em></td>
</tr>
</tbody>
</table>

10.00 – 11.30

**FREE PAPER SESSION 25**

**Vascular Diseases & Diabetic Retinopathy VII**

Room C1

Chairpersons:  
M. de Smet **SWITZERLAND**  
G. Richard **GERMANY**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00</td>
<td>H. Kaldırım, A. Kirgiz, O. Ozdemir, A. Yilmaz, S. Yazgan</td>
<td><strong>TURKEY</strong></td>
<td><em>The role of postinjection topical antibiotics prophylaxis on conjunctival bacterial flora and antibiotic resistance patterns after serial intravitreal injections in type 2 diabetic patients</em></td>
</tr>
<tr>
<td>10.06</td>
<td>T. Kiseleva, V. Neroev, A. Chudin, N. Balatskaya, I. Khoroshilova, A. Shchipanova</td>
<td><strong>RUSSIA</strong></td>
<td><em>Effect of resveratrol on two different experimental models of retinal ischemia/reperfusion in rats</em></td>
</tr>
<tr>
<td>10.12</td>
<td>Y. Chen, Y. Shen</td>
<td><strong>TAIWAN</strong></td>
<td><em>The association between retinal vein occlusion and an increased risk of cerebrovascular accident: A 13-year population-based cohort study</em></td>
</tr>
<tr>
<td>10.18</td>
<td>O. Sever</td>
<td><strong>TURKEY</strong></td>
<td><em>The effect of intravitreal aflibercept on neovascular glaucoma in previously vitrectomized patients</em></td>
</tr>
<tr>
<td>10.24</td>
<td>H. Yetik, G. Dogan, T. Ogreden, O. Arslan</td>
<td><strong>TURKEY</strong></td>
<td><em>Fellow eye effects of monocular intravitreal bevacizumab (IVB) injection for retinopathy of prematurity (ROP)</em></td>
</tr>
<tr>
<td>10.30</td>
<td>M. Nghiem-Buffet, M. Le Hoang, S. Tabary, G. Quentel, S. Cohen</td>
<td><strong>FRANCE</strong></td>
<td><em>Insights into perifoveal exudative vascular anomalous complex</em></td>
</tr>
<tr>
<td>10.36</td>
<td>A. Dale, K. Price, I. Stratton, S. Aldington, P. Scanlon</td>
<td><strong>UK</strong></td>
<td><em>Reduction in blindness rates since the introduction of digital photographic screening in an English diabetic eye screening programme</em></td>
</tr>
<tr>
<td>10.42</td>
<td>R. Tadayoni, J. Sahni, S. Sadikyov, M. Pauly-Evers, P. Szczesny, R. Weikert</td>
<td><strong>FRANCE</strong></td>
<td><em>Anti-VEGF/Anti–angiopoietin-2 bispecific antibody RG7716 in diabetic macular edema: Key efficacy and safety results from the phase 2 BOULEVARD clinical trial</em></td>
</tr>
<tr>
<td>10.48</td>
<td>A. Eaton</td>
<td><strong>USA</strong></td>
<td><em>Real-world outcomes in the US following the use of the fluocinolone acetonide (FAc) 0.19 mg (ILUVIEN) implant in patients with diabetic macular edema: The results from the USER Study</em></td>
</tr>
<tr>
<td>10.54</td>
<td>S. Liakopoulos, G. Spital, K. Lorenz, A. Stahl, J. Voegeler, C. Quiering, G. Lang</td>
<td><strong>GERMANY</strong></td>
<td><em>Morphological outcomes of the PRIDE study using fluorescein angiography and a modified ETDRS severity scale grading for PDR-patients treated with ranibizumab and/or panretinal photocoagulation (PRP)</em></td>
</tr>
</tbody>
</table>
FREE PAPER SESSION 26

Mixed Session III

Room C4

Chairperson: G. Querques ITALY

10.00  A. Senatore, E. Borrelli, A. Aharrh Gnama, L. Agnifili, A. Lappa, P. Carpineto ITALY
       Uveo-scleral outflow pathways post scleral buckling in retinal detachment: An anterior segment optical coherence tomography and in vivo confocal microscopy study

10.06  H. Ng, K. Vermeer, E. La Heij THE NETHERLANDS
       Association between retinal microvasculature and visual recovery after surgery for rhegmatogenous retinal detachment with macular involvement

10.12  F. Zicarelli, C. Preziosa, G. Staurenghi ITALY
       A novel hypothesis of multiple evanescent white dot syndrome pathogenesis based on multimodal imaging

10.18  S. Ben Yahia, R. Kahloun, M. Belajouza, A. Zayani, R. Damak TUNISIA
       Visual loss following intravitreal injection of aflibercept

       Intravitreal anti-VEGF for choroidal neovascularization in angiod streaks: Comparison of short and long-term outcomes

10.30  M. Romano, C. Gatto, L. Giurgola, M. Ferrara, J. D’Amato Tothova ITALY
       Perfluorocarbons for intraocular use: cytotoxicity test validation study according to ISO 10993-5

10.36  A. Oishi, K. Noda, T. Hasegawa, M. Miyata, M. Oishi, S. Numa, A. Tsujikawa JAPAN
       Detrimental effect of smoking on retinitis pigmentosa patients

10.42  F. Berquet, T. Cheny, M. Afriat, A. Benyelles, D. Bartolomeu, A. Henry, C. Arndt FRANCE
       Heads-up visualization system versus standard binocular operating microscope visualization: a comparative study in anterior and posterior segment surgeries

10.48  R. Muni, Q. Paracha, M. Bamakrid, V. Juncal CANADA
       Ranibizumab levels and its impact on vascular endothelial growth factor in human breast milk following intravitreal injection

10.54  H. Madi, A. Kotagiri, M. Habib, D. Steel UK
       Malposition of fluocinolone acetonide implants in patients with diabetic macular oedema: A possible cause of reduced efficacy
10.00 – 11.30

SYMPOSIUM
JAPANESE RETINA & VITREOUS SOCIETY (JRVS)

Retinal Imaging from Cells to Patients

Room D1

Chairpersons:  K. Kadonosono  
T. Sakamato  
M. Takahashi

10.00  A. Uemura  
Live imaging of cell dynamics in pericyte deficient retina

10.08  M. Takahashi  
Retinal cell therapy using iPS cells

10.16  S. Wolf  
Fluorescence lifetime imaging

10.24  K. Tsuboi  
New insights into BRVO using OCT-Angiography

10.32  O. Sawada  
OCT-Angiography in the diagnosis of diabetic retinopathy

10.40  J-F. Korobelnik  
Widefield OCT-Angiography and diabetic retinopathy

10.48  S. Ishiko  
Multimodal imaging

10.56  S. Sonoda  
Recent development of choroidal imaging

11.04  H. Koizumi  
Polypoidal choroidal vasculopathy: New observations and therapeutic implications

11.12  Discussion

11.30  End of symposium
SUNDAY 23 SEPTEMBER

10.00 – 11.30

SYMPOSIUM
CONTROLLED RELEASE SOCIETY
Gene & Drug Delivery for Retinal Diseases: What is Next?
Room D5

Chairperson:  F. Behar-Cohen SWITZERLAND

10.00  A. Utti FINLAND
       Posterior segment pharmacokinetics

10.15  R. Herrero-Vanrell SPAIN
       Microparticles as therapeutic tools in retinal disease

10.30  E. Stefánsson ICELAND
       Cyclodextrin nanoparticle eye drops for retinal diseases

10.45  F. Behar-Cohen SWITZERLAND
       Viral / non-viral gene delivery for retinal diseases

11.00  Round-table discussion
       - Is intravitreous route optimal to target chorio-retinal diseases?
       - Can we reduce drug doses and maintain long-term effects?
       - What are the obstacles for clinical use of particulate systems?
       - The place of gene therapy in clinical practice

11.30  End of symposium

10.00 – 11.30

INSTRUCTIONAL COURSE 42
Understanding Retinal Imaging: A Guide to Clinical Interpretation of OCT, OCT-Angiography & Fundus Autofluorescence
Room C2

Course Organiser:  A. Pollreisz AUSTRIA

10.00  M. Pircher AUSTRIA
       Current technologies of retinal imaging for clinicians

10.15  T. Ach GERMANY
       Anatomy meets clinical imaging: Solving the mysteries behind OCT and autofluorescence signals in health and disease

10.30  A. Pollreisz AUSTRIA
       OCT-angiography: Tips and pearls for quick and accurate image interpretation

10.45  S. Sivaprasad UK
       Prognostic indications of macular diseases using clinical imaging

11.00  Discussion

11.30  End of course
SUNDAY 23 SEPTEMBER

10.00 – 11.30

INSTRUCTIONAL COURSE 43
Polypoidal Choroidal Vasculopathy: Diagnosis & Treatment
Room C3

Course Organisers:  A. Koh SINGAPORE
                    R. Silva PORTUGAL

10.00  A. Koh SINGAPORE
       Introduction

10.04  A. Carneiro PORTUGAL
       PCV characterisation: An overview

10.17  G. Staurenghi ITALY
       The diagnosis: multimodal imaging of PCV: colour images, autofluorescence, infrared reflectance, OCT, FA, ICGA

10.30  R. Silva PORTUGAL
       OCT-A: Is it useful?

10.43  M. Falcao PORTUGAL
       The differential diagnosis: CSC, nAMD; tumours, others

10.56  S. Sadda USA
       The treatment: Clinical evidence of anti-VEGF monotherapy

11.09  A. Koh SINGAPORE
       The treatment: Clinical evidence for combination therapy. How and when to treat and re-treat

11.22  Discussion

11.30  End of course

10.00 – 11.30

INSTRUCTIONAL COURSE 44
Swept Source OCT-A: How it Changes My Practice
Room D2

Course Organiser:  W. Soliman EGYPT

10.00  M. Sharaf Eldin EGYPT
       Basics of swept source OCT-Angiography

10.12  M. Moussa EGYPT
       Wide-field swept source OCT-Angiography

10.24  M. Larsen DENMARK
       Swept source OCT-Angiography in diabetic retinopathy

10.36  W. Soliman EGYPT
       Swept source OCT-Angiography in AMD

10.48  Z. Eldaly EGYPT
       Swept source OCT-Angiography in RVO

11.00  M. Moussa EGYPT
       Solving Challenging cases using swept source OCT-Angiography

11.12  Discussion

11.30  End of course
**SUNDAY 23 SEPTEMBER**

**10.00 – 11.30**

**INSTRUCTIONAL COURSE 45**

**Achieving Optimal Cataract Surgery Outcomes**

Room D4

Course Organiser: Z. Shalchi *UK*

10.00 Z. Shalchi *UK*  
Introduction

10.05 R. Hamilton *UK*  
Cataract surgery in eyes with exudative and non-exudative AMD

10.20 Z. Shalchi *UK*  
Cataract surgery in the diabetic eye

10.35 N. Jones *UK*  
Managing the uveitic cataract

10.50 A. Tufail *UK*  
Managing post-operative cystoid macular oedema

11.05 A. Grabowska *UK*  
Case presentation and surgical pearls

11.15 Discussion

11.30 End of course

**12.00 – 13.30**

**EURETINA MAIN SESSION 10**

**Myopia: A Full Update**

Hall D3

Chairpersons: C.C.W. Klaver *THE NETHERLANDS*  
Y. Ogura *JAPAN*  
R. Tadayoni *FRANCE*

12.00 C.C.W. Klaver *THE NETHERLANDS*  
Genetics, risk factors and epidemiology of myopia

12.10 J. Jonas *GERMANY*  
Progression of myopia and myopic maculopathy

12.20 G. Cheung *SINGAPORE*  
Prevention of myopia and its evolution

12.30 A. Grzybowski *POLAND*  
Refractive and lens surgery in highly myopic eyes from the retina perspective

12.40 T. Iida *JAPAN*  
Modern imaging of the retina in high myopia

12.50 D. Gaucher *FRANCE*  
Domeshape macula news

13.00 G. Querques *ITALY*  
Myopic choroidal neovascularization management update

13.10 R. Tadayoni *FRANCE*  
Update on modern surgery in highly myopic eyes to achieve best possible results

13.20 M. Figueroa *SPAIN*  
New techniques for closing myopic macular holes

13.30 End of session
12.00 – 13.30
FREE PAPER SESSION 27
AMD V
Room C4

Chairperson: S. Schmitz-Valckenberg GERMANY

12.00 L. Wang, S. Schmidt, C. Brandstetter, P. Fang, E. Latz, F. Holz, T. Krohne GERMANY
Efficacy of novel small molecule-based NLRP3 inhibitors in retinal pigment epithelial cells

12.06 C. Skevas, M. Spitzer, C. Grohman GERMANY
Surgical management of acute submacular hemorrhage (ASH) due to wet age related macular degeneration (wAMD): A direct comparison between three surgical methods: Pneumatic displacement with or without vitrectomy in combination with subretinal or intr

12.12 C. Turksever, C. Pruente, K. Hatz SWITZERLAND
A retrospective pilot study assessing the vessel density in nAMD after long-term anti-VEGF treatment and compared to recently started anti-VEGF treatment

12.18 A. Leys, E. Mangelschots, J. Jacob BELGIUM
Omega-3 and Vitamin D blood serum dosage in a population with moderate to high risk of AMD determined by S.T.A.R.S questionnaire

Longterm safety and real life efficacy outcomes after combined stereotactic radiotherapy and treat-and-extend anti-VEGF treatment for neovascular AMD

12.30 T. van Rijssen, E. van Dijk, S. Fauser, G. Querques, S. Downes, C. Hoyng, C.J. Boon THE NETHERLANDS
Clinical characteristics and outcome in chronic central serous chorioretinopathy with focal versus extensive abnormalities

12.36 T. Krohne, P. Larsen, C. Clemens, M. Guttleisch, N. Eter, A. Wolf, F. Holz GERMANY
Ranibizumab in pigment epithelial tears secondary to age-related macular degeneration; a prospective study (the RIP Study)

Effectiveness and safety of repeated ranibizumab 0.5 mg injections in Taiwanese patients newly diagnosed with neovascular age-related macular degeneration: 12-month real-life outcomes from the RACER study

Inflammaging in polypoidal choroidal vasculopathy and neovascular age-related macular degeneration

12.54 R. Serra, F. Coscas, D. Cabral, M. Lupidi, G. Coscas, E. Souied ITALY
Long-term progression of naïve quiescent choroidal neovascularization in intermediate age-related macular degeneration, by multimodal imaging and optical coherence tomography angiography

13.00 G. Neri, G. Neri, M. Orlandini, F. Fusco, M. Gelmi, T. Bacci, G. Tosi ITALY
CD93 is a potential new target for CNV treatment

Longitudinal analysis and prognostic value of outer retinal layer intensities by SD-OCT in eyes with age-related macular degeneration

Registry of AMD In Turkish population (REGAIN): Patient demographics and treatment approaches in neovascular age related macular degeneration (nAMD)

13.18 R. Hamilton, T. Wong, A. Weichselberger, Z. Butuner, P. Dugel UK
A comparison of the anatomical efficacy of brolucizumab and aflibercept in neovascular age-related macular degeneration (nAMD): an analysis of Weeks 12–16 in the HAWK and HARRIER studies

13.30 End of session
SUNDAY 23 SEPTEMBER

12.00 – 13.30

SYMPOSIUM

Posterior Segment Complications of Cataract Surgery

Room D1

Chairperson: B. Chanana INDIA

12.00 B. Chanana INDIA
Management of dropped IOL and nucleus

12.10 A. Amphornphruet THAILAND
Management of cystoid macular edema: When and how to treat?

12.20 H. Heimann UK
Retinal detachment in mismanaged cataract surgery: Prevention, etiology and management

12.30 M. Zinkernagel SWITZERLAND
Inadvertent globe perforation during local anaesthesia for cataract surgery and its management

12.40 B. Chanana INDIA
Endophthalmitis: Early detection, differentiation from sterile reaction and management

12.50 V. Chaikitmongkol THAILAND
Expulsive haemorrhage: early detection and management

13.00 Discussion

13.30 End of symposium

12.00 – 13.30

SYMPOSIUM

MEDITERRETINA SOCIETY

Role of Vitrectomy in Diabetic Patients in the Era of Anti-VEGF

Room D5

Chairpersons: G. Fasolino ITALY/BELGIUM
A. Nikolakopoulos GREECE

12.00 T. Rotsos GREECE
Pathophysiology of diabetic macular edema

12.10 F. Boscia ITALY
DRCR protocols: IST and U new model of treatment for DME and PDR

12.20 L. Mavroudis GREECE
How early anti-VEGF in diabetic retinopathy

12.30 F. Patelli ITALY
Vitrectomy: How, when, why

12.40 F. Fayad JORDAN
Vitreous surgery for abnormal vitreomacular interface abnormalities in diabetic patients

12.50 S. Gotzaridis GREECE
3d surgery in diabetic retinopathy

13.00 C. Papadopoulou GREECE
Vitrectomy in vitreous haemorrhage

13.10 A. Nikolakopoulos GREECE
Heads up vitrectomy video

13.20 Discussion

13.30 End of session
12.00 – 13.30
INSTRUCTIONAL COURSE 46
Recognition of Key Signs of OCT Influencing Our Decisions in Daily Practice
Room D2
Course Organisers:  A. Ambresin SWITZERLAND
F. Coscas FRANCE

12.00  I. Mantel SWITZERLAND
OCTs in systemic diseases

12.12  F. Coscas FRANCE
OCTs in vein occlusions

12.24  L. Zografos SWITZERLAND
OCTs in adult and paediatric oncology

12.36  P-R. Rothschild FRANCE
OCTs in diabetic retinopathy

12.48  A. Ambresin SWITZERLAND
OCTs in age related macular degeneration

13.00  J.A. Pournaras SWITZERLAND
OCTs in vitreo-macular interface pathologies

13.12  Discussion

13.30  End of course

12.00 – 13.30
INSTRUCTIONAL COURSE 47
Surgery for Neovascular AMD: Long-term Multimodal Imaging of Postoperative Response & Physiopathological Implications
Room D4
Course Organiser:  A. Polito ITALY

12.00  S. van Romunde THE NETHERLANDS
Early and late neurosensory retina changes following surgery: Photoreceptor rescue

12.15  A. Polito ITALY
Early and late choriocapillary/choroid changes following surgery

12.30  M. Mete ITALY
Early and late RPE changes between the graft and the recipient bed: Development and progression of GA

12.45  E. Maggio ITALY
CNV recurrence

13.00  G. Pertile ITALY
Future trends in RPE transplantation: Lessons learned from AMD's surgery

13.15  Discussion

13.30  End of course
A WORLD OF BENEFITS INCLUDING:

- Online Education Programme (CME Accredited)
- Observership Grant Scheme
- Research Funding Opportunities
- Young Retina Specialists Forum (YOURS)
- Online Interviews & Panel Discussions with Experts (Media Player)
- Membership Promotions including:
  - 20% Discount for Members of National Retina Societies
  - Free Membership for under 40s

FIND US AT:
BOOTH C300, EXHIBITION HALL C
Visit the Resource Centre to Discover our Membership Benefits

**EURETINA InSight**  
CME accredited online interactive courses

**EURETINA On Demand**  
Online library of presentations from EURETINA Congresses

**Access to Ophthalmologica**  
The Official Journal of EURETINA

**Reduced Congress Registration Fees**

Visit our newly designed website  
www.euretina.org
CLOSING RECEPTION

Including Best Free Paper & Poster Awards from the 18th EURETINA Congress

SUNDAY 23 SEPTEMBER
13.30, Foyer Hall D3
ePOSTER Presentations & VIDEO Competition
AMD

A. Alsafty, D. Ting, S. Pushpoth, P. Severn UK
Efficacy of Aflibercept in wet age-related macular degeneration non-responsive to Ranibizumab

M. Ankan Yogun, Y. Toklu TURKEY
Effect of cataract surgery in patients with high-risk early age-related macular degeneration

O. Artunay, A. Sengul, M. Yenerel, G. Erdogan, I. Perente TURKEY
Comparision of choroidal thickness using enhanced depth imaging in adult-onset vitelliform macular dystrophy and wet age-related macular degeneration

A. Avunduk, K. Bozkurt TURKEY
The assessment of efficacy of intravitreal aflibercept injections for the treatment of naïve wet type age-related macular degeneration

G. Bátor, A. Zelko, B. Rozman, M. Kovacs, A. Halmosi, E. Toldy, Z. Biro HUNGARY
Relationship between the level of vitamin 25(OH)D, the age-related macular degeneration and the simplex glaucoma

M. Budzinska, J. Bubnova, A. Kurguzova RUSSIA
Influence of corneal biomechanical properties on IOP indices after intravitreal injections.

A. Cabrera Marenco, T. Ortiz Basso, S. Cura, C. Challiol ARGENTINA
Correlations between anatomical and functional outcomes after switch to Aflibercept monotherapy in patients with previous intravitreal Bevacizumab treatment in different neovascular membranes: Our experience in 25 patients

C. Calvo, J. Reche, M. Jimenez, A. Otto SPAIN
Refractory ranibizumab wet-AMD switched to Aflibercept: ICG findings

P. Cardoso, J. Meira, A. Pedrosa, J. Costa, M. Falcao, F. Falcao-Reis, A. Carneiro PORTUGAL
One year outcomes in early vs late switch aflibercept in the treatment of neovascular age-related macular degeneration

A. Cimbalas, Z. Vieversyte, A. Bojarun LITHUANIA
Five-year outcomes of treatment of neovascular age-related macular degeneration

J. Coelho, L. Malheiro, C. Abreu, S. Monteiro, M. Gomes, M. Furtado, M. Lume PORTUGAL
Subfoveal choroidal thickness response to anti-VEGF after 2 years of treatment in neovascular age-related macular degeneration

E. Costales Mier, A. Mateos Hernandez, L. Monje Fernandez, N. Spagnoli Santa Cruz, I. Garzo Garcia, C. Plaza LaGuardia, E. Pertejo Fernandez SPAIN
Full thickness macular hole development after initial ranibizumab loading dose, in a naïve AMD patient

LIGHTSITE I Clinical Analysis: A double-masked, randomized, sham-controlled, parallel group study to assess the safety and efficacy of photobiomodulation in subjects with dry age-related macular degeneration

Z. Elhousscini, N. Kozato, D. Mitry, R. Asaria UK
Long-term outcome of submacular haemorrhage treated with sub-retinal Tpa and anti VEGF

G. Esposti, G. Palendri, B. Pieri, P. Esposti ITALY
Subthreshold yellow micropulsed 577 nm laser resensitisation of medially unresponsive neovascular age-related macular degeneration

M. Figueras-Roca, J. Zarranz-Ventura, A. Parrado, R. Casaroli-Marano, D. Barthelmes, M. Gillies SPAIN
One-year comparison of fixed bimonthly and treat-and-extend regimes for treatment naïve neovascular age-related degeneration: data from an observational study of outcomes in routine clinical practice

J. Forster, M. Stattin, A. Graf, D. Ahmed, I. Krebs, S. Ansari-Shahrezaei AUSTRIA
Five-year outcomes of a personalized pro re nata treatment regimen with anti-VEGF for neovascular age-related macular degeneration

A. Francesca, A. Pedinielli, R. Blanco Garavito, P. Astroz, A. Miere, F. Gheradaoui, E. Souled FRANCE
OCTA-guided Navilas therapy for choroidal neovascular membranes

Short-term changes in choroidal thickness after intravitreal injection of vascular endothelial growth factor antagonists in age related macular degeneration

K. Giannopoulos, O. Makri, A. Pallikari, K. Kagkelaris, E. Kostopoulou, A. Mpakouli, C. Georgakopoulos GREECE
Effect of intravitreal injection of aflibercept on blood coagulation parameters in patients with age related macular degeneration

B. Gorodetskiy, Y. Gorodetskaya RUSSIA
AMD ranibizumab treatment in combination with photodynamic therapy by verteporfin: Clinical case

M. Guma SAUDI ARABIA
Intravitreal aflibercept injections in the treatment of combined CNVM (choroidal neovascular membrane) and C.S.M.E (clinically significant diabetic macular edema)

Ranibizumab treatment in real-life conditions: 12-month interim analysis of the German neovascular age related macular degeneration (nAMD) population within the observational, non-interventional PACIFIC study

Exploiting options in AMD treatment: Results of a 12 months pre-structured aflibercept protocol

B. Horsman USA
SDM laser for leaking CNVM

R. Hua, L. Wang CHINA
Ranibizumab and conbercept for neovascular age-related macular degeneration: A meta-analysis

A. Invernizzi, V. Nguyen, J. Arnold, S. Young, D. Barthelmes, M. Gillies ITALY
Early and Late retinal pigment epithelial tears following anti-VEGF therapy for neovascular age-related macular degeneration

L. Jones, D. Taylor, L. Edwards, A. Binns, D. Crabb UK
“It makes me unhappy that others can see things that I can’t see”: Patient’s experiences of dry AMD

Intravitreal injections: How informed are the patients?

M. Kaya, N. Kocak, T. Ozturk, S. Kaynak TURKEY

Intravitreal ranibizumab monotherapy in naive eyes with myopic choroidal neovascularisation

P. Kertes, T. Sheidow, G. Williams, M. Greve, I. Galic, J. Gavalakis, A. Scarino CANADA

Canadian treat and extend analysis trial with ranibizumab in patients with neovascular AMD: CANTREAT study two-year results

Y. Khazardzhan, V. Fokin, L. Boriskina, T. Efremova RUSSIA

Intravitreal aflibercept in treatment of high pigment epithelium detachment in wet age-related macular degeneration: a retrospective study

Y. Khazardzhan, V. Fokin, L. Boriskina, T. Efremova RUSSIA

Intravitreal aflibercept in treatment of high pigment epithelium detachment in wet age-related macular degeneration: a retrospective study

P. Kiyat, J. Mentes TURKEY

Initial lesion characteristics of eyes with inadequate response to aflibercept treatment in neovascular age-related macular degeneration

A. Kopić, M. Vinkovic, T. Benasíc, M. Bradvica, V. Kopić CROATIA

The effect of intravitreal bevacizumab injections on retinal nerve fiber layer thickness in glaucoma patients

A. Korol, T. Kustryn, O. Zadorozhnyy, S. Fedchenko, A. Nevska UKRAINE

Efficacy of 577-nm retinal pigment epithelium micropulse laser photocoagulation in age-related maculopathy patients with various extents of morphological and functional loss

M. Kotoula, V. Vasileiou, E. Papageorgiou, N. Voutsas, A. Tantou, E. Tsironi GREECE

Quality-adjusted life year (QALY) in patients with age related macular degeneration in a tertiary hospital in central Greece

M. Krogh Nielsen, Y. Subhi, C. Molbech, L. Nilsson, T. Sorensen DENMARK

Imbalances in tissue inhibitors of metalloproteinases differentiate choroidal neovascularization from geographic atrophy

A. Kurt, R. Kilic, F. Milletli, O. Polat TURKEY

Evaluation of serum YKL-40 levels in patients with age related macular degeneration

D. Lee, J. Wang TAIWAN

Comparison of intravitreal aflibercept and ranibizumab injection in patients with neovascular age-related macular degeneration (nAMD)

I. Malinouuskaya BELARUS

Comparative effect of intravitreal injections (Bevacizumab vs Aflibercept) in neovascular age-related macular degeneration treatment

V. Manoharan, Z. Madanat, F. Ghanchi UK

Morphological features and prognosis of retinal pigment epithelium (RPE) rips in neovascular macular degeneration (nAMD)

I. Mantel, A. Nguyen, D. De Azevedo, E. D’Alessandro SWITZERLAND

Central retinal thickness measurements in anti-VEGF refractory AMD: the influence of time course and time interval from last injection

A. Marta, P. Baptista, L. Malheiro, S. Monteiro, M. Furtado, M. Lume PORTUGAL

Switching From bevacizumab to aflibercept in neovascular age-related macular degeneration: Clinical outcomes and identification of clinical findings associated with suboptimal response


Real-life long-term outcomes for patients receiving intravitreal Aflibercept for neovascular age related macular degeneration (nAMD): four-year follow-up

L. Mikhailova, I. Vorobyova RUSSIA

The results of diagnostic and treatment of patients with diabetic retinopathy and age-related macular degeneration at a diabetes type 2

S. Mondal INDIA

Intravitreal ranibizumab versus its biosimilar (razumab) in the treatment of neovascular age-related macular degeneration: A noninferiority study

M. Morales, S. Saker, C. Wilde, W. Amoaku UK

Biofeedback fixation training (BFT) as a therapeutic alternative to improve eccentric visual acuity in patients with advanced dry AMD

M. Morimoto, H. Matsumoto, H. Akiyama JAPAN

Short-term outcomes of switching therapy from intravitreal anti-VEGF to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy

P. Müller, M. Pfau, P. Moeller, L. de Sisternes, P. Herrmann, F. Holz, M. Fleckenstein GERMANY

Choroidal flow-signal in late-onset Stargardt disease and age-related macular degeneration

K. Nandi INDIA

A rare case report of Choroidal neovascular membrane following endogenous endophthalmitis with sub-retinal abscess in one eye caused by Scedosporium apiospermum fungus

G. Nerl, F. Galvagni, F. Fusco, A. Tarantola, A. Tarantello, G. Tosi ITALY

Active TGF-β concentration and activity in the aqueous humor of patients with neovascular age-related macular degeneration

F. Oner, M. Kaya, F. Yilmaz, E. Mentes TURKEY

Focal choroidal excavation associated with choroidal neovascularization: Case series

M. Oshallah, A. Sepetis, A. Theodorakis, D. Inzerillo UK

Cataract surgery in neovascular age-related macular degeneration. Best approach
S. Ozdogan Erkul, O. Ayranci Osmanbasoglu  TURKEY
The real effect of loading dose time interval on injection number, best corrected visual acuity and central macular thickness change in neovascular age related macular degeneration

A. Parrado-Carrillo, M. Figueras-Roca, R. Casaroli-Marano, D. Barthelmes, M. Gillies, J. Zarranz-Ventura  SPAIN
Big data and intravitreal therapy: Barcelona's cohort results, fight retinal blindness project

One and two-year outcomes of a treat-and-extend regimen in AMD: comparison between bevacizumab, ranibizumab and aflibercept

R. Rosa, P. Corazza, C. Mochi, M. Musolino, M. Nicolò', C. Traverso, G. Maiello  ITALY
Drusen and choroid: A swept-source optical coherence tomography and swept-source optical coherence tomography angiography analysis

M. Sabaner, M. Dogan, R. Duman, R. Duman  TURKEY
One-year outcomes of aflibercept intravitreal injection for wet age-related macular degeneration treatment in naive patients

P. Schlottmann, B. Day, L. Tuomi  ARGENTINA
A cross trial comparison of patients achieving visual gains or stability following quarterly anti-VEGF dosing for the treatment of nAMD

N. Semenova, V. Akopyan  RUSSIA
Prevalence of vitreomacular adhesion in early and intermediate age-related macular degeneration

F. Sermet, S. Demirel, E. Temel, M. Degirmencı, E. Ozmert  TURKEY
Comparison of choriocapillaris vasculature in different types of drusen and healthy eyes: An optical coherence tomography angiography study

J. Shin, C. Park, H. Kim  SOUTH KOREA
Risk of ischemic stroke in exudative age-related macular degeneration patients treated with ranibizumab or aflibercept using Korean claims data

G. Siasou, I. Akram  UK
Spontaneous closure of a full thickness macular hole secondary to intravitreal anti-VEGF injection

S. Sızmaz, F. Kibar, E. Esen, N. Demircan  TURKEY
Ocular surface bacterial load in intravitreal injections: Lid speculum vs. manually assisted retraction

M. Stamenković, M. Skuletic, V. Jakšić  SERBIA
The powerful treatment for the exudative AMD: case report

S. Sül, A. Karalezli, M. Karabulu  TURKEY
First year outcomes of cataract surgery combined with intravitreal ranibizumab injection in neovascular age-related macular degeneration

J. Takeuchi, K. Kataoka, Y. Ito, T. Yasuma, H. Kaneko, H. Terasaki  JAPAN
Microvascular changes in choroidal neovascularization assessed by optical coherence tomography angiography in response to anti-vascular endothelial growth factor

C. Tan, S. Parikh  SINGAPORE
Screening failure rates in the EVEREST II clinical trial reveal the challenges in the diagnosis of symptomatic macular polypoidal choroidal vasculopathy

T. Tew, T. Lai, Y. Hsieh, T. Ho, C.M. Yang, C.H. Yang  TAIWAN
Morphology of type 1 choroidal neovascularization in age-related macular degeneration detected by optical coherence tomography angiography

T. Tran, V. Rufin, A. Barakat, J. Hung  FRANCE
Second year outcome in naïve patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept

O. Truneva  RUSSIA
Results of Aflibercept treatment in patients with AMD who were incomplete responders to Ranibizumab injections.

M. Ulusoy, A. Kai  TURKEY
Comparison of anti-VEGF treatments on pigment epithelial detachments in age-related macular degeneration

P. Vassileva  BULGARIA
Long term results of anti-VEGF therapy for various retinal disorders

H. Wang, C. Lai, S. Chen, H. Choi, C. Tsai, C. Yang, C. Kuo  TAIWAN
Treatment outcomes with ranibizumab in Taiwanese patients with neovascular age-related macular degeneration: results from the 12-month Phase IV, observational RENOWNED study

Intravitreal aflibercept in patients with different subtypes of exudative maculopathy

S. Wijetilleka, G. Williams, C. Yeo, C. Gunasekera  UK
To drape or not to drape for intravitreal injections

D. Yakupova, M. Bikbov, R. Fayzrakhmanov, I. Iuzianbaeva, V. Mavljeva, R. Zainullin  RUSSIA
Correlations of myopic maculopathy among adults

U. Yayla  TURKEY
Assessment of intravitreal Aflibercept activity using the wait and stretch regimen in Ranibizumab limited responsive neovascular age-related macular degeneration.

M. Zhang  CHINA
One-year outcomes of intravitreal conbercept for treatment-resistant neovascular age-related macular degeneration
Anterior/Posterior Segment Surgery

S. Arya, M. Pereira, S. VR, L. Singh Jhiala **INDIA**
Diabetic macular periling in end stage nephropathy cases

P. Beliaukoski, N. Pozniak, N. Kovshel, G. Krshtopenko, I. Kuderko **BELARUS**
The impact of autologous segments corneal limbus in macular and optic nerve degeneration

Multicenter study of retropupillary iris-claw intraocular lens implantation in patients with aphakia secondary to complicated cataract surgery or dislocated intraocular lens

P. Bhende, R. Saxena **INDIA**
Scleral fixed iol (SFIOL) using polytetrafluoroethylene (gore-tex) suture combined with prior or concurrent pars plana vitrectomy (PPV): Techniques and initial experience

C. Caglar, E. Kucukkomurcu **TURKEY**
The rate of intraoperative complications during cataract surgery in eyes with previous intravitreal injections

R. Calamita, C. Mariotti, V. Pirani, P. Pelliccioni, N. Lassandro, P. Bisceglia **ITALY**
Utility of an ab interno suprachoroidal micro-stent in the management of persistent glaucoma after silicon oil removal in vitrectomized eyes

O. Celik, O. Kari, M. Zengin, T. Kusbeci **TURKEY**
The evaluation of the anterior and posterior ocular segment parameters in patients presenting with photopsia and floaters

D. Chakraborty, T. Sinha, A. Mukherjee, S. Majumdar **INDIA**
No suture no glue Intraocular lens implant in eyes with no capsular support

W. Chen, D. Zheng **CHINA**
Intraoperative amaurosis under sub-tenon’s anesthesia during combined phacoemulsification and vitrectomy

Iris diaphragm intra-ocular lens implantation in traumatic aniridia: A retrospective analysis

A. Dzhapparkhanova, G. Zhurgumbayeva **KAZAKHSTAN**
The results of the use of anti-VEGF therapy in combination with drainage surgery with in patients with neovascular glaucoma at distant observation times

S. Elhashan, G. Williams **UK**
Do patients only remember who performed their cataract surgery if complications occur?

M. Ghara, E. Assia, Y. Ton **ISRAEL**
evaluating the safety of intracocular lens or intraocular telescope implant and scleral fixation using a lens exchange system (LES)

F. Hagenau, D. Vogt, L. Mautone, A. Wolf, S. Priglinger, R. Schumann **GERMANY**
ILM flap technique in macular hole surgery: Pros and cons from the histopathological perspective

M. He, J. Zhang, Y. Lee **TAIWAN**
Anterior migration of dexamethasone implant in a post phacovitrecomty patient with intact posterior capsule

M. He, W. Tsai **TAIWAN**
Two lenses decentered in A eye with Marfan Syndrome

I. Ianilina, L. Kryl **RUSSIA**
The combined laser surgery of vitreous hemorrhages due to retinal hozeshoe tears prevention

R. Jorge, K. Viana, D. Lucena, C. Gordillo, F. Almeida, I. Scott, A. Messias **BRAZIL**
Combined pars plana vitrectomy (PPV) and phacoemulsification (phaco) versus PPV and deferred phaco for patients with macular hole: One-year outcomes

Z. Koshy, O. Williams **UK**
IOL exchange surgery: indications, challenges and outcomes

A. Kurt, R. Kilic **TURKEY**
The effects of uncomplicated cataract surgery on retinal layer thickness

V. Melnyk **UKRAINE**
Effectiveness of new method of implantation of the dexamethasone intravitreal implant OZURDEX® combined with phacoemulsification in patients with diabetic macula oedema

M. Moura-Coelho, D. Hipolito Fernandes, A. Basilio, L. Costa, A. Dias-Santos, M. Reina, M. Dutra-Medeiros **PORTUGAL**
Clinical outcomes of Ahmed glaucoma valve implantation in secondary glaucoma related to retinal surgery: A case series

G. Murthy, P. Mahajan, P. Kumar, A. Prakash **INDIA**
Comparison of central retinal thickness changes in diabetic patients undergoing cataract surgery with and without anti-VEGF

G. Mylonas, B. Wetzel, C. Bernhart, F. Prager, G. Kahraman, P. Malamos, M. Amon **AUSTRIA**
Retinal thickness change following cataract surgery in eyes with epiretinal membrane

M. Osman **EGYPT**
Incidence of posterior vitreous detachment after femtosecond LASIK compared with microkeratome LASIK

T. Parmar, D. Yeo, D. Morris **UK**
A multi-centred study to evaluate visual outcomes with the time taken to repair open globe injuries in South East Wales

S. Sabour, M. Naderi, S. Khodakarim, F. Daneshgar **IRAN**
Studying the factors related to refractive errors regression after PRK surgery

A. Shetty, A. Sharma, V. Reddy, S. Abdul Kader, U. Halder **INDIA**
Long-term efficacy of the aurolab aqueous drainage implant placed in vitreous cavity

I. Tzovitchas, C. Keskini, Z. Tegou, C. Kamos, A. Michonidou, E. Karasavvidoy, G. Sarkias **GREECE**
Transcleral fixation of 1-piece IOLs that were posteriorly dislocated in the vitreous cavity without their explantation: 2 year outcomes

A. Zafar, I. Ablanides, V. Selimis **UK**
Uneventful anterior migration of intravitreal dexamethasone implant in a patient with iris-sutured intraocular lens and descemet stripping automated endothelial keratoplasty
Imaging

F. Aboalazayem EGYPT
Best's vitelliform dystrophy in Muckle-well's syndrome: a rare association that does exist

Intraobserver reproducibility of foveal avascular zone manual measurement with optical coherence tomography angiography (OCT-A)

Detection of treatment-naïve choroidal neovascularization in age-related macular degeneration by swept source optical coherence tomography angiography

D. Alex, G. Anantharaman, I. V INDIA
Explicating the importance of minimally interventional therapeutic approach in a unique case of chronic central serous retinopathy with peripheral neovascularisation of retina

H. Al-Nashar, M. AlNaimy EGYPT
Retinopathy with peripheral neovascularisation of retina

D. Alex, G. Anantharaman, I. V INDIA
Explicating the importance of minimally interventional therapeutic approach in a unique case of chronic central serous retinopathy with peripheral neovascularisation of retina

H. Al-Nashar, M. AlNaimy EGYPT
Assessment of myopic choroidal neovascularization using optical coherence tomography angiography

R. Arora UK
Torpedo maculopathy: Clinical presentation and OCT features

G. Balanikas, C. Georgiadou, D. Nanas, G. Athanasopoulos, S. Maloutas, D. Christodoulou GREECE
Diseases of the fundus oculi with atlas by Adalbert Fuchs

B. Bavaharan, S. Gadde, N. Yadav INDIA
A SD OCT correlation of pigment epithelial detachment (PED) and branching vascular network (BVN) in idiopathic polypoidal choroidal vasculopathy (IPCV)

H. Behboudi IRAN
Central areolar macular dystrophy

L. Berger, A. Ebneter, M. Munk, K. Schaal, M. Zinkernagel, S. Wolf SWITZERLAND
Long term follow-up in dome shaped macula with subretinal fluid: a case series

Reduction of foveal avascular zone after vitrectomy demonstrated by optical coherence tomography angiography

P. Cakar Ozdal, Y. Ozdamar Erol, O. Budakoglu TURKEY
The role of imaging in diagnosing posterior scleritis

I. Careba, G. De Salvo, H. Almuhtaseb UK
Sectoral autosomal dominant retinitis pigmentosa mimicking glaucomatous field defect

G. Cennamo, C. Comune, G. de Crecchio ITALY
OCT angiography of Retinal capillary hemangiomas

F. Chew, T. Aslam, P. Keane, A. Denniston, D. Charteris, P. Banerjee UK
Objective measures of vitreous inflammation using optical coherence tomography in eyes with proliferative vitreoretinopathy

H. Cho, D. Kim, E. Hong, Y. Shin, M. Lee SOUTH KOREA
The assessment of the degree of Silicone oil emulsification using Ultra-wide fundus photography and Optical coherence tomography

M. Citirik, A. Kocak Altintas, M. Teke TURKEY
Optical coherence tomography angiography findings in a case of asymmetric bietti crystalline dystrophy

M. Citirik, M. Teke, A. Kocak Altintas TURKEY
Bilateral dome-shaped macula with mild myopia and astigmatism

R. Cobo-Soriano, I. Lozano, J. Zarallo, A. Fernandez-Hortelano, P. Moreno SPAIN
When OCT-A is the key: Imaging secondary choroidal neovascularization by OCT-Angiography in other pathologies different than Age-Related Macular Degeneration

F. Costales Mier, A. Mateos Hernandez, L. Monje Fernandez, J. Sanchez Canizal, E. Pertejo Fernandez SPAIN
Photic maculopathy development after uneventful cataract surgery, a rare complication to be aware of

M. Cozzi, A. Rajter, S. Parrulli, F. Zicarelli, P. Lanzetta, S. Sadda, G. Staurenghi ITALY
Does lens influence green component in short 450 nm color autofluorescence? A cross-sectional study in heathy Caucasian population

S. Degli Esposti, T. Heeren, P. Maloca, K. Balaskas, C. Egan, A. Tufail UK
Optical coherence tomography (OCT) phenotypic features in patients with MIDD (maternally inherited diabetes and deafness)

S. Demirel, G. Condu, F. Sermet, E. Ozmerz TURKEY
Vascular and structural alterations evaluated by optical coherence tomography angiography and optical coherence tomography in choroid after half-fluence photodynamic therapy

S. Di Lauro, S. Crespo, A. Valisena, M. Lopez Galvez, I. Pinilla, S. Pastor-Idoate, J. Pastor SPAIN
Retinal vascular changes after retinal detachment with OCTA: a retrospective study

S. Di Simplicio, M. Mikhail, R. Newsom UK
Diagnosis of schisis-retinal-detachment using ultra-widefield imaging

M. Diab, M. El Shehari, M. Omar SAUDI ARABIA
Corneal confocal microscopy detects neuropathy in patients with type 1 diabetes without retinopathy or microalbuminuria

A. Djatikusumo INDONESIA
Structural changes in persistent macula edema after vitrectomy and internal limiting membrane peeling for epi retina membrane

G. Ducos De Lahitte FRANCE
En face optical coherence tomography in eyes after macular surgery: new insights in anatomic results

Z. Eldaly EGYPT
Choroidal morphological changes and choroidal thickness difference between affected and sound eyes in Central Serous Chorioretinopathy
E. Esen, B. Cam, M. Buyuksemeck, S. Sizmaz, B. Sahin, N. Demircan TURKEY
Resolution of subfoveal serous retinal detachment after treatment with lenalidomide in a patient with multiple myeloma

J. Feki, D. Sellami, I. Kaibi, I. Zone, S. Gargouri TUNISIA Multimodal imaging of pattern maculadystrophy

Detection of progressive changes in the retinal structure of patients with Parkinson’s Disease with spectral-domain optical coherence tomography

T. Fiore, M. Lupid, G. Tosi, A. Cerquaglia, D. Fruttini, C. Cagnini ITALY
Changes of foveal avascular zone and vascular plexuses after epiretinal membrane surgery: an optical coherence tomography angiography study

I. Flores-Moreno, J. Ruiz-Medrano, J. Caminal-Mitjana, J. Ruiz-Moreno SPAIN
Leber’s miliary aneurysms. A multimodal imaging study

I. Garcia-Basterra, J. Diaz-Bernal, J. Mora-Castilla SPAIN Ultra-wide-field angiography for detection of peripheral ischemia in diabetic retinopathy

G. Garhöfer, K. Fondo, D. Schmidl, R. Werkmeister, L. Schmetterer AUSTRIA
Retinal oxygen extraction in patients with type 1 diabetes

G. Gulkilik, O. Balci, C. Tanriverdio, F. Senturk TURKEY
A case of retinal hamartoma associated with epiretinal membrane

D. Hipólito Fernandes, M. Elias Luis, J. Cardigos, M. Vieira, C. Xavier, R. Flores, L. Vieira PORTUGAL
Presence of flow doesn’t mean presence of function – a case report

E. Interlandi, F. Pellegrini, D. Cirone, G. Prosdocimo ITALY
Early and late phase OCT-Angiography in a case of hyperhomocystenemia-related PAMM

C. Iovino, G. Caminiti, A. Den Hollander, E. Peiretti ITALY
Optical coherence tomography angiography characteristics in patients with early onset Drusen

M. Ivanishević CROATIA
First retinal atlasses

M. Karabulut, A. Karalezli, S. Karabulut, S. Sul TURKEY
Microvascular changes in ambliopic eyes detected by optical coherence tomography angiography

M. Karliychuk, P. Bezditko UKRAINE
Retinal morphology changes in patients with diabetes mellitus depending on the scleral lamina cribrosa thickness

O. Kartı, M. Zengin, S. Karabulut, M. Karabulut, T. Kusbeci TURKEY
Anterior and posterior ocular segment findings associated with pathological myopia: A community-based study from the Aegean region of Turkey

U. Kayabası TURKEY
Retinal brain mapping in chiasmal compression

O. Kayikcioglu, M. Altinisi, H. Yamali, M. Yıldırım, E. Kurt, S. Ilker TURKEY
Ultra wide field imaging in retinal diseases

M. Khairallah, S. Khochtali, H. Ben Amor, S. Kammoun, S. Zaouali, R. Messaoud, B. Jelliti TUNISIA
Evidence of choriocapillaris hypoperfusion on swept-source optical coherence tomography angiography in multiple evanescent white dot syndrome

M. Khairallah, S. Khochtali, M. Kechida, H. Ben Amor, Z. Trinta, S. Zaouali, S. Attia TUNISIA
Optical coherence tomography angiography findings in systemic lupus erythematosus

Correlation between optical coherence tomography angiography and structural swept-source OCT findings in macular edema associated with uveitis

R. Kiliç, A. Kurt TURKEY
A patient with acute retinal pigment epithelitis: a rare case presentation

E. Kim, J. Kim, K. Kim, S. Yu SOUTH KOREA
Changes of OCTA findings after treatment in polypoidal choroidal vasculopathy

M. Kim, E. Han, H. Yu UAE
Presence of vascular leakage in ultra wide field fluorescein angiography in idiopathic epiretinal membrane

Y. Koh, J. Chia SINGAPORE
A case of unilateral serous retinal detachment

R.A. Kurt TURKEY
Spontaneous resolution of the subretinal fluid in a patient with central serous retinopathy and focal choroidal excavation

N. Lassandro, C. Mariotti, G. Porri, P. Pelliccioni, P. Bisceglia, V. Pirani, R. Calamita ITALY
Foveal sparing in suspected Bietti crystalline dystrophy

S. Lee, J. Park, E. Lee SOUTH KOREA
Retinal and choroidal findings in active toxoplasmic retinochoroiditis: A swept-source optical coherence tomography angiography study

E. Lee, J. Lee, S. Lee SOUTH KOREA
Foveal microvascular structures in eyes with silicone oil tamponade for rhegmatogenous retinal detachment: A swept-source optical coherence tomography angiography study

W. Lin, W. Li, V. Li, C. Li TAIWAN
Improved automated method for monitoring treatment effectiveness of anti-VEGF therapy in retinal disease using curvelet analysis of fluorescein angiograms

M. Lupidi, F. Cardillo Piccolino, A. Cerquaglia, A. Caricato, G. Coscas, C. Cagini ITALY
Ultra-high density cross-sectional OCT-angiography of retinal and choroidal neovascularization

D. Maltsev, A. Kulikov, M. Burnasheva RUSSIA
Retro-mode scanning laser ophthalmoscopy in imaging of choroidal nevi
G. Mathur INDIA
FORUS for detection of macular diseases by trained optometrist to save eyesight

A. Matsou, A. Dastiridou, M. Dermenoudi, E. Anastasopoulos, D. Tzetzi, S. Androudi, P. Brazitikos GREECE
Retinal vascular network alterations in multiple sclerosis associated optic neuritis measured with optical coherence tomography angiography

P. Milani, M. Pellegrini, A. Massaccesi, S. Moschini, M. Setaccioli, F. Bottoni, F. Bergamini ITALY
Neuroretinal changes after anti-VEGF therapy in myopic neovascularization

A. Mirshahi, M. Abrishami, A. Lashay, H. Faghihi IRAN
Consequences of inadvertent intravitreal mitomycin C injection

Y. Miura, A. Hutfilz, B. Lewke, S. Sonntag, S. Grisanti, R. Brinkmann GERMANY
Change of RPE's autofluorescence lifetime during wound healing after laser irradiation

N. Moura-Coelho, M. Dutra-Medeiros, M. Vieira, M. Deslandes Noronha, A. Basilio, R. Flores PORTUGAL
The role of multimodal imaging in central serous chorioretinopathy: a case report

D. Mucciolo, V. Murro, A. Sodi, I. Passerini, G. Virgili, S. Rizzo ITALY
Retinal dystrophy in young choroideremia (CHM) patients

V. Murro, D. Mucciolo, A. Sodi, F. Boraldi, D. Quaglino, G. Virgili, S. Rizzo ITALY
Clinical features of retinal dystrophy in Italian patients affected with Pseudoxantoma Elasticum (PXE)

Changes of choroidal structure and circulation during water drinking test in normal eyes

Y. Nikolaeva BULGARIA
Optical coherence tomography angiography (OCTA) as a method for diagnosis and follow-up in cases with maculopathy due to laser-burn in discotheque

A. Oros, Z. Grgic, M. Kostic SERBIA
Image processing for retinopathy of prematurity

M. Oshallah, G. De Salvo UK
SPECTRALIS glaucoma module premium edition as a new tool in the diagnosis of branch retinal artery occlusion

M. Ouederni, H. Sassi, J. Brour, M. Cheour TUNISIA
Type-2 Macular Telangiectasia: Optical coherence tomography angiography findings

S. Pehlivanoglu, Z. Bayraktar, B. Karini, S. Albayrak, M. Karakaya TURKEY
Assessment of lens autofluorescence in patients with well-controlled hypertension and those with renal failure caused by hypertension who have undergoing hemodialysis

E. Peiretti, C. Iovino, G. Caminiti, R. Sacconi, G. Querques ITALY
Optical coherence tomography angiography characteristics of polypoidal choroidal vasculopathy secondary to chronic central serous chorioretinopathy

D. Pelayes, A. Folgar, J. Zarate ARGENTINA
Morphological changes of the Pigmentary Epithelium, in choroidal tumors in general and in melanocytic tumors in particular, through OCT and what was observed using the principles of Digital Optical Biopsy

A. Pereira, P. Mahendradas, A. Kawali, A. Mohan, R. Mehta INDIA
Retinal oxygen saturation in cases of presumed ocular tuberculosis in Asian Indian eyes

E. Pilotto, F. Leonardi, G. Stefanon, E. Longhin, T. Torresin, D. Deganello, E. Midena ITALY
Early retinal and choroidal OCT and OCT angiography signs of inflammation after uncomplicated cataract surgery

N. Pomytkina RUSSIA
The use of angio-OCT for the evaluation of diabetic retinopathy progression in pregnant women

T. Qian, S. Yu CHINA
Innovative method of synthesis and volume calculation of fluid in retina using OCT images: comprehensive grasp of macular edema

E.R. de Carvalho, A. Robson, G. Arno, A. Webster, M. Michaeiades UK
Classification of fundus autofluorescence patterns in enhanced s-cone syndrome

H. Ra SOUTH KOREA
Observation of changes after peripheral retinal injury by cosmetic laser using wide-field scanning laser ophthalmoscope

Detection of choroidal blood flow alterations with OCT angiography in central serous chorioretinopathy

A. Rodriguez Castelblanco, A. Mateos, F. Costales SPAIN
Middle retinal analysis with En Face Optical Coherence Tomography, as a therapeutic decision tool in patients with clinically significant epiretinal membranes

G. Saban, H. Yilmaz, S. Gedik, A. Bozkurt Oflaz, B. Turgut Ozturk, M. Sahin TURKEY
The change in choroidal thickness and retinal nerve fiber layer (RNFL) in morbidly obese patients who underwent obesity surgery

K. Schaal, M. Eastline, A. Melmer, M. Munk, L. Laimer, M. Zinkernagel, S. Wolf SWITZERLAND
Severity of diabetic retinopathy in widefield swept source OCT angiography and color fundus grading in correlation with HbA1c level and renal function

F. Senturk, S. Erdur Karaman TURKEY
Spectral domain optical coherence tomography findings in autosomal recessive Best’s disease

E. Seven, B. Yavuzer, M. Batur, S. Tekin TURKEY
Nanophthalmos with macular folds: Case reports

R. Shah INDIA
Portable ROP screening is a reality: use of forus neo as low cost portable rop screener

I. Shandurkov BULGARIA
Optical coherence tomography angiography (OCTA) findings in follow-up of a child with myopic choroidal neovascular membrane (mCNV) treated with aflibercept
R. Siggel, C. Spital, S. Liakopoulos  
**GERMANY**  
Optical coherence tomography angiography (OCTA) cross-sectional B-scans with flow information vs en face OCTA imaging for detection of choroidal neovascularization

J. Singh  
**INDIA**  
Differentiation of postoperative CME from DME in diabetic patients by measuring RNFL thickness using OCT and its response to treatment

C. Spital, R. Siggel, S. Liakopoulos  
**GERMANY**  
Sensitivity and specificity for CNV detection using automated vs manually modified segmentation lines to generate optical coherence tomography angiography en face images

**AUSTRIA**  
Detection of secondary choroidal neovascularization in chronic central serous chorioretinopathy by swept source optical coherence tomography angiography

T. Stavropoulou, P. Dimitrakas, D. Pagoulatos, K. Mani, I. Georgalas, C. Koutsandrea  
**GREECE**  
Association of spectral-domain optical coherence tomography changes with visual outcome after successful surgical treatment of macula-off rhegmatogenous retinal detachment

C. Tan, L. Lim, K. Li, K. Cheong  
**SINGAPORE**  
Variation of macular choroidal and retinal thicknesses in healthy young adults

A. Theodorakis, G. de Salvo  
**UK**  
Spectral domain optical coherence tomography of macula and disc in nutritional optic neuropathy

O. Toygar, O. Yabas Kiziloglu, Y. Coskun, N. Guven  
**TURKEY**  
Macular thickness in preschool children who were born preterm

P. Trans, E. Karassavidou, C. Chrissafis, E. Tsirampidou, N. Jaccard, S. Trikha  
**GREECE**  
Evaluation of a deep learning system for diabetic retinopathy and age related macular degeneration screening

F. Ünal, E. Giloglu  
**TURKEY**  
Evaluation of foveal avascular zone and capillary plexus in smokers with optical coherence tomography angiography

V. Vlačik, F. Munier, I. Drumare-Bouvet  
**SWITZERLAND**  
Macular dystrophy in Kabuki syndrome: Further understanding using optical coherence tomography angiography

B. von Jagow, C. Niederstadt  
**GERMANY**  
Automated OCT-segmentation of all layers of the parafoveal retina to analyze the changes after ERM-and ILM-peeling for epiretinal membranes

B. von Jagow  
**GERMANY**  
Angio OCT with manual layer segmentation to analyze the intraretinal vascular distortion in eyes with symptomatic epiretinal membranes

Z. Yazar, N. Alimova  
**TURKEY**  
Comparison of central foveal and subfoveal choroidal thickness in degenerative myopia measured with different optical coherence tomography devices

D. Yeo, W. Moore, E. Beales, I. Lloyd, R. Henderson, S. Wijetilleka, D. Thompson  
**UK**  
Patterns of fundus autofluorescence in young patients with Bardet-biedl syndrome-1 (BB1) retinopathy using wide-field retinal imaging and green-wavelength (532nm) excitation

**POLAND**  
Disturbances of microcirculation around the optic nerve head and macula in patients with Alzheimer’s disease in the OCTA. Comparison of results with a group of patients with glaucoma and healthy controls

O. Zaytseva, V. Nereev, T. Okhotsimskaya, V. Fadeeva  
**RUSSIA**  
Multicolor confocal scanning laser ophthalmoscopy in management of severe proliferative diabetic retinopathy patients

M. Zengin, O. Kartı, A. Korkmaz, T. Kusbeci  
**TURKEY**  
Comparison of subfoveal choroidal thickness and central macular thickness in smokers and non-smokers central serous retinopathy patients

A. Zubiccoa, M. Echeverrieta, J. Andonegui, L. Tabuenca, M. Mozoo, P. Plaza, N. Zubiesta  
**SPAIN**  
Coat’s disease treated with laser photocoagulation

A. Zubiccoa, J. Andonegui, L. Tabuenca, M. Mozoo, P. Plaza, A. Montoliu  
**SPAIN**  
Vitrectomy for macular schisis without optic disc pit

**Intraocular Tumours**

N. Abroug, M. Ladhhari, A. Toumi, S. Aroui, S. Zaauali, S. Attia, M. Khairallah  
**TUNISIA**  
Central retinal venous occlusion complicating a type 2 congenital retinal arteriovenous communication

D. Alex, M. Gopalakrishnan, G. Anantharaman  
**INDIA**  
An unusual case of retinal arterial occlusion in a circumscribed choroidal hemangioma treated with full fluence photodynamic therapy

Y. Alzahrani  
**SAUDI ARABIA**  
ILM peeling in combined hamartoma of retina and retinal pigment epithelium: Does it make difference?

A. Arora, I. Fabian, A. Stacey, L. Al-Harby, M. Sagoo, V. Cohen  
**UK**  
Primary photodynamic therapy with verteporfin for pigmented posterior pole cT1a choroidal melanoma: a 3-year retrospective analysis

R. Bulaj, A. Lala  
**ALBANIA**  
Case report: B-cell intraocular lymphoma masquerading as CMV-retinitis in a patient with acquired immune deficiency syndrome

J. Diaz Bernal, I. Garcia-Basterra, J. Mora Castilla, J. Yanguas, Lucena  
**SPAIN**  
Unilateral uveal metastases secondary to prostate adenocarcinoma

M. Elashry  
**SAUDI ARABIA**  
Morphologic characteristics, ultrasound backscatter and prognosis of uveal melanoma in Swindon: A case series

F. Espejo Arjona, B. Dominguez Garcia, A. Gomez Escobar, M. Diaz Granda  
**SPAIN**  
Use of OCT-Angiography in choroidal melanoma: amelanotic melanoma
POSTER PRESENTATIONS

F. Espejo Arjona, B. Dominguez Garcia, A. Gomez Escobar, M. Diaz Granda, I. Relimpio Lopez, L. Coca Gutierrez SPAIN
Side effects after brachytherapy of uveal melanomas

C. Fernandez-Martinez, J. Martinez-Toldos, F. Hernandez-Artola SPAIN
Laser and ranibuzumab combination for retinal vasoproliferative tumor’s management

Comparison of iodide-125 and ruthenium-106 brachytherapy in the treatment of choroidal melanomas

E. Gyuntner, I. Panova, M. Prokopieva RUSSIA
Transpupillary thermotherapy in choroidal melanoma treatment

A. Ismail, C. Karen SINGAPORE
Choroidal metastasis as initial presentation in lung adenocarcinoma, resolved with erlotinib therapy

S. Karaca Adıyeke, G. Ture, E. Talay TURKEY
Optical coherence tomography findings of noncalcified retinal astrocytic hamartoma

G. Karastatiras, S. Giannikakis, L. Zografos, S. Chaidoulis, K. Glavota, A. Pasalic, V. Glavota CROATIA
Varix of the vortex vein ampula as pseudomelanoma: case report

K. Molka, N. Abroug, A. Mahmoud, K. Chaabouni, A. Kadri, S. Attia, M. Khairallah TUNISIA
Primary vitreoretinal lymphoma: A case-report of a rare disease

S. Khochtali, M. Gargouri, H. Ben Amor, I. Ksiaa, S. Zouari, S. Attia, M. Khairallah TUNISIA
Development of exudative retinal detachment during pregnancy in a patient with circumscribed choroidal hemangioma

R. Marques, D. Sousa, J. Prates Canelas, M. Faria, F. Pinto, F. Campos PORTUGAL
Retinal vascular tumors: a series of 17 patients

M. Oll, M. Park ESTONIA
Multimodal imaging of circumscribed choroidal hemangioma

M. Ratković, A. Pasalic, V. Glavota CROATIA
Varix of the vortex vein ampulla as pseudomelanoma: case report

A. Romero Martinez, D. Gonzalez Dominguez, M. Luque Del Castillo SPAIN
Intraocular lymphoma diagnosed after false post vitrectomy endophthalmitis in vitreous haemorrhage surgery

E. Samkovich, I. Panova RUSSIA
Photodynamic therapy in treatment of amelanotic choroidal melanoma

A. Upadhyay, D. Misra, D. Das, H. Bhattacharjee INDIA
Nuances in pathological evidence for bilateral diffuse uveal melanocytic proliferation (BDUMP)

Miscellaneous

O. Abdullah IRAQ
Presumed central serous retinopathy in nine years old male

D. Ahmed, M. Stattin, C. Glittenberg, I. Krebs, S. Ansari-Shahrezaei AUSTRIA
Stellate non-hereditary idiopathic forearmacular retinoschisis accompanied by contralateral peripheral retinoschisis

B. Akova Budak, S. Kivanc, A. Yucel TURKEY
Unusual scleral thinning following blunt ocular trauma

A. Al-Talbishi, D. Sharon, E. Banin, C. Yahalom, L. Zelinger, P. Namburi, C. Zeitz PALESTINE
TRPM1 mutations are the most common cause of autosomal recessive congenital stationary night blindness in the Israeli and the Palestinian populations

R. Anguita, J. Marquez, A. Salinas, R. Moya, L. Fernandez UK
The spectrum of the uveal effusion syndrome, medical therapy and surgical treatment

G. Balanikas, D. Peironidis, C. Georgiadou, D. Christodoulou GREECE
Oppo Haab and his remarkable work about ophthalmoscopy

S. Balendra, A. Sepetis, D. Farnworth, A. Lockwood UK
Case series and literature review: Antiviral prophylaxis against acute retinal necrosis is imperative in patients following herpetic encephalitis

The impact of vitreomacular interface status and miopic macular disorders on the outcomes of intravitreal anti-VEGF therapy for myopic choroidal neovascularization

L. Bereznvyuk, V. Sakovich, S. Ustimenko, N. Garkava, I. Curban UKRAINE
Treatment of the patient with central retinal vein occlusion and macular edema: A case report

J. Birtel, M. Gliem, A. Oishi, P. Herrmann, F. Holz, H. Bolz, P. Charbel Issa GERMANY
Genetic testing in patients with retinitis pigmentosa – features of unsolved cases may impact future clinical pre-selection and patient counselling

J. Braga, M. Oliveira, D. Rodrigues, R. Rothwell, L. Ribeiro, S. Fonseca, R. Varandas PORTUGAL
Choroidal thickness in patients with systemic lupus erythematosus nephritis

R. Bulaj, A. Lula ALBANIA
Case Report: Ocular manifestations of congenital syphilis in late childhood

Y. Chen, M. Vrahimi, A. Kotagiri UK
Identification of a rare pathogenic mutation in the ABCC6 gene leading to pseudoxanthoma elasticum

Y. Chen, A. Kotagiri UK
Pseudovitelliform macular lesions secondary to desferrioxamine therapy

R. Chigara, A. Haddad, Y. Ouldboouama, I. Taibi, O. Ouhadj ALGERIA
Intravitreal anti-VEGF monotherapy in retinopathy of prematurity management
H. Cilliers, CAYMAN ISLANDS
Pinpoint disease with eye manifestations in a Caribbean Island population over 10 years by using 'Big Data'

B. de Lucas-Viejo, J. Sambricio, M. Fernandez-Reyes, E. Gutierrez-Diaz, SPAIN
Glaucoma-associated retrograde maculopathy: about a case

A. Demircan, E. Esen, S. Sizmaz, O. Oruz, Z. Kunt, TURKEY
Chorioretinitis scleropetaria

P. Dhir, H. Dekha, H. Bhattacharjee, D. Das, M. Burman, D. Mishra, S. Hawaiibum, INDIA
The Raccoose Hacmangom: Wyburn Mason Syndrome

B. Dominguez Garcia, A. Gomez Escobar, M. Diaz Granda, G. Estanislao, SPAIN
Optical coherence tomography angiography findings of choroidal neovascularization in angioid streaks

M. Elcioglu, D. Yildiz, B. Erden, S. Bolukbasi, TURKEY
Retinitis pigmentosa sine pigmenta: a case report

B. Erden, A. Aslan, S. Bolukbasi, S. Erendoz, M. Elcioglu, TURKEY
Real-life results of intravitreal ranibizumab in myopic choroidal neovascular membranes

S. Erendoz, G. Maden, B. Erden, A. Cakir, D. Ekici, G. Zirciirci, M. Elcioglu, TURKEY
Comparison of intraocular pressure changes just before and immediately after intravitreal ranibizumab, alicfercept and dexamethasone implant injection

G. Fernandez-Sanz, R. Alcaniz-Sobrino, SPAIN
Bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents: a retrospective review

A. Filloy Rius, J. Rodriguez Bonet, SPAIN
Posterior traumatic choroidal rupture: OCT Swept Source and angiography follow-up

C. Franzetti, C. Pisano, V. Belloli, F. Aouizerate, G. Gasson, FRANCE
Morphological correlation between optical coherence tomography angiography and spectral domain optical coherence tomography in choroidal neovascularization associated with flat irregular pigment epithelium detachment in chronic central serous chorio

N. Garcia Gallardo, A. de Casas Fernandez, S. Abenza, J. Marin Sanchez, SPAIN
Retrospective study of axial length in patients with regmatogenous retinal detachment

Effect of nepafenac 0.3% on pain associated with intravitreal injections

Retinitis Scleropetaria in a 15-year-old boy after blunt injury to the globe

R. Gizicki, D. Chow, M. Mak, CANADA
Evolving trends in practice patterns of North American vitrectinal surgery fellows from 2010-2016

A. Gomez Escobar, B. Dominguez Garcia, M. Diaz Granda, E. Gutierrez Sanchez, E. Rodriguez de la Rua Franch, SPAIN
Optical Coherence Tomography Angiography in the optic disc drusen: case series

P. Gouveia, J. Pires, J. Pereira Costa, PORTUGAL
An uncommon presentation of arteritic anterior ischemic optic neuropathy

S. Grixioll Mazzon, S. Ruiz, F. Vilaplana, P. Diaz, E. Castillo, SPAIN
Retinopathy associated with ritonavir in HIV positive patient simulating a retinitis pigmentosa

Two cases of idiopathic macular hole with asteroid hyalosis

E. Infantes Molina, M. Pradas Gonzalez, J. Lara Peñaranda, M. Dominguez Fernandez, A. Arias Palomero, A. Nunez Sanchez, F. Gonzalez del Valle, SPAIN
Cow hitch: Outcome and complications of this new technique for suturing intraocular lens to sclera

C. Irigoien, J. Ruiz-Ederra, M. Ezquerra-Inchausti, O. Barandika, A. Anasagasti, SPAIN
Clinical and molecular epidemiological study of retinitis pigmentosa in Gipuzkoa

M. Kamel, SAUDI ARABIA
Diode laser photocoagulation for retinopathy of prematurity: Outcomes after 7 years of treatment

H. Kanar, A. Ozdemir, M. A, TURKEY
Comparison of the effect of systemic tamsulosin hydrochloride and silodosin on choroidal thickness measured by enhanced depth imaging spectral domain optical coherence tomography

Z. Kapsala, D. Pagoulatos, I. Georgalas, C. Georgakopoulos, GREECE
Factors affecting duration of central serous chorioretinopathy episodes

Mutations in more than one gene: Results of molecular genetic screening in patients with inherited retinal dystrophies from one German reference center

A. Lamin, Z. Jarrar, A. Garg, K. Basheer, S. Sivaprasad, C. Hammond, O. Mahroo, UK
Exploration of relative genetic and environmental contributions to variance in macular retinal layer thicknesses as measured by spectral domain optical coherence tomography in a twin study

I. Lertjirachai, W. Prasert, THAILAND
Endogenous nocardia endophthalmitis as multifocal subretinal abscesses in systemic lupus erythematosus patient

F. March de Ribot, A. March de Ribot, T. Torrent, D. Martin, J. Tarros, F. Escalada, SPAIN
Chronic inflammation related to lens serie

A. Menezes, D. Crosby-Nwaobi, UK
Blepharitis presentations at the accident and emergency (A and E) department, Moorfields Eye Hospital
D.K. Misra, P. Bawankar, M. Barman, R. Soibam, H. Bhattacharjee, P. Dhir, A. Upadhyay \textit{India}

Clinical profile, risk analysis and treatment outcomes of post-cataract surgery cluster endophthalmitis caused by multidrug resistant pseudomonas aeruginosa

J. Montero-Moreno, J. Garcia-Garcia, C. Gonzalez-Uruena, M. Fernandez-Munoz \textit{Spain}

Early detection of drug-induced toxic retinopathy using multifocal electroretinogram

S. Moutzouri, E. Kanonidou \textit{Greece}

Bilateral visual impairment as primary manifestation of ischemic leukoencephalopathy

N. Munoz Sanz, J. Serrano de la Iglesia \textit{Spain}

Unilateral diffuse uveal melanocytic proliferation (DUMP) as first manifestation of breast cancer

M.A. Muriel-Herrero, V. Fuertes-Barahona \textit{Spain}

Development of a rubric assessment tool for intravitreal injection technique formative evaluation

S. Numa, A. Oishi, M. Oishi, M. Miyata, T. Hasegawa, A. Tsujikawa \textit{Japan}

In-silico prediction tool and interpretation of variants pathogenicity in patients with retinitis pigmentosa.

A. Onder, B. Komur, N. Solmaz \textit{Turkey}

Vision loss as a first sign of lung carcino (CAR Syndrome)

D. Pagoulatos, Z. Kapsala, O. Makri, I. Georgalas, C. Georgakopoulos \textit{Greece}

Acute bacterial endophthalmitis and visual acuity outcomes

A. Papazacharia, E. Kanonidou \textit{Greece}

Visual loss in a middle aged male with atypical ocular manifestations: one night with venus, a lifetime with mercury

A. Pereira, P. Mahendradas, A. Kawali \textit{India}

A detour from the “silk route”: An Indian perspective on ocular Behçet

A. Piedro, V. Sofic-Drino, M. Ratkovic \textit{Bosnia and Herzegovina}

Photothermal stimulation for treatment of central serous retinopathy: case report

J. Placeres, M. Calatayud, E. Salinas \textit{Spain}

Acute macular neuroretinopathy (AMN) in a healthy young patient. A case report

D. Ratra, D. Dalan, D. Jaisankar, A. M. K. Mani \textit{India}

Multifocal electroretinogram and microperimetry can help predict visual outcome and risk of developing macular hole in the fellow eye of patients with unilateral macular holes

M. Romano, C. Gatto, L. Giurgola, M. Ferrara, J. D’Amato Tothova \textit{Italy}

Cytotoxicity testing according to ISO 10993-5 of perfluorocarbon manufacturing process residuals

S. Sabour \textit{Iran}

Validity analysis in ophthalmology researches; limitation and challenges

M. Sauza, N. Vaquez \textit{Mexico}

A case of unilateral purtscher retinopathy with subretinal and intraretinal fluid: 6 month follow-up

E. Seven, M. Batur, S. Tekin, M. Akaltun, T. Yasar \textit{Turkey}

Pathologies Associated with Penetrating Eye Injuries and Complications

A. Stamate, M. Dragomir \textit{Romania}

Torpedo maculopathy: a case report

Z. Tegou, E. Kanonidou \textit{Greece}

Complete restoration of visual field defects following surgical treatment of pituitary adenoma

M. Teke, S. Ozates, M. Citrik \textit{Turkey}

Spontaneous closure of macular hole secondary to central retinal vein occlusion

M. Teke, S. Ozates, M. Citrik \textit{Turkey}

Diffuse choroidal hemangioma in a patient with Sturge-Weber Syndrome

V. Trantou \textit{Greece}

Ocular complications after heart surgical procedures

K. Tsousis, S. Deol, A. Matsou, G. de la Mata, V. Konidaris \textit{UK}

Clinical outcomes of myopic choroidal neovascularization after treatment with anti-VEGF: a retrospective study

N. Ucgun, C. Zeki Fikret, S. Bayramova, D. Ozek, O. Evren Kemer \textit{Turkey}

Change analysis of macular pigment optical density in Pseudoxfoilation Syndrome and primary open angle glaucoma cases in Turkish population

D. Valkenburg, J. Groenewoud, B. Klevering, C. Hoyng \textit{Netherlands}

Age of onset best predicts the natural, nonlinear visual acuity course in patients with Stargardt Disease

V. Vanzan, J. Chhablani, R. Turchetti, L. Lima, R. Vianna \textit{Brazil}

Natural history and visual outcome in patients with idiopathic acute exudative polymorphous vitelliform maculopathy (AEPVM)

A. White, G. Almeida \textit{UK}

Rapid resolution of clinical features in leukaemic retinopathy

A. White, G. Almeida \textit{UK}

Peripheral exudative haemorrhagic chorioretinopathy: Should we manage as ARMD?

Z. Yazar, N. Alinova \textit{Turkey}

Are the central macular and choroidal thicknesses in high myopic eyes different than in the emmetropic eyes?

New Drug Treatment and Technology

A. Aurora, N. Singh, V. Dhyani, A. Aurora \textit{India}

A new safe avastin puncture assist device (APAD)

D. Buryakov, A. Doga, B. Normaev \textit{Russia}

YAG laser vitreolysis in different types of vitreous floaters removal

V. Chaudhary, S. Mullen, J. Qian, R. Muni, T. Ceyhan, M. Nguyen, M. Mak \textit{Canada}

The level of evidence of retina subspecialty abstracts presented at the Canadian ophthamological society conferences

A. Aurora, S. Mullen, J. Qian, R. Muni, T. Ceyhan, M. Nguyen, M. Mak \textit{Canada}

The level of evidence of retina subspecialty abstracts presented at the Canadian ophthamological society conferences
L. Di Antonio, L. Toto, E. Doronzo, C. De Nicola, L. Brescia, E. Erroi, L. Mastropasqua ITALY
Clinical and laboratory assessment of treatment-naïve myopic choroidal neovascularization after intravitreal injection of Aflibercept

O. Eski Yucel TURKEY
Intravitreal aflibercept for the treatment of choroidal neovascularization secondary to angiod streaks

P. Francis, J. Holt, D. Kirn, M. Kottermann, T. Vazin, K. Barglow, D. Schaffer USA
Development of an intravitreal gene therapeutic for retinal disease

S. Ganekal, P. VS INDIA
Intravitreal bevacizumab combined with sequential sub threshold transpupillary thermotherapy (TTT) for atypical central serous chorioretinopathy (CSCR)

E. Ivanova, P. Volodin, S. Vladislav RUSSELL
Oral mineralocorticoid-receptor antagonists: Chorioidal parameters changes using optical coherence tomography in central serous chorioretinopathy

P. Ghassemi, F. Ghassemi, V. Mohammadzadeh, A. Nabavi, S. Faghihi, S. Kadivar IRAN
Oral mineralocorticoid-receptor antagonists: Chorioidal parameters changes using optical coherence tomography in central serous chorioretinopathy

F. Ghassemi, S. Faghihi, S. Kadivar IRAN
Oral mineralocorticoid-receptor antagonists: Chorioidal parameters changes using optical coherence tomography in central serous chorioretinopathy

P. Glinzitsa, K. Takhchidi, G. Kachalina, N. Takhchidi, R. Manoyan RUSSIA
Morphological characteristics of phosphenes during selective activation of Argus II epiretinal prosthesis’s electrodes in patients with retinitis pigmentosa

V. Gurumoorthy INDIA
Biosimilar ranizumab (RAZUMAB) a safe and cost effective solution for diabetic retinopathy

H. Hasan, S. Khan, S. Ahmed, N. Shah UK
InVitria® enlightening the way for nurse-led intravitreal injections service

E. Ivanova, P. Volodin, S. Vladislav RUSSIA
Personalized laser treatment of central serous chorioretinopathy using a micropulse mode with individual selection of parameters on Navilas laser system 577s

M. Kamel SAUDI ARABIA
Intravitreal bevacizumab (avastin) with peripheral retinal cryotherapy for patients with posterior ROP and vitreous hemorrhage

K. Kang, J. Jeung, H. Hwang, S. Kim SOUTH KOREA
Anthocyanin oligomers counteracts ischemic and oxidative insults to retinal cells and lipid peroxidation to brain membranes.

H. Kim, J. Lee, S. Lee, H. Lee SOUTH KOREA
Surveying the prevalence of antibodies that neutralize adeno-associated virus (AAV) serotypes 2, 5, 8, and 9 in the intravitreal fluids and sera of patients with vitreoretinal diseases

Ziv-alphabect: from the lab to real-world multicenter use; Collaborative Ziv-alphabect group report

A. Mansour, A. Charbaji, J. Chhablani, M. Farah LEBANON
Thirty month outcome of treat and extend intravitreal Ziv-Alphabect

H. Matsumoto, S. Sugio, H. Akiyama, Y. Ishizaki, K. Shibasaki JAPAN
Retinal detachment-induced Müller cell swelling activates TRPV4 (transient receptor potential vanilloid 4) ion channels and triggers photoreceptor cell death

J. Nassaralla, A. Nassaralla, M. Hage Amaro, J. Nassaralla Neto BRAZIL
Efficacy of ranibizumab aflibercept therapy with dexamethasone intravitreal injection in patients with diabetic macular edema

N. Nigmatova UZBEKSTAN
Experience in the use of angiogenesis inhibitors in diabetic retinopathy in Uzbekistan

S. Ozal, S. Erdogan TURKEY
Esculetin protects human retinal pigment epithelial cells from lipopolysaccharide-induced inflammation and cell death through NF-κB inhibition

T. Parmar, S. Tung, G. Williams UK
A survey to determine ophthalmic trainee confidence in undertaking research in the Wales Deanery

E. Pedanova, A. Doga, A. Mayorova RUSSIA
Central choroidal thickness after combined therapy for polypoidal choroidal vasculopathy

F. Quhill, C. Putri, H. Quhill UK
36-month real-world outcomes in patients with refractory chronic diabetic macular oedema treated with the 190 micrograms fluocinolone acetonide intravitreal implant

C. Quijano, A. Goodluck, A. Alnahrawy, S. Younis UK
Micropulse subthreshold laser in acute and chronic central serous chorioretinopathy: 2 years of safety and efficacy treatment

A. Rajendran INDIA
An analysis of the comparative efficacy of subthreshold micropulse 577-nm yellow laser versus 577 nm green laser for central serous chorioretinopathy

D. Ratra, A. Rakshit, V. Ratra INDIA
Video game play as a means to stimulate vision in Stargardt disease

N. Sayin, N. Kara, S. Bayramoglu, M. Erdogan, F. Uzun TURKEY
Subfoveal choroidal and parachoroidal thickness in patients using amiodarone

Y. Solberg, C. Dysli, S. Wolf, M. Zinkernagel SWITZERLAND
Fluorescence lifetime characteristics in geographic atrophy secondary to age-related macular degeneration

P. Trottier CANADA
Impact of late switch from ranibizumab to aflibercept on frequency of intravitreal injections and best-corrected visual acuity

L. Xu, C. Liu, R. Li, D. Liu CHINA
The follow-up study of 1/3-dose photodynamic therapy in chronic central serous chorioretinopathy

W. Yu, H. Zhou, J. Ye CHINA
Functional and structural effects of Conbirect versus laser

N. Yudina, A. Tereshchenko, I. Trifanenkova, M. Tereshchenkova, V. Kirillov RUSSIA
Technology of hexagonal "honeycomb" pattern scan laser photocoagulation of the retina in active stages of ROP

G. Zhurgumbayeva, A. Dzhapparkhanova, A. Kanatbekova KAZAKHSTAN
Long term outcome of myopic maculopathy with aflibercept
Uveitis

O. Adepegba, A. Tasiopoulou, C. Pavesio UK
Ocular toxoplasmosis in HIV positive patients: clinical presentation and treatment outcome

H. Adusumilli, L. Krupa, N. Shetty, Y. Singh INDIA
Enigma of posterior scleritis, diagnosis and management: A case series in Indian population

Panuveitis secondary to actinobacillus actinomycetemcomitans endocarditis

R. Arora UK
Tubulo-interstitial nephritis and uveitis syndrome (TINU) in adults: A prospective study

H. Ben Amor, M. Kechida, D. Nezfi, F. Gafsaoui, S. Attia, M. Khairallah TUNISIA
Inflammatory choroidal neovascularization in myopic patients

E. Cetin, S. Akbulut, K. Bozkurt, G. Pekel, G. Otar Yener, S. Yuksel TURKEY
Anterior segment morphology in pediatric uveitis

E. Cetin, K. Bozkurt, S. Akbulut, G. Pekel TURKEY
Irido-corneal angle measurements in eyes with inactive uveitis

Y. Chen, C. Geenen, D. Bell, A. Kotagiri UK
Uveitis associated with immune checkpoint inhibitor treatment for advanced melanoma

H. Chien, Z. Hung TAIWAN
Combination treatment with intravitreal dexamethasone implant (OZURDEX®) and intravitreal ranibizumab in recurrent sympathetic ophthalmia with macular edema: a case report

P. Dhir, R. Soibam, M. Burman, D. Das, D. Mishra, H. Deka, H. Bhattarcharjee INDIA
Dexamethasone implant: Choice in chronic, resistant infectious and non infectious posterior uveitis

M. Dourandeesh, S. Hosseini, M. Mazouchi IRAN
Vogt-Koyanagi-Harada with unilateral and asymmetric clinical manifestation: A case report

M. Dourandeesh, S. Hosseini IRAN
Ocular findings in sympathetic ophthalmia: A case series

R. Duman, M. Erol, R. Duman, F. Gulyesil TURKEY
The importance of early treatment in ocular toxocariasis: Three case reports

V. Felcida, N. Ajith Kumar, A. Tyagi UK
A case of posterior sympathetic ophthalmia

L. Fu, A. Walkden, R. Chhabra, N. Jones, L. Steeplees UK
Management of ganciclovir resistant cytomegalovirus retinitis in the context of solid organ transplant: clinical challenges and novel therapy with anti-cytomegalovirus hyperimmune globulin

SS-OCT choroidal thickness measurement in convalescent/quiescent Vogt-Koyanagi-Harada disease

N. Jain, A. VK, V. P, N. V INDIA
Role of OCTA in Rickettsial uveitis

B. Kim, H. Yu, U. Park SOUTH KOREA
Subcutaneous injection of Adalimumab in Korean patients with Behcet's uveitis

N. Labrousse, J. Ben Ammar, P. Robert FRANCE
Acute Retinal Necrosis: a retrospective case series of 10 patients at the hospital of Limoges, France

I. Leal, R. Amin, L.R. Steeples, N.P. Jones, R. Chhabra UK
Optical coherence tomodraphy angiography (OCTA) in inflammatory choroidal neovascular membrane: lesion analysis and correlation with OCT features

I. Leal, S. Zhuan Tan, T. Aslam, R. Chhabra UK
Intra and inter-rater agreement of inflammatory choroidal neovascular membrane measurements using optical coherence tomodraphy-angiography

S. Luthra, S. Das, M. Bhende, V. Lingam, V. Gupta, J. Biswas INDIA
The Mummy Returns: management of unilateral recurrent neovascular glaucoma in a case of stable bilateral Eales' disease

P. Maitra, D. Ashokumar, A. Mairay INDIA
Morphometric analysis of optical coherence tomodraphy (OCT) characteristics of epiretinal membrane (ERM) in uveitis and correlation with visual acuity, uveitis profile and treatment modalities

A. Mairay, E. Rishi INDIA
Endogenous endophthalmitis in children and adolescents: Is it that uncommon?

A. Mansour LEBANON
Dexamethasone implant as sole therapy in sympathetic ophthalmia

N. Mehrotra, M. Naggal, H. Jain INDIA
Vitrectomy with per-operative dexamethasone implant (0.7mg) in refractory non infectious intermediate and posterior uveitis

L. Mendonca, J. Souza Filho, A. Leone BRAZIL
Multimodal evaluation of atypical multiple evanescent white dot syndrome with increased choroidal thickness and subfoveal exudate leading to secondary choroidal neovascularization: Case report

V. Mitkova-Hristova, M. Konareva-Kostianeva, N. Stoyanova, N. Stolinov BULGARIA
Comparison of macular thickness measured with two different scanning protocols of spectral-domain optical coherence tomodraphy RTVue -100 in healthy eyes and eyes with uveitis – with and without macular edema

S. Mokadam, S. Upadhye, V. Raja, N. Madhivanan, S. Mokadam INDIA
Study of diverse spectrum of isolated presumed ocular tuberculosis from urban population of same area

S. Mondal, S. Mandal INDIA
Inflammatory choroidal neovascular membrane secondary to healed presumed tubercular chorioretinitis: Presentation and Management

N. Munoz Sanz, J. Serrano, E. Carreno SPAIN
Flow citometry of subretinal fluid for the diagnosis of primary intraocular lymphoma (PIOL)

S. Nachi, N. Ouahlin ALGERIA
An interesting case of unilateral uveitis of presumed tubercular etiology
K. Nandi India
Posterior scleritis: Clinical profile, risk factors and visual outcome in a series of 32 patients

T. Novoselova, V. Kazaukin, A. Kleymenov Russia
Etiologic diagnostics method in uveitis complicated by exudative retinal detachment

A. Oleśnik Memmel, M. Fernandez, F. Romero Garcia Spain
Inflammatory choroidal neovascularization

Vogt-Koyanagi-Harada syndrome: a well succeeded case

Y. Ozdamar Erol, P. Ozdal Turkey
Intravitreal clindamycin in the treatment of toxoplasmic retinochoroiditis with serous macular detachment

B. Ozturk, S. Gonul, S. Gedik Turkey
Ocular syphilis presenting as papillitis and periphlebitis

F. Pellegrini, E. Interlandi, D. Cirone, G. Prosdocimo Italy
Acute Zonal Occult Outer Retinopathy (AZOOR): further considerations about choroid, photoreceptors and retinal function

A. Pereira, P. Mahendradas, A. Kavali India
Clinical spectrum of viral retinitis in an Indian subpopulation

F. Pichi UAE
Quantitative assessment of the iris vasculature in acute anterior uveitis with OCT angiography

T. Pilkevych, N. Samoluk Ukraine
Measles and its complications

Q. Pilson, D. Kilmartin Ireland
Current profile of sympathetic ophthalmia (SO) in Republic of Ireland: Effects of increasing trends in microincision retinal surgery and biologic therapy

C. Rangel, A. Ortiz, N. Moreno, M. Acuata, R. Sanchez-Avila, C. Varon, E. Villareal Colombia
Ocular syphilis in Colombia: Clinical manifestations and treatment outcomes

A. Romero Martinez, P. Catalan Munoz, W. Menijvar Aguilar Spain
The difficult diagnosis of presumed ocular histoplasmosis when the patient is a young woman in a non-endemic area

A. Romero Martinez, S. Gomez-Salvago Sanchez, E. Frias Marrero Spain
Relationship between Fabry disease and birdshot retinochoroidopathy in a family study

R. Roohipoor, M. Zarei, N. Mohsenzadeh, H. Riazi Iran
Are anti-inflammatory drugs necessary in the management of Tubercular Multifocal Serpiginous-like Choroiditis? A case report with multimodal imaging

Tocilizumab in juvenile idiopathic arthritis-associated uveitis

V. Stebnev, S. Stebnev, N. Skladchikova Russia
Phakovitrectomy in combination with intravitreal implant OZURDEX® in the treatment of chronic panuveitis

R. Takada, A. Fukushima Japan
Pembrolizumab-triggered uveitis suspected to be Vogt–Koyanagi–Harada disease in a patient with pulmonary adenocarcinoma

K. Tsaousis, P. Kumar, S. Deol, A. Matsou, A. Brent UK
Clinical characteristics of an HLA-B27-positive population with acute anterior uveitis in a British tertiary university teaching hospital

N. Ünlü, M. Acar, D. Hazirolan, G. Uney, F. Ornek Turkey
Late presentation and good outcome in a case with endophthalmitis after intravitreal injection of triamcinolone acetate

H. Vannadil, A. Singh, M. Khan, S. Shankar India
Is it scleritis? Is it a tumor? No, it's ocular tuberculosis

M. Wintergerst, F. Holz, R. Finger Germany
Evaluation of novel 450 nm excitation wavelength fundus autofluorescence with color-coded emission detection in posterior and panuveitis

O. Zaytseva, V. Neroev, T. Okhotsimskaya, G. Davydoeva, L. Katarzyna, T. Lisitsyna, Z. Alekberova Russia
OCT-angiography in management of Behçet's disease patients

O. Zaytseva, V. Neroev, G. Davydoeva, T. Okhotsimskaya, L. Katarzyna, T. Lisitsyna, Z. Alekberova Russia
BOS24 index in Behçet’s disease patients monitoring

S. Zina, W. Nabi, N. Abroug, A. Mahmoud, S. Attia, S. Zaaouali, M. Khairallah Tunisia
Clinical features and outcomes of vitreous hemorrhage associated with ocular inflammatory conditions

Vascular Diseases and Diabetic Retinopathy

M. Abdelmseih Germany
Idiopathic macular hemorrhage (IMH)

M. Abouhussein Egypt
Real life results of aflibercept in treatment naïve macular edema after branch retinal vein occlusion

M. Abouhussein Egypt
Effect of micropulse laser on number of aflibercept injections for treatment naïve diabetic macular edema

M. Abrishami, A. Mirshahi, R. Tadayoni Iran
Efficacy of adjuvant topical timolol-dorzolamide with intravitreal bevacizumab injection in diabetic macular edema: Contralateral eye pilot study

J. Ahn, S. Byun, K. Park, S. Park South Korea
Body-mass index and risk of retinal vein occlusion: A nationwide 12-year population-based study

D. Ahnood, A. Sourihi, G. Samuel Williams UK
Assessing patient acceptance of virtual clinics for diabetic retinopathy: A large scale postal survey
C. Akkin, C. Değirmencı, S. Nalcaci, I. Korkmaz, M. Palamar, F. Afrashi TURKEY
Effect of intravitral dexamethasone implant (OZURDEX®) injections on corneal biomechanical properties measured by using ocular response analyzer

M. Alexik SLOVAKIA
Laser vs. intravitreal injections: how do they drive PVD progression in patients with DME?

A. Al-Saedi, H. Al-Dhibi, A. Badawi SAUDI ARABIA
Systemic and ocular associations of central retinal vein occlusion in young versus old patients

P. Amat Peral, F. Lugo Quintas, C. de la Vega Galiana SPAIN
Resolution of refractory diabetic macular edema after hemodialysis due to diabetic nephropathy: a case report

R. Anguita, A. Salinas, R. Kubos, M. Astete, C. Nazar, F. Peata UK
Bilateral ocular ischemic syndrome as a manifestation of Takayasu arteritis in a child, case report

N. Artells de Jorge, C. Ossa Calderon, S. Sanchez Tabernero, M. Lopez Galavez, J. Juberías Sanchez SPAIN
Systemic morbidity associated to neovascular glaucoma secondary to central retinal vein occlusion

I. Ashfaq, J. Da Costa, S. Talks UK
Real World data on the effectiveness of Intravitreal fluocinolone acetonide (ILUVIEN®) utilised as monotherapy or in combination with anti-vascular endothelial therapy in patients predominantly with long-standing chronic diabetic macular oedema

A. Bagchi, R. Muniraju UK
Real world outcomes of dexamethasone 0.7mg intra-vitreal implant (OZURDEX®) and anti-vascular endothelial growth factors in retinal vein occlusions with macular oedema

A. Bagchi, R. Muniraju UK
Referral to treatment time-line for patients referred with sight threatening diabetic retinopathy for diabetic eye screening programme in Surrey

C. Beckford, C. Arruabarrena SPAIN
Comparison of absolute versus relative values of anatomical improvement in patients with diabetic macular edema treated with antiangiogenics in routine clinical practice

E. Beyazyildiz TURKEY
Efficacy of low dose versus conventional dose intravitreal bevacizumab therapy in retinopathy of prematurity

P. Biletska, I. Gapunin CZECH REPUBLIC
Postthrombotic cystoid macular edema: real patient, real treatment clinical case

E. Borrelli, M. Palmieri, P. Viggiano, G. Ferro, L. Mastropasqua USA
Macular ischemia and photoreceptor loss in diabetic retinopathy

P. Brito, J. Costa, N. Gomes, S. Costa, J. Correia-Pinto, R. Silva PORTUGAL
Peripheral blood metabolic and inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF

Ö. Budakoğlu, P. Cakar Ozdal TURKEY
Bilateral dexamethasone implant in naive diabetic macular edema

Choroidal neovascularization in a young patient: idiopathic vs secondary to beta thalassemia

J. Calster, J. Jacob, M. Wirix, C. Peettermans, G. Devos, T. Arnaut, A. Smeets BELGIUM
A Belgian retrospective study in patients treated for macular edema secondary to CRVO: 1-year real-world aflibercept data

A. Carneiro, A. Meireles, J. Castro Sousa, C. Teixeira PORTUGAL
A retrospective cohort study of the clinical outcomes of ILUVIEN® in four ophthalmology centres in Portugal: The results of the ILUVIEN® clinical evidence study in the Portugal (ICE-PT)

Anatomical patterns and functional outcomes of recidives in diabetic macular edema after OZURDEX®

G. Catena, S. Petroni, G. Iarossi, G. Zinzanella, L. Buzzonetti ITALY
The management of Coats Disease: our experience

Anatomical and functional outcomes in diabetic retinopathy with serous retinal detachment treated with OZURDEX®

D. Chakraborty, T. Sinha, A. Mukherjee, S. Majumdar INDIA
Role of preoperative anti VEGF in altering macular status in PDR with vit haem

Y. Chang TAIWAN
Comparison of continuous-loading, delayed-loading, and dropout ranibizumab treatment in neovascular age-related macular degeneration

C. Chaudhary INDIA
Comparative evaluation of dexamethasone implant (DEX) and ranibizumab in treatment naive diabetic macular edema

G. Chichua, A. Chichua, T. Jikurashvili, N. Pargalava, E. Magalashvili GEORGIA
Superior ophthalmic vein thrombosis (SOVT): case report

Leucine-rich G protein-coupled receptor-5 is significantly increased in the aqueous humor of human eye with proliferative diabetic retinopathy

K. Chwiejczak, S. Biswas, E. Tsamis, P. Stanga UK
Can segmented swept source optical coherence tomography angiography provide new information on morphology and pathophysiology of submacular fibrosis in unilateral Coats’ disease?
H. Cilliers CAYMAN ISLANDS
Neuro-protection in non-arteritic anterior ischaemic optic neuropathy

E. Giloğlu, E. Unal TURKEY
The evaluation of diabetic retinopathy with optical coherence tomography angiography

J. Coelho, B. Pessoa, N. Silva, N. Ferreira, N. Correia, J. Beirao, A. Meireles PORTUGAL
Clinical outcomes of fluocinolone acetonide implant for treatment of chronic diabetic macular edema

J. Costa, P. Brito, M. Joao, N. Gomes PORTUGAL
Micropulse laser therapy for the treatment of extrfoveal macular edema – short-term results

S. Cutting, Y. Neo, S. Zhou, S. George UK
Impact of bariatric surgery on diabetic retinopathy: A systematic review

P. Datlinger, F. Datlinger AUSTRIA
ICG guided and OCT controlled focal laser treatment of aneurysmatic lesions in macular edema

M. Davari, G. Karimi, D. Alavi IRAN
The relationship between diabetic retinopathy and senosri-neural hearing loss in patients with Type 2 diabetes mellitus

B. de Lucas-Viejo, J. Sambricio, L. Moreno-Garcia SPAIN
Diabetic macular edema and pregnancy: intravitreal dexamethasone implant as a choice

M. Dell’Acqua, V. Vignano’, G. Trabucchi ITALY
Subthreshold diode micropulse laser treatment for retinovascular macular edema after intravitreal therapy: a 6 months follow-up

P. Diaz Aljaro, L. Broc Iturralde, S. Grixolli Mazzon SPAIN
Successfully combined treatment with intravitreal Dexamethasone implant (OZURDEX®) and laser photocoagulation in adult onset Coats disease

P. Dimitrakas, A. Mani, T. Stavropoulou, D. Pagoulatos, I. Georgalas, C. Koutsandrea GREECE
Topical Nepafenac 0.3% for prevention of post-cataract surgery macular edema in patients with Diabetic Retinopathy (DR)

C. Dinah, C. Cleland, A. Ghulakhzsian, D. Ramcharan UK
Prevalence of centre-involving diabetic macula oedema in inner city London

M. Dogan, M. Sabaner TURKEY
One-year outcomes of intravitreal dexamethasone implant treatment for persistent diabetic macular edema resistant to anti-VEGF therapy

R. Duman, N. Efe, R. Duman TURKEY
Subclinical retinopathy in Type 1 diabetes mellitus diseases

V. Dzinic, A. Oros, N. Babic SERBIA
Macular morphology characteristics assessed by optical coherence tomography (OCT) as prediction factors of visual acuity improvement in the treatment of diabetic macular edema (DME)

D. Ekinci, D. Ekinici, A. Vural, S. Bayramoglu, I. Onur TURKEY
Assessment of vascular leakage and its development with FFA among patients treated with intravitreal Anti-VEGF due to aggressive posterior ROP

M. Erdogan, N. Sayin, S. Bayramoglu, D. Ekinci TURKEY
Resolution of diabetic papillopathy after a single intravitreal injection of dexamethasone implant (OZURDEX®): Case report

R. Fayzrakhmanov, M. Bikbov, M. Kalanov, R. Zainullin RUSSIA
Macula morphology change in venous occlusion with the introduction of an dexamethasone implant

R. Fayzrakhmanov, M. Bikbov, M. Kalanov, R. Zainullin RUSSIA
Anti-VEGF therapy for macular edema due to central retinal vein occlusion

T. Fernandes, L. Mendonca PORTUGAL
Purtscher-like retinopathy as a complication of chronic kidney disease

C. Fernandez-Martinez, J. Martinez-Toldos, J. Ruiz-Moreno, E. Caminos, A. Murcia SPAIN
 Intravitreal administration of lysine-acetylsaliclylate could be an effective approach to preserve retinal vessels and to inhibit leukostasis in experimental diabetic retinopathy

R. Figueiredo, T. Morais Sarmento, B. Pina, J. Carvalho, A. Ramalho, A. Candelas PORTUGAL
Eales disease – a mysterious condition

W. Gan, K. Khan UK
Early and long term responses to aflibercept (Eylea) in macular oedema secondary to retinal vein occlusion

S. Ganekal, U. Nair, M. S INDIA
Effect of single session panretinal photocoagulation (PRP) on macular morphology and thickness in eyes with proliferative diabetic retinopathy (PDR)

Vision-related quality of life in patients with diabetic macular edema treated with intravitreal aflibercept: the AQUA study

S. Gedik, A. Bozkurt Oflaz, B. Turgut Ozturk, B. Bakbak, S. Gonul, S. Okudan TURKEY
Measurement of aqueous flare in patients with diabetic macular edema treated with intravitreal dexamethasone implant

K. Ghasemi Falavarjani, A. Habibi, M. Ashraf Khorasani, P. Anvari, S. Sadda IRAN
Time course of changes in optic disk neovascularization after a single intravitreal bevacizumab injection

K. Ghasemi Falavarjani, Y. Hadi, S. Jafari, M. Parvareshe, M. Modarres, M. Naseripour, P. Anvari IRAN
Efficacy of topical timolol for non-center-involving diabetic macular edema

T. Giannopoulos, E. Papathomas, A. Malamas, F. Topouzis GREECE
Grading of diabetic retinopathy in all newly referred diabetic patients to the retinal clinic of a tertiary university hospital

N. Goncharova, I. Pastukh, U. Diomin, O. Shkil, U. Pastukh UKRAINE
Dexamethasone intravitreal implant in treatment of macular edema related to branch retinal vein occlusion
A. Grigoreva, T. Iureva, S. Zhukova, E. Ivanova, J. Korsakova RUSSIA
Dependence of the development of myopic chorioretinal neovascularization on the level of reproductive hormones in women

E. Gucciardo, S. Loukovaara, A. Korhonen, H. Vihinen, E. Jokitalo, K. Lehti FINLAND
Microenvironment of proliferative diabetic retinopathy supports lymphatic neovascularization

R. Guthoff, C. Schnitzerz, A. Fleitmann, K. Spaniol, K. Schroeder GERMANY
Retinal vascular occlusion in pregnancy

J. Gutierrez Vasquez, M. Romero Sanz, T. Martinez Rincon, A. Fanlo Zarazaga, N. Pardinas Baron, P. Calvo Perez SPAIN
Lupus choroiditis and bilateral retinal detachment preceding multi-organ involvement. Case report

D. Guven, S. Tiryaki Demir, B. Dirim, Y. Sendul, E. Karatas, M. Almeida UK
Evaluation of one year follow-up results of macular telangiectasia type 2 patients by optical coherence tomography angiography

I. Hajji, M. Bakhch, H. Ahammadou, Y. El Bakkoury, A. Moutouaakil MOROCCO
Diabetic retinopathy: which impact on the daily activities of young patients?

A. Hamoud, G. Almeida UK
Fluocinolone acetone intravitreal implant 0.19 mg: A review in diabetic macular oedema

Correlation of morphological features to visual function and quality of life in early diabetic retinopathy in type 1 diabetes mellitus under intensified insulin therapy

A. Henry, C. Boulagnon-Rombi, T. Menguy, C. Barbe, M. Labrousse, C. Garbar, C. Arndt FRANCE
CD160 expression in retinal vessels is associated with retinal neovascular diseases

M. Hertanto, A. Ramayudantha INDONESIA
Central macular thickness and visual acuity of the contralateral eyes in patients with diabetic macular edema after single intravitreal aflibercept injection

S. Hewick UK
Fixed dosing regime for delivering anti-VEGF in retinal vein occlusions (RVO)

F. Horner, R. Chavan, A. Mitra, B. Mustaq, P. Lip UK
Three-year real-world results on combination therapy (RandOL Protocol) for treating macular oedema in retina vein occlusion

N. Ibragimova, N. Normatova, S. Djalalov UZBEKISTAN
Frequency of diabetic retinopathy occurrence in people with newly diagnosed type 2 DM in Uzbekistan

H. Iijima JAPAN
Real-world outcomes of intravitreal anti-vascular endothelial growth factor agents for macular edema associated with central retinal vein occlusion

C. Isanta Otal, F. Bartol-Puyal, B. Abadia Alvarez, G. Verdes Sanz, P. Calvo Perez, L. Pablo Julvez, A. Ferreras Amez SPAIN
Type 2 diabetes progression and choroidal changes

B. Ivanovska Adjiyevska, N. Gineva, S. Boskurt MACEDONIA
Efficacy of intravitreal bevacizumab and peripheral laser photocoagulation in macular edema due to retinal vein occlusion

M. Jawad, A. Malem, S. Tiromoul, S. Padroni UK
Fluocinolone acetone intravitreal implant (LUVIEN®) for the treatment of diabetic macular oedema (DMO) in a district general hospital: the first 36 months.

T. Josifova SWITZERLAND
Anti-VEGF treatment in cases of macular edema, a helpful tool in prevention of ischemic retinal changes

V. Juncal, T. Felfeli, M. Mak, E. Ojaimi, R. Hillier, R. Muni CANADA
Aqueous cytokines as predictors of long-term response to intravitreal ranibizumab for treatment of diabetic macular edema

Z. Kalanova RUSSIA
The effectiveness of preliminary anti-VEGF therapy before vitrectomy at proliferative diabetic retinopathy

H. Kaldırım, A. Kirgiz, S. Yazgan, K. Atalay TURKEY
Intraocular pressure changes after dexamethasone intravitreal implant: pseudophakia versus phakia

B. Kambo, A. Belshi ALBANIA
Aflibercept therapy for diabetic macular edema resistant to bevacizumab

M. Kamel SAUDI ARABIA
Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema

M. Kamel SAUDI ARABIA
Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity

H. Kanar, A. Arsan, A. Altun TURKEY
Comparison of subthreshold micropulse yellow laser and intravitreal aflibercept in the treatment of diabetic macular edema

U. Kanj, M. Sodeinde, N. Manjunatha UK
Real-world outcome of crossover from intravitreal Anti-VEGF to dexamethasone in patients with persistent cystoid macular edema

Z. Kapsala, D. Pagoulatos, O. Makri, I. Georgalas, C. Georgakopoulos GREECE
Cataract surgery combined with intravitreal anti-VEGF injection in diabetic macular edema

V.L. Karabas, M. Akdogan TURKEY
An epidemiological and clinical assessment of the preterms followed up at our clinic

G. Karagiannidis Stampoulis, C. Keskini, E. Kanonidou GREECE
Unilateral patent cilioretinal artery in bilateral central retinal artery occlusion: an interesting case report

O. Karti, M. Zengin, D. Karti, M. Oguztoreli, T. Kusbeci TURKEY
Acute unilateral anterior ischemic optic neuropathy secondary to optic nerve head Drusen

R. Kawasaki, T. Konta, K. Nishida JAPAN
Lipid lowering medication is associated with decreased risk of treatments for diabetic retinopathy in a Japanese real-world healthcare claims database
Airs and patients with proliferative diabetic retinopathy

A. Khallouli, A. Maalej, Y. Weslati, R. Rannen TUNISIA
Changes in choroidal thickness after anti-vascular endothelial growth factor therapy for diabetic macular edema and correlation with visual acuity

R. Kılıç, A. Kurt, C. Karaca TURKEY
Eales disease presenting with cystoid macular edema

S. Kimyon TURKEY
Comparison of retinopathy of prematurity incidence between Turkish citizens and Syrian refugees

T. Kiseleva, V. N酌o DON, V. Okhotsimskaya, V. Fadeeva RUSSIA
Effect of antiangiogenic therapy on retrolubal blood flow and retinal microcirculation in the diabetic macular edema

N. Kocak, T. Ozurtuk, S. Ipek, M. Kaya, S. Kaynak TURKEY
Outcomes of intravitreous ranibizumab monotherapy and dexamethasone implant combination regimen in the treatment of central retinal vein occlusion seen within the first five decades of life

A.G. Kocak Altintas, C. Ilhan, M. Citirik TURKEY
Bilateral consecutive branch retinal vein occlusion in heterozygot protein C deficiency

I. Ksiaa, N. Abroug, A. Mahmoud, S. Zina, S. Artia, R. Messaoud, M. Khalirah TUNISIA
Chronic rhegmatogenous retinal detachment misdiagnosed as retinal vasculitis

R. Laiginhas, M. Kotoula, A. Karathanou, N. Voutsas, S. Kalampalikis, E. Tsironi, S. Androudi GREECE
Macular ischemia changes in patients with diabetic macular edema treated with aflibercept: a clinical study

N. Campos
Hyperreflective foci and its correlation with visual acuity in diabetic macular edema treated with OZURDEX

MultiColor imaging of proliferative diabetic retinopathy

D. Misiou, A. Makri, K. Andrianopoulou, D. Mitsiou, S. Stamelou, E. Makri GREECE
Vitreomacular traction in a patient with macular oedema secondary to central retinal vein occlusion

J. Liu CHINA
Intravitreous injections of conbercept in PDR patients

T. Loureiro, S. Parreira, D. Lopes, A. Miranda, A. Escada, N. Campos PORTUGAL
Idiopathic choroidal neovascularization in a young man

Z. Madanat, F. Ghanchi UK
ILUVIEN® in chronic diabetic macular edema ‘DMO’ – 3 year data

S. Mahuli INDIA
Role of intravitreal dexamethasone implant for macular hard exudates

S. Mamorta, D. Leadbetter, H. Hasan, J. Pandit, S. Dhanrireddy, M. El-Ashry, N. Shah UK
How frequently do patients with sight-threatening diabetic retinopathy have their HbA1c measured?

E. Mangunkusumo SINGAPORE
Response of treatment diabetic macular edema with bevacizumab 1.25mg in different glycated hemoglobin control

S. Mano, J. Prates Canelas, S. Yaz-Pereira PORTUGAL
MultiColor imaging of proliferative diabetic retinopathy

Macular ischemia changes in patients with diabetic macular edema treated with aflibercept: a clinical study

V. Mavljeva, M. Bikboy, R. Fayzakhmanov, M. Kalanov, R. Zainullin, I. Uzianbaeva RUSSIA
Parameters of the optic disc in patients with Central retinal vein occlusion according to swept-source OCT

H. Melville, D. Varma UK
Real-world clinical outcomes of intravitreal Ranibizumab in the treatment of macular oedema secondary to Branch Retinal Vei Occlusion in a tertiary centre

D.K. Misra, P. Bawankar INDIA
Relation between mean platelet volume and central retinal vein occlusion in hypertensive patients

Hyperreflective foci and its correlation with visual acuity in diabetic macular edema treated with OZURDEX®

M. Mterahi, Z. Merad, M. Belouzid ALGERIA
Idiopathic retinopathy (DR) barometer report for Algeria

U. Mulla, A. Al-Hiry, M. Gavim, M. Gupta, S. Park, W. Wykes, K. Wong UK
A Scottish clinical perspective of dexamethasone 0.7mg (OZURDEX®) treatment in retinal vein occlusions: Scordex study

1 year efficacy and safety data from the use of fluocinolone acetonide implant (ILUVIEN®) in patients treated in Scotland with diabetic macular edema (DME) after a suboptimal response to previous intravitreal therapies

D. Muramatsu, Y. Wakabayashi, R. Mihi, S. Kawakami, K. Yamamoto, K. Uzame, H. Goto JAPAN
Aflibercept treatment for diabetic macular edema in Japan

Anatomical and functional outcomes in diffuse retinal thickening secondary to diabetic macular edema treated with OZURDEX®
ePOSTER PRESENTATIONS

J. Ng, K. Oswal, D. Vaideanu-Collins UK
Real-world outcomes following intravitreal fluocinolone acetonide implant for chronic diabetic macular oedema patients: 30 months follow-up study

J. Ng, S. Salceanu, B. James, D. Vaideanu-Collins UK
Real world audit on visual and anatomical outcomes of intravitreal dexamethasone implant for management of macular oedema secondary to retinal vein occlusion and non-infectious uveitis

W. Ngo, C. Tan, T. Lim SINGAPORE
Severity of diabetic macular edema and background diabetic retinopathy affects macular perfusion: an optical coherence tomography angiography study

K. Nowomiejska, A. Kalinowska, R. Rejdak POLAND
Metamorphopsia score and central visual field outcomes in diabetic cystoid macular edema

A. Oleśnik Memmel, I. Alonso, E. Fernandez Cogolludo, M. Martínez Perez, F. Romero García-Alix SPAIN
Central serous chorioretinopathy after the application of topical corticosteroid in the oral mucosa

M. Ornelas, P. Neves, I. Matias, S. Diniz, P. Gomes, J. Rodrigues, D. Martins PORTUGAL
Use of long-term corticosteroids in retinal diseases in patients treated previously with antiangiogenics: Outcomes of fluocinolone acetonide based on a real-world population

M. Ornelas, P. Neves, I. Matias, S. Diniz, P. Gomes, J. Rodrigues, D. Martins PORTUGAL
Bilateral administration of fluocinolone acetonide (FAc): ILUVIEN® intravitreal implant in patients with diabetic macular edema (DME) – Real world evidence

B. Ozturk, A. Bozkurt, S. Gedik, S. Gonul TURKEY
Effect of Dexamethasone implant on diabetic retinopathy severity

G. Pacelli, C. Pisano, F. Pennacchiotti, V. Belloli ITALY
Case report of central retinal vein occlusion resulting in a perivascular pattern of para-central acute middle maculopathy

T. Paraskevopoulos, A. Kouropaki, D. Pagoulatos, P. Kosmidis GREECE
Branch retinal vein occlusion following tamoxifen treatment

I. Park, B. Cho, S. Bac, S. Park, M. Shin, H. Kim, S. Kwon SOUTH KOREA
Comparison of systemic conditions at diagnosis between central retinal vein occlusion and branch retinal vein occlusion

S. Pehlivanoglu, O. Seferoglu, Z. Bayraktar, M. Karakaya, S. Albayrak TURKEY
Quantitative correlation of OCT angiography between fellow eyes of healthy population

B. Pessoa, J. Coelho, L. Malheiro, J. Melo Beirao, A. Meireles PORTUGAL
Contralateral eye-to-eye comparison of intravitreal ranibizumab and sustained-release fluocinolone acetonide (0,2 µg/day FAc) intravitreal implant in chronic diabetic macular edema

A. Piatti ITALY
Diffusion of diabetic retinopathy in the territory of ASL TO5 (Italy): focus on sight threatening diabetic retinopathy

D. Podkowskiński, B. Słaba, A. Mursch-Edlmaier, M. Bolz AUSTRIA
Differentiating capillary non-perfusion from imaging artifacts in diabetic macular edema

O. Polat, A. Kurt, R. Kılıç, R. Nar, O. Kocamis TURKEY
Is there any association between the retinal vein occlusion and the thiol-disulfide homeostasis?

M. Raimundo, A. Santos, M. Lopes, S. Pestana, R. Silva, J. Figueira, J. Cunha-Vaz PORTUGAL
Patterns of improvement in micropereimetry and multifocal electroretinogram after three months intravitreal ranibizumab treatment for diabetic macular edema

M. Relah, C. Busch, P. Wiedemann GERMANY
Anti-VEGF treatment of macular edema due to central retinal vein occlusion in real-world setting: Predictors for long time visual outcomes

R. Rewbury, Q. Mohamed, E. Fletcher UK
Can OCT features predict anatomical response to intravitreal dexamethasone implants in patients with refractory diabetic macular oedema following serial anti-VEGF injections?

P. Rodrigues, J. Nascimento, J. Henriques, P. Rosa, V. Agoa PORTUGAL
Real world evidence of the management of retinal vasculopathies with Fluocinolone Acetonide (FAc) intravitreal implant – 2 years experience

M. Rudyk POLAND
Effectiveness of combined therapy for advanced proliferative diabetic retinopathy: case report

O. Ruiz Moreno, F. Bartol-Puyal, C. Isanta Otal, G. Verdes Sanz, B. Abadía Alvarez, P. Calvo Perez, L. Pablo Julvez SPAIN
Relationship between anthropometric measurements and choroidal thickness in healthy adults

M. Sabaner, R. Duman, R. Duman, M. Dogan, S. Inan TURKEY
Analysis of retinal layers and choroidal thicknesses in asymptomatic fellow eyes of acute central serous chorioretinopathy

N. Sahinoglu-Keskek, H. Canan, H. Gulcan, B. Cetinkaya, B. Torer, G. Yılmaz, I. Akkoyun TURKEY
Anti-VEGF treatment in cases of Zone-1 aggressive retinopathy of prematurity

N. Sahinoglu-Keskek, I. Akkoyun, G. Yılmaz TURKEY
Case with proliferative diabetic retinopathy in hyperopic eye and choroidal neovascular membrane in myopic eye

D. Sahota, J. Ainsworth UK
Unilateral macular oedema in a 5-year-old girl caused by type 1 idiopathic macular telangiectasia

D. Sahota, J. Ainsworth UK
Managing idiopathic macular telangiectasia in a 5 year old

N. Sanduja, A. Seth, A. Aurora INDIA
To evaluate efficacy, safety and appropriate timing of intravitreal dexamethasone implant in diabetic macular edema

O. Sannikov RUSSIA
Preliminary results of target retinal laser coagulation in diabetic retinopathy
E. Seven, T. Artuc, M. Batur, S. Tekin **TURKEY**
Orbital cellulitis complicated by hemisentral retinal artery occlusion

E. Seven, M. Batur, S. Tekin, M. Demir, T. Yasar **TURKEY**
Intravitreal recombinant tissue plasminogen activator, ranibizumab and sulfur hexafluoride combined injection results in patients with submacular haemorrhage

O. Sever **TURKEY**
The effect of single dose adjunctive dexamethasone implant on diabetic macular edema: 1 year follow up from a real life practice

A. Shchuko, V. Bukina, M. Akulenko, T. Iureva, A. Zlobina, A. Sereguina **RUSSIA**
Transpupillary thermotherapy of the optic nerve disc: new approaches to the treatment of anterior ischemic neuroretinopathy

S. Shidik, M. Hertanto, S. Kirana, A. Ramayudhanta, A. Djatikusumo **INDONESIA**
Full Field Electroretinography in Indonesian diabetic retinopathy patients

D. Singh, G. Mathur, A. Sharma, R. Reddy **INDIA**
Prolonged Anti-VEGF treatment for eyes with hard exudates encroaching fovea in diabetic macular edema with good visual acuity – Is there need to redefine endpoint?

M. Subash, P. Rezai, P. Abiose **UK**
Switching from ranibizumab to aflibercept for the treatment of retinal vein occlusion

A. Suzuki, J. Ogawa, Y. Takano, M. Ishida, T. Kawakita, Y. Imamura **JAPAN**
Central macular thickness 1 day after anti-VEGF injection: A biomarker for functional and anatomical outcomes in retinal vein occlusion

A. Tantou, M. Kotoula, E. Papageorgiou, V. Vasileiou, N. Voutsas, E. Tsironi **GREECE**
Cost and utility analysis of treatments for macular edema in retinal vein occlusion based on QALY

D. Taylor, O. Cooper, D. Crabb, D. Sim, H. McBain **UK**
The impact of diabetic eye disease on vision related quality of life and psychosocial well-being: trends within the literature

I. Umari, M. Urbancic **SLOVENIA**
Anti-VEGF therapy in the management of a patient with idiopathic macular telangiectasia type 2 complicated by subretinal neovascular membrane – case report

A. Upadhyay, M. Barman, R. Soibam, D. Das **INDIA**
Associated ocular pathologies with branch or central vein occlusion: a case series

The use of antivegf in retinopathy of prematurity (ROP). Our experience: 40 months-125 patients screened

R. Vemala, Y. Mohgaddam, V. Sampat **UK**
Case report of a bilateral CRVO heralding early sinister haematological abnormality

A. Victor **INDONESIA**
The role of laser photocoagulation in vasoocclusive retinopathy in systemic lupus erythematosus

P. Volodin, I. Yablokova **RUSSIA**
Early manifestation of Coat’s disease: diagnostic and treatment algorithm

P. Volodin, E. Ivanova, V. Solomin **RUSSIA**
Navigation technology of aiming topographically-oriented laser photocoagulation for the treatment of focal diabetic macular edema

J. Wang, C. Chiu **TAYWAN**
Patients with diabetic macular edema refractory to ranibizumab monotherapy responding to combined intravitreal ranibizumab and posterior subtenon triamcinolone acetonide injections

S. Warudkar **INDIA**
Retrospective efficacy and safety analysis of zyveb (biosimilar of bevacizumab) use at tertiary eye care centres in India: SPECTRA study

N. Yablokova, O. Fabrikantov **RUSSIA**
Examination of the relative vessel density in macular area by OCT-angiography following panretinal lasercoagulation for diabetic retinopathy

A. Yavorskiy, Y. Astakhov, A. Riabtseva, E. Smirnov, A. Yakimov, A. Kulagina, A. Shelankova **RUSSIA**
Results of retrospective study for collection of data on patients receiving OZRURDEX® (intravitreal dexamethasone implant) 0.7 MG injections for therapy of macular edema against retinal vein occlusion in Russia

I. Yilmaz, I. Perente, G. Erdogan **TURKEY**
Intravitreal Bevacizumab in treatment of proliferative type 2 idiopathic juxtafoveal telangiectasia

S. Yu, K. Kim, S. Yu **SOUTH KOREA**
Diabetic neurodegeneration as a predictive marker for progression of diabetic retinopathy in type 2 diabetes

N. Yudina, A. Tereschenko, I. Trifanenkova, O. Kulikov **RUSSIA**
Ultrasonic biomicroscopy in the choice of tactics of surgical treatment IV active stage of retinopathy of prematurity

R. Zainullin, M. Bikbov, R. Fayzrakhmanov, M. Kalanov **RUSSIA**
Functional status of the retina in patients with diabetic macular edema on the background of intravitreal pharmacotherapy

I. Zakieh, T. Begum **UK**
An audit of patients treated with the ILUVIEN® 190 micrograms intravitreal implant in applicator at the Stockport NHS Foundation Trust in the UK

O. Zaytseva, V. Nerroev, T. Okhotsimskaia, T. Kiseleva, V. Fadeeva **RUSSIA**
OCT-angiography results compared to dopplerography data in diabetic retinopathy

M. Zengin, O. Karti, D. Top Karti, A. Korkmaz, B. Yuksel, T. Kusbeci **TURKEY**
Anterior ischemic optic neuropathy secondary to Buerger’s disease: a case report of a rare entity
Vitreoretinal Surgery

M.S. Suleimenov, E.G. Kanafyanova, M. Alastal KAZHAKSTAN
Management of surgical treatment of patients with retinal detachment recurrence

M. Abrishami, A. Mirshahi IRAN
Successful treatment of traumatic rhegmatogenous retinal detachment associated with retinal dialysis and large macular hole by scleral buckling: A case report

D. Abulon, H. Gariepy USA
27 gauge vitreous traction comparison: Dual-cutting vs single-cutting vitrectomy probes

D. Abulon, H. Gariepy USA
Vitreous flow rates of 27 gauge dual-cutting 20,000 cpm vitrectomy probes

M. Acebes Garcia, M. Prieto del Cura, M. Crespo Carballes SPAIN
Autologous free internal limiting membrane (ILM) flap as treatment of a recurrent macular hole (MH). Management of intraocular pressure (IOP).

H. Ahmadieh, R. Nourinia, F. Borna, A. Rahimi, M. Jabbarpoor Bonyadi IRAN
Repeated methotrexate injections in silicone-filled eyes for proliferative vitreo-retinopathy

L. Akhundova AZERBAIJAN
Prediction of visual acuity after successful rhegmatogenous retinal detachment surgery

A. Al-Abdullah, O. Al Abdulsalam, H. Al Habboubi, M. Mura SAUDI ARABIA
Pars plana vitrectomy (PPV) versus combined PPV–scleral buckle for secondary repair of pediatric RRD

M. Alberti, A. Thomsen, M. Nissen, U. Christensen, M. la Cour DENMARK
Quality measures of macular surgery – can we characterize surgical skill?

Y. Alibet, G. Levytska UKRAINE
Anterior chamber depth changes at different stages of treatment of eyes with rhegmatogenous retinal detachment complicated by ciliochoroidal detachment

Y. Alibet, O. Zadorozhnyy, L. Galyna, N. Pasyechnikova UKRAINE
Dimensions of ciliary body structures in various axial lengths in patients with rhegmatogenous retinal detachment

27 gauge vitrectomy in lamellar macular holes associated with epiretinal membrane

I. Ammons, W. Mili, I. Zhioua, M. Boukari, R. Zhioua TUNISIA
Retinal redetachment in silicone filled eyes: risk factors and management

A. Appeltans, G. Bamonte BELGIUM
Macular hole development after vitrectomy for floaters: a case report

L. Arana, A. Grandinetti, C. Moreira Jr, A. Moreira BRAZIL
A novel vicryl releasable suture technique to close leaking sclerotomies in a transconjunctival vitrectomy

C. Aras, F. Senturk, G. Gulkilik, C. Burke TURKEY
Long term outcomes of primary circumferential scleral buckling for chronic rhegmatogenous retinal detachment

A. Arsan, M. Bulut, G. Akcay, A. Hacisalihoglu TURKEY
The evaluation of safety and efficacy of PerfluoroOctane liquid used as temporary tamponade during vitreo retinal surgery

H. Aslankara, A. Kocakaya, A. Dvalishvilli, C. Yildirim TURKEY
A comparison of intraoperative ranibizumab and dexamethasone intravitreal implant used during vitrectomy for refractory diabetic macular edema

C. Atencia, S. Arrascue, J. Rueda, L. Pacheco, M. Izquierdo, C. Abdala COLOMBIA
Functional and anatomical results of retinal detachment surgeries performed by fellows at clínica unidad del atlántico eye clinic in Barranquilla, Colombia

M. Attya, M. Zayed, A. Sherif EGYPT
Evaluation of OCT morphological pattern in prediction of visual outcome after pars plana vitrectomy with ILM peeling for persistent diffuse nontraumatic diabetic macular edema

R. Balan, S. VR, N. V INDIA
Post-vitrectomy taut internal limiting membrane in a case of Parafoveal Telangiectasia

Y. Bandeh Moghaddam, R. Vemala, V. Sampat UK
Delayed full-thickness macular hole closure and visual acuity improvement after intravitreal ocriplasmin injection

Y. Bayborodov, K. Zhogolev, I. Khiznyak RUSSIA
The rate of recovery of visual acuity after surgical treatment of macular holes of large diameter

I. Bayer, N. Arend, J. Siedlecki, S. Priglinger, B. Weber, A. Wolf GERMANY
Prospective evaluation of single nucleotid polymorphisms as a predicting factor for proliferative vitreoretinopathy after retinal detachment surgery

A. Berarducci, A. Laborante ITALY
Managing unexpected situations in retinal detachment redo surgery

G. Bhattacharya, P. Banerjee, M. Zvogbo, D. Charteris UK
Correlation between outer retinal foveal morphology and visual outcome following successful repair of rhegmatogenous retinal detachment with primary proliferative vitreoretinopathy; a longitudinal study

P. Bhende, A. Maitray INDIA
Clinical characteristics and treatment outcomes of surgically managed suprachoroidal haemorrhage
A. Brent, S. Bedi, M. Wakefield, S. Banerjee  **UK**  
A comparison study to illustrate different approaches in vitrectinal surgery practices in the United Kingdom (UK) and India with regards to management of the lens status in patients with retinal detachments

A. Calvo Álvarez, M. Castany Aregall, A. Boixadera Espax, O. Subira Gonzalez, A. Dou Saenz de Vizmanos, V. Martínez-Castillo  **SPAIN**  
Vitrectomy for the management of malignant glaucoma. A 10-year retrospective study

L. Ceklic, B. Kovac  **BOSNIA AND HERZEGOVINA**  
Eplerenon for subretinal fluid resolution after rhegmatogenous retinal detachment surgery

I. Chatziralli, E. Dimitriou, A. Chatzipanteli, A. Chatzirallis, A. Androu, S. Kabanarou, P. Theodossiadis  **Greece**  
Refractive changes after pars plana vitrectomy for epiretinal membrane and macular hole treatment

H. Chen  **TAIWAN**  
Rapidly progressive macular pucker after successful reattachment surgery for giant retinal tear retinal detachment

S. Chiu, R. Sheard, S. Habal, K. Spiteri-Cornish, Y. Ramkisson, S. Winder, A. Chawla  **UK**  
Visual outcomes in submacular haemorrhage treated with vitrectomy, subretinal tissue plasminogen activator (tPA), and gas.

S. Ch'ng, A. Jalil, A. Papayannis, F. Stringa, E. Tsamis, P. Stanga  **UK**  
Timing and effectiveness of bevacizumab before vitrectomy for diabetic tractional retinal detachment demonstrated on optical coherence tomography angiography

S. Ch'ng, I. El-Araoud, D. Karl, E. Carreras  **UK**  
No macular hole is too big

S. Churashov, A. Kulikov, S. Sofnovski, A. Mikhin  **RUSSIA**  
Removing of metal magnetic intraocular foreign body in open globe injury using 25 G magnetic tip

S. Copete, C. Blanco, A. Donate, F. Lopez-Martinez, S. Perez-Pascual, C. Cava-Valenciano  **SPAIN**  
Long-term functional results after epiretinal membrane surgery

M. Coppola, A. Marchese, A. Rabiolo, M. Cicinelli, C. La Spina, G. Querques, F. Bandello  **ITALY**  
Heads-up 3D vision system for retinal detachment surgery

S. Crespo, A. Valisena, S. Di Lauro, M. Lopez, F. Manco, L. Manzanas Leal  **SPAIN**  
Vitrectomy and vitreomacular interphase pathology. One year results and tomographic changes

A. de Casas, S. Abenza Baeza, N. Garcia Gallardo, J. Marin Sanchez, B. Canizares  **SPAIN**  
Free Internal Limiting Membrane (ILM) Autograft for a macular hole after vitrectomy for epiretinal membrane

C. De Giacinto, R. D’Aloisio, G. Cirigliano, M. Pastore, D. Tognetto  **ITALY**  
Autologous neurosensory retinal free patch transplantation for persistent full-thickness macular hole

A. Deligiannidis  **SPAIN**  
Macular changes after rhegmatogenous retinal detachment surgery

M. Demir, D. Guven, M. Karapapak, S. Tiriyaki  **TURKEY**  
External and internal approaches for rhegmatogenous retinal detachment treatment

P. Dimitrakas, A. Mani, T. Stavropoulou, D. Pagoulatos, I. Georgalas, C. Koutsandreou  **GREECE**  
Restoration of photoreceptor outer segments up to 12 months after pars plana vitrectomy in patients with diabetic macular edema

P. Dsoouza, R. Ranjan, U. Babu, P. Shah, S. VR, N. V  **INDIA**  
Scleral autograft versus autologous internal limiting flap for optic disc pit induced chronic maculopathy

S. Elgouhary  **EGYPT**  
Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents for treatment of retinal diseases in lower-middle-income countries

A. Ellabban, A. Benson, M. Costen, A. Babar  **UK**  
Safety and stability of plate-haptics IOL (CT Asphina 409M/MP) in combined phaco-vitrectomy

A. Ellabban  **UK**  
Central retinal artery occlusion during vitrectomy: Immediate restoration of retinal circulation following induction of posterior vitreous detachment

T. Eltayeb  **SUDAN**  
Surface wrinkling retinopathy

R. Fayzrakhmanov, M. Bikbov  **RUSSIA**  
Surgery of high retinal pigment epithelium detachment in subpigmental neovascularization

E. Foo, K. Spiteri-Cornish  **UK**  
Early surgical intervention in non-diabetic vitreous haemorrhage: case series

F. Fozilova, V. Zakharov, D. Shkvorchenko, S. Kakunina, K. Norman, M. Veselkova  **RUSSIA**  
Functional results of rhegmatogenous retinal detachment surgical treatment by vitreoretinal intervention with internal limiting membrane peeling

S. Freissinger, I. Bayer, C. Kern, S. Priglinger, A. Wolf  **GERMANY**  
Multifocal IOLs: visual outcome after pars plana vitrectomy for retinal detachment repair

M. Gaber, H. Mortada, T. Macky, M. Abd ElHakim, M. Khafagy  **EGYPT**  
Functional and structural outcomes of ILM peeling in uncomplicated macula-off RRD using microperimetry and en-face OCT

S. Ganekal  **INDIA**  
Modified temporal inverted ILM flap for large macular hole

H. Gariepy, D. Abulon  **USA**  
Performance evaluation of 25 gauge 20,000 cpm vitrectomy probes: Vitreous flow rates

H. Gariepy, D. Abulon  **USA**  
Vitreous traction comparison of 25 gauge high-speed dual-pneumatic vitrectomy probes: 20,000 cpm vs. 10,000 cpm

M. Genaidy, A. Sabry  **EGYPT**  
Subthreshold Micropulse laser 532 µm (green) treatment in acute central serous chorioretinopathy
M. Gharra, F. Hadad, I. Yushorun, E. Bartov **ISRAEL**
Perfluorocarbon-decalin short term tamponade post pars plana vitrectomy in retinal detachment surgery efficacy and safety

Functional and anatomical results of vitreectomy and delamination in diabetic patients with tractional retinal detachment and vitreous hemorrhage

S. Hoshi, F. Okamoto, T. Sakai, T. Murakami, Y. Shinohara, M. Nakatani, T. Oshika **JAPAN**
In vitro cytotoxicity of degradable fast-forming hydrogel with ultralow polymeric content as an artificial vitreous body

T. Imshenetskaya, V. Yarmak, V. Markevich, D. Abelski, V. Krasilnikova, O. Dudich **BELARUS**
Paediatric retinal detachment: the efficiency and the safety of surgical treatment

M. Iqbal **PAKISTAN**
Changes in vitreomacular interface in patients treated with bevacizumab or pan retinal photocoagulation for proliferative diabetic retinopathy

A. Irannejad, S. Tambat, D. Abulon **USA**
Retropulsion and Mass flow of 27-gauge Vitrectomy Probes: Comparison of Dual-blade/flat-tipped probes and single-blade/beveled probes

A. Irannejad, S. Tambat, D. Abulon **USA**
Sphere of influence and fluid velocity analysis of 27-gauge cutters: 20,000 cpm dual-cutting probes vs. 10,000 cpm single-cutting probes

K. Jeong **SOUTH KOREA**
Relationship between pain and injection site during intravitreal injection

R. Jones, R. Dubey, A. Chawla **UK**
Case series: Vasoproliferative lesions requiring vitrectorectal surgical intervention

M. Kalanov, M. Bikbov, R. Fayzrakhmanov, R. Zaynullin **RUSSIA**
Efficacy of vitrectoral intervention in combination with internal limiting membrane peeling against the background silicone oil tamponade of vitreous cavity at proliferative diabetic retinopathy

Y. Kato, M. Inoue, Y. Itoh, K. Hirota, T. Koto, Y. Kita, A. Hirakata **JAPAN**
The impact of glycemic control and renal function on surgical outcomes of 25-gauge vitrectomy for proliferative diabetic retinopathy

S. Kaynak, M. Kaya, T. Ozturk, N. Kocak **TURKEY**
Intravitreal sulfur hexafluoride injection for the treatment of symptomatic focal vitreomacular traction

A. Kidess, T. Koinonas **UK**
Our learning point from persistent to conventional treatment Macular Hole

Y. Kirilova, K. Racheva, P. Vassileva **BULGARIA**
Rhegmatogenous retinal detachment: diagnosis and management of bilateral involvement

N. Kislitsina, N. Kislitsina, S. Novikov, S. Kolesnik, A. Kolesnik **RUSSIA**
“Cataract flip side” anatomic and topographic features of anterior vitreous cortex

Y. Komiya, A. Takeyama, M. Shibata, Y. Imamura, M. Ishida **JAPAN**
Comparison of idiopathic macular hole surgery with and without internal limiting membrane staining with Brilliant Blue G

I. Kozak, J. Yepez, F. Murati **UAE**
Simultaneous bilateral pars plana vitrectomy in indicated cases

S. Kubo, Y. Kato, H. Keino, M. Inoue, A. Okada, A. Hirakata **JAPAN**
A case of unidentified uveitis effusion treated with vitrectomy and scleral fenestration

N. Lassandro, C. Mariotti, P. Pelliccioni, V. Pirani, R. Calamita, G. Gennari, P. Bisceglia **ITALY**
Inverted internal limiting membrane flap technique for repair of a iatrogenic macular hole after subretinal injection of recombinant tissue plasminogen activator and ranibizumab for submacular hemorrhage in angiod streaks

O. Makhzoun **UK**
Management of vitreomacular traction with intravitreal perfluoropropane (C3F8) gas injection

A. Makuloluwa, S. Tiew, I. Pearce **UK**
Does Ocriplasmin still have a role?

C. Mariotti, P. Bisceglia, R. Calamita, N. Lassandro, P. Pelliccioni, V. Pirani **ITALY**
Primary 27-gauge airbag-vitrectomy with air endotamponade in the treatment of rhegmatogenous retinal detachment: our technique and our experience

R. Mittal, U. Vashist, P. Narang, V. Mittal **INDIA**
Never say die!

S. Morikawa, F. Okamoto, Y. Okamoto, T. Oshika **JAPAN**
Clinical characteristics and visual outcomes of work-related open globe injuries in Japan

A. Mukherjee **INDIA**
Refurbished insights: vitrectomy for fresh retinal detachments: encirclage or not

A. Naik, A. Bhosale, K. Kumarswamy, V. Saravanan, V. Narendran **INDIA**
Management of post pars plana vitrectomy persistent vitreous haemorrhage with Nd:YAG laser capsulotomy in pseudophakic patients—a novel technique

K. Ohta, A. Sato, N. Senda, E. Fukui **JAPAN**
Stereopsis after unilateral macular hole surgery with internal limiting membrane peeling

A. Ozkaya, B. Kemer, H. Tarakcioglu **TURKEY**
Surgeon’s experience influences the tamponade preference in retinal detachment surgery with 23-gauge vitrectomy: A single surgeon study

A. Ozkaya, G. Erdogan, B. Tulu, H. Tarakcioglu **TURKEY**
The outcomes of subtotal vitrectomy in macular surgeries: A single surgeon case series

M. Ozturk, D. Guven, M. Demir, H. Kacar, M. Karapapak **TURKEY**
Functional and morphological results of epiretinal membrane surgery in idiopathic versus diabetic epiretinal membranes

D. Pagonulatos, Z. Kapsala, O. Makri, I. Georgalas, C. Georgakopoulos **GREECE**
Silicone oil removal and clinical outcomes
I. Papandreou, V. Tanner **UK**
Is monitoring an option? A case report of myopic foveoschisis

E. Papavasileiou, M. Niestrata-Ortiz, L. Abeywickrama, H. Laviers, C. Garnavou-Xirou, S. Velissaris, T. Jackson **UK**
Vitreoretinal and vitreomacular interface abnormalities in eyes treated with endothelial keratoplasty.

G. Pappas **GREECE**
The choice of IOL in phacovitrectomy cases based on the fellow eye biometry

J. Guber
Vitrectomy with internal limiting membrane flap technique for serous macular detachment associated optic disc pit

S. Parrulli, M. Cereda, I. D’Agostino, G. Staurenghi **ITALY**
Inverted flap for large macular holes: A functional evaluation

O. Pavloskiy, R. Fayzrakhmanov **RUSSIA**
Closure of large macular hole without removal of the internal limiting membrane

O. Pavloskiy, R. Fayzrakhmanov **RUSSIA**
The method of determining the quantity of ILM incisions in surgical treatment of the macular hole

M. Pencak, Z. Stranak, M. Veith **CZECH REPUBLIC**
25-gauge vitrectomy with expansive gas tamponade for rhegmatogenous retinal detachment – experienced vs. beginner surgeon

M. Pereira, S. Arya, S. V R **INDIA**
Recurrent retinal detachment surgery outcomes following the primary repair of rhegmatogenous retinal detachment complicated by choroidal detachment

I. Perente, G. Erdogan, O. Artunay, I. Yilmaz **TURKEY**
Transient additional sclerotomy in retinal detachment cases with subretinal proliferative vitreoretinopathy

Z. Pracharova, B. Babkova, M. Sin **CZECH REPUBLIC**
Extraction of intraocular foreign bodies by pars plana vitrectomy – our experience

M. Prieto del Cura, M. Acebes, M. Crespo **SPAIN**
Secondary macular hole (MH) associated with branch artery occlusion (BRAO) treated with inverted flap technique

E. Pritchard, S. Winder **UK**
Audit of outcomes of laser retinopexy in a busy tertiary vitreoretinal service

H. Ra **SOUTH KOREA**
Contralateral autologous internal limiting membrane transplantation for closure of a refractory macular hole: Surgical technique

A. Romero Martinez, W. Menjivar Aguilar, P. Catalan Munoz **SPAIN**
Small macular hole following blunt trauma in an 8-year-old child, progressing to stage 4 and requiring surgery

T. Sakurai **JAPAN**
Vitrectomy with internal limiting membrane flap technique for serous macular detachment associated optic disc pit

M. Schawkat, C. Valmaggia, C. Lang, H. Scholl, J. Guber **SWITZERLAND**
Influence of postoperative posture on retinal shift after retinal detachment repair

A. Schuster, J. Schneider, U. Vossmerbaeumer **GERMANY**
Intraocular pressure after minimally invasive vitrectomy

J. Seo, S. Kim, T. Rim **SOUTH KOREA**
Physical activity and incidence of retinal detachment under in South Korea during 2010-2015

S. Sheta **EGYPT**
Results of vitrectomy with inverted ILM flap for the management of traumatic macular holes

S. Sheth **INDIA**
Surgical removal of subfoveal hard exudate plaque by iatrogenic macular hole induction

Y. Shinkai, K. Yoneda, C. Sotozono **JAPAN**
Inverted internal limiting membrane flap technique for recurrent optic disc pit: A case report

A. Sbpak, D. Shkovorchenko, E. Krupina **RUSSIA**
Comparative efficacy of surgical treatment of macular holes with the use of platelet-rich plasma

R. Siantar, R. Rajagopal **SINGAPORE**
A rare complication after epiretinal membrane surgery

R. Soibam, D. Misra, P. Dhir, A. Upadhyay, H. Bhattacharjce **INDIA**
Chromo Visco assisted inverted ILM flap technique for management of failed surgery for large macular holes

S. Sosnovskii, A. Kulikov, D. Oskanov, D. Maltsev, R. Berezin **RUSSIA**
Vitrectomy with internal limiting membrane peeling for diabetic macular edema refractory to anti-VEGF therapy

D. Sousa, G. Costa de Andrade, H. Nascimento, A. Maia, C. Muccioli **PORTUGAL**
Macular hole associated with toxoplasmosis: A surgical case-series

Visual outcomes and oct findings of eyes having pars plana vitrectomy for primary macula-off retinal detachment in relation to the duration of the detachment

M. Stamenković, I. Sencanic, V. Jakšić, Z. Zikic, M. Mavija, A. Radosavljevic, D. Risimic **SERBIA**
Internal limiting membrane patch technique for the initial treatment of large macular holes

T. Stavropoulou, D. Pagoulatos, P. Dimitrakas, K. Mani, I. Georgalas, C. Koutsandrea **GREECE**
Idiopathic macular hole surgery: Long term visual acuity and anatomical success rate

S. Stebnov, V. Stebnov, N. Sladchikova **RUSSIA**
Combined endovitreal dye brilliant peel dual dye in the process of chromovitrectomy 27-gauge

S. Stebnov, V. Stebnov, N. Sladchikova **RUSSIA**
New combined endovitreal dye for chromovitrectomy

V. Stebnov, S. Stebnov, I. Malov, N. Sladchikova **RUSSIA**
The role of chromovitrectomy in reducing the risk of late re-proliferation of epimacular membranes

M. Stopa, A. Gotz-Wieckowska, J. Mazela, P. Rakowicz, M. Dalz, M. Pawlak **POLAND**
Anatomical outcomes of 27G transconjunctival vitrectomy for advanced retinopathy of prematurity
**POSTER PRESENTATIONS**

P. Susvar, G. Sood, P. Bhende **INDIA**
Macular buckling for myopic tractional maculopathies associated with posterior staphyloma: A case series

S. Tan, L. Steeples, N. Jones, N. Patton, S. Charles, A. Jalil **UK**
The surgical outcomes of rhegmatogenous retinal detachment secondary to viral retinitis

D. Tognetto, M. Pastore, G. Cirigliano, C. De Giacinto **ITALY**
Comparative analysis of 23-, 25-, and 27 gauge vitreous forceps stiffness and related displacement

T. Tran, D. Zaier, J. Proenca, J. Rouland **FRANCE**
Posterior segment intraocular implant (IOL) dislocation: Retrospective analysis of 72 cases

A. von Studnitz, C. Wertheimer, A. Hillenmayer, S. Kassumeh, A. Wolf, S. Priglinger **GERMANY**
Human recombinant galectin mitigate the cellular mechanisms of proliferative vitreoretinopathy in primary human tractive membranes in-vitro

U. Vossmerbaeumer **GERMANY**
Visual perception during vitreoretinal surgery

W. Wu, Y. Chang **TAIWAN**
Sustained-release dexamethasone (OZURDEX®) intravitreal implant for persistent macular edema after epiretinal membrane peeling surgery

M. Yablokov, O. Fabrikantov **RUSSIA**
Macular examination by OCT-angiography following endovitreal interventions for rhegmatogenous retinal detachment with tamponade by silicone oil and after its removal

X. Yang, S. Du, Y. Zha **CHINA**
Treatment of intractable hypotony and atrophic eyes

N. Yudina, A. Tereschenko, N. Yudina **RUSSIA**
Injector MicroDose injection kit in subretinal hemorrhage treatment

R. Zainullin, M. Bikbov, R. Fayzrakhmanov, M. Kalanov **RUSSIA**
Comparative study of combined vitrectomy/ranibizumab vs vitrectomy alone for diabetic macular edema: long-term results

R. Zainullin, M. Bikbov, R. Fayzrakhmanov, M. Kalanov **RUSSIA**
Internal limiting membrane peeling in patients with diabetic macular edema and epiretinal membrane

R. Zainullin, M. Bikbov, R. Fayzrakhmanov, M. Kalanov, T. Gilmanshin **RUSSIA**
Spatial distribution of macular pigment after surgical treatment of diabetic macular edema

V. Zakharov, P. Yakushev, Y. Gorodetskaya **RUSSIA**
Surgical treatment of proliferative diabetic retinopathy complicated by cataract (preliminary results)

M. Zgoba, P. Lyskin, V. Zaharov **RUSSIA**
The influence of intraoperative Lasercoagulation-Induced Inflammation on cytokine status

G. Zhurgumbayeva, L. Tashitova, R. Botabekov, D. Kyrkybayev **KAZAKHSTAN**
Elimination of vitreomacular traction syndrome at patients with primary pigmentary degeneration of retina in long period of observation

V. Zotov, N. Pashtaev **RUSSIA**
“Monoinstrumental” 27G-vitrectomy in treatment of proliferative diabetic retinopathy
EURETINA 2018
SUSTAINABLE CONGRESS

As the EURETINA Congress continues to grow, we are conscious of the environmental impact associated with an event of its scope. We are thus committed to reducing waste, lowering carbon emissions and using sustainable and ethically sourced congress materials.

Township Delegate Bags
EURETINA is delighted to partner for the first time with Township, an integrated social enterprise based in the township communities of Cape Town and dedicated to the production of high quality, ethically sourced and eco-friendly delegate bags.

Eco-friendly fabrics
This reusable EURETINA bag is made out of certified biodegradable fabric.

Fair Trade
Township is recognised by the World Fair Trade Organisation for its focus on long term sustainable impact through supporting women’s entrepreneurship in impoverished areas.

Recycled PET Lanyards
This year we have made the switch to PET lanyards produced with repurposed plastic materials which are globally recognised as an environmentally safe, recyclable product.

Recycled Paper
The programme in your hands is made of recycled paper, with water-based binding glue, making it 100% recyclable. The paper is also FSC approved which means that it comes from trees in well-managed forests.

The paper production method used is carbon neutral; the carbon used in transport of materials and labour is offset with a fee to plant new trees and neutralise the effects of the carbon.

www.euretina.org
O. Abdullah  IRAQ
Single corneal incision, non-instrumental scleral fixation, and three pieces intra ocular lens

F. Afrashi  TURKEY
pars plana vitrectomy and silicone oil tamponade for retinal detachment in the eye with choroidal coloboma

V. Agrawal  INDIA
The big bubble peel – Modified Sub-PFCL Inverted ILM Peeling for Macular Holes

H. Al Hasid  UAE
Increase success of scleral regrafting with pars plana vitrectomy by biological blockers in Wegener disease

A. Al-Abdullah  SAUDI ARABIA
In Action: Cannula-Controlled Drainage (CCD)

A. Al-Abdullah  SAUDI ARABIA
Vitreous With Volume Vs Volumeless Vitreous

F. Altomare  CANADA
Bimanual retinal and optic nerve head biopsy

J.A. Amigo  SPAIN
Avoiding triamcinolone in vitreoretinal surgery

J.A. Amigo  SPAIN
Traumatic paralytic mydriasis combined with hypermature luxated cataract in the vitreous cavity

K. Amissah-Arthur  GHANA
A case of 360 degree Giant Retinal Tear

K. Anastasilakis  GREECE
Dealing with proliferative vitreoretinopathy

B. Bavaharan  INDIA
ILM (Internal limiting membrane) Unlimited!!! – Overcoming the lump in the throat

R.K. Biswas  INDIA
Macular grafting in refractory macular hole

R.K. Biswas  INDIA
Do or die, save the eye

L. Broc Iturralde  SPAIN
The tip of the iceberg

D. Chakraborty  INDIA
Modern day UGH syndrome

B. Chanana  INDIA
Managing vitreo-retinal interface in diabetic vitrectomy: Different case scenario

B. Chanana  INDIA
Ahmed Glaucoma Valve surgery in vitrectomized eyes…… This is not the end!

J. Chaves  PORTUGAL
From anterior to posterior pole surgery in a single eye severe ocular trauma

J. Chhablani  INDIA
Complex diabetic vitrectomy – tips and tricks

D. Chow  CANADA
Autologous lens capsular graft for persistent macular hole

P.A. da Costa  CHILE
Modified Hamilton’s controlled encircling procedure for retinal detachment

A. de Casas  SPAIN
Management of iatrogenic traumatic cataract and posterior lens nucleus displacement following an intravitreal injection of Ranibizumab.

S. Demirel  TURKEY
How to manage choroidal detachment in patients with retinal detachment

R. Gandhi  INDIA
Managing complex diabetic tractional retinal detachments

J. Garcia Sanchez  SPAIN
Macular intraocular foreign body: surgical removal through 23-gauge pars plana vitrectomy using perfluorocarbon liquid and forceps

R. Geraldies  PORTUGAL
Central macroaneurysm hemorrhage surgery: from 20/800 to 20/25 vision

A. Gomez Moreno  SPAIN
Intermediate uveitis due to intraocular perfluorocarbon liquid retention after retinal detachment surgery

F. Gonzalez del Valle  SPAIN
Management of posttraumatic aphakia, aniridia, corneal leukemia and retinal detachment case: a total surgical solution including a capsular bag transplant

F. Gonzalez del Valle  SPAIN
A Fistfull of Intraocular Pellets S. Rai Gupta  INDIA
SFIOI to the rescue of Subluxated IOL-CTR-Bag Complex

D. Guven  TURKEY
Argus epiretinal prosthesis implantation with simultaneous phacoemulsification and IOL implantation

S. Hansraj  INDIA
Overcoming pitfalls of optic pit surgery

T. Imshenetskaya  BELARUS
Two ways to one problem solving: removal of large non-magnetic metallic intraocular foreign body (IOFB) through pars plana vitrectomy

Videos submitted to the EURETINA video competition 2018 are available for viewing at the ePoster & Video Terminals in the congress centre.
The competition winners will be announced at the Opening Ceremony taking place from 16.00 – 17.00 in Hall D3 on Thursday 20 September.
VIDEO COMPETITION

V.L. Karabas **TURKEY**
Resection of Hemangioblastoma

A. Lakimov **RUSSIA**
Complex stepwise phased rehabilitation of a patient with severe postoperative panophthalmitis

S. Luthra **INDIA**
Hungry Eyes! – Management of Live Intravitreal Cysticercus Cyst with Retinal Detachment with Proliferative Vitreoretinopathy

S. Mandal **INDIA**
“Don’t worry, be cool” – Accidents & complications can happen at any moment!

F. March de Ribot **SPAIN**
Multiple intraocular foreign bodies

F. March de Ribot **SPAIN**
Phacoemulsification in silicone oil

N. Mehrotra **INDIA**
Keep Calm and Rescue on!

N. Mehrotra **INDIA**
Behind the bars

P. Mondal **INDIA**
Proportional reflux hydrodissection technique in the management of tractional retinal detachment

R. Muni **CANADA**
Novel technique to remove retained subfoveal perfluorocarbon liquid

M.A. Muriel-Herrero **SPAIN**
Combined phaco-vitrectomy for myopic foveoschisis with an extrafoveal hole and Fuchs’ spot

R. Narula **INDIA**
The elusive vitreous sheath: myopic hole with detachment

R. Narula **INDIA**
My sojourn with subretinal haemorrhage

M. Oliveira **PORTUGAL**
Post traumatic vitreous hemorrhage: when everything seems lost

A. Pereira **INDIA**
Pulling the right strings – Different surgical approaches for tackling Tractional retinal detachment

J. Providência **PORTUGAL**
A Sneaky IOL

J. Providência **PORTUGAL**
Hide and Seek

M. Raimundo **PORTUGAL**
Surgical management of optic pit maculopathy with a free ILM/posterior hyaloid graft

D. Ruiz Casas **SPAIN**
RPE-choroid graft in RAP

H. Saigol **PAKISTAN**
Intraocular foreign body and traumatic cataract removal with foldable intraocular lens implantation: in a go:

N. Sanduja **INDIA**
Conquering retinal detachment in complex situations

S. Sheth **INDIA**
Vitrectomy with Fragmenting and Surgical Milking of a Visible Embolus to distal arterioles and restoring circulation in Central Retinal Artery Occlusion

D. Shroff **INDIA**
Ray of hope

J. Simão **PORTUGAL**
Ab externo removal of a long-standing metallic IOFB

J. Singh **INDIA**
A Novel technique for Instant Removal of Multiple Intraocular (glass) foreign bodies

O. Subira **SPAIN**
Giant retinal tears: how to avoid retinal slippage

P. Susvar **INDIA**
Needle Drainage of Subretinal Fluid in Scleral Buckling - A Novel Technique

C. Tan **SINGAPORE**
The Use of Triamcinolone Acetonide (TA) in Cortical Vitreous Removal during Vitrectomy in High Myopes

C. Tan **SINGAPORE**
Optical coherence tomography angiography of the parafoveal vaculature and its variation with ocular parameters

S. Tiwary **INDIA**
Scleral fixated IOL, different strokes

H. Vannadil **INDIA**
Vitreoretinal surgery with anterior segment system: Different strokes, similar outcome

S.H. Vidal **COLOMBIA**
Contractile peripapillary staphyloma with retinal detachment and macular hole

V. Zaika **RUSSIA**
Choice of the surgical intervention volume in the treatment of severe eye injury
GENERAL INFORMATION & EXHIBITION
GENERAL INFORMATION

Venue
Entrance D, Reed Messe Wien, Austria
U2 Subway Station – Krieau

Opening Hours
Registration
Hall D
Wednesday 19 September 14.00 – 19.00
Thursday 20 September 07.00 – 18.30
Friday 21 September 07.00 – 18.30
Saturday 22 September 07.00 – 18.30
Sunday 23 September 07.00 – 13.30

Speaker Check-In
Adjacent Stolz Rooms
Wednesday 19 September 14.00 – 18.00
Thursday 20 September 07.00 – 18.00
Friday 21 September 07.00 – 18.00
Saturday 22 September 07.00 – 18.00
Sunday 23 September 07.00 – 13.30

All speakers must check or upload their presentations 3 hours prior to their session.

Exhibition
Halls B & C
Friday 21 September 09.00 – 17.00
Saturday 22 September 09.00 – 17.00
Sunday 23 September 09.00 – 17.00
Monday 24 September 09.00 – 17.00
Tuesday 25 September 09.00 – 17.00

Wi-Fi
Wi-Fi is available free of charge throughout the venue.
Network: Vienna2018
Password: EYLEA57

Welcome Reception
Thursday 20 September 17.00, Foyer Lecture Hall D3

Closing Reception
Sunday 23 September 13.30, Foyer Lecture Hall D3

Speakers’ Corner
Entrance, Hall D

First Aid
Halls C & D

Kuoni Desk
Registration Area

Multi-Faith Prayer Room
Hall C

Lost & Found
Please check at the Registration Desk in Foyer Hall D for any lost items

General Assembly
Friday 21 September 09.30, Room C3

EURETINA Resource Centre
Exhibition Hall C, Booth C300

Insurance
Delegates are advised to take out travel insurance to cover medical expenses, accidents, loss etc. No responsibility will be accepted by the Congress Organisers.

Currency
The official currency of the Congress is Euro

Boarding Pass Printing
& Device Charging Stations
Refer to Congress Plan

ATM, Cloakroom & Cafés
Refer to Congress Plan

CME Credits
The 18th EURETINA Congress, Vienna, Austria, 20/09/2018-23/09/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 27 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits TM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form for each session.
The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day.
Each delegate should contact his/her national CME body directly in order to claim their credits for the Congress.

Join the Conversation
#EURETINA18
Connect with EURETINA during the Congress by following us on:
An online space to learn in your own time and place

Developed in conjunction with EURETINA course presenters

Forums to connect and discuss with other members

Interactive and assessed, including animations and videos to challenge and engage

Accredited earn CME credits and learn about the latest techniques

Visit our Resource Centre
Exhibition Hall C, Booth C300
EURETINA would like to thank the following sponsors for their support:
Clinical research in ophthalmology with special focus on management of retina and vitreous diseases

Ophthalmologica

THE OFFICIAL JOURNAL OF THE

EURETINA

FREE ONLINE ACCESS VIA
www.euretina.org (membership area)
CONGRESS CENTRE

LEVEL 0

HALL D

D3
D2
D1
D4
D5

HALL C

C4
C3
C2
C1

EXHIBITION

C300 EURETINA Resource Centre

LEVEL 1

Hall D

Restaurant
Mozart Room

ATM

Device Charging Stations

Prayer Room

Boarding Pass Printing

Metro Stop U2 - Krieau

Restaurant

Metal Stop U2 - Messe Prater
LEVEL 1

Congress Centre

HALL B GALERIE ROOMS

Wetlab Rooms 1-6

Recording Studio Business Suite 2

To Level 0
**EXHIBITOR LIST**

<table>
<thead>
<tr>
<th>Exhibitor Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>1stQ Deutschland GmbH</td>
<td>B207</td>
</tr>
<tr>
<td>2Eyes Vision S.L</td>
<td>C224</td>
</tr>
<tr>
<td>9GLENS® MEDICAL LTD.</td>
<td>B505</td>
</tr>
<tr>
<td>A.R.C. Laser GmbH</td>
<td>B309</td>
</tr>
<tr>
<td>Aaren Scientific</td>
<td>B317</td>
</tr>
<tr>
<td>ACMED CO., LTD.</td>
<td>C313</td>
</tr>
<tr>
<td>Acufocus, Inc.</td>
<td>B310</td>
</tr>
<tr>
<td>Adaptsa srl</td>
<td>C505</td>
</tr>
<tr>
<td>Aeon Astron Europe B.V.</td>
<td>B344</td>
</tr>
<tr>
<td>AJL OPHTHALMIC, SA</td>
<td>B211</td>
</tr>
<tr>
<td>akrus</td>
<td>C413</td>
</tr>
<tr>
<td>AKive</td>
<td>B607</td>
</tr>
<tr>
<td>AL-CHLMLA. S.r.l.</td>
<td>C301</td>
</tr>
<tr>
<td>Albert Heiss GmbH &amp; Co. KG</td>
<td>B321</td>
</tr>
<tr>
<td>Albomed GmbH Germany</td>
<td>B121</td>
</tr>
<tr>
<td>ALCON</td>
<td>B201</td>
</tr>
<tr>
<td>Alfa Intes</td>
<td>B320</td>
</tr>
<tr>
<td>Alimera Sciences Limited</td>
<td>C303</td>
</tr>
<tr>
<td>Allergan</td>
<td>C500</td>
</tr>
<tr>
<td>ALSANZA</td>
<td>C404</td>
</tr>
<tr>
<td>American Academy of Ophthalmology</td>
<td>B319</td>
</tr>
<tr>
<td>Amidia AG</td>
<td>B351</td>
</tr>
<tr>
<td>Anodyne Surgical</td>
<td>C517</td>
</tr>
<tr>
<td>APACRS</td>
<td>B326</td>
</tr>
<tr>
<td>APPASAMY ASSOCIATES</td>
<td>B127</td>
</tr>
<tr>
<td>Aprofol AG</td>
<td>C217</td>
</tr>
<tr>
<td>ARCADOPHTA</td>
<td>C212</td>
</tr>
<tr>
<td>ASCRS/Eyeworld</td>
<td>B325</td>
</tr>
<tr>
<td>ASICO LLC</td>
<td>B334</td>
</tr>
<tr>
<td>AST Products, Inc.</td>
<td>B329</td>
</tr>
<tr>
<td>AUROLAB</td>
<td>B113</td>
</tr>
<tr>
<td>Avedro, Inc.</td>
<td>B318</td>
</tr>
<tr>
<td>Avellino Labs</td>
<td>C619</td>
</tr>
<tr>
<td>b o n Optic</td>
<td>B108</td>
</tr>
<tr>
<td>BaiShum Medical Instrument Factory</td>
<td>C227</td>
</tr>
<tr>
<td>BAUSCH+LOMB</td>
<td>B101</td>
</tr>
<tr>
<td>BAYER</td>
<td>C600</td>
</tr>
<tr>
<td>Benz Research &amp; Development</td>
<td>B137</td>
</tr>
<tr>
<td>BIOTECH HEALTH CARE HOLDING GMBH</td>
<td>B610</td>
</tr>
<tr>
<td>Blink Medical Ltd.</td>
<td>B112</td>
</tr>
<tr>
<td>Block Optic Ltd.</td>
<td>B609</td>
</tr>
<tr>
<td>Bohus BioTech AB</td>
<td>B345</td>
</tr>
<tr>
<td>BRASCRS – Brazilian Association of Cataract and Refractive Surgeons</td>
<td>B301A</td>
</tr>
<tr>
<td>BRUMABA GmbH &amp; Co. KG</td>
<td>B122</td>
</tr>
<tr>
<td>Bürki inno med AG</td>
<td>B323</td>
</tr>
<tr>
<td>BVI Medical</td>
<td>B410</td>
</tr>
<tr>
<td>C.L.O.M. Srl</td>
<td>C312</td>
</tr>
<tr>
<td>Canon Europa N.V.</td>
<td>C205</td>
</tr>
<tr>
<td>CeGaT GmbH</td>
<td>C410</td>
</tr>
<tr>
<td>CenterVue SpA</td>
<td>C604</td>
</tr>
<tr>
<td>chongqing kanghuaruiming S&amp;T Co.,Ltd.</td>
<td>C509</td>
</tr>
<tr>
<td>ChongQing SunKingdom Medical Instrument Co., Ltd</td>
<td>C215</td>
</tr>
<tr>
<td>CLILTA LLC</td>
<td>B312</td>
</tr>
<tr>
<td>Contamac</td>
<td>B128</td>
</tr>
<tr>
<td>CorneaGen (formerly known as Sightlife Surgical)</td>
<td>C518A</td>
</tr>
<tr>
<td>CRISTALENS INDUSTRIE</td>
<td>B119</td>
</tr>
<tr>
<td>CROMA PHARMA GMBH</td>
<td>C507</td>
</tr>
<tr>
<td>CRST EUROPE/RETINA TODAY</td>
<td>C309</td>
</tr>
<tr>
<td>Crystalvue Medical Corporation</td>
<td>C324</td>
</tr>
<tr>
<td>CSO srl</td>
<td>B413</td>
</tr>
<tr>
<td>Daud Jee Mfg. Co.</td>
<td>C219</td>
</tr>
<tr>
<td>DEVINE MEDITECH PVT LTD.</td>
<td>C414</td>
</tr>
<tr>
<td>DGH Technology, Inc.</td>
<td>B619</td>
</tr>
<tr>
<td>Diamatrix Ltd.</td>
<td>B314</td>
</tr>
<tr>
<td>Diopsys, Inc.</td>
<td>C614</td>
</tr>
<tr>
<td>D J Apple Lab</td>
<td>C310</td>
</tr>
<tr>
<td>DORC International</td>
<td>C204</td>
</tr>
<tr>
<td>Duckworth &amp; Kent Ltd.</td>
<td>B118</td>
</tr>
<tr>
<td>E.Janach® srl</td>
<td>B413</td>
</tr>
<tr>
<td>Eagle Labs</td>
<td>B507</td>
</tr>
<tr>
<td>EAGLE OPTICS PVT. LTD.</td>
<td>B313</td>
</tr>
<tr>
<td>ELLEGI MEDICAL OPTICS SRL</td>
<td>B407</td>
</tr>
<tr>
<td>Ellex</td>
<td>B304</td>
</tr>
<tr>
<td>Entod Research Cell UK Ltd.</td>
<td>B414</td>
</tr>
<tr>
<td>Epsilon USA</td>
<td>B506</td>
</tr>
<tr>
<td>ESASO</td>
<td>C316</td>
</tr>
<tr>
<td>ESCRs Resource Centre</td>
<td>B501</td>
</tr>
<tr>
<td>ESPANSIONE GROUP</td>
<td>C607</td>
</tr>
<tr>
<td>ESW Vision</td>
<td>B141</td>
</tr>
<tr>
<td>EURETINA Resource Centre</td>
<td>C300</td>
</tr>
<tr>
<td>EVER</td>
<td>C108</td>
</tr>
<tr>
<td>EXCEL OPTICS (P) LIMITED</td>
<td>C314</td>
</tr>
<tr>
<td>Excelsius Medical® GmbH</td>
<td>C324</td>
</tr>
<tr>
<td>EYE LOVE KOREA</td>
<td>C239</td>
</tr>
<tr>
<td>Company Name</td>
<td>Booth</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Eye Pharma</td>
<td>C305</td>
</tr>
<tr>
<td>Eye Technology Ltd.</td>
<td>B123</td>
</tr>
<tr>
<td>EyeKon Medical, Inc.</td>
<td>B511</td>
</tr>
<tr>
<td>Eyenuk, Inc.</td>
<td>C107A</td>
</tr>
<tr>
<td>Eyeol UK Ltd.</td>
<td>C624</td>
</tr>
<tr>
<td>EyeYon Medical</td>
<td>C331</td>
</tr>
<tr>
<td>Farmigea Srl.</td>
<td>C520</td>
</tr>
<tr>
<td>FB VISION SRL</td>
<td>C240</td>
</tr>
<tr>
<td>FCI S.A.S.</td>
<td>B400</td>
</tr>
<tr>
<td>Frastema S.r.l.</td>
<td>C401</td>
</tr>
<tr>
<td>Freedom Ophthalmic Pvt., Ltd.</td>
<td>C225</td>
</tr>
<tr>
<td>Freudenberg Medical Europe GmbH</td>
<td>C220</td>
</tr>
<tr>
<td>Frey S.I.</td>
<td>C209</td>
</tr>
<tr>
<td>FRIMEN CO,LTD.</td>
<td>B418, C409</td>
</tr>
<tr>
<td>GAMMA VISION</td>
<td>C308</td>
</tr>
<tr>
<td>Gaush Medical Corporation</td>
<td>B335A</td>
</tr>
<tr>
<td>Gebauer Medizintechnik</td>
<td>B503</td>
</tr>
<tr>
<td>Gemma Medical AG</td>
<td>B351</td>
</tr>
<tr>
<td>Geuder AG</td>
<td>B102</td>
</tr>
<tr>
<td>Glaukos Corporation</td>
<td>B330</td>
</tr>
<tr>
<td>Guangdong Fortune Optoelectronics Ltd.</td>
<td>C334</td>
</tr>
<tr>
<td>HAAG-STREIT GROUP</td>
<td>B311</td>
</tr>
<tr>
<td>HAAG-STREIT SURGICAL GmbH</td>
<td>B311</td>
</tr>
<tr>
<td>HAAG-STREIT UK</td>
<td>B311</td>
</tr>
<tr>
<td>HANGZHOU MOCULAR MEDICAL</td>
<td>C223</td>
</tr>
<tr>
<td>Hangzhou Singlean</td>
<td>C236</td>
</tr>
<tr>
<td>Hanita Lenses</td>
<td>B518</td>
</tr>
<tr>
<td>Heidelberg Engineering</td>
<td>B603</td>
</tr>
<tr>
<td>HEINE Optotechnik</td>
<td>B517</td>
</tr>
<tr>
<td>HORUS PHARMA</td>
<td>C601</td>
</tr>
<tr>
<td>HOYA Surgical Optics GmbH</td>
<td>B209</td>
</tr>
<tr>
<td>HS DOMS INTERNATIONAL</td>
<td>B311</td>
</tr>
<tr>
<td>HumanOptics AG</td>
<td>B106</td>
</tr>
<tr>
<td>Huvitz Co., Ltd.</td>
<td>B144</td>
</tr>
<tr>
<td>Icare Finland</td>
<td>B331</td>
</tr>
<tr>
<td>iifa systems AG</td>
<td>B613</td>
</tr>
<tr>
<td>Imagine Eyes</td>
<td>C406</td>
</tr>
<tr>
<td>I-MED Pharma, Inc.</td>
<td>C621</td>
</tr>
<tr>
<td>i-Medical Ophthalmic Intern.</td>
<td>B110</td>
</tr>
<tr>
<td>Inami &amp; Co., Ltd.</td>
<td>B114</td>
</tr>
<tr>
<td>INCYTO CO., LTD.</td>
<td>C235</td>
</tr>
<tr>
<td>INDO WEBAL.</td>
<td>C323</td>
</tr>
<tr>
<td>IOptima Ltd.</td>
<td>C232</td>
</tr>
<tr>
<td>IRIDEX</td>
<td>C501</td>
</tr>
<tr>
<td>iSTAR Medical sa</td>
<td>B513</td>
</tr>
<tr>
<td>iVIS Technologies S.r.l.</td>
<td>C606</td>
</tr>
<tr>
<td>JAMJOOM PHARMA</td>
<td>B333</td>
</tr>
<tr>
<td>Janach* srl</td>
<td>B413</td>
</tr>
<tr>
<td>JETT</td>
<td>C523</td>
</tr>
<tr>
<td>John Weiss &amp; Son Ltd.</td>
<td>B311</td>
</tr>
<tr>
<td>Johnson &amp; Johnson Vision</td>
<td>B500</td>
</tr>
<tr>
<td>JP Medical Publishers</td>
<td>C101</td>
</tr>
<tr>
<td>Kai Europe GmbH</td>
<td>B338</td>
</tr>
<tr>
<td>Kanger Publishers</td>
<td>C402</td>
</tr>
<tr>
<td>Karl Kaps GmbH &amp; Co. KG</td>
<td>C415</td>
</tr>
<tr>
<td>Katalyst Surgical®, LLC</td>
<td>C102</td>
</tr>
<tr>
<td>Katena</td>
<td>B107</td>
</tr>
<tr>
<td>Keeler Ltd.</td>
<td>C612</td>
</tr>
<tr>
<td>KHOSLA SURGICAL IND.</td>
<td>C210</td>
</tr>
<tr>
<td>KIDE Systems</td>
<td>C412</td>
</tr>
<tr>
<td>KITE HELLAS NOVAX PHARMA</td>
<td>C329</td>
</tr>
<tr>
<td>Konan Medical USA, Inc.</td>
<td>B328</td>
</tr>
<tr>
<td>KORYOYEYETECH CO., LTD.</td>
<td>C516</td>
</tr>
<tr>
<td>Kowa Optimed Deutschland GmbH</td>
<td>B305</td>
</tr>
<tr>
<td>Kowa Pharmaceutical Europe Ltd.</td>
<td>B300</td>
</tr>
<tr>
<td>Kuwait Specialized Eye Center</td>
<td>C513</td>
</tr>
<tr>
<td>Laboratoires Théa</td>
<td>B205</td>
</tr>
<tr>
<td>Lacrivera</td>
<td>B504</td>
</tr>
<tr>
<td>LAMBDA-X S.A.</td>
<td>B130</td>
</tr>
<tr>
<td>LCA PHARMACEUTICAL</td>
<td>B343</td>
</tr>
<tr>
<td>Leica Microsystems</td>
<td>C504</td>
</tr>
<tr>
<td>Lens Tec</td>
<td>B125</td>
</tr>
<tr>
<td>LIFELINE MEDICAL DEV. PVT LTD.</td>
<td>B212</td>
</tr>
<tr>
<td>LIGHTMED</td>
<td>B117</td>
</tr>
<tr>
<td>LKC Technologies</td>
<td>C216</td>
</tr>
<tr>
<td>Lumenis</td>
<td>C510</td>
</tr>
<tr>
<td>LamiThera, Inc.</td>
<td>C608</td>
</tr>
<tr>
<td>LUNEAU TECHNOLOGY</td>
<td>B336</td>
</tr>
<tr>
<td>M&amp;S Technologies</td>
<td>B315</td>
</tr>
<tr>
<td>MacuLogix</td>
<td>C623</td>
</tr>
<tr>
<td>Madhu Instruments Pvt Ltd.</td>
<td>C407</td>
</tr>
<tr>
<td>MANI, INC.</td>
<td>B140</td>
</tr>
<tr>
<td>MDT POLAND</td>
<td>B116</td>
</tr>
<tr>
<td>MECCANOTTICA MAZZA S.R.L.</td>
<td>C302</td>
</tr>
<tr>
<td>MEDA Co., Ltd.</td>
<td>B515</td>
</tr>
<tr>
<td>Medennium Inc.</td>
<td>C311</td>
</tr>
<tr>
<td>Medecig AG Swiss Technology for Surgery</td>
<td>B307</td>
</tr>
<tr>
<td>Medicare HTM International</td>
<td>C519</td>
</tr>
<tr>
<td>EXHIBITOR LIST</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td></td>
</tr>
<tr>
<td>MEDICONTUR INTERNATIONAL</td>
<td>B208</td>
</tr>
<tr>
<td>Medimaging Integrated Solution, Inc.</td>
<td>C618</td>
</tr>
<tr>
<td>MEDINSTRUS UAB</td>
<td>C417</td>
</tr>
<tr>
<td>Mediphacos</td>
<td>B617</td>
</tr>
<tr>
<td>MED-LOGICS, INC.</td>
<td>B316</td>
</tr>
<tr>
<td>MedOne Surgical, Inc.</td>
<td>C100</td>
</tr>
<tr>
<td>MERIDIAN AG</td>
<td>B323</td>
</tr>
<tr>
<td>Metrovision</td>
<td>C411</td>
</tr>
<tr>
<td>Microspecialties, LLC</td>
<td>C230</td>
</tr>
<tr>
<td>MicroSurgical Technology</td>
<td>B324</td>
</tr>
<tr>
<td>Microtrack Surgeries</td>
<td>C319</td>
</tr>
<tr>
<td>Millennium Biomedical, Inc.</td>
<td>B120</td>
</tr>
<tr>
<td>MIRAY MEDIKAL</td>
<td>C104</td>
</tr>
<tr>
<td>MLase AG</td>
<td>C318</td>
</tr>
<tr>
<td>Moptim</td>
<td>C602</td>
</tr>
<tr>
<td>MORCHER GmbH</td>
<td>B126</td>
</tr>
<tr>
<td>MORIA SA</td>
<td>B204</td>
</tr>
<tr>
<td>Mynosys Cellular Devices Inc.</td>
<td>C206</td>
</tr>
<tr>
<td>Natus Newborn Care</td>
<td>C508</td>
</tr>
<tr>
<td>NEITZ INSTRUMENTS CO., LTD.</td>
<td>B114</td>
</tr>
<tr>
<td>Network Medical Products</td>
<td>B348</td>
</tr>
<tr>
<td>NETWORK TECHNOLOGY DEVELOPMENT</td>
<td>C226</td>
</tr>
<tr>
<td>New Vision Meditec Co., Ltd.</td>
<td>C321</td>
</tr>
<tr>
<td>New World Medical</td>
<td>B308</td>
</tr>
<tr>
<td>Next Sight</td>
<td>C622</td>
</tr>
<tr>
<td>NIDEK CO., LTD.</td>
<td>B303</td>
</tr>
<tr>
<td>NIETZ</td>
<td>C514</td>
</tr>
<tr>
<td>Nordset GmbH &amp; Co.KG</td>
<td>B138</td>
</tr>
<tr>
<td>Novartis</td>
<td>C202</td>
</tr>
<tr>
<td>NTC</td>
<td>C211</td>
</tr>
<tr>
<td>OASIS Medical, Inc.</td>
<td>B301</td>
</tr>
<tr>
<td>Ocular Instruments, Inc.</td>
<td>C103</td>
</tr>
<tr>
<td>Ocu lentis &amp; Teleon</td>
<td>B403</td>
</tr>
<tr>
<td>OCULUS Optikgeräte GmbH</td>
<td>B404</td>
</tr>
<tr>
<td>OCuSOFT</td>
<td>B111</td>
</tr>
<tr>
<td>ODC Industries</td>
<td>C416</td>
</tr>
<tr>
<td>ODC Medical</td>
<td>C416</td>
</tr>
<tr>
<td>OD-OS GmbH - Navilas</td>
<td>C207</td>
</tr>
<tr>
<td>Oertli Instrumente AG</td>
<td>B100</td>
</tr>
<tr>
<td>Omesis Ophthalmic Medical Systems</td>
<td>C512</td>
</tr>
<tr>
<td>OMNI LENS PVT LTD.</td>
<td>B145</td>
</tr>
<tr>
<td>OPHTEC</td>
<td>B402</td>
</tr>
<tr>
<td>Ophtechnics Unlimited</td>
<td>B341</td>
</tr>
<tr>
<td>OPTICO LTD</td>
<td>B508</td>
</tr>
<tr>
<td>Optimal Saglik Ltd. Sti.</td>
<td>B509</td>
</tr>
<tr>
<td>Optimed®</td>
<td>B332</td>
</tr>
<tr>
<td>OPTITECH EYECARE</td>
<td>C518</td>
</tr>
<tr>
<td>OPTOMED OY (LTD.)</td>
<td>C506</td>
</tr>
<tr>
<td>OPTOPOL Technology</td>
<td>C306</td>
</tr>
<tr>
<td>Optos plc</td>
<td>C503</td>
</tr>
<tr>
<td>Optorex Medical</td>
<td>C605</td>
</tr>
<tr>
<td>Optovue</td>
<td>B203</td>
</tr>
<tr>
<td>Panasonic Marketing Europe GmbH</td>
<td>C315</td>
</tr>
<tr>
<td>Peschke Trade</td>
<td>B339</td>
</tr>
<tr>
<td>pfM medical ag</td>
<td>B124</td>
</tr>
<tr>
<td>PHAKOS</td>
<td>C307</td>
</tr>
<tr>
<td>Phoenix ICON</td>
<td>C609</td>
</tr>
<tr>
<td>PhysIOL.</td>
<td>B105</td>
</tr>
<tr>
<td>Plusoptix GmbH</td>
<td>B606</td>
</tr>
<tr>
<td>Pieceys BV</td>
<td>C238</td>
</tr>
<tr>
<td>Presbia PLC</td>
<td>B200</td>
</tr>
<tr>
<td>Precisio, Inc.</td>
<td>C317</td>
</tr>
<tr>
<td>PRICON-ISCNS SURGICALS LIMITED</td>
<td>C222</td>
</tr>
<tr>
<td>QUANTEL MEDICAL</td>
<td>B103</td>
</tr>
<tr>
<td>Ray Vision</td>
<td>B406</td>
</tr>
<tr>
<td>Rayner</td>
<td>B409</td>
</tr>
<tr>
<td>Refocus Group, Inc.</td>
<td>B408</td>
</tr>
<tr>
<td>Reichert Technologies</td>
<td>C616</td>
</tr>
<tr>
<td>Remidio Innovative Solutions</td>
<td>C419</td>
</tr>
<tr>
<td>Reper-NN Ltd.</td>
<td>C322</td>
</tr>
<tr>
<td>RET, Inc.</td>
<td>B139</td>
</tr>
<tr>
<td>Retina Implant AG</td>
<td>C237</td>
</tr>
<tr>
<td>Rexxam Co., Ltd.</td>
<td>C613</td>
</tr>
<tr>
<td>RIGHT MFG. CO., LTD.</td>
<td>B108</td>
</tr>
<tr>
<td>Rini</td>
<td>B136</td>
</tr>
<tr>
<td>Roche</td>
<td>C400</td>
</tr>
<tr>
<td>ROLAND CONSULT Stasche &amp; Finger GmbH</td>
<td>C213</td>
</tr>
<tr>
<td>ROTLEX OPTICS</td>
<td>C408</td>
</tr>
<tr>
<td>RUCK GmbH</td>
<td>B109</td>
</tr>
<tr>
<td>Rumex International Co.</td>
<td>B306</td>
</tr>
<tr>
<td>Santen Switzerland SA</td>
<td>B206</td>
</tr>
<tr>
<td>SAV-IOL</td>
<td>B134</td>
</tr>
<tr>
<td>SBM Sistemi</td>
<td>C325</td>
</tr>
<tr>
<td>SCHWIND eye-tech-solutions</td>
<td>B605</td>
</tr>
<tr>
<td>SciCan Ltd.</td>
<td>C203</td>
</tr>
<tr>
<td>Second Sight Medical Products</td>
<td>C511</td>
</tr>
<tr>
<td>SERVimed Industrial Spa</td>
<td>B129</td>
</tr>
<tr>
<td>SHAH EYE CARE PVT. LTD.</td>
<td>B350</td>
</tr>
<tr>
<td>Company Name</td>
<td>Booth</td>
</tr>
<tr>
<td>---------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Shanghai MediWorks</td>
<td>B135A</td>
</tr>
<tr>
<td>Sharpont- Surgical Specialties Corporation</td>
<td>B131</td>
</tr>
<tr>
<td>SHENYANG XINGQI PHARMACEUTICAL CO., LTD.</td>
<td>C617</td>
</tr>
<tr>
<td>Shire International</td>
<td>B335</td>
</tr>
<tr>
<td>SIDAPHARM</td>
<td>B416</td>
</tr>
<tr>
<td>SIFI</td>
<td>C603</td>
</tr>
<tr>
<td>Sihong Ophsurfian Co., Ltd.</td>
<td>B347</td>
</tr>
<tr>
<td>SOE 2019</td>
<td>B327</td>
</tr>
<tr>
<td>Soleko S.p.A</td>
<td>B413</td>
</tr>
<tr>
<td>SOMETECH INC.</td>
<td>C330</td>
</tr>
<tr>
<td>Sonomed Escalon</td>
<td>B340</td>
</tr>
<tr>
<td>SOOFT ITALIA SPA</td>
<td>B616</td>
</tr>
<tr>
<td>SPeye</td>
<td>C515</td>
</tr>
<tr>
<td>SPEEDWAY SURGICAL CO.</td>
<td>C328</td>
</tr>
<tr>
<td>STAAR Surgical</td>
<td>B104</td>
</tr>
<tr>
<td>Stephens Instruments</td>
<td>B504</td>
</tr>
<tr>
<td>Sterimedix Limited</td>
<td>B132</td>
</tr>
<tr>
<td>STERLING ULTRA PRECISION</td>
<td>B614</td>
</tr>
<tr>
<td>SurgiCube International</td>
<td>C214</td>
</tr>
<tr>
<td>Surgistar, Inc.</td>
<td>B412</td>
</tr>
<tr>
<td>Surgitrac Europe</td>
<td>B213</td>
</tr>
<tr>
<td>Susruta Instruments Pvt. Ltd.</td>
<td>C221</td>
</tr>
<tr>
<td>SUZHOU KANGJIE MEDICAL INC.</td>
<td>C320</td>
</tr>
<tr>
<td>Suzhou MicroClear Medical</td>
<td>C610</td>
</tr>
<tr>
<td>Takagi Europe Ltd.</td>
<td>B135</td>
</tr>
<tr>
<td>TEAC Europe GmbH</td>
<td>B516</td>
</tr>
<tr>
<td>Tecfen Medical</td>
<td>B512</td>
</tr>
<tr>
<td>Thirona</td>
<td>C107</td>
</tr>
<tr>
<td>This - Think in System</td>
<td>C106</td>
</tr>
<tr>
<td>Thrombogenics</td>
<td>C228</td>
</tr>
<tr>
<td>Tianjin Suowei Electronic Technology Co., Ltd.</td>
<td>C615</td>
</tr>
<tr>
<td>TITAN MEDICAL LLC</td>
<td>B322</td>
</tr>
<tr>
<td>Titan Surgical LLC</td>
<td>B405</td>
</tr>
<tr>
<td>Tomey GmbH</td>
<td>B210</td>
</tr>
<tr>
<td>Topcon Europe Medical B.V.</td>
<td>B604</td>
</tr>
<tr>
<td>Tracey Technologies</td>
<td>B337</td>
</tr>
<tr>
<td>TRIOPTICS GmbH</td>
<td>C234</td>
</tr>
<tr>
<td>Tristel</td>
<td>B346</td>
</tr>
<tr>
<td>Trusetal Verbandstoffwerk GmbH</td>
<td>B115</td>
</tr>
<tr>
<td>U.S. IOL.</td>
<td>B504</td>
</tr>
<tr>
<td>UFSK-International OSYS</td>
<td>B415</td>
</tr>
<tr>
<td>Ursapharm Arzneimittel GmbH</td>
<td>B611</td>
</tr>
<tr>
<td>VectorVision/Guardion Health</td>
<td>B342</td>
</tr>
<tr>
<td>Vesper Biotechnology Co., Ltd.</td>
<td>C335</td>
</tr>
<tr>
<td>Vision Ophthalmology Grp</td>
<td>C405</td>
</tr>
<tr>
<td>VISUfarma B.V.</td>
<td>C502</td>
</tr>
<tr>
<td>Vitreq B.V.</td>
<td>B411</td>
</tr>
<tr>
<td>Volk Optical Inc.</td>
<td>C611</td>
</tr>
<tr>
<td>VOPTICA S.L.</td>
<td>C403</td>
</tr>
<tr>
<td>Vortex Surgical, Inc.</td>
<td>C327</td>
</tr>
<tr>
<td>VRmagic GmbH</td>
<td>B349</td>
</tr>
<tr>
<td>VSY Biotechnology</td>
<td>B510</td>
</tr>
<tr>
<td>WISEPRESS LTD.</td>
<td>C208</td>
</tr>
<tr>
<td>Wuxi Vision Pro Ltd.</td>
<td>C229</td>
</tr>
<tr>
<td>YILMAZ MEDIKAL</td>
<td>B514</td>
</tr>
<tr>
<td>YURATEK LTD STI</td>
<td>B615</td>
</tr>
<tr>
<td>ZEISS</td>
<td>B401</td>
</tr>
<tr>
<td>Zhejiang Jingjia Medical Technology Co., Ltd.</td>
<td>C524</td>
</tr>
<tr>
<td>Ziemer Ophthalmic Systems AG</td>
<td>B502</td>
</tr>
</tbody>
</table>
Giving retinal images a new dimension

The next generation of Optos innovation

Visit us at EURETINA/ESCRS 2018  Booth c503
Find out more www.OptosNextGen.com
Join Optos at Euretina/ESCRS

Trial the latest UWF imaging device from Optos.

Friday Satellite Meeting, 1pm

200° Ultra-widefield Retinal Imaging:
Clinical Advances and Emerging Applications
with
Dr. SriniVas Sadda, Prof. Lloyd Paul Aiello,
Prof. Ramin Tadayoni & Prof. Tunde Peto

Join us to learn how our suite of imaging devices help facilitate the early detection, management and effective treatment of disorders and diseases evidenced in the retina.

Optos Booth C503
EURETINA is delighted to host the 7th Retina Race at the 18th EURETINA Congress in Vienna.

Date: Saturday 22 September 2018, 6.30am
Online & Onsite Registration Fee: €40 in Aid of Orbis

Information at www.euretina.org
Thursday 20 September

LUNCHTIME SYMPOSIA

13.00 – 14.00
Room C1

DME Management: Optimising Real World Outcomes
Moderator: A. Loewenstein ISRAEL
Chair: F. Bandello ITALY

Sponsored by Allergan

13.00 – 14.00
Room D2

Clinical Advances and Applications with Swept Source OCT & Angiography
Moderator: J.M. Ruiz-Moreno SPAIN

Sponsored by Topcon

13.00 – 14.00
Lehar 1

Photobiomodulation: An Innovative, Mitochondria-targeted Therapy for Dry AMD and Other Ocular Diseases
Moderators: J. Eells USA
M. Munk SWITZERLAND

Sponsored by LumiThera.

Friday 21 September

MORNING SYMPOSIA

10.00 – 11.00
Room C1

Lessons Learned From the Real World: Improving Patient Care
Moderator: J-F. Korobelnik FRANCE

Sponsored by Bayer

10.00 – 11.00
Room D1

Seeing the Future: Gene Therapy for Inherited Retinal Disease
Moderators: B. Leroy BELGIUM
C. Fasser SWITZERLAND

Sponsored by Novartis

10.00 – 11.00
Room D4

The OCTA Trinity
Moderator: D. Pauleikhoff GERMANY

Sponsored by Heidelberg Engineering
Friday 21 September

**LUNCHTIME SYMPOSIA**

**Room C3**

Continuous Microdosing with ILUVIEN: Optimising the Treatment of Persistent or Recurrent DME

Moderator: F. Bandello *ITALY*

Sponsored by

---

**Room C2**

Proactive Dosing for Effective Patient Management: What do the Latest Data Show?

Moderator: P. Lanzetta *ITALY*

Sponsored by Bayer

---

**Room C4**

*Ranibizumab* – New Evidence; New Insights: *Partnering* for Better Patient Outcomes

Moderator: N. Eter *GERMANY*

Sponsored by Novartis

---

**Room C5**

200° Ultra-Widefield Retinal Imaging: Clinical Advances and Emerging Applications

Moderator: L. Aiello *USA*

Sponsored by Optos

---

**Room D1**

200° Ultra-Widefield Retinal Imaging: Clinical Advances and Emerging Applications

Moderator: L. Aiello *USA*

Sponsored by Optos

---

**Room D5**

Illuminating the Future of DME Management

Moderator: N. Bressler *USA*

Sponsored by Roche

---

**Room D2**

Understanding and Measuring Functional Loss in Macular Disease: Multimodal Diagnostics

Moderator: U. Schmidt-Erfurth *AUSTRIA*

Sponsored by Nidek
Saturday 22 September

MORNING SYMPOSIA

10.00 – 11.00
Room C3

Fusing Technologies into Integrated Solutions for Every Vitreoretinal Surgery

Moderator:  R. Tadayoni FRANCE

Sponsored by Alcon

10.00 – 11.00
Room C1

Changing the Course: Disease Modification with Intensive Early Treatment for DME

Moderator:  I. Pearce UK

Sponsored by Bayer

10.00 – 11.00
Room C4

Retinal Disease Management: Transferring Bench to Bedside

Moderator:  A. Loewenstein ISRAEL

Sponsored by Allergan

10.00 – 11.00
Room D2

SubLiminal Laser Therapy: When Subthreshold Laser Yields Good Macular Outcomes

Moderator:  V. Chong UK

Sponsored by Quantel Medical

10.00 – 11.00
Room D4

Complement C3 Inhibition in Geographic Atrophy

Moderator:  J. Slakter USA

Sponsored by Apellis

Saturday 22 September

LUNCHTIME SYMPOSIA

13.00 – 14.00
Room D1

2RT for Early AMD: The Role of Nanosecond Laser Therapy

Moderator:  U. Chakravarthy UK

Sponsored by ellex

13.00 – 14.00
Room D2

How Can Innovation Deliver Real Benefits to Improve VR Surgery?

Moderator:  P. Stalmans BELGIUM

Sponsored by DORC
SATellite Education Programme

Saturday 22 September

LUNCHTIME SYMPOSIA

13.00 – 14.00
Room C4

Advancing Therapy for nAMD

Moderator: U. Schmidt-Erfurth AUSTRIA

Sponsored by NOVARTIS

---

Complete Retinal Imaging Platform – A View into Integrating WideField Fundus and OCT-A

Moderator: J-F. Korobelnik FRANCE

Sponsored by ZEISS

---

13.00 – 14.00
Room C3

Breaking News in Retina

Moderator: T. Aslam UK

Sponsored by Thēa

---

13.00 – 14.00
Room D4

Innovations to Inspire New Surgical Techniques

Moderator: J. van Meurs THE NETHERLANDS

Sponsored by BAUSCH+LOMB

---

Saturday 22 September

LUNCHTIME SYMPOSIA

13.00 – 14.00
Room D5

Complete Retinal Imaging Platform – A View into Integrating WideField Fundus and OCT-A

Moderator: J-F. Korobelnik FRANCE

Sponsored by ZEISS

---

13.00 – 14.00
Room C3

Breaking News in Retina

Moderator: T. Aslam UK

Sponsored by Thēa

---

13.00 – 14.00
Room D4

Innovations to Inspire New Surgical Techniques

Moderator: J. van Meurs THE NETHERLANDS

Sponsored by BAUSCH+LOMB
be global. be one.

oneworld® is proud to be your official airline alliance. The oneworld network covers more than 1,000 destinations in 150 plus countries, so we can get you anywhere you need to be. Learn more at oneworld.com
INDEX

A

Aberg, T. 74
Abdala, C. 87
Abdelhamid, A. 19
Abdelmessih, M. 123
Abdullah, O. 118, 137
Abdullatif, A. 85
Abeywickrama, L. 65
Abotalayem, F. 114
Abouhussein, M. 123
Abou-Laif, S. 27
Abreu-Gonzalez, R. 114
Abrihami, M. 123, 130
Abroug, N. 117
Abu El Asrar, A. 14
Abulon, D. 130
Accebes Garcia, M. 47, 130
Ach, T. 100
Adepegba, O. 122
Adriono, G. 50
Adsumilli, H. 22, 25, 77, 122
Afshari, F. 137
Agrawal, V. 137
Ahmadieh, H. 130
Ahmed, D. 51, 114, 118
Ahn, J. 123
Anh, D. 84, 123
Aielo, L. 156
Akindova, L. 130
Akiyama, K. 91
Akkin, C. 124
Akkoynun, I. 90
Akova Budak, B. 118
Al-Abdullah, A.E. 92, 130, 137
Alarcon Valero, I. 122
Alberti, M. 71, 130
Alé-Chilet, A. 19
Alex, D. 22, 57, 114, 117
Alexis, M. 124
Al-Hasid, H. 50, 137
Alibert, Y. 91, 130
Ali, Z. 59
Allegrini, D. 80
Allen, P. 88
Allman, K. 17
Almamoori, F. 92
Almarzooqi, A. 58
Almuhitaseb, H. 93
Al-Nashar, H. 92, 114
Al-Rayes, E. 88
Al-Saeidi, A. 124
Alsafi, A. 110
Al-Talibishi, A. 118
Altomare, F. 137
Altun, A. 54
Alyamac Sukgen, E. 98
Aly, M. 91, 130
Alzahrani, Y. 117
Almatery, P. 124
Ambresin, A. 16, 105
Amer, R. 44
Amigo, J.A. 137
Amissah-Arthur, K. 28, 137
Amoros, I. 130
Ambastias, A. 104
Angermann, R. 20, 81
Anguita, R. 118, 124
Apostolopoulos, S. 71
Appel高尚, A. 130
Aranas, L. 91, 130
Aras, C. 130
Arendt, P. 79
Arias, L. 42, 88
Ankaran Yorgun, M. 110
Arndt, C.F. 38
Arora, A. 117
Arora, R. 114, 122
Arrigo, A. 66, 90
Arruabarrena, C. 40
Arruda, H. 77, 84
Arsan, A. 130
Aretells de Jorge, N. 124
Artho Dewi, N. 66
Artunay, O. 110
Arya, S. 113
Ashfaq, I. 124
Aslam, T. 15, 36, 59, 83, 158
Asllanul, H. 130
Assi, A. 97
Atencia, C. 130
Atia, S. 70
Atiya, M. 130
Audo, I. 72, 94
Augustin, A. 19, 27
Ayu, L. 88
Aurora, A. 120
Auxiliadora Monteiro Frazao, M. 37
Avunduk, A. 110
Awh, C. 29, 36, 74
Aydin, R. 51
Aylward, B. 2

B

Bagchi, A. 42, 124
Bailey, C. 50
Baillif, S. 36
Bainbridge, J. 84
Balakshina, G. 114, 118
Balas, R. 130
Balaskas, K. 15, 43, 94
Balandra, S. 118
Balan, O. 42
Bandh, Y. 130
Bandello, F. 2, 16, 20, 21, 28, 37, 49, 55, 67, 73, 87, 155, 156
Baptista, P. 118
Barak, A. 27, 34, 44
Barisani-Arnbauer, T. 34
Barraso Rodrigo, M. 18, 43
Barsam, A.
Barthelmes, D. 43
Bátor, G. 110
Battaglia-Parodi, M. 19, 49
Bavaharan, B. 114, 137
Bayborodov, Y. 130
Bayer, I. 130
Bechrakis, N. 17, 39
Beckford, C. 124
Behar-Cohen, F. 93, 100
Behboudi, H. 114
Behera, U. 82
Belakouski, P. 113
Ben Amor, H. 122
Bennis, A. 54
Bentivoglio, M. 54
Ben Yahia, S. 98
Benzerroug, M. 80
Berarducci, A. 130
Bereznyuk, L. 118
Berger, L. 114
Berker, N. 55
Bernal-Morales, C. 113
Bergoet, F. 98
Beyaziyldiz, E. 124
Bhardwaj, G. 130
Bhatia, D. 73
Bhatnagar, A. 70
Bhende, P. 80, 113, 130
Billital, P. 124
Birtel, J. 118
Biswas, R.K. 137
Blair, M. 60
Bleidtiel, N. 91
Bocker, T. 13, 48
Bogunovic, H. 81
Boisard Espax, A. 35
Bolme, I. 78
Boon, C.J. 18, 25, 26, 53, 61, 71, 72, 93, 94
Bopp, S. 38, 90
Borfeld, N. 16, 17, 46, 61
Borrelli, E. 90, 124
Bossia, F. 84, 104
Bottoni, F. 68, 95
Bouzika, P. 114
Braga, J. 118
Brancato, R. 2
Bravo-Filho, V. 37
Brennan, N. 71
Brent, A. 131
INDEX

Guacciardo, E. 126
Gulkilik, G. 115
Guma, M. 110
Gupta, S.R. 137
Gurumoorthy, V. 121
Guthoff, R. 126
Gutierrez Vasquez, J. 126
Guven, D. 54. 126. 137
Guymer, R. 43. 55. 78
Gyntner, E. 118

H

Hafner, J. 73. 96
Hagenau, F. 113
Hajji, I. 126
Hamilton, R. 102. 103
Hammond, C. 64
Hamoud, A. 126
Hamoudi, H. 55
Hansraj, S. 137
Haritoglou, C. 110
Harmening, W. 72
Harnett, M. F. 60
Hasan, H. 110. 121
Hasebe, H. 83
Hassan, T. 29. 74
Hata, M. 71
Hattenbach, L.O. 38
Hatz, K. 103. 126
Heimann, H. 17. 38. 39. 41. 48. 90. 104
Hellbig, H. 90
He, M. 113
Henriques Recine, M. 99
Henry, A. 126
Herbert, C.P. 14
Heniot, W. 95. 97
Herrero-Vanrell, R. 100
Herrtanto, M. 126
Heufelder, J. 53
Hewick, S. 126
Hillenkamp, J. 95
Hillier, R. 35
Hind, J. 36
Hipólito Fernandes, D. 115
Hobby, A. 20
Hoerauf, H. 68
Holz, F. 2. 28. 31. 46. 49. 54. 55. 72. 78. 103
Horner, F. 126
Horsman, B. 110
Hoshi, S. 132
Ho, T. 65
Hoyn, C. 25. 46. 79. 94
Hua, R. 79. 110
Hu, T. 79

I

Iannikina, I. 113
Ibragimova, N. 126
Iida, T. 102
Iljima, H. 126
Ikuno, Y. 26
Ideda, T. 119
Imshenetskaya, T. 132. 137
Inatani, M. 19
Infantes Molina, E. 119
Interlandi, E. 115
Invernizzi, A. 43. 110
Iovino, C. 115
Iqbal, M. 132
Irannajad, A. 132
Irigoyen, C. 119
Isanta Oral, C. 73. 126
Ishiko, S. 99
Ismail, A. 118
Ivanisevic, M. 115
Ivanova, E. 18. 121
Ivanovska Adjievska, B. 126
Iwase, T. 96

J

Jackson, T. 64
Jain, A. 84
Jain, N. 122
Jali, P. 52
Jalil, A. 27
Jamiolowska, I. 20
Januschowsky, C. 45
Jarc-Vidmar, M. 90
Jawad, M. 126
Jayawickrema, N. 25
Jeung, K. 132
Jeung, J.G. 76
Jimenez Santos, M.A. 26. 66
Jiramongkolchai, K. 71
Jonas, J. 102
Jones, L. 110
Jones, N. 14. 102
Jones, R. 132
Jorge, R. 86. 113
Joseph, S. 20
Josifova, T. 126
Joussen, A. 29. 41. 53. 87
Junmengedararasame, C. 22
Juncai, V. 18. 126
Junemann, A. 49

K

Kadayifcilar, S. 77. 78
Kadonoosono, K. 74. 99
Kaiser, P. 74
Kalanova, Z. 126
Kalanov, M. 85. 132
Kaldim, H. 97. 126
Kambo, B. 126
Kamel, M. 119. 121. 126
Kanar, H. 119. 126
Kang, K. 121
Kanj, U. 55. 126
Kanonidou, E. 111
Kapsala, Z. 119. 126
Karabas, V.L. 126. 138
Karabulut, M. 115
Karaca Adjieyc, S. 118
Karagiannidis Stampoulis, G. 126
Karamitos, A. 54
Karapetyan, A. 47
Karastirar, G. 118
Karlikyuchuk, M. 115
Kartli, O. 115. 126
Kataoka, K. 51
Kato, Y. 132
Kawasaki, K. 126
Kayabasi, U. 79. 115
Kaya, G. 42. 127
Kaya, M. 111
Kayikcioglu, O. 115
Kaynak, S. 65. 132
Kazennov, A. 127
Keane, P. 15. 34. 72
Keegan, D. 48
Keliner, U. 119
Kerei, S. 92
Kertes, P. 111
Kestelyn, P. 14
Kuener, J. 66. 82
Khairallah, M. 14. 115
Khalife, M. 87
Khalloul, A. 127
Khazardzhan, Y. 35. 111
Khochner, S. 115. 118
Khoramnia, R. 22
Khudiakov, A. 83
Kides, A. 132
Ki Lee, W. 22
Kim, B. 122
Kim, E. 115
Kim, H. 121
Kim, J.T. 70
Kim, M. 115
Kim, R. 23
Kim, S.H. 20
Kimyon, S. 85. 127
Kinvane, S.A. 83
INDEX

N
Nabih, M. 67
Nach, S. 122
Nagasato, D. 116
Nail, A. 132
Nair, R. 42
Nalcaci, S. 70
Nandi, K. 111, 123
Narula, R. 82, 138
Nasaralla, J. 121
Natarajan, S. 80.87
Navarro-Palop, C. 127
Neffendorf, J. 91
Nelson, M. 44
Neri, G. 103.111
Neri, P. 34
Neroev, V. 96
Neubauer, J. 71
Ng, H. 98
Ng, J. 128
Nghiem, A. 90
Nghiem-Buffet, M. 97
Ngo, W. 128
Nicholson, L. 93
Niestrata-Ortiz, M. 40
Nikolaeva, Y. 116
Nikolakopoulos, A. 74.87.104
Nishi, T. 96
Normatova, N. 121
Novoselova, T. 123
Nowomiejska, K. 128
Nubile, M. 77
Nujits, R. 77
Numa, S. 120

O
Ogura, Y. 2.91.102
Ohayon, A. 44
Ohji, M. 43
Ohra, K. 132
Oishi, A. 83.98
Okamoto, F. 83
Olea Vallejo, J. 56
Oleňik Memmel, A. 123,128
Oliveira-Ferreira, C. 123
Oliveira, M. 138
Oll, M. 118
Onder, A. 120
Oner, A. 35
Oner, F. 111
Ophir, A. 92
Ornelas, M. 128
Oros, A. 116
Oshallah, M. 111,116
Oshima, Y. 74
Osman, M. 113
Oubraham, H. 44
Ouederni, M. 116
Ozal, S. 121
Ozdamar Erol, Y. 123
Ozdlogan Erkül, S. 112
Ozkaya, A. 132
Ozmert, E. 85
Ozturk, B. 123,128
Ozturk, M. 132
Ozturk, T. 73

P
Pacelli, G. 128
Packo, K. 29
Pagoulatos, D. 120.132
Pajtler Rosar, A. 57,71,91
Palaric, N. 70
Palkovits, S. 18
Palmieri, M. 92
Panadreou, C. 40
Papadopoulou, C. 104
Papandreou, I. 133
Papasavvas, I. 90
Papavasileiou, E. 133
Papazacharia, A. 120
Pappas, G. 133
Paraskevopoulos, T. 128
Parikh, S. 73
Park, I. 128
Parmar, T. 113,121
Parodi Battaglia, B. 55
Paroikakis, I. 74
Paroloni, B. 38
Parrado-Carrillo, A. 112
Parreira, S. 25.80
Parrulli, N. 123
Pastor, J.C. 45
Pastore, M. 42
Pasu, S. 34
Patelli, F. 48.56.104
Patel, R. 73
Patricio, M. 56
Patton, N. 41
Pauleikhoff, D. 68.90.155
Pavésio, C. 14.22.34.76
Pavlaki, O. 133
Pearce, I. 94.157
Pedanova, E. 42.121
Peñalverno, S. 116.128
Peiretti, E. 116
Pelayes, D. 69.87.90.116
Pellegrini, F. 77.123
Pencak, M. 133
INDEX

Peralta Gomez, M.Y. 26
Pereira, A. 116, 120, 123, 138
Pereira, M. 133
Perente, I. 133
Perrot-Reynolds, R. 44
Pershin, B. 84
Pertile, G. 48, 95, 97, 105
Pessoa, B. 128
Peto, T. 29, 64, 72
Petachkov, D. 28
Pfau, M. 78
Piazzia, A. 128
Pichi, F. 14, 85, 123
Pico, A. 120
Pier, L. 57
Pilcseych, T. 123
Pilotto, E. 29, 59, 64, 84, 116
Pilson, Q. 123
Pircher, M. 100
Placeres, J. 120
Pleyer, U. 75
Podkowinski, D. 128
Polat, O. 128
Polito, A. 95, 105
Pollreisz, A. 35, 100
Pomykina, N. 116
Porcu, M. 56
Porto, F.B.O. 37
Potic, J. 91
Pournaras, C.J. 37, 43, 103
Pournaras, J.A. 16, 74, 91, 105
Pracharova, Z. 133
Prakas, P. 36
Priceto del Cura, M. 23, 76, 133
Prigione, G. 95
Priginger, S. 68
Pritchard, E. 133
Providencia, J. 58, 138
Puri, V. 42

Q

Qian, T. 73, 83, 116
Qi, H. 83
Querques, G. 2, 25, 44, 59, 93, 94, 98, 102
Quihill, F. 121
Quijano, C. 121
Qureshi, M. 47

R

Ra, H. 116, 133
Rahman, R. 54, 55
Rai Gupta, S. 82, 137
Raimundo, M. 27, 128, 138
Raja, L. 20
Rajalakshmi, R. 85
Rajendran, A. 51, 121
Ramu, J. 40
Randolph, J. 59
Rangel, C. 22, 123
Rao, G. 58
Ratković, M. 118
Ratra, D. 120, 121
Rauf, A. 19
Razavi, S. 51
Rehak, M. 128
Rejdak, R. 49
Relimpio Lopez, I. 41
Reppucci, V. 87
Rewbury, R. 128
Rezaei, K. 80
Ribiero, M. 73
Richard, G. 2, 54, 87, 97
Riemann, C. 74, 80
Riga, P. 116
Rizzo, S. 35, 49, 60, 65, 74, 80, 84
Roberta, P. 59
Robinson, J. 20
Rodrigues, P. 128
Rodrigues, T. 43, 50
Rodríguez Castelblanco, A. 116
Rodriguez-Ficioo, D. 112
Romano, F. 73, 90
Romano, M. 29, 41, 45, 59, 98, 120
Romero Martinez, A. 118, 123, 133
Roohipoor, R. 96, 123
Rosa, R. 112
Rosenfeld, P.J. 49
Rossi, T. 29, 59
Rothschild, P-R. 105
Rotsos, T. 104
Rougier, M.B. 52
Ruamviboonsuk, P. 23, 38
Rudenko, V. 92
Rudýk, M. 128
Ruiz Casas, D. 138
Ruiz, D. 69
Ruiz-Medrano, J. 58
Ruiz-Moreno, J.M. 18, 42, 88, 91, 155
Ruiz Moreno, O. 73, 128
Runhart, E. 85
Rustambayova, G. 77

S

Saare, A. 76
Saban, M. 112, 128
Saban, G. 70, 116
Sabour, S. 113, 120
Sabti, K. 80, 87
Sacconi, R. 71
Sahada, S. 101, 103
Sadeghpour, A. 81
Sagoo, M. 17
Sahinoglu-Keskek, N. 128
Sahota, D. 128
Saidkasimova, S. 41, 88
Saigol, H. 138
Sakamoto, T. 99
Sakurai, T. 133
Saleh, M. 50, 57, 75
Sallo, F. 68
Sambroio, J. 47, 70
Samokovskh, E. 118
Sanabria, M.R. 83
Sanchez, C. 64
Sanduja, N. 128, 138
Sannikov, O. 128
Santos, A. 50
Sarao, V. 47
Sauza, M. 120
Sawad, O. 99
Saw, S. 80
Sayin, N. 121
Scarpa, G. 59
Schaal, K. 116
Schalengbour, A. 39
Schawar, M. 133
Schlingermann, R. 16, 27, 53, 61, 64
Schlottmann, P. 50, 112
Schmetter, L. 19
Schmid, M. 51
Schmidt-Erfurth, U. 2, 15, 21, 34, 45, 49, 81, 156, 158
Schmidt, J. 12, 13
Schmitz-Valckenberg, S. 18, 26, 46, 103
Schneider, S. 28
Scholl, H. 28
Schrader, W. 87
Schumann, R. 26, 68
Schuster, A. 133
Schwartz, R. 51
Schwarz, B. 56
Seibel, J. 39
Semenova, N. 112
Senatore, A. 98
Sengal, A. 47
Senra, H. 59
Senturk, F. 116
Sco, J. 133
Seregard, S. 2, 17, 22, 53, 87
Stahl, A. 79, 90
Stalmans, P. 74, 157
Stamate, A. 120
Stamenković, M. 112, 133
Stanford, M. 14
Stanga, P. 29, 48, 73, 79
Stanzel, B. 35, 79
Stattin, M. 57, 117
Staurenghi, G. 24, 27, 36, 46, 52, 68, 72, 79, 94, 101, 103
Stavvakas, P. 41, 48
Stavrev, V. 47
Stavropoulou, T. 117, 133
Stebevec, S. 133
Stebevec, V. 123, 133
Steel, D. 27, 64, 95, 97
Stefánsson, E. 50, 100
Stehouwer, C. 77
Stewart, S. 66
Stolba, U. 8
Stopa, M. 133
Strauss, R. 43
Subash, M. 129
Subhi, Y. 71, 103
Subira, O. 138
Sudhalkar, A. 12, 13
Sugiyama, Y. 40
Suleimenov, M.S. 130
Sullivan, P. 76, 87
Sül, S. 112
Sundaram, N. 69
Sussvar, P. 134, 138
Suzuki, A. 129
Szegedi, S. 83
Szurman, P. 88
T
Tadayoni, R. 2, 22, 34, 48, 68, 74, 78, 80, 97, 102, 157
Takada, R. 123
Takahashi, M. 99
Takeuchi, J. 112
Talks, J. 94
Tan, A. 18
Tan, C. 36, 112, 117, 138
Tan, S. 134
Tantou, A. 129
Tarek, M. 67
Taylor, D. 129
Te, J. 84
Tegou, Z. 120
Teke, M. 120
Temming, P. 46, 61
Teo, K. 71
Teo, M. 40
Terasaki, H. 23
Terashima, H. 96
Tew, T. 112
Theelen, T. 25, 58
Theodorakis, A. 117
Thiele, S. 103
Thouvenin, R. 28
Tian, M. 18
Ting, D. 71
Tiwary, S. 138
Tognetto, D. 12, 13, 134
Tök, L. 70
Toklu, Y. 20
Tomkinson, C. 47, 70
Topeu Yılmaz, P. 90
Torres-Costa, S. 99
Toto, L. 70
Toygár, O. 65, 117
Tranos, P. 35, 48, 117
Tran, T. 112, 134
Trantou, V. 120
Trese, M. 21
Trottier, P. 121
Truneva, O. 112
Tsamousis, K. 120, 123
Tsokolas, G. 20
Tsoukalos, K. 66, 99
Tucker, W. 30, 99
Tufail, A. 15, 24, 26, 46, 51, 68, 102
Turksever, C. 103
Turner, G. 24
Tzamichas, I. 113
U
Ucguğ Atılgan, C. 86
Ucgun, N. 35, 120
Udaondo, P. 27, 83
Uemura, A. 99
Ulanova, N. 42
Ulusoy, M. 112
Umari, I. 129
Ünal, F. 117
Unla, N. 54
Ünlü, N. 123
Upadhyay, A. 22, 118, 129
Urta, A. 100
INDEX

V
Vadavik, V. 117
Valkenburg, D. 120
Valverde-Megias, A. 129
van Dijk, E. 36, 71
van Meurs, J. 2, 15, 22, 27, 68, 75, 95, 97, 158
Vannadil, H. 123, 138
van Overdam, K. 41, 97
van Rijssen, T. 71, 103
van Romunde, S. 105
van Schooneveld, M. 52
Vanzan, V. 120
Vassileva, P. 112
Vemala, R. 129
Verma, L. 38
W
Waheed, N. 27, 45
Waldstein, S. 81
Walkden, A. 47
Wang, H. 112
Wang, J. 85, 129
Wang, L. 103
Wang, S. 96
Warudkar, S. 129
Weigert, G. 112
Wells, J. 64
Westborg, I. 51
Westcott, M. 14
Whiteman, A. 120
Wijetilleka, S. 47, 112
Williamson, T. 48
Wintergerst, M. 123
Wolf, A. 78, 90
Wolfensberger, T.J. 16, 22, 27, 41, 48, 60, 75
Wolf, S. 2, 24, 31, 41, 49, 54, 55, 68, 77, 86, 99
Wolf, S.F. 34
Wong, D. 22, 29, 54
Wong, D.T. 92
Wong, I. 25
Wong, S.C. 21
Wong, T.Y. 23, 31
Wright, C. 40
Wu, W. 103, 134
X
Xu, K. 91
Xu, L. 76, 121
Y
Yablokova, N. 129
Yablokov, M. 134
Yahaghi, B. 27
Yakupova, D. 112
Yamamoto, S. 12, 13
Yang, X. 81, 134
Yasar, C. 20
Yavorskiy, A. 129
Yayla, U. 97
Yelik, H. 97
Yildirim, C. 65
Yilmaz, I. 129
Yorston, D. 95
Yudina, N. 121, 129, 134
Yun, C. 20
Yu, S. 129
Yu, S-Y. 50
Yu, W. 121
Yvon, C. 23
Z
Zabel, P. 117
Zafar, A. 113
Zaika, V. 138
Zainullin, R. 129, 134
Zakharov, V. 134
Zakieh, I. 129
Zamysliik, E. 25
Zarbin, M. 49
Zarranz-Ventura, J. 26, 56, 93
Zaytseva, O. 117, 123, 129
Zengin, M. 117, 129
Zgoba, M. 134
Zhang, H. 19, 58
Zhang, M. 112
Zhao, Q. 57
Zhgal, I. 55
Zhurgumbayeva, G. 121, 134
Zicarelli, F. 98
Zina, S. 123
Zinkernagel, M. 17, 24, 38, 55, 78, 104
Zografos, L. 17, 37, 105
Zolotareva, E. 70
Zotov, V. 134
Zrenner, E. 79
Zubicoa, A. 117
Zweifel, S. 16, 57
IQ 577™ Laser System

With MicroPulse laser and the IQ 577 Laser System, it is possible to address foveal leakage in a safer and more effective manner — not only around the fovea, but when treating refractory edema over the fovea.¹

“I use MicroPulse to treat DME, macular edema, and patients with CSR.”
Stela Vujosevic, MD, PhD, FEBO
University Hospital Maggiore della Carità, Novara, Italy

“IRIDEX lasers are known for being extremely durable and lasting for years.”
Julia Shulman, MD
Retina Specialist, NYC Retina, USA

“MicroPulse significantly reduced the amount of injections I have been using in patients.”
Munir Escaf, MD
Retina Specialist, Clínica Carriazo, Barranquilla, Colombia

“In my practice, non-damaging MicroPulse Laser has now completely replaced conventional continuous-laser treatment for most macular diseases.”
Kishiko Ohkoshi, MD, PhD
St. Luke's International University, Tokyo, Japan


© 2018 IRIDEX. All rights reserved. IRIDEX, the IRIDEX logo, IQ 577, TxCell, MicroPulse, and the MicroPulse logo are trademarks or registered trademarks of IRIDEX.
the treatment of adult patients with macular oedema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) due to diabetic macular oedema.

**Use of OZURDEX**

**Indications:**
- Macular oedema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) due to diabetic macular oedema.

**Dosage and Administration:**
- The intravitreal injection procedure should be carried out under controlled aseptic conditions as described in the Summary of Product Characteristics. The patient should be instructed to report any symptoms suggestive of endophthalmitis or any of the above mentioned events without delay. All patients with posterior capsular opacities should be under careful review and monitored following the injection to permit early treatment if an infection or increased IOP occurs.

**Warnings/Precautions:**
- Intravitreal injections, including OZURDEX, can be associated with endophthalmitis.
- Intravitreal injections are contraindicated in patients with active ocular infection or active intraocular inflammation.

**Adverse Effects:**